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Glossary of terms 
 
Assessment A procedure used to generate data required by the study 
Control drug A study drug used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug 
Enrollment Point/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
Inadequate response to TNFα  Active disease despite stable treatment with anti-TNFa for at least 3 months at a stable dose or for at least one dose in the case of lack of 
tolerance 
Investigational drug The study drug whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is synonymous 
with “investigational new drug.”
Medication number A unique identifier on the label of each study drug package in studies that 
dispense study drug using an IVR system
Patient number A number assigned to each patient who enrolls in the study. When 
combined with the center number, a unique identifier is created for each 
patient in the study.
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.
Phase A major subdivision of the study timeline; begins and ends with major 
study milestones such as enrollment, randomization, completion of 
treatment, etc. 
Premature patient withdrawal Point/time when the patient exits from the study prior to the planned 
completion of all study drug administration and assessments; at this time 
all study drug administration is discontinued and no further assessments 
are planned
Randomization number A unique identifier assigned to each randomized patient, corresponding to 
a specific treatment arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when 
study drug was discontinued whichever is later 
Study drug Any drug administered to the patient as part of the required study 
procedures; includes investigational drug and any control drugs
Study drug discontinuation Point/time when patient permanently stops taking study drug for any 
reason; may or may not also be the point/time of premature patient 
withdrawal
Variable Information used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at specified timepoints
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Protocol synopsis 
Title of study: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to 
demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 
2 years in patients with active psoriatic arthritis 
Purpose and rationale: The purpose of this 2 year study is to demonstrate efficacy on signs and 
symptoms of psoriatic arthritis and to assess the long term safety, tolerability and efficacy on joint/bone 
structure of secukinumab given as intravenous (i.v.) loading doses, followed by sub-cutaneous (s.c.) 
injections of two dose levels of secukinumab versus placebo in patients with active PsA. Efficacy at 
Week 24 will be assessed based on signs and symptoms according to the American College of 
Rheumatology response criteria (ACR 20 response), whereas long term efficacy will be based on 
joint/bone structural preservation (X-ray) and physical function (HAQ-DI), as well as skin assessment 
for psoriasis signs. Treatment will continue up to 2 years to assess inhibition of joint damage and 
physical function. 
Objectives: 
Primary objective: To demonstrate that the proportion of patients achieving ACR20 response criteria at 
Week 24 is greater on secukinumab as compared to placebo in the subgroup of patients who are 
TNFα inhibitor naïve. 
Key secondary objectives: 
1. The proportion of subjects achieving ACR20 response criteria at Week 24 is greater on 
secukinumab as compared to placebo in the entire study population. 
2. The improvement (change) from baseline on secukinumab is superior to placebo for the HAQ-DI 
after 24 weeks of treatment in the subgroup of subjects who are TNFα inhibitor naïve. 
3. The improvement (change) from baseline to Week 24 on secukinumab is superior to placebo for 
joint/bone structural damage (van der Heijde modified total Sharp score) in the subgroup of 
subjects who are TNFα inhibitor naïve. 
4. 12 months treatment with secukinumab is superior to delayed treatment with secukinumab 
placebo / secukinumab with regards to the proportion of subjects achieving Major clinical response 
in the subgroup of subjects who are TNFα inhibitor naïve. 
Population: The study population will consist of a representative group of rheumatoid factor negative 
subjects at least 18 years of age, fulfilling the CASPAR criteria for active psoriatic arthritis. Subjects 
included must report active disease despite current or previous NSAID, DMARD and/or TNFα inhibitor 
therapy. 
Concomitant therapy with MTX (≤25 mg/week) will be acceptable, if dose and route of administration 
have been stable for at least four weeks prior to the randomization visit. Subjects must have signs of 
skin manifestations of psoriasis, defined by at least one psoriatic plaque of ≥2 cm diameter (but not in 
armpits, or chest between breasts, or groin) or nail changes consistent with psoriasis or documented 
history of plaque psoriasis. 
Patients cannot be re-screened more than once. 
This is a multinational study and it is expected that subjects will be enrolled at approximately 150 sites. 
About 750 subjects will be screened for approximately 600 subjects to be randomized). A screening 
failure rate of 30 % and post-randomization drop out rate of 25 % is anticipated. Enrollment will stop as 
soon as the target number of randomized subjects is reached.  
Inclusion/Exclusion criteria:  
Inclusion criteria: 
Subjects eligible for inclusion in this study have to fulfill all of the following criteria: 
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1. Male or non-pregnant, non-lactating female subjects at least 18 years of age 
2. Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with 
moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out 
of 76 (dactylitis of a digit counts as one joint each) 
3. Rheumatoid factor and anti-CCP antibodies negative 
4. Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2 cm diameter (but not 
in intertriginous areas such as armpits, or chest between breasts, or groin) or nail changes 
consistent with psoriasis or documented history of plaque psoriasis 
Exclusion criteria: 
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study: 
1. Chest X-ray with evidence of ongoing infectious or malignant process, obtained within 3 months of 
screening and evaluated by a qualified physician 
2. Subjects who have previously been treated with more than 3 different TNFα inhibitors 
(investigational or approved) 
3. Subjects taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine) 
4. Subjects who have ever received biologic immunomodulating agents except for those targeting 
TNFα, investigational or approved  
5. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 
receptor  
6. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20, 
investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19) 
Investigational and reference therapy: At baseline, elgibile patients will be randomized to one of the 
following three treatment arms in a ratio of 1:1:1. 
• Group 1: secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then secukinumab 75 mg s.c. 
starting at Week 8 and injected every 4 weeks 
• Group 2: secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then secukinumab 150 mg s.c. 
starting at Week 8 and injected every 4 weeks 
•  Group 3: Placebo i.v. at BSL, Weeks 2 and 4 then placebo s.c. starting at Weeks 8 and 12. 
At Week 16 (Visit 8), subjects will be classified as responders ( ≥ 20% improvement from baseline in 
both tender and swollen joint counts) or non-responders and will be re-assigned/re-randomized at 
Week 16 by the IRT to receive double-blind treatment up to 2 years, as follows: 
• Subjects on placebo (Group 3) who are non-responders will be re-randomized to receive 
secukinumab 75 mg s.c. or 150 mg s.c. (1:1) every 4 weeks 
• Subjects on placebo (Group 3) who are responders will continue to receive secukinumab 
placebo every 4 weeks until Week 24. At Week 24, these subjects will be re-randomized to 
receive secukinumab 75 mg s.c. or 150 mg s.c. (1:1) every 4 weeks regardless of responder 
status 
Study design: This pivotal study uses a double-blind, randomized, parallel-group, placebo-controlled 
design. A screening (SCR) period running 4 weeks before randomization will be used to assess 
eligibility followed by a treatment period of 2 years. 
At Week 24, efficacy of secukinumab treatment will be assessed based on an ACR20 response. 
Subjects who complete the 2 year study may be eligible to enter a planned extension trial. 
Efficacy assessments:  
• ACR 20, 50 70  
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• PsARC response 
• Disease Activity Score (DAS28) and EULAR response criteria 
• HAQ-DI 
• Progression of structural damage by X-ray – van der Heijde total modified Sharp score and 
subscores 
• Leeds Enthesitis Index (LEI) 
• Leeds Dactylitis Index (LDI) 
• Psoriasis Area and Severity Index (PASI) 
• Investigator’s Global Assessment (mod 2011) for overall psoriatic disease 
• Target lesion assessment 
• Modified Nail Psoriasis Severity Index (mNAPSI) 
• MRI on hands (incl. wrist) (at selected centers and in TNFα inhibitor naïve patients with a swollen 
wrist)) 
• Quality of Life, fatigue, utilities and work productivity (SF-36 v2 Acute Form, FACIT-Fatigue, DLQI, 
PsAQoL, EQ-5D, WPAI-GH) 
Other assessments:  
• Safety and tolerability: Evaluation of all AEs and SAEs including injection site reactions, vital signs 
and laboratory assessments 
• Smoking history 
• Pharmacokinetics 
• Soluble plasma protein markers related to targeted pathway and cardiovascular risk markers 
• Exploratory: pharmacogenetics 
• ANA, anti dsDNA antibodies, anti-CCP antibodies 
Data analysis:  
The primary endpoint in the study is ACR20 at Week 24 for subjects who are TNFα inhibitor-naïve. 
Key secondary objectives will be to compare secukinumab to placebo according to a sequential testing 
procedure and include ACR20 for the full population, change from baseline in HAQ-DI for the TNFα 
inhibitor-naïve subjects, change from baseline in van der Heijde total modified Sharp score TNFα 
inhibitor-naïve subjects, and major clinical response in TNFα inhibitor-naïve. Safety analyses will 
include summaries of adverse events, laboratory measurements and vital signs. 
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1 Introduction 
1.1 Background 
Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease belonging to 
the spectrum of conditions commonly referred to as spondyloarthritidies (SpA). The scientific 
community is split over the question whether to view these conditions together or consider 
them as separate entities (Nash 2005). For example, inflammatory back pain associated with 
psoriasis fit two classifications (1) AS with psoriasis or (2) psoriatic spondylitis (Gladman 
2007). However, while diverse in their clinical presentations, common environmental as well 
as genetic factors associated with susceptibility to SpA are suspected (Turiewicz 2007). This 
latter notion was recently corroborated by findings in a large-scale single nucleotide 
polymorphism (SNP) scan study, where IL23R variants that were previously linked to 
Crohn`s disease and psoriasis (diseases that may both co-exist with spondylarthritides) 
conferred risk to developing ankylosing spondylitis (Barrett 2008). Together, a common 
pathway including the IL-23/IL-17 axis may play a role in seronegative SpAs including 
psoriatic arthritis. 
Psoriatic arthritis is a frequent chronic immune-mediated disease encompassing a spectrum of 
overlapping clinical entities (Moll and Wright 1973). About 10 - 40% of patients with 
psoriasis suffer from PsA. Recent efforts were aimed at defining more stringent classification 
criteria for standardized recruitment into clinical trials (Taylor 2006). PsA is associated with 
significant morbidity and disability, and thus constitutes a major socioeconomic burden. It is 
not only more common but also more severe than previously thought (Gladman 2004). The 
majority of patients will have psoriasis prior the associated arthritis occurs and will be under 
treatment for their skin disease. NSAIDs are used for musculoskeletal pain symptoms. 
Traditional disease modifying anti-rheumatic drugs (DMARDs) include methotrexate (MTX), 
sulfasalazine, cyclopsorine, and leflunomide and are inadequate for a number of patients 
because these drugs only partially control established disease (Mease 2008).  
Several lines of evidence support the notion of prominent T cell involvement in the 
pathogenesis of PsA. Memory CD4+ and CD8+ cells are present in skin lesions as well as the 
inflamed synovium that express activation markers and have characteristics of oligoclonal 
expansion. (Curran 2004, Tassiulas 1999) Clinical trials demonstrated efficacy of T cell 
targeted therapy in PsA (cyclosporine A, CTLA4 Ig, alefacept). TNF blocking therapy was 
successfully introduced to the treatment of patients with PsA (Mease 2000). Despite these 
efforts, an unmet clinical need exists for patients with PsA for better disease control and long 
term prevention of structural damage beyond mere abrogation of inflammatory processes. In 
addition, current treatment options for patients with intolerance or an inadequate response to 
anti-TNF-α agents are limited. 
IL-17 antagonism represents a novel therapeutic approach aimed at interference with the 
chronic inflammatory process by selectively targeting the predominant proinflammatory 
cytokine of the helper T17 cell subset. Additional effects of anti-IL17 on bone homoeostasis 
via RANKL and IL-1, upstream of TNFα, can be inferred from animal studies (Koenders 
2005). Assuming a potential role of TH17 cells in the inflammatory infiltrate in PsA, it can be 
speculated that locally disturbed homeostasis of osteoclastogenic and osteoblastogenic 
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mechanisms characteristic of PsA might be affected by IL-17 blockade. Such effects may be 
additive or synergistic to anti-TNF, and thus may provide a therapeutic advancement to 
prevent structural damage in PsA. 
Secukinumab (AIN457) is a high-affinity fully human monoclonal anti-human antibody that 
neutralizes IL-17A activity. IL-17A is the key cytokine in the newly discovered TH17 
pathway which is thought to be an important mediator of autoimmunity. Neutralization of IL-
17A has strong pre-clinical and clinical target validation and documentation of efficacy in a 
proof of concept study (CAIN457A2101) and a phase II study (CAIN457F2201) in 
Rheumatoid Arthritis (RA). IL-17A has been shown to play a pivotal direct pathogenetic role 
in both inflammatory and destructive joint tissue manifestations of RA and has direct effects 
on matrix metalloprotease (MMP) activation and stimulation of osteoclast-mediated bone 
resorption (Stamp 2004; Witowski 2004; Moseley 2003). Interim analysis of all 42 patients 
enrolled in the PsA PoC study CAIN457A2206 who completed week 6, together with 
preliminary data from the later time points up to week 16, suggest that a clinically meaningful 
response for signs and symptoms is induced as early as 2 weeks after start of secukinumab 
treatment, with further improvement up to week 6 and maintenance of response up to week 
16. Therefore, treatment with secukinumab may also reduce loss of cartilage and erosion of 
bone in PsA and may result in improvement of symptoms and functional joint manifestations 
in afflicted patients. Furthermore, In a completed proof of concept study (CAIN457A2102), 
the effects of secukinumab administered at 3 mg/kg as a single intravenous infusion were 
compared with that of placebo in thirty-six subjects with active chronic plaque-type psoriasis. 
The study demonstrated efficacy at the 4- week endpoint and continuous efficacy at 12 weeks 
based on Psoriasis Area and Severity Index (PASI) and Investigator’s Global Assessment mod 
2009 (IGA mod 2011) endpoints.  
To date, over 2,000 subjects with a variety of diseases and healthy volunteers have been 
enrolled into completed and ongoing studies with secukinumab, and over 1,400 subjects have 
been newly exposed to secukinumab at single and multiple doses ranging from 0.3 mg/kg to 
10 mg/kg intravenous (i.v.) and 25 mg to 300 mg subcutaneous (s.c.).  Of these, over 300 
subjects have been continued on secukinumab through enrollment into extension trials. In 
total, 333 RA and 61 PsA patients have been enrolled into trials with secukinumab. Full safety 
results including all reported adverse events are currently available for eight studies (across 
autoimmune indications) that have been completed. These show comparable numbers of 
adverse events in subjects treated with secukinumab compared to placebo without indication 
of any specific organ toxicity. Please refer to the Investigator Brochure for a more detailed 
review of the pre-clinical and clinical information on secukinumab. 
1.2 Purpose  
The purpose of this study is to demonstrate at Week 24 the efficacy and assess the safety of 
secukinumab given as intravenous (i.v.) loading doses, followed by sub-cutaneous (s.c.) 
injections of 2 dose levels of secukinumab versus placebo in subjects with active PsA. At 
Week 24, efficacy will be assessed based on improvement in signs and symptoms according 
to the American College of Rheumatology response criteria (ACR20 response), whereas long 
term efficacy up to 2 years will be based on joint/bone structure preservation (X-ray) and 
improvement in physical function (HAQ-DI), as well as skin and nail improvement for 
psoriasis signs. 
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Data from this study are aimed at supporting a global submission of the psoriatic arthritis 
indication. 
2 Study objectives 
2.1 Primary objectives 
To demonstrate the efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo 
in patients with active PsA based on the proportion of patients achieving an ACR20 response 
in the subgroup of subjects who are TNFα inhibitor naïve. 
2.2 Key Secondary objectives 
The key secondary objectives of the study are to demonstrate: 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving an ACR20 response in the entire study population. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the HAQ-DI at Week 24 in the subgroup of subjects who are TNFα inhibitor 
naïve. 
• The improvement (change) from baseline to Week 24 on secukinumab 75 and 150 mg is 
superior to placebo for joint/bone structural damage (van der Heijde modified total Sharp 
score) in the subgroup of subjects who are TNFα inhibitor naïve. 
• Secukinumab 75 or 150 mg is superior to placebo (as originally randomized) with regards 
to the proportion of subjects achieving Major Clinical Response at Week 52 in the 
subgroup of subjects who are TNFα inhibitor naïve. 
2.3 Secondary Objectives 
To evaluate the efficacy of secukinumab compared to placebo, as applicable, on:  
1. Joint/bone structure preservation at Weeks 52 and 104 
2. Erosion and Joint space narrowing (van der Heijde modified Sharp sub scores) at 
Weeks 24, 52 and 104 
3. Proportion of subjects with no joint/bone structural progression (change in van der 
Heijde modified total Sharp score ≤ 0) at Weeks 24, 52 and 104. 
4. Maintenance of effect by comparing progression in Year 1 (up to Week 52) and Year 
2 (Week 52 to Week 104) of the different treatment regimens (van der Heijde 
modified total Sharp score and subscores). 
5. Psoriatric arthritis response criteria (PsARC) and ACR 50 and 70 response at Week 24  
6. PsARC, ACR 20, ACR 50 and ACR 70 response at Weeks 1, 2, 4, 8, 12, 16, and 20 
and up to Week 104  
7. Major Clinical Response  at week 104 
8. HAQ-DI over time at Weeks 1, 2, 4, 8, 12, 16, 20, and over time up to Week 104 
9. ACR components, including markers of inflammation (hsCRP and ESR) at Weeks 1, 
2, 4, 8, 12, 16, 20, and 24 and over time up to Week 104 
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10. Change in Disease Activity Score (DAS) 28-CRP score at Week 1, 2, 4, 8, 12, 16, 20, 
24 versus placebo, and over time up to Week 104 
11. DAS 28-CRP remission (defined as a DAS28 < 2.6) and low disease activity (defined 
as DAS28 ≤ 3.2) at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 and over time up to Week 104  
12. EULAR response criteria Weeks 1, 2, 4, 8, 12, 16, 20, and 24 and over time up to 
Week 104 
13. Leeds Dactylitis Instrument (LDI) and Leeds Enthesitis Index (LEI) at Weeks 2, 4, 8, 
12, 16, and 24 and up to Week 104 
14. PASI 75 response, investigator’s global assessment for psoriasis, (IGA mod 2011), 
Target Lesion Score (TLS) and modified Nail Psoriasis Severity Index (mNAPSI) at 
Weeks 1, 2, 4, 8, 12, 16, and  24 and up to Week 104 
15. Quality of life and fatigue (SF-36 , FACIT-Fatigue), Psoriatic Arthritis Quality of life 
(PsAQoL), Dermatology life Quality Index (DLQI), EQ-5D and Work Productivity 
and Impairment-General Health (WPAI-GH) assessment at Weeks 2, 4, 8, 16, and 24 
and over time up to Week 104 
AND 
16. To evaluate the overall safety and tolerability of secukinumab up to Week 104 
17. To investigate the development of immunogenicity against secukinumab 
2.4 Exploratory objectives 
1. To explore the PK/PD relationship of secukinumab  
2. To perform exploratory pharmacogenetic assessments to examine whether individual 
genetic variation in genes relating to drug metabolism, PsA, and the drug target pathway 
confer differential response to secukinumab 
3. To conduct exploratory biomarker assessments aiming to identify potential markers 
associated with treatment response to secukinumab, or that possibly correlate with the 
severity or progression of psoriatic arthritis, and to assess the impact of secukinumab on 
cardiovascular surrogate biomarkers. 
4. To measure the effect of secukinumab on joint/bone structure preservation using MRI 
measurements (modified RAMRIS and JSN score) in the subgroup of subjects who are 
TNFα inhibitor naïve. 
3 Investigational plan 
3.1 Study design 
This pivotal phase III study uses a double-blind, randomized, parallel-group, placebo 
controlled design. A screening period running up to 4 weeks before randomization will be 
used to assess eligibility followed by a treatment period of two years. At baseline (BSL), 
subject whose eligibility is confirmed will be randomized to one of three treatment groups:  
• Group 1: Secukinumab i.v. (10mg/kg) at BSL, Weeks 2 and 4, then secukinumab 75 mg 
s.c. starting at Week 8 and injected every 4 weeks  
• Group 2: Secukinumab i.v. (10mg/kg) at BSL, Weeks 2 and 4, then secukinumab 150 mg 
s.c. starting at Week 8 and injected every 4 weeks 
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• Group 3: Placebo i.v. at BSL, Weeks 2 and 4, then placebo s.c. starting at Week 8 and 
Week 12.  
The subjects will be stratified according to being either TNFα inhibitor incomplete responders 
(IR) or TNFα inhibitor naïve subjects. 30% of subjects are planned to be TNFα inhibitor 
inadequate responders to ensure a representative subject population for the assessment of 
efficacy and safety. Thus, it is planned to randomize approximately180 TNFα inhibitor IR 
subjects and 420 TNFα inhibitor naïve subjects. 
At Week 16 (Visit 8), subjects will be classified as responders ( ≥20% improvement from 
baseline in both tender and swollen joint counts) or non-responders. Subjects who were 
randomized to placebo at baseline will be re-randomized by the Interactive Response 
Technology (IRT) to receive double blind treatment up to 2 years, as follows (see Figure 3-1): 
¾ Subjects on secukinumab placebo (Group 3) who are responders will remain on 
placebo until week 24. At Week 24, these subjects will be re-randomized (1:1) to 
receive either secukinumab 75 or 150 mg every 4 weeks 
¾ Subjects on secukinumab placebo (Group 3) who are non-responders will be re-
randomized (1:1) at Week 16 to receive either secukinumab 75 mg or 150 mg s.c. 
every 4 weeks. 
Rescue medication will not be allowed until Week 24. However, subjects deemed not to be 
benefiting from the study treatment by the investigator or for any reason on their own accord 
will be free to discontinue participation in the study at any time. 
Subjects who complete the study may be eligible to enter a planned extension trial. 
 
 
 
 
 
 
 
This document (090095a88362b521 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 5/12/2011 2:47:40 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by Ambs Petra in Basel at Thu, May 12, 2011 16:41:36 CEST
Novartis Confidential Page 19 
Clinical Trial Protocol  Protocol No. CAIN457F2306 
 
Figure 3-1 Study design 
8 16 24 48Week -4 to BSL 32 40 56 100 104524
NR
75mg  or 150mg AIN457 (1:1)
Escape treatment: 75mg  or 150mg AIN457 (1:1)
Group 1
AIN457 i.v. loading 
followed by 75 mg s.c.
n = 200
NR
Randomization 
AIN457 administration (s.c.)
Placebo to AIN457 administration (s.c.)
Non-responder (<20% reduction in TJC and SJC)
AIN457 10 mg/kg administration (i.v.)
Placebo to AIN457 administration (i.v.)
Group 2
AIN457 i.v. loading 
followed by 150 mg s.c.
n = 200
Group 3
Placebo i.v. 
followed by placebo s.c.
n = 200
F112
 
3.2   Rationale of study design 
The double-blind, randomized, parallel-group placebo controlled design used in this study is 
aligned with Phase III trials of other biologics and is in accordance with EMA guidelines 
(EMA 2003). The treatment duration of the placebo group is kept short and the group will be 
re-assigned to active treatment at the end of the primary endpoint analysis. The blinding is 
maintained beyond the primary endpoint so as to ensure reliable efficacy and safety measures. 
The regular assessments of disease activity ensures that subjects who are experiencing 
worsening of disease in any of the treatment groups can exit the study upon their own wish or 
based on the advice of the investigator at any time. Long term treatment data up to two years 
are being generated to demonstrate long-term efficacy and to support the safety database in 
this population. 
3.3 Rationale of dose/regimen, duration of treatment 
The dosing rationale for psoriatic arthritis (PsA) and ankylosing spondylitis (AS) relies upon 
the dose-efficacy relationship data obtained in the proof of concept (PoC) studies in 
Rheumatoid Arthritis (RA) (CAIN457A2101), in Ankylosing Spondylitis (AS) 
(CAIN457A2209) and in PsA (CAIN457A2206) along with data from the RA dose ranging  
trial (CAIN457F2201).  
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Interim analysis of all 42 subjects enrolled in study CAIN457A2206 (dosed with i.v. 
2 x 10mg/kg) who completed Week 6, together with preliminary data from the later time 
points up to Week 16, suggest that a clinically meaningful response is induced as early as 2 
weeks after start of secukinumab treatment, with further improvement up to Week 6 and 
maintenance of response up to Week 16. 
Evidence to support a similar dose-efficacy relationship for secukinumab across the arthritides 
(RA, AS and PsA) is substantiated by existing evidence which indicates a degree of 
commonality in the pathways leading to joint damage in these chronic inflammatory diseases 
and a comparatively similar acute phase response and cytokine profile in the pathogenesis of 
the diseases. In further support of common inflammatory pathways all three conditions are 
responsive to both anti-IL17 and anti-TNFα therapy. 
In the RA PoC study (CAIN457A2101), two doses of secukinumab 10 mg/kg i.v. 
administered at BSL and Week 3, achieved an ACR20 of 46% at Week 6 and 54% at Week 
16 compared to a placebo response of 27% and 31% respectively at these time points. In 
contrast fixed doses of secukinumab administered at BSL and then every 4 weeks at 75, 150 
and 300 mg in the RA Ph II study (CAIN457F2201) achieved an ACR20 of 48%, 40% and 
39% at Week 8 and 50%, 47% and 54% at Week 16. However, placebo responses in this trial 
were 24% at Week 8 and 36% at Week 16. Thus the i.v. regimen employed in the PoC trial 
resulted in a 19% improvement in ACR20 over placebo at Week 6 and 23% at Week 16 
(Figure 3-2). The fixed monthly doses of secukinumab at 75, 150 mg and 300 mg resulted in 
24%, 16% and 15% improvement in ACR20 over placebo at Week 8 and 14%, 11% and 18% 
respectively at Week 16 (Figure 3-2). These data suggest that early high doses of 
secukinumab lead to increased efficacy in the first 8 weeks. Based upon these data currently 
planned Phase III studies in RA will be employing an i.v. loading regimen induction therapy 
with 10 mg/kg secukinumab administered at BSL, 2 and 4 followed by monthly secukinumab 
s.c. at either 75 mg or 150 mg.  
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Figure 3-2 Placebo corrected ACR20 over time comparing two doses of 
secukinumab 10 mg/kg i.v. at BSL and 3 (CAIN457A2101) to fixed s.c. 
doses of secukinumab every 4 weeks (CAIN457F2201) 
 
To define the optimal dose for maintenance ACR, DAS28 and HAQ efficacy parameters were 
considered based on study CAIN457F2201. Data available from this study up to 24 weeks 
indicates that efficacy responses can be maintained or improved with the proposed monthly 
doses of 75 or 150 mg s.c.. 
The efficacy data from the RA study CAIN457F2201 showed that at Week 24 in the overall 
population as originally randomized ACR20 responses were 38 % for 25 mg, 57% for 75 mg, 
58% for 150 mg and 51% for 300 mg. Non-responders in the 25 and 75 mg dose had received 
1 dose of 150mg at Week 20 and non-responders in the 150 mg group had received one dose 
of 300 mg at Week 20. Subjects in the 300 mg cohort remained on 300 mg. Subjects switched 
from placebo to 150 mg after week 16 attained a 56% ACR 20 response by Week 24. These 
data indicate that 25 mg has similar efficacy to placebo and that 75 mg and 150 mg provided 
the best efficacy.  
Both 75 mg and 150 mg s.c. dosed every 4 weeks in maintenance are proposed based on the 
totality of the data from CAIN457F2201 for phase III for the following reasons: 
1) To ensure optimal assessment of efficacy potential for ACR responses using 2 effective s.c. 
doses used in phase II. 
2) To ensure that subjects with increased inflammatory burden (i.e. high CRP) receive 
adequate doses of secukinumab as there is indication that they may require >75 mg. 
3) To assess in a sufficient subject population if subjects with increased body weight require 
higher doses than 75 mg of secukinumab. 
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4) To assess the effect of secukinumab on structural benefit of the two proposed doses to see 
if there is a differential between these doses on this endpoint (to date no joint structure data is 
available for secukinumab). 
5) The availability of longer term safety data for 75, 150 and 300 mg administered s.c. every 4 
weeks (CAIN457F2201, CAIN457C2303). 
3.4 Rationale for choice of comparator 
A placebo arm up to the primary endpoint at Week 24 is included in this study. Due to the 
nature of the disease and the outcome measures used (ACR20 criteria) a placebo arm is 
necessary to obtain reliable efficacy measurements. The continuation of the placebo group up 
to the primary endpoint at Week 24 can be supported from an ethical standpoint. Moreover 
the inclusion of a placebo group is in accordance with health authority guidelines, including 
(FDA 1999/ EMA 2003). 
3.5 Purpose and timing of interim analyses/design adaptations 
An interim analysis will be performed after all subjects have completed Week 52. The 
investigators, site personnel and monitors will continue to remain blinded to the treatment 
each subject received until the end of the trial. The X-Ray and MRI interpretation will be 
performed by an imaging service provider and readers will be blinded to the treatment as well 
as visit information. 
4 Population 
The study population will consist of a representative group of RF and anti-CCP negative 
subjects at least 18 years of age, fulfilling the CASPAR criteria (see Appendix 2) and must 
have active PsA. Subjects included must have active disease despite current or previous 
NSAID, DMARD and / or TNFα inhibitor therapy. 
Concomitant therapy with MTX (≤25 mg/week) will be acceptable, if dose and route of 
administration have been stable for at least four weeks prior to the randomization visit. 
Subjects must have signs of skin manifestations of psoriasis, defined by at least one psoriatic 
plaque of ≥2 cm diameter (but not in armpits, or chest between breasts, or groin) or nail 
changes consistent with psoriasis or a documented history of plaque psoriasis. 
This is a multinational study and it is expected that subjects will be enrolled at approximately 
150 sites. About 750 subjects will be screened for approximately 600 subjects to be 
randomized). 
A screening failure rate of 30 % and post-randomization drop out rates of 20% at 1 year and 
25% at 2 years are anticipated. Enrollment will stop as soon as the target number of 
randomized subjects is reached. 
Subjects may only be re-screened once. 
4.1 Inclusion criteria 
Subjects eligible for inclusion in this study have to fulfill all of the following criteria: 
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1. Subject must be able to understand and communicate with the investigator and be able 
to comply with the requirements of the study and must give a written, signed and dated 
informed consent before any study assessment is performed 
2. Male or non-pregnant, non-lactating female subjects at least 18 years of age 
3. Diagnosis of PsA classified by CASPAR criteria (see Appendix 2) and with symptoms 
for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 
tender joints out of 78 and ≥3 swollen joints out of 76 (dactylitis of a digit counts as 
one joint each) 
4. RF and anti-CCP antibodies negative 
5. Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2 cm 
diameter (but not in intertriginous areas such as armpits, or chest between breasts, or 
groin) or nail changes consistent with psoriasis or a documented history of plaque 
psoriasis 
6. Subjects with PsA should have been on NSAIDs for at least 4 weeks prior to 
randomization with inadequate control of symptoms or intolerant to NSAIDs 
7. Subjects who are regularly taking NSAIDs as part of their PsA therapy are required to 
be on a stable dose for at least 2 weeks before study randomization and should remain 
on a stable dose up to Week 24 
8. Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or 
equivalent for at least 2 weeks before randomization and should remain on a stable 
dose up to Week 24 
9. Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the 
dose is stable for at least 4 weeks before randomization and should remain on a stable 
dose throughout the study  
10. Subjects on MTX must be on folic acid supplementation at randomization 
11. Subjects who are on a DMARD other than MTX must discontinue the DMARD 
28 days prior randomization except for leflunomide, which has to be discontinued for 
8 weeks prior to randomization unless a cholestyramine washout has been performed 
12. Subjects who have been on a TNFα inhibitor must have experienced an inadequate 
response to previous or current treatment with a TNFα inhibitor given at an approved 
dose for at least 3 months or have stopped treatment due to safety/tolerability 
problems after at least one administration of a TNFα inhibitor 
13. Subjects who have previously been treated TNFα inhibitors (investigational or 
approved) will be allowed entry into study after appropriate wash-out period prior to 
randomization: 
a. 4 weeks for Enbrel® (etanercept) – with a terminal half-life of 102 ± 30 hours (s.c. 
route) 
b. 8 weeks or longer for Remicade® (infliximab) – with a terminal half-life of 8.0-9.5 
days (i.v. infusion) 
c. 10 weeks or longer for Humira® (adalimumab) – with a terminal half-life of 10-20 
days (average 2 weeks) (s.c. route) 
d. 10 weeks or longer for Simponi® (golimumab) – with a terminal half-life of 11-14 
days 
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e. 10 weeks or longer for Cimzia® (certolizumab) – with a terminal half-life of 
approx. 14 days 
4.2 Exclusion criteria 
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study: 
1. Subjects taking high potency opioid analgesics (e.g., methadone, hydromorphone, or 
morphine) 
2. Subjects who have ever received biologic immunomodulating agents except for those 
targeting TNFα, investigational or approved  
3. Subjects who have previously been treated with more than 3 different TNFα inhibitors 
(investigational or approved) 
4. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 
or IL-17 receptor  
5. Use of any investigational drug and/or devices within 4 weeks of randomization or 5 
half-lives of the investigational drug, whichever is longer 
6. Ongoing use of prohibited psoriasis treatments / medications (e.g., topical 
corticosteroids, UV therapy) at randomization. The following wash out periods need to 
be observed: 
a. Oral or topical retinoids 4 weeks 
b. Photochemotherapy (e.g. PUVA) 4 weeks 
c. Phototherapy (UVA or UVB) 2 weeks  
d. Topical treatments (except in face, scalp and genital area during screening, only 
corticosteroids with mild to moderate potency) 2 weeks 
6. Any intramuscular or intravenous corticosteroid treatment within 4 weeks before 
randomization 
7. Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before 
randomization 
8. Previous treatment with any cell-depleting therapies including but not limited to anti-
CD20 and investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, 
anti-CD19) 
9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a 
female after conception and until the termination of gestation, confirmed by a positive 
hCG laboratory test  
10. Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, unwilling to use effective contraception during the study and for 
16 weeks after stopping treatment. Effective contraception is defined as either: 
a. Barrier method: Condom or Occlusive cap (diaphragm or cervical/vault caps) with 
spermicides (where available).  
Spermicides alone are not a barrier method of contraception and should not be 
used alone 
The following methods are considered more effective than the barrier method and are 
also acceptable: 
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b. Total abstinence: When this is in line with the preferred and usual lifestyle of the 
subject  [Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception] 
c. Female sterilization: have had a surgical bilateral oophorectomy (with or without 
hysterectomy) or tubal litigation at least six weeks before taking study treatment. 
In case of oophorectomy alone, only when the reproductive status of the woman 
has been confirmed by follow up hormone level assessment 
d. Male partner sterilization. [For female subjects on the study, the vasectomised 
male partner should be the sole partner for that subject] 
e. Use of established oral, injected or implanted hormonal methods of contraception, 
intrauterine device (IUD) or intrauterine system (IUS) 
NOTE: Women are considered post-menopausal and not of child bearing potential if they 
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous 
amenorrhea as defined by the central lab FSH and/or estradiol levels. 
12. Active ongoing inflammatory diseases other than PsA that might confound the evaluation 
of the benefit of secukinumab therapy as judged by the investigator 
13. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, 
infectious or gastrointestinal conditions or the management thereof which in the opinion 
of the investigator places the subject at unacceptable risk for participation in an 
immunomodulatory therapy 
14. Significant medical diseases / problems, including but not limited to the following: 
Uncontrolled hypertension (≥160/95 mmHg), congestive heart failure [New York Heart 
Association status of class III or IV], uncontrolled diabetes, or very poor functional status 
unable to perform self care 
15. History of clinically significant liver disease or liver injury as indicated by abnormal liver 
function tests such as SGOT (AST), SGPT (ALT), alkaline phosphatase, or serum 
bilirubin. The Investigator should be guided by the following criteria: 
a. Any single parameter may not exceed 2 x upper limit of normal (ULN). A single 
parameter elevated up to and including 2 x ULN should be re-checked once more as 
soon as possible, and in all cases, at least prior to randomization, to rule out lab 
error 
b. If the total bilirubin concentration is increased above 2 x ULN, total bilirubin 
should be differentiated into the direct and indirect reacting bilirubin. In any case, 
serum bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L) 
16. History of renal trauma, glomerulonephritis, or subjects with one kidney only, or a 
creatinine level exceeding 1.5 mg/dl (132.6 µmol/L) at screening 
17. Screening total WBC count <3,000/µl, or platelets <100,000/µl or neutrophils <1,500/µl 
or hemoglobin <8.5 g/dl (85 g/L) 
18. Active systemic infections during the last two weeks (exception: common cold) prior to 
randomization 
19. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis 
infection as defined by either a positive PPD skin test (the size of induration will be 
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measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5mm or 
according to local practice/guidelines) or a positive QuantiFERON TB-Gold test as 
indicated in the assessment schedule (see Table 6-1). Subjects with a positive test may 
participate in the study if further work up (according to local practice/guidelines) 
establishes conclusively that the subject has no evidence of active tuberculosis. If presence 
of latent tuberculosis is established then treatment according to local country guidelines 
must have been initiated  
20. Chest X-ray with evidence of ongoing infectious or malignant process, obtained within 3 
months of screening and evaluated by a qualified physician 
21. Known infection with HIV, hepatitis B or hepatitis C at screening or randomization 
22. History of lymphoproliferative disease or any known malignancy or history of malignancy 
of any organ system within the past 5 years (except for basal cell carcinoma or actinic 
keratoses that has been treated with no evidence of recurrence in the past 3 months, 
carcinoma in situ of the cervix or non-invasive malignant, colon polyps that have been 
removed) 
23. Current severe progressive or uncontrolled disease which in the judgment of the clinical 
investigator renders the subject unsuitable for the trial 
24. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability or lack of access to veins) 
25. Any medical or psychiatric condition which, in the Investigator’s opinion, would preclude 
the participant from adhering to the protocol or completing the study per protocol 
26. Donation or loss of 400 mL or more of blood within 8 weeks before dosing 
27. History or evidence of ongoing alcohol or drug abuse, within the last six months before 
randomization 
28. Plans for administration of live vaccines during the study period or 6 weeks prior 
randomization 
No additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible subjects. 
5 Treatment 
5.1 Investigational and control treatment 
The appearance of the lyophilized cake for secukinumab 150 mg Powder for Solution is 
slightly different from secukinumab placebo to 150 mg Powder for Solution.  Also, the caps 
for the vials of secukinumab 150 mg powder and secukinumab placebo are different colors.  
Therefore, in order to maintain the blind in the study, an unblinded pharmacist or unblinded 
qualified site personnel will be appointed at site to prepare the study treatment. 
Novartis will supply the following study treatments: 
Novartis will supply the following study treatments: 
• Investigational Treatment: Secukinumab  
Secukinumab 150 mg Powder for Solution for s.c. injection or i.v. infusion is provided in 
glass vials each containing 150 mg secukinumab as lyophilized cake. Secukinumab 
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150 mg vials are labeled as AIN457 150 mg. The vials contain a 20% overfill to allow a 
complete withdrawal of the labeled amount of secukinumab. The 150 mg Powder for 
Solution is used to prepare both the 75 mg and the 150 mg dose. 
• Reference Therapy: Secukinumab placebo (for s.c. injection):  
Secukinumab placebo to 150 mg Powder for Solution for s.c. injection is provided in glass 
vials as lyophilized cake. Secukinumab placebo vials are labeled as AIN457 placebo. Each 
vial contains a mixture of inactive excipients, matching the composition of the 
secukinumab 150 mg Powder for Solution.  
Reference therapy (Secukinumab placebo for i.v. infusion): 100 mL 0.9% NaCl solution is to 
be used as placebo for i.v. secukinumab, and is to be provided locally. 
The supply will be open label. 
For detailed instructions for storage, handling, reconstitution and administration of all study 
treatments, please refer to the pharmacist manual. 
5.2 Treatment arms 
At baseline, eligible subjects will be randomized to one of the following 3 treatment arms in a 
ratio of 1:1:1: 
• Group 1: Secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4, then secukinumab 75 mg 
s.c. starting at Week 8 and injected every 4 weeks 
• Group 2: Secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4, then secukinumab 150 mg 
s.c. starting at Week 8 and injected every 4 weeks 
• Group 3: Placebo i.v. at BSL, Weeks 2 and 4, then placebo s.c. starting at Week 8 and 
Week 12. 
At Week 16 (Visit 8), subjects will be classified as responders (≥20% improvement from 
baseline in both tender and swollen joint counts) or non-responders. Subjects who were 
randomized to placebo at baseline will be re-randomized by the Interactive Response 
Technology (IRT) to receive double blind treatment up to two years, as follows (see Figure 3-
1): 
• Subjects on placebo (Group 3) who are responders will be re-randomized (1:1) to receive 
either secukinumab 75 or 150 mg every 4 weeks, regardless of responder status.  
• Subjects on placebo (Group 3) who are non-responders will be re-randomized (1:1) at 
Week 16 to receive either secukinumab 75 mg or 150 mg s.c. every 4 weeks. 
5.3 Treatment assignment 
At baseline (Visit 2), all eligible subjects will be randomized via the Interactive Response 
Technology (IRT) to one of the treatment arms. The IRT can be contacted via the Interactive 
Voice Response System (IVRS) or interactive web response system (IWRS). The investigator 
or his/her delegate will contact the IRT after confirming that the subject fulfills all the 
inclusion criteria and does not fulfill any exclusion criterion.  The IRT will assign a 
randomization number to the subject, which will be used to link the subject to a treatment arm 
and will specify unique medication numbers for the first packages of study treatment to be 
prepared for the subject. The unique medication number will be communicated to the 
This document (090095a88362b521 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 5/12/2011 2:47:40 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by Ambs Petra in Basel at Thu, May 12, 2011 16:41:36 CEST
Novartis Confidential Page 28 
Clinical Trial Protocol  Protocol No. CAIN457F2306 
 
unblinded pharmacist or unblinded qualified site personnel. The randomization number will 
not be communicated to any of the site staff including the unblinded pharmacist or unblinded 
qualified site personnel. However, the unblinded pharmacist/unblinded qualified site 
personnel will know what treatment the subject is receiving due to the open-label packaging 
of the study treatments and the fact that he/she will prepare the study medication to be 
administered to the subject by the blinded site personnel.  
At Visit 8 (Week 16), the IRT will also ask for the subject’s responder status (responder/non-
responder).  The IRT will not generate the medication number of the vial(s) to be 
administered for Week 16 if the subject’s responder status is missing. IRT will only 
communicate to the caller the medication numbers, not the randomization number.  
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A 
subject randomization list will be produced by the IRT provider using a validated system that 
automates the random assignment of subject numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by or under the 
responsibility of Novartis Drug Supply Management using a validated system that automates 
the sequential assignment of medication numbers to study treatment packs containing each of 
the study treatments.  
Randomization will be stratified according to being either TNFα IR or TNFα inhibitor naïve 
subjects. 30% of subjects should be TNFα inhibitor IR to ensure a representative subject 
population for the assessment of efficacy and safety. It is planned to randomize approximately 
180 TNFα inhibitor IR subjects and 420 TNFα inhibitor naïve subjects. 
The randomization scheme for subjects will be reviewed and approved by a member of the 
Novartis Audit Readiness, Validation and Randomization Group within IIS IA&R (Integrated 
Information Science Integrated Analytics and Reporting). 
5.4 Treatment blinding 
This is a double-blind, randomized treatment trial. Subjects, investigator staff (with the 
exception of the unblinded pharmacist), persons performing the assessments, and data 
analysts will remain blinded to the identity of the treatment from the time of randomization 
until database lock, using the following methods: (1) Randomization data are kept strictly 
confidential until the time of unblinding, and will not be accessible by anyone else involved in 
the study with the exception of the bioanalyst, the Novartis unblinded monitors and for the 
preparation of the study medication, an independent, unblinded pharmacist/nurse/physician or 
authorized personnel at the investigator’s site who will prepare the study medication for 
subjects. (2) The identity of the secukinumab/placebo treatments will be concealed by the use 
of study treatments in form of syringes or i.v. infusion bags filled with reconstituted 
secukinumab/placebo solutions that are identical in appearance, but the actual secukinumab or 
placebo vials with lyophilisate will be supplied “open-label.” 
The independent, unblinded pharmacist/nurse/physician or authorized personnel will make 
sure that no other person will have access to the medication and drug administration 
documentation. 
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The bioanalyst will have access to the randomization list to facilitate analysis of the PK/PD 
and immunogenicity samples (i.e. to avoid the unnecessary analysis of placebo samples). 
Whenever needed or requested by the clinical team, the bioanalyst will share information 
from PK measurements before clinical database lock in a blinded fashion with the 
pharmacokineticist.  
The independent, unblinded pharmacist/nurse/physician or authorized personnel will contact 
the IRT after randomization to receive the treatment assignment information. He/she will then 
prepare the study treatment. The independent, unblinded pharmacist/nurse/physician or 
authorized personnel will contact the IRT again at each visit between V4 and V29 to get the 
treatment assignment information for the subject. 
The X-Ray and MRI interpretations performed by central Imaging CRO personnel will not be 
disclosed to investigators, site personnel, subjects and monitors during the trial. 
An interim analysis will be performed at Week 52. A selected Novartis clinical team will be 
unblinded to the Week 52 results. Summary results may be shared internally and externally, 
however individual unblinded subject data will not be disclosed. A final database lock will 
occur when all subjects have completed the study. 
Unblinding will only occur in the case of subject emergencies (see Section 5.5.10). 
5.5 Treating the subject 
5.5.1 Subject numbering 
Each subject is uniquely identified in the study by a combination of his/her center number and 
subject number. The center number is assigned by Novartis to the investigative site. After the 
subject has signed the ICF, the investigator or his/her staff will contact the IRT and provide 
the requested identifying information for the subject. At each site, the first subject is assigned 
subject number 1, and subsequent subjects are assigned consecutive numbers (e.g. the second 
subject is assigned subject number 2, the third subject is assigned subject number 3). Once 
assigned to a subject, a subject number will not be reused. If the subject fails to be 
randomized for any reason, the IRT must be notified within 2 days and the reason for not 
being randomized will be entered on the Screening Phase Disposition Form. The appropriate 
eCRF(s) should also be completed 
Subjects who are re-screened will keep their originally assigned subject number in all 
systems. Subjects can only be re-screened once. 
 
5.5.2 Dispensing the study treatment 
At each visit that drug is dispensed, an independent, unblinded pharmacist/nurse/physician or 
authorized personnel will identify the study treatment vials to administer to the subject by 
interacting with the IRT and obtaining the medication numbers for the s.c. injection or 
infusion. The unblinded pharmacist/nurse/physician or authorized personnel may contact the 
IRT to review the treatment assignment of a subject at any time. 
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Immediately before preparing the drug for administration to the subject, the unblinded 
pharmacist/nurse/physician or authorized personnel will document which drug has been 
prepared in the source documents, Pharmacist Log, Drug Preparation Form for Unblinded 
Personnel, Pharmacist Drug Dispensing Form, containing that subject’s unique subject 
number. 
The study medication packaging has a 2-part label. A unique medication number is printed on 
each part of this label which corresponds to a vial to be used (active or placebo). Immediately 
before preparation of the study medication, the unblinded pharmacist/nurse/physician or 
authorized site personnel will detach the outer part of the label from the packaging and affix it 
to the source document (Drug Label Form) for that subject’s unique subject number. 
5.5.3 Supply, storage and tracking of study treatment 
Study treatment will be supplied to each study site by Novartis as open labeled bulk 
medication. 
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly, and kept in a secured location to which only the unblinded 
pharmacist/nurse/physician or authorized personnel has access. Upon receipt, all study 
treatment should be stored according to the instructions specified on the drug labels. Clinical 
supplies are to be dispensed and administered only in accordance with the protocol. 
Secukinumab lyophilisate (150 mg active/placebo) must be stored in a locked refrigerator at 
2-8°C and must be carefully controlled in accordance with regulations governing 
investigational medicinal products and local regulations. 
Medication labels will be in the local language and comply with the legal requirements of 
each country. They will include storage conditions for the drug, but no information about the 
subject except for the medication number. 
The unblinded pharmacist/nurse/physician or authorized personnel must maintain an accurate 
record of the shipment and dispensing of study treatment in a drug accountability log. 
Monitoring of drug accountability will be performed by the field monitor during site visits and 
at the completion of the trial.  
At the conclusion of the study, and as appropriate during the course of the study, the 
pharmacist will return all used, partly used and unused study treatment, packaging, drug 
labels, as well as the empty vials and a copy of the completed drug accountability log to the 
Novartis monitor or to the Novartis address provided in the investigator folder at each site. 
Destruction of the unused drug should be done according to local requirements and after 
approval Novartis by clinical team. 
5.5.4 Instructions for prescribing and taking study treatment 
Study treatment will be administered s.c. or by i.v. infusion throughout the study. Dose levels 
of 10 mg/kg for i.v. and either 75 mg or 150 mg s.c. of secukinumab or placebo will be 
administered. 
Before administration to the subject, the study medication will have to be prepared by an 
unblinded pharmacist/nurse/physician or authorized site personnel appointed at the study site. 
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The syringes or infusion bags with the ready-to-use study medication solution prepared will 
be provided by the unblinded pharmacist/nurse/physician or authorized personnel to the 
investigator or assigned site staff, who will inject or infuse the subject during the study visit. 
Detailed instructions on the preparation and administration of the study treatment will be 
described in the Pharmacist Manual and provided to each site. 
Dosing should occur in the morning in order to coordinate sample collection times for PK 
assessments (see Section 6.6.3). Subjects should remain at the study site for observation for 1 
hour following study treatment administration. 
The first study treatment administration will occur at BSL (Visit 2) after all study scheduled 
assessments have been performed (and inclusion/exclusion criteria confirmed) and only after 
the scheduled blood samples have been drawn.  
At BSL, Week 2 and Week 4 subjects will receive study medication i.v. starting at Week 8 
subjects will receive study medication as s.c. injections every 4 weeks. 
At study visits when pre-dose blood samples have to be drawn (Table 6-1), the study 
medication will be injected to the subject only after the blood samples have been taken. 
At Week 1 (Visit3), Week 104 (visit 30) and during the follow-up period (Visit F112), no 
study treatment will be administered.  
All study treatments assigned to the subject during the study will be recorded in the IRT. 
The subject should be instructed to contact the investigator if he/she is unable for any reason 
to attend the study visit as scheduled. 
All dates and times of injections and infusions administered to the subject during the study 
must be recorded on the Dosage administration record eCRF. All injections and infusions 
prepared by the pharmacist should be documented in the Source Documents for Pharmacy 
Drug Handling. 
5.5.4.1 Preparation of secukinumab solution and secukinumab placebo 
solution for s.c. injection or infusion 
The vials containing the lyophilisate will be appropriately diluted in order to attain the correct 
dosage. For full details, refer to the Pharmacist Manual. 
5.5.4.2 Administration 
For i.v. administration 
Secukinumab active/placebo should be administered i.v. using only the materials (infusion 
bags, infusion lines and in-line filter) specified in writing by the sponsor and as outlined in the 
pharmacist manual. 
The entire diluted secukinumab solution in 100 mL of 0.9% NaCl solution or 100 mL of 0.9% 
NaCl solution for placebo doses should be administered (please see pharmacist manual for 
details of administration).  
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For s.c. administration 
Secukinumab active/placebo should be administered using a 27Gx0.5`` needle (1 injection of 
1 mL per visit) as outlined in the pharmacist manual. 
The investigator or designee should administer the study medication by rotating body sites 
(thighs, arms and abdomen).  
5.5.4.3 After reconstitution 
From a microbiological point of view, the secukinumab Solution and secukinumab Placebo 
Solution for s.c. injection or for i.v. infusion, either reconstituted lyophilisate in vial, infusion 
bag or into the administration syringe, should be used immediately. 
If study treatment preparation has been performed under aseptic conditions, the secukinumab 
Solution and secukinumab Placebo Solution for s.c. injection or for infusion might be stored 
at 2-8°C for no longer than 24 hours. The standing time of 24 hours is defined as the time 
from the first lyophilisate vial has been pierced until end of s.c. injection or infusion. If the 
solution is not used within 15 minutes after preparation, it should be kept at 2 - 8 °C, and 
allowed to come to room temperature for at least 5 to10 minutes before administration. 
Chemical and physical in-use stability of the secukinumab Solution and secukinumab Placebo 
Solution for s.c. injection or infusion, either reconstituted lyophilisate in vial, infusion bag or 
administration syringe, has been demonstrated for up to 24 hours at 2 to 8°C.  
Any unused product or waste material should be disposed of in accordance with local 
requirements. 
5.5.5 Permitted dose adjustments and interruptions of study treatment 
Study treatment dose adjustments are not permitted. Study treatment interruption is also not 
permitted with the following exceptions: 
Study treatment interruption is permitted if a subject in the opinion of the investigator 
develops a serious infection. In such a case study treatment must be interrupted until the 
infection is controlled. Study treatment can be started again at the next scheduled visit after 
resolution of the infection at the discretion of the investigator regardless of concomitant 
antibiotic treatment. 
Study treatment may also be temporarily interrupted for surgical procedures but only in 
consultation with the Novartis study team. 
Live vaccines must not be administered during the first 24 weeks of participation in the study. 
After Week 24 live vaccines should also not be administered until 12 weeks after the last dose 
of study treatment. In case a live vaccine has been administered due to a medical urgency after 
completion of 24 weeks, study treatment should be interrupted for at least 12 weeks. 
Any study treatment interruption must be recorded on the corresponding eCRF(s). 
5.5.6 Rescue treatment 
Rescue medication must not be used before completion of Visit 10 (Week 24). Please see 
Sections 5.5.7 and Section 5.5.8 for details. 
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Any use of rescue medication must be recorded on the corresponding Concomitant 
Medications eCRF. 
5.5.7 Concomitant treatment 
The investigator should instruct the subject to notify the study site about any new medications 
(including over-the-counter drugs, calcium and vitamins) he/she takes after the start of the 
study treatment. All medications (other than study treatment) and significant non-drug 
therapies (including physical therapy and blood transfusions) administered after the subject 
starts treatment with study treatment must be listed on the corresponding eCRF. The reason 
and the name of the drug should be listed. 
Guidelines for the use of specific medications are provided below: 
Methotrexate 
Subjects on MTX have to be treated with stable treatment of MTX (≤25 mg/week) for at least 
4 weeks before randomization and maintained stable throughout the treatment period.  
Folic acid  
Subjects on MTX must be taking folic acid supplementation before randomization and during 
the trial to minimize the likelihood of MTX associated toxicity. Folic acid supplementation 
should not be taken on the same day than MTX intake. 
Leflunomide wash-out with cholestyramine 
In case of leflunomide treatment, a drug wash-out of 8 weeks has to be performed. However, 
another wash-out procedure might be considered. Cholestyramine could be given orally to 
wash-out the drug at a dose of 8 g t.i.d. Cholestyramine reduced plasma levels of the active 
leflunomide metabolite by approximately 40 % in 24 hours and by 49 % to 65 % in 48 hours 
in three healthy volunteers. The administration of cholestyramine is recommended in subjects 
who require a drug elimination procedure. If a subject receives the therapy of 8 g t.i.d. for 11 
days, he/she could be safely randomized 4 weeks after completion of this 11-day therapeutic 
period. 
Systemic corticosteroids 
Treatment with systemic corticosteroids will be allowed if the dose was stable for at least 4 
weeks before randomization and maintained stable throughout the study period. A maximum 
dosage of 10 mg equivalent of daily prednisone will be allowed. 
Corticosteroid dose reductions are permitted after Week 16. However, for any dose reductions 
after Week 16, the corticosteroid dose should not be reduced more than 1 mg prednisone 
equivalent every 4 weeks. 
Intra-articular corticosteroids are not permitted within 4 weeks prior to baseline and up to 
week 24. After week 24, no more than 1 joint per 24-week period may be injected. No single 
injection should exceed 40 mg of triamcinolone (or equivalent) and the total dose of intra-
articular corticosteroid may not exceed 80 mg of triamcinolone (or equivalent) during any 52-
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week period. Injection of intra-articular steroids is not permitted within 8 weeks prior to 
Weeks 24, 52, and 104. 
However, any change in the dose of oral corticosteroids during the trial should be recorded on 
the corresponding eCRF. 
Non-steroidal anti-inflammatory drugs (NSAIDs) (COX-1 or COX-2 inhibitors), 
low strength opioids and acetaminophen/paracetamol 
Subjects on regular use of NSAIDs or paracetamol/acetaminophen should be on stable dose 
for at least 4 weeks before randomization to allow inclusion and during the treatment period. 
Subjects taking NSAIDs, low strength opioids, or paracetamol/acetaminophen PRN within the 
4 weeks before randomization can continue to do so in the study, however, they have to 
refrain from any intake during at least 24 hours before a visit with disease activity assessment. 
However, any change of the NSAIDs, opioids, or paracetamol/acetaminophen treatment 
during the trial should be recorded on the corresponding eCRF. 
5.5.8 Prohibited treatment 
Use of the treatments listed in Table 5-1 is NOT allowed after the start of the washout period. 
Live vaccines should not be given until 12 weeks after last study treatment administration. 
Table 5-1 Prohibited treatment 
Prohibited treatments Washout period   
(before randomization)
Biological immunomodulating agents ≥ 3 different TNFα 
inhibitors 
Never 
Etanercept 
Infliximab 
Adalimumab, golimumab, certolizumab 
 
 
4 weeks 
8 weeks 
10 weeks 
Unstable dose of MTX 4 weeks 
Other DMARD (except MTX) 4 weeks  
Leflunomide  8 weeks  
Leflunomide with Cholestyramine washout 4 weeks 
Unstable dose of NSAIDs (COX1 or COX2 inhibitors) 4 weeks 
Systemic corticosteroids ≥ 10 mg prednisone equivalent  4 weeks  
Intra-articular steroid  injections up to Week 24 4 weeks 
Oral or topical retinoids 4 weeks 
Photochemotherapy (e.g. PUVA) 4 weeks 
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Prohibited treatments Washout period   
(before randomization)
Phototherapy (UVA or UVB) 2 weeks 
Topical treatments (except in face, scalp and genital area 
during screening, only corticosteroids with mild to moderate 
potency) 
2 weeks 
Any investigational treatment or participation in any 
interventional trial 
4 weeks or 5 half-lives 
(whichever is longer)  
Analgesics other than paracetamol/acetaminophen and low 
strength opioids PRN 
4 weeks 
Live vaccinations up to Week 24 6 weeks 
 
5.5.9 Discontinuation of study treatment and premature subject withdrawal 
Study treatment must be discontinued and the subject withdrawn from the trial if the 
investigator determines that continuing it would result in a significant safety risk for that 
subject. The following circumstances require study treatment discontinuation: 
• Withdrawal of informed consent 
• Emergence of the following adverse events: 
• Any severe or serious adverse event that is not compatible with administration of 
study treatment, including adverse events that require treatment with an unacceptable 
co-medication up to Week 24 
• Onset of lymphoproliferative disease or any malignancy except for treated basal cell 
carcinoma, treated actinic keratoses, treated in situ carcinoma of the cervix or non-
invasive malignant colon polyps which are being or have been removed. 
• Life threatening infection 
• Administration of a live vaccine up to Week 24 
• Any of the following laboratory abnormalities (based on recommendations by CTEP 
(Cancer Therapy Evaluation Program, National Institute of Health)): 
• AST or ALT value >5 x ULN 
Note:  For an AST or ALT value between >3 x ULN and ≤5 x ULN, the test should 
be repeated within 2 weeks. Subjects with a value greater than or equal to 
the previous one at repeat testing should be discontinued. 
• Hemoglobin value <85 g/L (8.5 g/dL) and decreased by at least 20 g/L (2 g/dL) from 
screening 
• Creatinine value >2 x ULN 
• Pregnancy 
• Use of the following medication(s): 
• Any biologic immunomodulating agent except secukinumab 
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• Any other protocol deviation that results in a significant risk to the subject’s safety 
In case of undue safety risk for the subject, the subject should discontinue study treatment at 
the discretion of the investigator.  
In addition to these requirements for study treatment discontinuation, the investigator should 
discontinue study treatment for a given subject if, on balance, he/she thinks that continuation 
would be detrimental to the subject’s well-being. 
Subjects who discontinue study treatment should not be considered withdrawn from the study. 
A Study treatment Discontinuation form should be completed, giving the date and primary 
reason for stopping study treatment. For subjects remaining in the trial, all Week 52 
assessments must be performed on the day of study treatment discontinuation or as early as 
possible after study treatment discontinuation; all subsequent visits will be performed 
according to the assessment schedule (Table 6-1).  
The appropriate personnel from the site and Novartis will assess whether study treatment 
should be discontinued for any subject whose treatment code has been broken inadvertently 
for any reason. 
The investigator must also contact the IRT to register the subject’s discontinuation from study 
treatment. 
Subjects may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they state an intention to withdraw, or fail to return for visits, or 
become lost to follow up for any other reason. 
If premature withdrawal occurs for any reason, the investigator must determine the primary 
reason for a subject’s premature withdrawal from the study and record this information on the 
Study completion eCRF.  
The investigator should ensure that the subject returns for an end of study visit (week 104) 4 
weeks after last study treatment, and a follow-up visit (F112) 12 weeks after last study 
treatment. Even if the subject is not willing to come back for all assessments, every effort 
should be made to collect the scheduled X-ray assessments. 
For subjects who are lost to follow-up (i.e. those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), the investigator should 
show "due diligence" by documenting in the source documents steps taken to contact the 
subject, e.g. dates of telephone calls, registered letters, etc. 
Subjects who are prematurely withdrawn from the study will not be replaced. 
5.5.10 Emergency unblinding of treatment assignment 
Emergency unblinding should only be undertaken when it is essential to treat the subject 
safely and efficaciously. Most often, study treatment discontinuation and knowledge of the 
possible treatment assignments are sufficient to treat a study subject who presents with an 
emergency condition. Emergency code breaks are performed using the IRT. When the 
investigator contacts the system to unblind a subject, he/she must provide the requested 
subject identifying information and confirm the necessity to unblind the subject. The 
investigator will then receive details of the study treatment for the specified subject and a fax 
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or email confirming this information. The system will automatically inform the Novartis 
monitor for the site and the Clinical Trial Head that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the IRT in case of emergency. The investigator will inform the subject how to contact 
his/her backup in cases of emergency when he/she is unavailable. The investigator will 
provide protocol number, study treatment name if available, subject number, and instructions 
for contacting the local Novartis CPO (or any entity to which it has delegated responsibility 
for emergency code breaks) to the subject in case emergency unblinding is required at a time 
when the investigator and backup are unavailable. 
Study treatment must be discontinued after emergency unblinding. 
5.5.11 Study completion and post-study treatment 
A subject will be considered to have completed the study if he/she received a maximum of 
100 weeks of study treatment and upon completion of all the scheduled study assessments and 
procedures up to and including Week 112. 
Information on the subject’s completion or discontinuation of the study and the reason for 
discontinuation of the study will be recorded on the appropriate Study Phase Completion 
eCRF page. 
Study Completion evaluations must also be performed when a subject prematurely withdraws 
from the study for whatever reason. 
The investigator must provide follow-up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care. This care may 
include initiating another treatment outside of the study as deemed appropriate by the 
investigator. This treatment may be any non-biologic DMARD. In case of a biologic 
treatment, a waiting period of 3 months is recommended before initiating the treatment. 
5.5.12 Early study termination 
The study can be terminated at any time for any reason by Novartis. Should this be necessary, 
the subject should be seen as soon as possible and treated as described in Section 6 for a 
prematurely withdrawn subject. The investigator may be informed of additional procedures to 
be followed in order to ensure that adequate consideration is given to the protection of the 
subject’s interests. The investigator will be responsible for informing IRBs and/or ECs of the 
early termination of the trial. 
6 Visit schedule and assessments 
Table 6-1 lists all of the assessments and indicates with an “X” the visits when they are 
performed. 
Subjects should be seen for all visits on the designated day or as closely as possible to the 
original planned visit schedule. For all infusion visits (Visits 2, 4 and 5), study treatment 
should not be administered within less than 1 week after the previous infusion. Starting at 
Visit 6 (Week 8), subjects should not receive study treatment within less than 2 weeks after 
the previous administration. 
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Table 6-1 Assessment schedule 
 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128  
Week ≤-4  BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Informed consent / 
optional PG informed 
consent 
X                              
 
Inclusion/Exclusion 
criteria 
X X                             
 
Relevant medical history/ 
current medical condition 
X                              
 
Cardiovascular medical 
history 
 X                             
 
Psoriasis/psoriatic arthritis 
medical history and 
previous 
psoriasis/psoriatic arthritis 
therapies 
X X                             
 
Smoking history  X                              
Demography X                               
Physical Exam1 X X X X X X X X X X X X X X X X X  X  X  X  X  X  X X X 
Height X                               
Weight X X        X       X        X     X X 
Vital signs X X X X X X X X X X X X X X X X X  X  X  X  X  X  X X X 
PPD skin test2 or 
QuantiFERON TB-Gold 
test 
X                              
 
Rheumatoid factor (RF) X                               
Anti-CCP antibodies X         X       X             X  
Chest X-ray3 X                               
ECG (central)  X      X         X             X  
Randomization  X      X4  X4                      
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 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128  
Week ≤-4  BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Administration of i.v. 
study treatment 
 X  X X                          
 
Administration of s.c. 
study treatment 
     X X X X X X X X X X X X X X X X X X X X X X X X  
 
Prior medication X X                              
Hematology, blood 
chemistry, local urinalysis 
X X X X X X X X X X X X  X   X  X  X  X  X  X   X X 
Serum pregnancy test X                               
Urine pregnancy test  X   X  X X  X  X  X   X  X  X  X  X  X   X X 
Con medication/non drug 
therapy  
 Update as necessary throughout the study 
Adverse Events/SAE5 
(including injection site 
reaction & infections) 
 Update as necessary throughout the study 
MRI (swollen hand/wrist; 
TNF-naïve subjects 
only)12  
 X     X   X                     
 
X-Ray (hands/wrists + 
feet)6 
 X      X9  X10       X             X11 
 
ANA  X        X       X             X  
Anti-dsDNA  X        X       X             X  
Immunogenicity  X        X       X             X X 
PK assessments (at 
predose) 
 X   X   X  X       X             X X 
Tender & Swollen joint 
counts (TSJ78 / SJC76) 
X X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
Patient’s assessment of PsA 
pain (VAS scale)  
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
Patient’s global 
assessment of disease 
activity (VAS scale) 
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
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 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128  
Week ≤-4  BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Physician’s global 
assessment of disease 
activity (VAS scale) 
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
Health Assessment 
Questionnaire (HAQ-DI) 
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
High sensitivity C-
Reactive protein (hsCRP) 
X X X X X X X X X X X X X X X X X  X  X  X  X  X   X X 
Erythrocyte 
Sedimentation Rate (ESR) 
X X X X X X X X X X X X X X X X X  X  X  X  X  X   X X 
Leeds Dactylitis Index X X  X X X X X  X  X  X   X  X  X  X  X  X   X  
Leeds Enthesitis Index X X  X X X X X  X  X  X   X  X  X  X  X  X   X  
PASI (only if  > 3% of 
BSA at BSL) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
IGA (only if  > 3% of 
BSA at BSL) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
Target Lesion Score 
(TLS; only if target lesion 
with > 2cm diameter) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
mNAPSI (only in patients 
with nail involvement) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
WPAI-GH v2  X      X  X       X             X  
SF-36 Acute Form v2   X   X X X X  X       X             X  
FACIT-Fatigue v4  X   X X X X  X       X             X  
PsAQoL  X   X X X X  X       X             X  
EQ-5D v3L  X   X X X X  X       X             X  
DLQI (only if  > 3% of 
BSA at BSL) 
 X   X X X X  X       X             X  
Lipids6  X    X  X  X       X      X       X  
Cardiovascular panel  X      X  X       X             X  
Serum biomarkers related 
to targeted pathway 
 X        X       X             X 
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 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128  
Week ≤-4  BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Pharmacogenetics7  X                              
Treatment Period 1 
Completion Form 
                X              
 
Treatment Period 2 
Completion Form 
                             X 
 
Follow-up period 
Completion Form 
                              
X 
1These assessments are source documentation only and will not be entered into the eCRF 
2 The PPD skin test can be performed at any time during the screening period but it has to be read within 72 hrs and before randomization 
3 A chest X-ray is required if it was not performed and evaluated within 3 months before screening 
4 Subjects will be re-assigned/re-randomized new treatment according to their response and to the treatment they were randomized to at visit 2 
5 AEs/SAEs occurring after the subject has provided informed consent must be reported 
6 Samples must be obtained fasting 
7 Pharmacogenetic sample should only be collected after separate Informed Consent Form (ICF) is signed 
8 Follow-up visit to be done 12 weeks after last study treatment administration for subjects who terminated the study early or for subjects who completed the study but do not enter the 
extension study 
9 X-rays only taken for subjects who are non-responder at Week 16 (not achieving a 20% reduction in both, TJC and SJC) 
10 X-rays only taken for subjects who are responder at Week 16 (achieving a 20% reduction in both, TJC and SJC) 
11 Subjects who discontinue will have their X-rays taken only if more than 60 days have elapsed since their last X-rays 
12 Subjects who undergo the MRI assessments need to be TNFα inhibitor naïve and should have a swollen wrist at baseline; the more swollen wrist should be scanned; if both hands are 
equally swollen, the dominant hand should be scanned 
13 In case of premature discontinuation, assessments to be done as soon as possible 
.
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6.1 Information to be collected on screening failures 
Subjects may discontinue from the study prior to. Those subjects are considered screening 
failures. 
If a subject discontinues before entering the double-blind treatment period at BSL, IRT must 
be notified within 2 days and the reason for not being randomized will be entered on the 
Screening Phase Disposition eCRF. In addition only the following eCRFs should be 
completed: Demography eCRF, Informed Consent eCRF, Inclusion/Exclusion eCRF, and the 
AE eCRF should be completed for any SAEs that occurred during the screening period. 
6.2 Demographics/other baseline characteristics 
Subject demographic and baseline characteristic data to be collected on all subjects and 
recorded in the eCRF include: 
• Date of birth, age, sex, race, ethnicity and source of subject referral 
• Relevant PsA/Psoriasis and general medical history/current medical condition data 
until the start of study treatment , such as date of diagnosis of PsA/Psoriasis, previous 
PsA/Psoriasis therapies with the status of TNFα inhibitor naïve or IR, cardiovascular 
medical history, and smoking history 
Whenever possible, diagnoses and not symptoms will be recorded. 
6.3 Treatment exposure and compliance 
All dates and times of study treatment administration will be recorded on the appropriate 
Dosage Administration Record eCRF. 
Drugs administered prior to start of treatment and other drugs continuing or started during the 
study treatment period will be entered in the Prior/Concomitant medications/significant non-
drug therapies eCRF. Compliance is expected to be 100% (unless temporary interruption is 
needed for safety reasons as described in Section 5.5.5) since study treatment will be 
administered by the investigator or site staff. Compliance will also be assessed by a Novartis 
monitor using vial counts and information provided by the unblinded 
pharmacist/nurse/physician or authorized site personnel 
6.4 Efficacy 
• ACR 20, 50 and 70 response (incl. Major Clinical Response) 
• PsARC response 
• Disease Activity Score (DAS28) and EULAR response criteria 
• HAQ-DI© 
• Leeds Enthesitis Index (LEI) 
• Leeds Dactylitis Index (LDI) 
• Progression of  structural damage by X-ray (hands/wrists and feet) – van der Heijde 
modified total Sharp score and subscores (erosion and joint space narrowing score) 
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• MRI of hand/wrist (in a subgroup of TNFα inhibitor naïve subjects at selected clinical 
sites only) 
• Psoriasis Area and Severity Index (PASI) 
• IGA (mod 2011) 
• Target lesion Score 
• Modified Nail Psoriasis Severity Index (mNAPSI) 
• Swollen Joint Count (SJC)/Tender Joint Count (TJC) 
• Patient’s assessment of pain intensity (VAS scale) 
• Patient’s global assessment of disease activity (VAS scale) 
• Physician’s global assessment of disease activity (VAS scale) 
• Erythrocyte Sedimentation Rate (ESR) and high sensitivity C-Reactive Protein (hsCRP) 
6.4.1 American College of Rheumatology (ACR) response 
The primary efficacy variable is the clinical response to treatment according to ACR20 
individual improvement in disease activity at Week 24. A subject is defined as an ACR20 
responder if, and only if, the following three conditions hold (See Appendix 3): 
1. they have a ≥ 20% improvement in the number of tender joints (based on 78 joints) 
2. they have a ≥ 20% improvement in the number of swollen joints (based on 76 joints) 
3. they have a ≥ 20% improvement in three of the following five domains 
• Patient Global Assessment (measured on a VAS scale, 0-100) 
• Physician Global Assessment (measured on a VAS scale, 0-100) 
• Patient’s assessment of PsA pain (measured on a VAS scale, 0-100) 
• Disability (HAQ-DI© score) 
• Acute phase reactant (hsCRP or ESR)  
Additionally, Major Clinical Response (continuous six-month period of ACR70 response) 
will be assessed as a key secondary objective at week 52 
6.4.1.1 Tender 78 joint count and swollen 76 joint count 
Joint counts will be performed at scheduled visits as indicated in Table 6-1, by the 
independent assessor(s) who must be well trained and part of the site personnel. Whenever 
possible, the same evaluator should perform these assessments at all visits. 
The 78 joints assessed for tenderness include the 2 temporomandibular, 2 sternoclavicular, 2 
acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 2 first carpometacarpal, 10 
metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 
the 2 hip, 2 knee, 2 talo-tibial, 2 mid-tarsal, 10 metatarsophalangeal, 10 proximal 
interphalangeal, and 8 distal interphalangeal joints of the feet. All of these except for the hips 
are assessed for swelling. Joint tenderness and swelling are to be graded present (1) or absent 
(0). Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive 
result for swollen joint count. Dactylitis of a digit in the foot or hand counts as one tender and 
swollen joint.  
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Data is recorded for tender and swollen joints (right or left side), i.e. a box (no, yes or not 
applicable) needs to be ticked for all joints. The total number of tender and swollen joints 
(right and left) will be automatically calculated in the eCRF. 
6.4.1.2 Patient’s assessment of PsA pain intensity 
The patient’s assessment of pain will be performed using 100 mm visual analog scale (VAS) 
ranging from “no pain” to “unbearable pain” after the question “Please indicate with a 
vertical mark ( | ) through the horizontal line the most pain you had from your psoriatic 
arthritis today”. 
6.4.1.3 Patient’s global assessment of disease activity 
The patient’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from ”very good” to ”very poor”, after the question "Considering all the ways 
psoriatic arthritis affects you, please indicate with a vertical mark ( | ) through the horizontal 
line how well you are doing today”.  
6.4.1.4 Physician’s global assessment of disease activity 
The physician’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from no disease activity to maximal disease activity, after the question "Considering 
all the ways the disease affects your patient, draw a line on the scale for how well his or her 
condition is today”. To enhance objectivity, the physician must not be aware of the specific 
patient’s global assessment of disease activity, when performing his own assessment on that 
patient. 
6.4.1.5 HAQ-DI 
The HAQ-DI is a key secondary efficacy endpoint for this study. The HAQ-DI© was 
developed by Stanford University and is one of the most widely used measures to assess the 
long-term influence of chronic disease on a subject's level of functional ability and activity 
restriction. The disability assessment component of the HAQ, the HAQ-DI, assesses a 
subject's level of functional ability and includes questions of fine movements of the upper 
extremity, locomotor activities of the lower extremity, and activities that involve both upper 
and lower extremities. There are 20 questions in eight categories of functioning including 
dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each 
item asks over the past week "Are you able to …" perform a particular task. Each item is 
scored on a 4-point scale from 0 to 3, representing normal (normal, no difficulty [0]), some 
difficulty (1), much difficulty (2), and unable to do (3).  
The purpose of the HAQ-DI in this study is to assess the functional ability of subjects with 
PsA. 
Patient reported outcomes (PROs) will be collected using the digital pen technology. Details 
relating to the administration of all PROs are provided in Appendix 9. 
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6.4.1.6  High Sensitivity C-reactive protein (hsCRP) 
Blood for this assessment will be obtained in order to identify the presence of inflammation, 
to determine its severity, and to monitor response to treatment. 
Since the results of this test may unblind study personnel, results from the central lab will be 
provided for screening and baseline only. The hsCRP results from samples collected during 
the treatment period will be revealed following database lock only. 
6.4.1.7 Erythrocyte sedimentation rate (ESR) 
Blood for ESR, which is helpful in diagnosing inflammatory diseases and is used to monitor 
disease activity and response to therapy, will be obtained at scheduled visits (see Table 6-1). 
6.4.2 DAS28 and EULAR response 
The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR 
or CRP and the Patient Global Assessment. A DAS28 score > 5.1 implies active disease, ≤ 3.2 
low disease activity, and < 2.6 remission. EULAR response criteria are based on DAS28 
status in combination with DAS28 improvements. 
6.4.3 PsARC response 
A subject is defined as a PsARC responder if, and only if, they have an improvement in two 
of the following four factors (with at least one factor being a joint count) and no worsening in 
the remaining factors 
• Patient global assessment (0-100 mm VAS scale, improvement defined as decrease of 
at least 20 mm) 
• Physician global assessment (0-100 mm VAS scale, improvement defined as decrease 
of at least 20 mm) 
• Tender 78-joint count (improvement defined as decrease of at least 30%) 
• Swollen 76-joint count (improvement defined as decrease of at least 30%) 
6.4.4 Radiographic assessments 
Separate radiographs of each hand/wrist (PA) and each foot (AP) will be taken at baseline, 
Week 24, 52, and 104. Bone erosion, joint space narrowing (JSN), and total radiographic 
scores will be determined using a PsA modified van der Heijde‐Sharp (vdH‐S) scoring 
method (van der Heijde 2005)  that includes the second through fifth distal interphalangeal 
(DIP) joints of each hand. Erosions (0–5 in the hands and 0–10 in the feet) and JSN (0–4) will 
be graded separately in six wrist joints, all metacarpal phalangeal, proximal interphalangeal, 
and DIP joints of each hand, and the first interphalangeal joint and all metatarsal phalangeal 
joints for each foot. The total radiographic score (hands and feet combined) ranges from 0 to 
528, with higher scores indicating more articular damage. The maximum total erosion score is 
360. The maximum total JSN score is 168.   
The change in the Van der Heijde modified Sharp score is calculated against the baseline 
value. Radiologists will be trained on the X-ray acquisition and further details will be 
provided in a manual for the radiologists, e.g. joint placement and beam positioning.  
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In case of analogue X-rays films, the original film will be sent to the central reading CRO and 
will undergo quality control and will be digitized. Standard film and cassettes will be 
provided to all centers that do not produce digital X-rays. In case of digital equipment, sites 
need to confirm minimum requirements with the imaging CROs Digital X-rays will be 
transferred electronically.  
In case of insufficient quality, the center will be advised and trained on any quality issues 
prior to the repeat X-ray and to keep any repeat X-rays to a minimum. 
Subjects who are non-responder at Week 16 (not achieving a ≥20% improvement from 
baseline in both TJC and SJC) will have their hands/wrists and feet X-rays taken at this visit 
(Week 16).  Subjects who are responder at Week 16 (≥20% improvement from baseline in 
both tender and swollen joint counts) will have their hands/wrists and feet X-rays taken at 
Week 24. Subjects who discontinue study treatment before the end of the trial, hands/wrists 
and feet X-rays will be taken at the time of study treatment discontinuation. However, if the 
radiograph performed at time of early discontinuation of study treatment is less than 60 days 
to a prior X-ray, it does not need to be performed. Likewise, if a scheduled X-ray at Week 24, 
52, or 104 is scheduled less than 60 days after any prior hands/wrists and feet X-rays, it does 
not need to be performed. All following X-rays will be performed as scheduled.  
The readings of the X-rays and the scoring will be performed centrally. Complete X-ray 
procedures will be defined in an Imaging Manual provided to the centers by an Imaging CRO 
designated by Novartis. 
6.4.5 Magnetic Resonance Imaging (MRI) 
MRI will be performed in a subgroup of approximately 90 subjects with at least one swollen 
wrist at baseline (approx. 30 subjects/treatment arm) at selected sites. The hand with the more 
swollen wrist should be chosen (determined at baseline by the investigator). If both wrists are 
equally affected, the dominant hand/wrist should be chosen. The site should ensure that the 
same hand/wrist selected at baseline will be scanned at the following visits. Subjects with any 
contraindications to MRI (e.g.: pacemakers, aneurysm clips, artificial heart valves, ear 
implants, metal fragments, foreign objects in the eyes, skin or body or severe claustrophobia) 
or to gadolinium injections (e.g. allergic or adverse reactions to gadolinium, estimated 
glomerular filtration rate below 60 mL/1.73 m2 (based on MRD formula)) should not perform 
an MRI evaluation.  
MRIs will be performed at BSL, Week 12 and Week 24 using a whole body MRI system. The 
MRI assessment will require gadolinium contrast agent injections. MRI machines should have 
a field strength of 1.5 Tesla. The MRI protocol and required sequences will be described in 
the imaging acquisition manual.  
The readings of the scan and the scoring will be performed centrally. Readers will be blinded 
to clinical information and to the sequence of the images. The MRIs will be scored according 
to a modified OMERACT RAMRIS system (Ostergaard 2010) for erosions, bone marrow 
edema (BME), and synovitis. In addition, JSN will be scored (Peterfy 2010).  
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6.4.6 Psoriasis Area and Severity Index (PASI) 
The PASI assessment will be conducted for subjects in whom at least 3% of the body surface 
area (BSA) was affected by psoriatic skin involvement at baseline (Visit 2). The PASI 
assesses the extent of psoriasis on four body surface areas (head, trunk and upper and lower 
limbs) and the degree of plaque erythema, scaling and thickness. A PASI score (Fredriksson 
and Pettersson 1978, Weisman 2003, Gottlieb 2005) will be derived as indicated in Table 6-2.  
The head, trunk, upper limbs and lower limbs are assessed separately for erythema, thickening 
(plaque elevation, induration), and scaling (desquamation).  The average degree of severity of 
each sign in each of the four body regions is assigned a score of 0-4.  The area covered by 
lesions on each body region is estimated as a percentage of the total area of that particular 
body region.  Further practical details help the assessment: 
1. The neck is assessed as part of the head. 
2. The axillae and groin are assessed as part of the trunk. 
3. The buttocks are assessed as part of the lower limbs. 
4. When scoring the severity of erythema, scales should not be removed. 
Table 6-2 The PASI scoring system 
Body  
region 
Erythema (E) 
 
Thickening 
(plaque elevation,
induration, I) 
Scaling 
(desquamation) 
(D) 
Area score 
(based on true 
area %, A)* 
Head  (H)** 0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Trunk,   
(T)*** 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Upper  
limbs (U) 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Lower  0=none  0=none  0=none  0 = 0% 
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Body  
region 
Erythema (E) 
 
Thickening 
(plaque elevation,
induration, I) 
Scaling 
(desquamation) 
(D) 
Area score 
(based on true 
area %, A)* 
limbs  
(L)**** 
1=slight  
2=moderate  
3=severe 
4=very severe 
1=slight  
2=moderate  
3=severe 
4=very severe 
1=slight  
2=moderate  
3=severe 
4=very severe 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
* Percentage (not score) of body region (not whole body) affected will be entered in the eCRF 
**Neck is assessed as part of the Head (H) body region. 
***Axillae and groin are assessed as part of the Trunk (T) body region. 
****Buttocks are assessed as part of the Lower limbs (L) body region. 
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the PASI score is calculated 
using the formula: 
PASI = 0.1(EH+IH+DH)AH + 0.2(EU+IU+DU)AU + 0.3(ET+IT+DT)AT + 0.4(EL+IL+DL)AL 
The keys for the letters are provided in Table 6-2. 
PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a 
theoretic maximum of 72.0. The investigator is only responsible for collecting the components 
or scoring signs and total regional area. More information is provided in Appendix 6.  
6.4.7 Investigator’s Global Assessment (IGA mod 2011) 
IGA mod 2011 will be conducted for overall psoriatic disease as indicated in Table 6-3 for 
subjects in whom at least 3% of the body surface area (BSA) was affected by psoriatic skin 
involvement at baseline (Visit 2).  It is recommended that the same evaluator conducts the 
assessment throughout the study wherever possible. 
The IGA mod 2011 rating scale for overall psoriatic disease is shown in Table 6-3. 
The IGA mod 2011 scale has been developed based on a previous version of the scale used in 
secukinumab phase II psoriasis studies in collaboration with health authorities in particular the 
FDA. The explanations/descriptions of the points on the scale have been improved to ensure 
appropriate differentiation between the points. 
The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease 
state at the time of the assessments, and does not attempt a comparison with any of the 
subject’s previous disease states, whether at baseline or at a previous visit.   
The IGA mod 2011 score will be recorded in the eCRF. 
Table 6-3 The IGA mod 2011 rating scale 
Score Short Description Detailed Description 
0 Clear No signs of psoriasis. Post-inflammatory hyperpigmentation may be present. 
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1 Almost clear Normal to pink coloration of lesions; no thickening; no to minimal focal scaling. 
2 Mild Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling. 
3 Moderate Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling. 
4 Severe 
Bright to deep dark red coloration; severe thickening with 
hard edges; severe / coarse scaling covering almost all or 
all lesions. 
Note:  Involvement of nails is not part of the assessment. 
Based on this scale, a subject will be considered as IGA 0 or 1 responder if the subject 
achieves a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to 
baseline. 
6.4.8 Target lesion score (TLS) 
The Target Lesion Score will be done for subjects enrolled in the study having a psoriatic 
target lesion that is at least 2 cm in diameter identified at baseline (Visit 2). At the visits 
indicated in Table 6-1, this target lesion will be scored for erythema, scaling, and thickness, 
each on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). The 
parameter scores will be summed automatically in the eCRF, giving a score ranging from 0 to 
12. 
6.4.9 Modified Nail Psoriasis Severity Index (mNAPSI) 
The mNAPSI is an instrument to assess psoriatic nail involvement in subjects with PsA and 
nail psoriasis. It will be collected only in subjects with psoriatic nail involvement. The 
modifications on the original NAPSI to create the mNAPSI were made by rheumatologists, 
with dermatologists’ input, as a tool for clinical trials. The creators’ goal was to develop a tool 
to assess disease severity and response to treatment in clinical trials, keeping in mind that the 
assessor in a clinical trial most likely would not be a trained dermatologist (Cassel 2007). 
More information is provided in Appendix 7. 
6.4.10 Leeds Dactylitis Index (LDI) 
The Leeds Dactylitis Index (LDI) (Helliwell 2005) basic measures the ratio of the 
circumference of the affected digit to the circumference of the digit on the opposite hand or 
foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of 
circumference is multiplied by a tenderness score, using a modification of LDI which is a 
binary score (1 for tender, 0 for non-tender). If both sides are considered involved, the number 
will be compared to data provided in the standard reference tables (see Appendix 8). This 
modification is referred to as LDI basic and will be applied in this study. The LDI requires a 
finger circumference gauge or a tape measure to measure digital circumference. 
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6.4.11 Leeds Enthesitis Index (LEI) 
LEI is a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral 
epicondyle humerus L + R, proximal achilles L + R and lateral condyle femur. The LEI 
demonstrated substantial to excellent agreement with other scores in the indication of psoriatic 
arthritis.   
6.4.12 Appropriateness of efficacy assessments  
The efficacy outcome measures used in this study are the standard measures used across many 
psoriatic arthritis trials and they are required for regulatory filing. 
6.5 Safety 
• Evaluation of all AEs and SAEs including injection site reactions, ECGs, physical 
examination, vital signs and laboratory assessments 
• Assessment of anti-secukinumab antibody development (immunogenicity) 
6.5.1 QuantiFERON TB-Gold test or PPD skin test 
Either a QuantiFERON TB-Gold test or a PPD skin test must be performed at screening, 
Subjects with a positive test may only participate in the study if further work up (according to 
local practice/guidelines) establishes conclusively that the subject has no evidence of active 
tuberculosis. If presence of latent tuberculosis is established then treatment according to local 
country guidelines must have been initiated. 
QuantiFERON TB-Gold test 
• A QuantiFERON TB-Gold test is to be performed at screening (Visit 1) and the results to 
be known prior to randomization to determine the subject’s eligibility for the trial. The test 
will be used to screen the subject population for latent tuberculosis infection.  
• The test will be performed by the central laboratory. Details on the collection, processing 
and shipment of samples and reporting of results by the central laboratory are provided in 
the laboratory manual. 
PPD skin test 
• A PPD skin test is to be performed at screening and read before randomization to 
determine the subject’s eligibility for the trial. The test dose is bioequivalent to 5 
tuberculin units of standard PPD injected intradermally usually into the volar surface of 
the forearm. The site is cleansed and the PPD extract is then injected into the most 
superficial layer under the skin. If given correctly, the injection should raise a small wheal 
of about 5 mm, which resolves within 10-15 minutes. 
Because the reaction (induration) will take 48-72 hours to develop, the subjects must return to 
the investigators’ site within that time for a proper evaluation of the injection site. This will 
determine whether the subject has had a significant reaction to the PPD test. A reaction is 
measured in millimeters of induration (hard swelling) at the site. A PPD skin induration 
≥5 mm (or according to local practice/guidelines) is interpreted as a positive result 
This document (090095a88362b521 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 5/12/2011 2:47:40 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by Ambs Petra in Basel at Thu, May 12, 2011 16:41:36 CEST
Novartis Confidential Page 51 
Clinical Trial Protocol  Protocol No. CAIN457F2306 
 
 
6.5.2 Physical examination 
A physical examination will be performed at each visit. Significant findings that are present 
before the subject has signed the Informed Consent Form must be included in the relevant 
medical history eCRF. Significant findings made after the subject has signed the Informed 
Consent Form which meet the definition of an AE must be recorded in the Adverse Event case 
report form. It will include the examination of general appearance, skin, neck, eyes, ears, 
nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological 
systems. 
6.5.3 Vital signs 
6.5.4 Height and weight 
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing) (both without shoes) will be measured. 
If possible, body weight assessments should be performed by the same study site staff 
member using the same scale throughout the study. 
6.5.5 Electrocardiogram (ECG) 
A standard 12-lead ECG will be performed at visits as indicated in Table 6-1.  
All ECGs must be performed on the ECG machines provided for the study. 
All ECGs will be independently reviewed. Instructions for the collection and transmission of 
the ECGs to the independent reviewer will be provided in the ECG investigator manual. 
Clinically relevant abnormalities should be recorded on the relevant Medical History/Current 
Medical Conditions eCRF for the baseline ECG.  
Clinically relevant abnormalities noted after the baseline ECG  should be reported as AEs (see 
Section 7). 
6.5.6 Local tolerability (injection site reactions) 
The local tolerability at the site of s.c. injection will be assessed in the case of any local 
reaction, until this has disappeared. 
The assessment of pain, redness, swelling, induration, hemorrhage and itching will be 
performed by a physician and will be recorded on the Adverse Event eCRF, including the 
severity (none, mild, moderate, severe) and the duration. 
6.5.7 Laboratory evaluations 
A central laboratory will be used in this study. Central laboratory information, including 
collection, shipment of samples and reporting of results, may be found in the laboratory 
manual. For the identification of notable values, see Appendix 1. All subjects with laboratory 
tests containing clinically significant abnormal values are to be followed until the values 
return to normal ranges or until a valid reason, other than drug related AE, is defined. 
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6.5.7.1 Hematology 
Hemoglobin, platelet, red blood cell (RBC), white blood cell (WBC) and differential white 
blood cell counts will be measured at scheduled visits.  
6.5.7.2 Clinical chemistry 
Serum chemistries will include glucose, urea, creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, 
total protein, albumin, and uric acid. 
6.5.7.3 Lipid panel 
A lipid profile including High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), 
cholesterol and triglycerides will be measured from a fasting blood sample. 
6.5.7.4 Cardiovascular panel 
A cardiovascular profile including lipoprotein (a), apolipoprotein B-100, apolipoprotein A-1, 
and adiponectin will be measured from a blood sample. 
6.5.7.5 Urinalysis 
Dipsticks will be provided by the central laboratory to the sites for local urinalysis 
assessments. The urinalysis results for standard parameters such as protein, glucose, blood 
and WBCs will be recorded in the appropriate eCRF page. 
6.5.8 Pregnancy and assessments of fertility 
Secukinumab must not be given to pregnant women; therefore effective methods of birth 
control must be used for women of child-bearing potential (see exclusion criteria definitions, 
Section 4.2). 
A serum β-hCG test will be performed in all women at Visit 1 (screening). All women who 
are not surgically sterile at screening will have local urine pregnancy tests as indicated in 
Table 6-1. A positive urine pregnancy test requires immediate interruption of study 
medication until serum β-hCG is performed and found to be negative. If positive, the subject 
must be discontinued from the trial. 
6.5.9 Tolerability of secukinumab 
Tolerability will be assessed by adverse events, laboratory values, injection site reaction and 
immunogenicity. 
6.5.10 Additional parameters 
Blood will be obtained at Visit 1 (screening) for ANA, dsDNA, anti-CCP antibodies, and 
Rheumatoid Factor (RF).  
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6.5.11 Immunogenicity 
Blood samples for immunogenicity (anti-secukinumab antibodies) will be taken pre-dose at 
the scheduled timepoints as indicated in Table 6-1. In addition, if a subject discontinues from 
the study at any timepoint, he/she will needs to provide a sample at the last visit. 
The actual sample collection date and exact time will be entered on the Immunogenicity blood 
collection eCRF. Sampling problems will be noted in the Comments section of the eCRF.  
All blood samples will be taken by either direct venipuncture or an indwelling cannula 
inserted in a forearm vein. 
A laboratory manual will be provided to the investigators with detailed information on sample 
collection, handling and shipment. 
Tubes and preprinted labels will be provided by the central lab to the sites. 
Analytical Method 
An electrochemiluminescence method will be used for the detection of potential anti-
secukinumab antibody formation. The detailed method description to assess immunogenicity 
will be described in the bioanalytical raw data of the study and in the respective Bioanalytical 
Data Report (BDR). 
 
Table 6-4 IG sample log 
Visit Week IG Sample number 
2 0 301 
10 24 302 
17 52 303 
30 104 304 
F112 112 305 
6.5.12 Appropriateness of safety measurements 
The safety measures used in this study are reliable and relevant standard measures for a 
biologic in PsA. The specific focus on infection rates in addition to the other safety measures 
ensures the ability to deliver data on a critical safety endpoint for this class of therapy. A 
Chest X-ray at screening is performed to rule out the presence of a pulmonary malignancy or 
infectious process, in particular tuberculosis. The radiation exposure that results from these X-
ray measurements is not necessary for medical care but is intended for research purposes only. 
The total amount of radiation from all X-ray measurements performed in this study (1 safety 
chest X-ray, 3-4 X-rays of hands/wrists and feet) is estimated to be around 1 mS over 104 
weeks, and is approximately equivalent to a uniform whole body exposure of 26 weeks of 
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exposure to natural background radiation.  For effective radiation doses under 3 mSv (300 
mrem), the risk is considered to be "minimal". Therefore, the radiation exposure in this study 
involves minimal risk and is necessary to obtain the research information desired and ensure 
reliable safety measures before the treatment with a biologic. 
The safety assessments selected are standard for this indication/patient population. 
6.6 Other assessments 
• Quality of Life questionnaire/ Patient reported outcomes (PROs) 
• Pharmacokinetics 
• Pharmacogenetics 
• Serum biomarkers related to targeted pathway 
6.6.1 Quality of Life questionnaires/Patient Reported Outcomes (PROs) 
The impact of PsA on various aspects of subjects’ health-related quality of life (HRQoL) will 
be assessed using the following validated instruments: 
 HAQ-DI (see Section 6.4.1.5) 
 SF-36 v2 (Acute form) 
 EQ-5D 
 FACIT-Fatigue 
 PsAQoL 
 DLQI 
All questionnaires will be available, where possible, in the local languages of the participating 
countries and should be completed by subjects before they see the study physician. The 
subject should be given sufficient space and time to complete the questionnaire. 
Responses will be collected on digital paper to allow the use of a digital pen.  Only the 
original digital paper provided can be used for the digital pens (i.e. these pages must not be 
photocopied). 
All questionnaires will be completed in the respondent’s local language. The study 
coordinator should check the questionnaires for completeness and encourage the subject to 
complete any missing responses. The original questionnaires will be kept with the subject’s 
file as the source document. 
Completed questionnaires should be reviewed and assessed by the investigator, before the 
clinical examination, for responses which may indicate potential AEs or SAEs. This 
assessment should be documented in the source records. If AEs or SAEs are confirmed the 
investigator should record the events as per instructions given in the relevant section of the 
protocol (see Section 7). 
Guidelines for administering the PRO questionnaires can be found in Appendix 9. 
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6.6.1.1 SF-36 Version 2 (Acute Form) 
The Short Form Health Survey (SF-36) is a widely used and extensively studied instrument to 
measure health-related quality of life among healthy subjects and patients with acute and 
chronic conditions. It consists of eight subscales that can be scored individually: Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-
Emotional, and Mental Health (Ware 1993). Two overall summary scores, the Physical 
Component Summary (PCS) and the Mental Component Summary (MCS) also can be 
computed (Ware 1994). The SF-36 has proven useful in monitoring general and specific 
populations, comparing the relative burden of different disease, differentiating the health 
benefits produced by different treatments, and in screening individual subjects. 
The purpose of the SF-36 in this study is to assess the HRQoL of subjects. Given the acute 
nature of this disease, version 2, with a 1-week recall period, will be used in this study.  
6.6.1.2 EQ-5D 
The EQ-5D is a widely used, self-administered questionnaire designed to assess health status 
in adults. The measure is divided into two distinct sections. The first section includes one item 
addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and 
anxiety/depression). Subjects rate each of these items from "no problem," "some problem," or 
"extreme problem." A composite health index is then defined by combining the levels for each 
dimension. The second section of the questionnaire measures self-rated (global) health status 
utilizing a vertically oriented visual analogue scale where 100 represents the "best possible 
health state" and 0 represents the "worst possible health state." Respondents are asked to rate 
their current health by placing a mark along this continuum. The recall period is "today," and 
the questionnaire requires approximately 5 to 10 minutes to complete. 
The EQ-5D contains six items designed to assess health status in terms of a single index value 
or health utility score. One of the strengths of the EQ-5D approach is that it allows 
"weighting" by the subject of particular health states and the generation of subject utilities. 
Published weights are available that allow for the creation of a single summary health utility 
score. Overall scores range from 0 to 1, with lower scores representing a higher level of 
dysfunction.  
The purpose of the EQ-5D in this study is to assess the health status of subjects. 
6.6.1.3 FACIT-Fatigue 
The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue©) is a 13-
item questionnaire (Cella 1993; Yellen 1997) that assesses self-reported fatigue and its impact 
upon daily activities and function. 
The purpose of FACIT-Fatigue© in this study is to assess the impact of fatigue on subjects 
with PsA. 
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6.4.5.1. PsAQoL 
The PsAQoL is a 20-item questionnaire designed to assess the impact of PsA and its treatment 
on quality of life. Each item of the questionnaire is in the form of a simple statement to which 
subjects indicate whether or not the statement is true for them at that moment. 
The theoretical basis for the PsAQoL is the needs-based model of QoL which argues that 
disease-related impairment and disability influences a person’s ability to meet his or her 
needs. 
6.6.1.4 DLQI 
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability 
index designed to assess health-related quality of life in adult subjects with skin diseases such 
as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994).  The measure is self-
administered and includes domains of daily activities, leisure, personal relationships, 
symptoms and feelings, treatment, and work/school.  The measure is widely used: it has been 
tested across 32 different skin conditions and is available in multiple languages.  The recall 
period is the past week, and the instrument requires 1 to 2 minutes for completion. 
Each item has four response categories ranging from 0 (not at all) to 3 (very much).  “Not 
relevant” is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 
questions.  Scores range from 0 to 30, and higher scores indicate greater health-related quality 
of life impairment.  Additionally, each subscale of the DLQI may be analyzed separately. 
6.6.1.5 Work Productivity and Activity Impairment (WPAI-GH) 
The Work Productivity and Activity Impairment (WPAI-GH) questionnaire is an instrument 
to measure impairments in both paid work and unpaid work. It measures absenteeism, 
presenteeism as well as the impairments in unpaid activity because of health problem during 
the past seven days. The WPAI-GH consists of six questions:  
1 = currently employed 
2 = hours missed due to health problems  
3 = hours missed other reasons  
4 = hours actually worked  
5 = degree health affected productivity while working (VAS)  
6 = degree health affected productivity in regular unpaid activities (VAS)  
The recall period for the questions 2 to 6 is seven days. Four main outcomes can be generated 
from the WPAI-GH and expressed in percentages.  
1. percent work time missed due to health for those who were currently employed  
2. percent impairment while working due to health for those who were currently 
employed and actually worked in the past seven days  
3. percent overall work impairment due to health  for those who were currently employed  
4. percent activity impairment due to health for all respondents 
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6.6.2 Pharmacokinetics 
Pharmacokinetic (PK) samples will be obtained for all subjects, and secukinumab 
concentrations will be assessed in serum. The PK samples will be collected pre-dose at 
scheduled visits as indicated in Table 6-1. 
All blood samples will drawn by direct venipuncture in a forearm vein. 
The actual sample collection date and exact time will be entered on the PK blood collection 
summary eCRF. Sampling problems will be noted in the Comments section of the eCRF. 
The bioanalyst will recieve a copy of the randomization schedule to facilitate analysis of the 
PK samples. The bioanalyst will provide the samples’ concentration data to the team under 
blinded conditions. Both the site’s unblinded pharmacist and bioanalyst will keep this 
information confidential until clinical database lock. 
PK sample handling, labeling and shipment instructions 
Laboratory manuals will be provided by the central laboratory with detailed information on 
sample collection, sample handling and shipment. 
Tubes and labels will be provided by the central laboratory with study/sample type 
information pre-printed on the label. 
Table 6-5 PK sample log 
Visit Week Time Sample 
number 
PK collection 
number 
2 0 0 (pre-dose) 1 1 
5 4 672 h (pre-dose) 2 1 
8 16 2688 h (pre-dose) 3 1 
10 24 4032 h (pre-dose) 4 1 
17 52 8736 h (pre-dose) 5 1 
30 104 17472 h (anytime) 6 1 
F112 112 18816 h (anytime) 7 1 
Analytical methods 
An ELISA method will be used for bioanalytical analysis of secukinumab in serum, with an 
anticipated lower limit of quantification (LLOQ) of 80 ng/mL. The detailed method 
description to assess secukinumab concentration will be described in the bioanalytical raw 
data of the study and in the respective Bioanalytical Data Report (BDR). 
6.6.3 Pharmacogenetics 
The pharmacogenetic endpoints are exploratory and are not intended to be used for regulatory 
judgments pertaining to the safety or efficacy of the investigational drug. However, these data 
may be considered for voluntary submission, consistent with applicable regulatory guidance 
on this topic, in order to develop the knowledge base necessary to establish the validity of 
new genomic biomarkers. 
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This study includes an optional exploratory pharmacogenetic assessment which requires 
signature of a separate informed consent if the subject agrees to participate. The identity of the 
subject will not be revealed. It is required as part of this protocol that the Investigator presents 
these options to the subject. 
Exploratory pharmacogenetics studies are planned as a part of this study with the objectives of 
identifying inherited genetic factors that may (1) be related to PsA, (2) predict response to 
treatment with secukinumab, (3) predict relative susceptability to drug-drug interactions, or 
(4) predict genetic predisposition to side effects. We hope to develop a better understanding of 
PsA and how subjects respond to secukinumab. 
The genetic markers (or polymorphisms) that may be studied that relate to the etiology of PsA 
include HLA C*0602 alleles. Polymorphisms in genes that relate to the mechanism of action 
may include the nonsynonymous polymorphisms in IL17A (S141S, R134R), IL17A receptor 
(V367A, Q562P) and related genes. 
Despite continuing advances in genetics research, not all of the polymorphisms relevant to 
drug metabolism, drug action and PsA have been identified. Therefore, additional 
polymorphisms will be added within the restricted scope of these studies as described above. 
In addition, recent advances in genotyping technologies have made genome-wide association 
(GWA) studies possible.  GWA studies may also be undertaken within the restricted scope of 
these studies as described above. 
At all study sites, one optional blood sample will be collected in subjects for 
pharmacogenetics assessment at baseline (Visit 2) as indicated in Table 6-1. 
Lab manuals will be provided with detailed information on sample collection, handling, and 
shipment. The actual sample collection date must be entered on the central lab assessment 
eCRF. 
Any DNA derived from the sample that remains after analysis may be stored for up to 15 
years to address scientific questions related to secukinumab or PsA. 
Table 6-6 PG sample log 
Visit Week PG Sample 
number 
mL 
2 0 1301 10 
Sample analytical methods:   
Covance Central Laboratory Services is using the Qiagen Autopure Extraction Robot for 
Genomic DNA Extraction from EDTA Whole Blood.  Genotyping will be conducted by the 
Genomic and Genetic Applications (GGA) Cambridge laboratory utilizing Taqman endpoint 
detection sequencing or real-time PCR-based techniques. 
6.6.3.1 Serum biomarkers related to targeted pathway 
Biomarkers are objectively measured and evaluated indicators of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention (Biomarkers 
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Definitions Working Group 2001). This search for biomarkers of disease and drug response 
will involve an integrated molecular approach examining genetic and serum protein profiles. 
These exploratory assessments aim to identify potential markers of response and/or loss of 
response, and to characterize molecular mechanisms of treatment with secukinumab. 
Any biomarker samples may be stored for up to 20 years (depending on local regulations) to 
research scientific questions related to secukinumab, RA and related diseases with a potential 
involvement of IL-17A. The material can be destroyed on subject’s request at any time point. 
Details on the collections, handling and shipment of the samples to the central laboratory will 
be provided to investigators in the laboratory manual. 
Any results from these exploratory biomarker assessments will be reported separately. 
Serum biomarkers related to systemic inflammation, bone and joint metabolism and 
cardiovascular risk will be measured. The final selection of analytes will be driven by assay 
availability, new information from the public domain, results obtained in other secukinumab 
clinical studies, as well as by hypotheses generated by other exploratory biomarker 
assessments. In addition, selected markers exploring the effect of secukinumab treatment on 
co-morbidities may be assessed. 
Blood collection and processing:  
At all study sites, blood samples will be collected for soluble serum markers pre-dose at the 
scheduled timepoints as indicated in Table 6-1. 
All blood samples will be taken by either direct venipuncture or an indwelling cannula 
inserted in a forearm vein. Samples should then be processed and shipped as detailed in the 
laboratory manual. 
The actual sample collection date will be entered on the corresponding eCRF. Sampling 
problems will be noted in the Comments section of the eCRF. 
7 Safety monitoring 
7.1 Adverse events 
An adverse event is the appearance or worsening of any undesirable sign, symptom, or 
medical condition occurring after the subject has signed the Informed Consent Form even if 
the event is not considered to be related to study treatment. Medical conditions/diseases 
present before the subject has signed the Informed Consent Form are only considered adverse 
events if they worsen after the subject has signed the Informed Consent Form. Abnormal 
laboratory values or test results constitute adverse events only if they induce clinical signs or 
symptoms, are considered clinically significant, or require therapy. 
The occurrence of adverse events should be sought by non-directive questioning of the subject 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by the subject during or between visits or through physical examination, laboratory test, or 
other assessments. All adverse events must be recorded on the Adverse Events CRF with the 
following information: 
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1. the severity grade (mild, moderate, severe) 
2. its relationship to the study treatment(s) (suspected/not suspected) 
3. its duration (start and end dates or if continuing at final exam) 
4. whether it constitutes a serious adverse event (SAE) 
An SAE is defined as an event which: 
• is fatal or life-threatening  
• results in persistent or significant disability/incapacity 
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
• routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition 
• elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since the start of study treatment 
• treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission  
• social reasons and respite care in the absence of any deterioration in the subject’s 
general condition 
• is medically significant, i.e. defined as an event that jeopardizes the subject or may require 
medical or surgical intervention to prevent one of the outcomes listed above 
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2. 
All adverse events should be treated appropriately. Action taken with study treatment should 
include one of the following: none, dose adjusted, temporarily interrupted, permanently 
discontinued, unkown or not applicable. Additionally, information must be provided whether 
a concomitant medication or non-drug therapy was given. The action taken to treat the 
adverse event should be recorded on the Adverse Event CRF.  
 Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently, if 
necessary) of any changes in severity, the suspected relationship to the study treatment, the 
interventions required to treat it, and the outcome. 
Information about common side effects already known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Investigator Notifications (IN). This information will be included in the subject 
informed consent and should be discussed with the subject subject the study as needed. 
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7.2 Serious adverse event reporting 
To ensure subject safety, every SAE (regardless of suspected causality) occurring after the 
subject has signed the Informed Consent Form and until 12 weeks after last administered dose 
of study treatment or 30 days after the subject has stopped study participation (whichever is 
later) must be reported to Novartis within 24 hours of learning of its occurrence.  
Any SAEs experienced after this period should only be reported to Novartis if the investigator 
suspects a causal relationship to the study treatment.  
Recurrent episodes, complications, or progression of the initial SAE must be reported as 
follow-up to the original episode, regardless of when the event occurs. This report must be 
submitted within 24 hours of the investigator receiving the follow-up information. An SAE 
that is considered completely unrelated to a previously reported one should be reported 
separately as a new event. 
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form. The investigator must assess the relationship of any SAE to study treatment, complete 
the SAE Report Form in English, and send the completed, signed form by fax within 24 hours 
to the local Novartis Drug Safety and Epidemiology Department (DS&E). The telephone and 
telecopy number of the contact persons in the local department of DS&E, specific to the site, 
are listed in the investigator folder provided to each site. The original copy of the SAE Report 
Form and the fax confirmation sheet must be kept with the case report form documentation at 
the study site. 
Follow-up information is sent to the same person to whom the original SAE Report Form was 
sent, using a new SAE Report Form stating that this is a follow-up to the previously reported 
SAE and giving the date of the original report. The follow-up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the subject continued or withdrew from study participation.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is 
thought to be related to the Novartis study treatment, a Drug Safety and Epidemiology 
Department associate may urgently require further information from the investigator for 
Health Authority reporting. Novartis may need to issue an IN to inform all investigators 
involved in any study with the same drug that this SAE has been reported.  Suspected 
Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per national regulatory requirements in participating countries. 
7.3 Pregnancies 
To ensure subject safety, each pregnancy in a subject on study treatment must be reported to 
Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up 
to determine outcome, including spontaneous or voluntary termination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. 
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Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the local Novartis DS&E Department. Pregnancy follow-up should be recorded 
on the same form and should include an assessment of the possible relationship to the 
Novartis study treatment of any pregnancy outcome. Any SAE experienced during pregnancy 
must be reported on the SAE Report Form. 
7.4 Data monitoring and adjudication committees 
Data monitoring committee 
A data monitoring committee (DMC) will review the safety data of this trial at regular 
intervals. Details regarding the DMC process will be available in the relevant secukinumab 
DMC charter. 
Adjudication committee 
An independent adjudication committee consisting of external experts may be used to monitor 
specific safety events, including, but potentially not limited to clinically significant cardio- 
and cerebro-vascular events. The events will be blindly reviewed and adjudicated as they 
occur during the conduct of the trial.  
Details regarding the adjudication process will be available in the relevant secukinumab 
Adjudication Committee charter. 
8 Data review and database management 
8.1 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and (e)CRFs with the investigators and their staff. 
During the study, the field monitor will visit the site regularly to check the completeness of 
subject records, the accuracy of entries on the (e)CRFs, the adherence to the protocol and to 
Good Clinical Practice (GCP), the progress of enrollment, and to ensure that study treatment 
is being stored, dispensed, and accounted for according to specifications. Key study personnel 
must be available to assist the field monitor during these visits. 
The investigator must maintain source documents for each subject in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on (e)CRFs must be traceable to these source documents in the 
subject’s file. The investigator must also keep the original informed consent form signed by 
the subject (a signed copy is given to the subject). 
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the (e)CRF entries. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion 
criteria, documentation of SAEs, and the recording of data that will be used for all primary 
and safety variables. Additional checks of the consistency of the source data with the (e)CRFs 
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are performed according to the study-specific monitoring plan. No information in source 
documents about the identity of the subjects will be disclosed. 
8.2 Data collection 
Designated investigator staff will enter the data required by the protocol into the OC/RDC 
system. Designated investigator site staff will not be given access to the system until they 
have been trained.  
Automatic validation procedures within the system check for data discrepancies during and 
after data entry and, by generating appropriate error messages, allow the data to be confirmed 
or corrected online by the designated investigator site staff. The Investigator must certify that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copies of the subject data for archiving at the 
investigational site.  
8.3 Database management and quality control 
Novartis staff review the data entered into the eCRFs by investigational staff for completeness 
and accuracy and instruct the site personnel to make any required corrections or additions. 
Queries are sent to the investigational site using an electronic data query. Designated 
investigator site staff is required to respond to the query and confirm or correct the data. If the 
electronic query system is not used, a paper Data Query Form will be faxed to the site. Site 
personnel will complete and sign the faxed copy and fax it back to Novartis staff who will 
make the correction to the database. The signed copy of the Data Query Form is kept at the 
investigator site. 
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employs the Anatomical Therapeutic Chemical (ATC) classification 
system. Medical history/current medical conditions and adverse events will be coded using 
the Medical dictionary for regulatory activities (MedDRA) terminology. 
Laboratory samples will be processed centrally and the results will be sent electronically to 
Novartis . 
ECG readings will be processed centrally and the results will be sent electronically to 
Novartis.  
Subjects will use electronic pens to enter PRO data. The system will be supplied by a vendor 
who will also manage the database. The data will be processed centrally and the results will 
be transferred electronically to the Novartis database. 
Randomization codes and data about all study treatment dispensed to the subject will be 
tracked using an IRT system. The system will be supplied by a vendor, who will also manage 
the database. The database will be sent electronically to Novartis (or a designated CRO). 
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  
The code break functionality will remain available until study shut down or upon request of 
Novartis. 
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Pharmacogenetic and exploratory biomarkers samples 
To maximize confidentiality, all samples and the information associated with the samples will 
be double-coded to prevent the exposure of the subject’s information and identity. This 
double-coding process allows Novartis to go back and destroy the sample at the subject’s 
request.  In addition, sample information is stored in one secured database while genetic data 
is stored in an independent secured database. 
The use of pharmacogenetics to search for biomarkers of disease and drug action is 
exploratory. Any results from this pharmacogenetic study will not be placed in the subject’s 
medical records. 
9 Data analysis 
Summary statistics for continuous variables include N, mean, standard deviation, minimum, 
lower quartile, median, upper quartile, and maximum.  For binary or discrete variables the 
absolute number of subjects in each category and relative frequencies will be provided.   
Unless otherwise specified, p-values will be presented as 2-sided p-values and the type I error 
rate (alpha) will be 5%. 
Inferential efficacy comparisons with placebo will generally focus on the first 24-weeks of 
treatment unless otherwise specified (e.g. Major clinical response). 
Efficacy and safety data for the placebo-controlled period (or the entire treatment period as 
appropriate) will be presented by the following 3 treatment groups.  Subjects may be included 
in more than one treatment group for some analyses (e.g. exposure-adjusted adverse events 
over the entire treatment period).  These treatment groups represent the regimens subjects will 
be eligible to be randomized to. 
Group 1: Secukinumab  regimen 1: secukinumab i.v. (10mg/kg) at BSL, Week 2 and 4 then 
secukinumab 75 mg s.c. starting at Week 8 every 4 weeks. 
Group 2: Secukinumab regimen 2: secukinumab i.v. (10mg/kg)  at BSL, Week 2 and 4 then 
secukinumab 150 mg s.c. starting at Week 8 every 4 weeks  
Group 3: Placebo regimen: Placebo i.v. at BSL, Week 2 and 4 then placebo s.c. starting at 
Week 8 injected every 4 weeks  
Note that the treatment groups above for a subject may differ depending on the time period of 
the analysis and whether one assesses the subject for efficacy or safety (see Section 9.1 for 
details).   
Data may also be presented by a combination of the ‘original’ and ‘switch’ treatment groups.   
These treatment groups represent the treatment combinations the subjects experience over the 
course of the entire trial in case of rescue or re-randomization.   
 
9.1 Analysis sets 
The following analysis sets will be used in this trial: 
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Randomized set: The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis-randomized subjects (mis-randomized in IRT) will be 
excluded from the randomized set.  
Full analysis set (FAS): The FAS will be comprised of all subjects from the randomized set 
to whom study treatment has been assigned. Following the intent-to-treat principle, subjects 
will be analyzed according to the treatment assigned to at randomization, but actual stratum, if 
stratified randomization is used.  
Safety set: The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period.  Subjects will be analyzed according to treatment received.  
9.2 Subject demographics and other baseline characteristics 
Summary statistics will be presented for continuous demographic and baseline characteristic 
variables for each treatment group and for all subjects in the randomized set. The number and 
percentage of subjects in each category will be presented for categorical variables for each 
treatment group and all subjects. 
Baseline comparability of the randomized treatment groups will be assessed for the following 
demographic variables:  
• Gender, age, race, ethnicity, weight, height, and BMI 
Baseline disease characteristics will also be compared for the following variables: 
• TNFα history (naive or inadequate responder), ACR components,  number of prior 
biologic PsA therapies, dose of methotrexate or other DMARD at randomization 
To evaluate baseline comparability, categorical variables will be evaluated by a Cochran-
Mantel-Haenszel test stratified by randomization stratum (TNFα history (naive or inadequate 
responder) and continuous variables will be evaluated by analysis of variance). 
Note that these tests of comparability are performed for descriptive purposes only, and will 
not serve as a basis for determining entry of explanatory variables into the respective models. 
However, when these tests yield significant results they can be used as supportive information 
in interpreting the statistical analyses performed on the primary and secondary efficacy 
variables.  
Medical history 
Any significant prior or active medical condition at the time of signing informed consent will 
be coded using the MedDRA dictionary. These medical conditions will be summarized by 
primary system organ class and preferred term. 
To establish a baseline level of cardiovascular risk, the number and percentage of subjects 
with pre-solicited cardiovascular risk factors will be summarized by treatment group. The 
number of cardiovascular risk factors that each subject has will also be summarized by 
treatment group. If it unknown whether or not a subject currently or previously experienced a 
specific cardiovascular risk factor, it will be assumed that cardiovascular risk factor did not 
occur for that subject. 
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9.3 Treatments (study treatment, rescue medication, other 
concomitant therapies, compliance) 
Study treatment 
The analysis of study treatment data will be based on the safety set.  The number of active and 
placebo injections and infusions received will be presented by treatment group and by epoch 
(study period).  Descriptive statistics the duration of study treatment administered and the 
volume in milliliters administered will be presented by actual treatment group. 
The duration of exposure to study treatment will also be summarized by treatment group. In 
addition, the number and percentage of subjects with cumulative exposure levels (e.g. any 
exposure, ≥ 1 week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
• Duration of exposure to study treatment is defined as the date of last dose of study 
treatment – date of first dose of study treatment plus 1 day 
• Duration of observation is defined as date of last study visit – date of first dose of study 
treatment plus 1 day. 
Prior and concomitant medication 
Prior and concomitant medications will be summarized in separate tables by treatment group. 
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of randomized 
study treatment and the date of the last study visit will be a concomitant medication, including 
those which were started pre-baseline and continued into the period where study treatment is 
administered. 
Medications will be presented in alphabetical order, by Anatomical Therapeutic Classification 
(ATC) codes and grouped by anatomical main group. Tables will show the overall number 
and percentage of subjects receiving at least one treatment of a particular ATC code and at 
least one treatment in a particular anatomical main group. 
Significant prior and concomitant non-drug therapies and procedures will be summarized by 
primary system organ class and MedDRA preferred term. 
The number and percentage of subjects receiving prior and concomitant psoriatic arthritis 
therapy will be presented by randomized treatment group as well as the reasons for stopping 
their therapies (primary lack of efficacy, secondary lack of efficacy, lack of tolerability, other) 
and the total duration of exposure to rheumatoid arthritis therapies previously. 
9.4 Analysis of the primary variable(s) 
Details of the testing strategy including primary and secondary endpoints are provided in 
Section 9.5.1. 
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9.4.1 Variable 
The primary efficacy variable will be ACR20 response at Week 24. The analysis of the 
primary efficacy variable will be based on the FAS subjects who are TNFα inhibitor-naive. 
Primarily, CRP will be used instead of ESR to calculate ACR response; ESR will only be 
used in the event CRP is missing.   
9.4.2 Statistical model, hypothesis, and method of analysis 
The statistical hypothesis for ACR20 being tested is that there is no difference in the 
proportion of subjects fulfilling the ACR20 criteria at Week 24 in any of the secukinumab 
regimens versus placebo regimen in subpopulation of subjects who are TNFα inhibitor-naïve. 
Let pj denote the proportion of ACR20 responders at Week 24 for treatment regimens j, j=0, 
1, 2, where  
• 0 corresponds to placebo regimen, 
• 1 corresponds to secukinumab 75 mg s.c., 
• 2 corresponds to secukinumab 150 mg s.c., 
In statistical terms, Hj: pj = p0, HAj: pj ≠ p0, for the jth secukinumab regimen, i.e. 
H1: secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 in the subpopulation of subjects who are TNFα 
inhibitor naïve 
H2: secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 in the subpopulation of subjects who are TNFα 
inhibitor naïve 
The primary endpoint of ACR20 at Week 24 will be analyzed via logistic regression with 
treatment as a factor and weight as a covariate.  Odds ratios will be computed for comparisons 
of secukinumab regimens versus placebo regimen utilizing the logistic regression model 
fitted.   
For subjects meeting the criteria for early escape at Week 16, their ACR20 will be set to non-
response at Week 24.  This applies for all three treatment regimens in order to minimize bias. 
9.4.3 Handling of missing values/censoring/discontinuations 
Missing data for ACR20 response and other binary efficacy variables (e.g. ACR50, ACR70, 
HAQ-DI response, etc.) will be handled based on a three tiered approach for drop-outs, 
complete missing data, and partial missing data. 
1. Subjects who drop out of the trial for any reason will be considered non-responders from 
the time they drop out through the rest of the trial. 
2. If a subject is missing all ACR components but has not dropped out of the trial, then 
response will be imputed using data from surrounding visits.  If the visit before and after 
are both responses, the subject will be considered a responder.  Otherwise, the subject will 
be considered a non-responder except when the last visit is missing, data from the two 
previous visits will be used with the same logic for determining response.   
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3. If a subject has partial missing data for a visit (i.e. only some of the ACR components), 
LOCF will be used to impute the missing components. 
LOCF will be used as the primary analysis method for continuous variables (e.g. ACR 
components, DAS, etc.).  For analyses of these parameters, if all post-baseline values are 
missing then these missing values will not be imputed and this subject will be removed from 
the analysis of the corresponding variable, i.e. it might be that the number of subjects 
providing data to an analysis is smaller than the number of subjects in the FAS. 
In general, the handling of data for subjects who meet the criteria for early escape at week 16 
will be handled in the following fashion:  For binary endpoints, subjects will be considered 
non-responders.   For continuous endpoints, LOCF from the point of escape will be used to 
impute data for week 24. This applies for all 3 treatment regimens in order to minimize bias. 
9.4.4 Supportive analyses 
Sensitivity analyses and supportive analyses will be conducted in order to provide evidence 
that the results seen from the primary analysis are robust.  These analyses will center on the 
deviations in model assumptions, and the treatment of missing data. 
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ACR20 response at Week 24 will also be evaluated using a non-parametric 
regression (Koch et. al 1998) model with the same independent variables as the logistic 
regression model.  In addition, further logistic regression models may be conducted which 
explore the impact of other baseline or disease characteristics on response.  Treatment by 
factor interactions will be explored. 
The generalized estimating equation (GEE) method extending the logistic regression analysis 
will be performed to evaluate the treatment effect of secukinumab compared to placebo over 
time and to assess the impact of missing data.  The exchangeable correlation matrix will be 
used, and treatment by time interaction will be explored. 
The impact of missing data on the analysis results will be assessed as well by repeating the 
logistic regression model using ways to handle missing data.  These may include, but are not 
limited to: 
• Multiple imputation 
• Observed data analysis 
• Missing data as non-response 
9.5 Analysis of secondary variables 
9.5.1 Key secondary variables 
Testing strategy 
The following primary and key secondary hypotheses will be included in the sequential 
testing strategy, and type-I-errors will be set such that a family-wise type-I-error of 5% is 
kept:  Primary objectives (as described in Section 9.4): 
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H1: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 in the subpopulation of subjects who are TNFα 
inhibitor naïve 
H2: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 in the subpopulation of subjects who are TNFα 
inhibitor naïve 
Key secondary objectives: 
H3: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 in the whole study population 
H4: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 in the whole study population 
H5: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to physical 
function (HAQ-DI) at Week 24 in the subpopulation of subjects who are TNFα inhibitor 
naïve 
H6: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to physical 
function (HAQ-DI) at Week 24 in the subpopulation of subjects who are TNFα inhibitor 
naïve 
H7: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to structural damage (van der Heijde modified total Sharp score) at week 24 
in the subpopulation of subjects who are TNFα inhibitor naïve 
H8: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24 in the subpopulation of 
subjects who are TNFα inhibitor naïve 
H9: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24 in the subpopulation of 
subjects who are TNFα inhibitor naïve 
H10: 12 months treatment with secukinumab 75 mg s.c. is not different to delayed 
secukinumab treatment (i.e. approximately 6 months placebo followed by 6 months 
secukinumab) with respect to major clinical response (continuous six-month period of 
ACR70 response) at Year 1 in the subpopulation of subjects who are TNFα inhibitor 
naïve 
H11: 12 months treatment with secukinumab 150 mg s.c. is not different to delayed 
secukinumab treatment (i.e. approximately 6 months placebo followed by 6 months 
secukinumab) with respect to major clinical response (continuous six-month period of 
ACR70 response) at Year 1 in the subpopulation of subjects who are TNFα inhibitor 
naïve 
The graphical approach of (Bretz 2009) for sequentially rejective testing procedures is used to 
illustrate the testing strategy: 
This document (090095a88362b521 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 5/12/2011 2:47:40 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by Ambs Petra in Basel at Thu, May 12, 2011 16:41:36 CEST
Novartis Confidential Page 70 
Clinical Trial Protocol  Protocol No. CAIN457F2306 
 
 
Figure 9-1 Testing strategy 
  
The family-wise error will be set to α=5% and it will be controlled with the proposed 
hierarchical testing strategy.  With this hierarchical testing approach, each of the hypotheses 
(H1 and H2) for the primary objective (based on signs and symptoms at week 24) for each 
secukinumab regimen versus placebo will be tested simultaneously at α/2. If at least one of H1 
and/or H2 are/is rejected, then the ACR20 endpoint will be tested for the full population (H3 
and/or H4, respectively).  If at least one of H3 and/or H4 is rejected, the hypothesis 
corresponding to physical function, H5 and/or H6, is tested, respectively. If either of H5 or H6 
is rejected, then the hypothesis corresponding to the key secondary objective on joint structure 
endpoint at Week 24 for testing pooled secukinumab doses versus placebo (H7) can be tested 
at α/2 or α depending on whether one or both of H5 and H6 is rejected. If this pooled 
hypothesis is rejected, then hypotheses concerning individual regimens of secukinumab 
versus placebo can be tested for a particular regimen at α/2, if the corresponding regimen’s 
hypothesis for the primary objective and key secondary objective relating to HAQ was 
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rejected. Once all hypotheses within a hierarchy for a secukinumab regimen are rejected, then 
the respective α/2 can be passed on to the other regimen’s hierarchy of hypotheses, if they 
were not already rejected at α/2. Of note, in the description above, rejection of a hypothesis 
refers to rejection of the two-sided hypothesis; however the level of a rejected hypothesis is 
only passed on according to the graphical procedure for the test of another hypothesis if the 
treatment effect is in favor of secukinumab. 
In addition to the sequential testing strategy described above, Hochberg's procedure will be 
used to test the primary hypotheses (H1 and H2) at an overall two-sided 0.125% level.  This is 
done in order to determine whether weight of the statistical evidence in support of the primary 
endpoints is equivalent to that which would be required if two independent trials were 
conducted in this population.  This additional test will be conducted in order to meet US 
health authority requirements. 
ACR20 at Week 24 in the whole study population 
Response at Week 24 to ACR20 in the FAS will be evaluated using a logistic regression 
model with treatment and randomization stratum (TNFα status -naive or IR ) as factors and 
weight as a covariate.  Sensitivity analyses similar to those conducted for the TNFα-naive 
population may be conducted.  The interaction between treatment and TNFα status (naive or 
IR) will be explored.   
Physical function (HAQ-DI) at Week 24 
The change from baseline to week 24 will be the primary analysis parameter for evaluating 
the effect of secukinumab on physical functioning as measured by the HAQ-DI in TNFα-
naïve subjects.  Treatments will be compared by means of an ANCOVA model with treatment 
regimen, weight, and baseline HAQ-DI as effects.  Confidence intervals for the difference 
between each dose of secukinumab and placebo will be calculated.  Missing data will be 
handled using LOCF.  
Sensitivity and supportive analyses for the variable will be performed as well.  An analysis 
will also be performed with observed data, and an additional sensitivity analysis will be 
conducted using a non-parametric regression model (Koch 1998) with treatment regimen, 
weight and baseline HAQ-DI as effects.  Changes from baseline in HAQ-DI values at Week 
24 and other timepoints will be evaluated using a longitudinal mixed effects ANCOVA model 
with treatment group, , and analysis visit as factors and weight and baseline HAQ-DI as 
covariates. An unstructured covariance structure will be assumed for this model.  The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo and/or secukinumab at the appropriate analysis visits. 
A responder approach will also be used; the HAQ-DI change from baseline to Week 24 will 
be classified into response or non-response using a 0.30 improvement from baseline or not, 
respectively. The analysis of the binary response variable will be done via logistic regression 
with treatment regimen, weight, and baseline HAQ-DI as independent variables. Odds ratios 
will be computed for comparisons of secukinumab regimens versus placebo regimen utilizing 
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the logistic regression model fitted. The handling of missing data for this binary endpoint will 
be carried out the same way as for ACR20. 
Joint/bone structural damage at Week 24 
The change at Week 24 from baseline van der Heijde total modified Sharp score will be 
evaluated using a non-parametric ANCOVA model with treatment regimen as factor and 
weight and baseline van der Heijde total modified Sharp score as covariates for in 
TNFαinhibitor naïve subjects. The main analysis to compare pooled secukinumab regimens 
(75 mgs.c. and 150 mg s.c.) and then compared to placebo followed by secukinumab regimen 
for the FAS TNFα inhibitornaive subjects. Then each of the secukinumab regimens will be 
compared versus the placebo regimen via pairwise comparisons for the FAS TNFα inhibitor 
naïve subjects.  
For subjects who meet the criteria for early escape at Week 16 and subjects who discontinue 
the study prior to Week 24, linear extrapolation will be used to impute the value at Week 24.  
In order to minimize bias, the extrapolation will use baseline and all post-baseline data up to 
the point the subject meets criteria for early escape treatment, or discontinues the study.   
If baseline or all post-baseline total modified Sharp score/s is/are missing for a subject, the 
subject will be excluded from the analyses.  
Sensitivity analyses will be performed using LOCF methodology: For subjects who meet the 
criteria for early escape at Week 16 and subjects who discontinue the study prior to Week 24, 
LOCF will be used to impute the value at Week 24. 
Major Clinical Response at Week 52 
Major Clinical Response (MCR) at Year 1 is defined as continuous six-months of ACR70 
response during the 1 year period. As the expected response rates are low, particularly in the 
placebo regimen, the analysis method of this binary response variable will be done using the 
Fisher’s exact test. Secukinumab regimens will be compared to placebo followed by 
secukinumab regimen in a pairwise fashion with respect to the proportion of TNFα 
inhibitornaïve subjects with MCR at Year 1.  
The derivation of MCR will use the ACR70 responses whose imputations for missing data 
done in the same fashion as the primary efficacy variable, ACR20.  Of note: 
• Subjects escaping early at Week 16 (including subjects meeting early escape criteria in 
secukinumab regimens) or discontinuing study treatment prior to Week 16 will be 
considered non-responders.  
• Subjects who discontinue the study before week 52 will be considered non-responders 
• In the 6-month period of continuous response, no more than 1 visit could be imputed. 
A sensitivity analysis will also be performed with observed data.  As additional sensitivity 
analysis, major clinical response at Year 1 will be evaluated using a logistic regression model 
with treatment regimen, and baseline DAS28 as effects. Odds ratios will be computed for 
comparisons of secukinumab regimens versus placebo regimen utilizing the logistic 
regression model fitted. 
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9.5.2 Efficacy variables 
The following secondary objectives will be analyzed for the FAS subjects.  Summaries by 
each randomization strata will also be performed. 
Joint/bone structural damage at Week 52 and 104 
Observed joint/bone structure data at Week 52 will be compared between subjects randomized 
at baseline to secukinumab regimen (pooled from 2 secukinumab regimens) and placebo 
followed by secukinumab regimen. The change from baseline to Week 52 will be evaluated 
using a non-parametric ANCOVA model utilized for Week 24 and including randomization 
strata as a covariate.   
As sensitivity analysis,  for subjects with missing modified Sharp score values at Week 52, 
their Week 52 value will be imputed by linear extrapolation from baseline, Week 16 and 
Week 24, and at subject discontinuation visit (if subject discontinued prior to Week 52) to 
Week 52. 
Summary statistics of observed data at Week 52 will be provided for each treatment regimens: 
secukinumab 75 mg,  secukinumab 150 mg, placebo escape or switch to secukinumab 75 mg 
at Week 16 or 24, placebo escape or switch to secukinumab 150 mg at Week 16 or 24. 
Summary statistics include mean, standard deviation, minimum, lower quartile, median, upper 
quartile and maximum as well as Hodges-Lehmann estimate for the median including 95% 
confidence interval. 
Observed Joint/bone structure data at Week 104 will be summarized by treatment group.  In 
addition, the change from week 52 will also be summarized within treatment regimen. 
MCR at Week 104 
Major clinical response at 104 will be summarized by treatment groups. 
Evidence of no disease progression at Week 24, 52 and 104 
The proportion of subjects without disease progression will be defined as those subjects who 
have a change in van der Heijde total modified Sharp score at Week 24 relative to 
baseline ≤ 0.  The proportion of subjects without disease progression at Week 24 will be 
evaluated using a logistic regression model with treatment group and randomization strata, as 
factors, weight and baseline van der Heijde total modified Sharp score as covariates. 
If a subject discontinues from the study prior to at Week 24 or meets the criteria of early 
escape due to pre-defined response criteria, the subject will be classified as being a non-
responder and will be classified as having experienced disease progression.  If measurements 
are available at the two previous timepoints prior to Week 24 and the subject was classified as 
a responder then the subject will be classified as a responder at Week 24. 
The proportion of subjects without disease progression at Week 52 and 104 will be evaluated 
in the same manner.  At week 104, the proportion of subjects with disease progression from 
week 52 will also be examined. 
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PsARC and ACR20/50/70 response over time 
PsARC and ACR response at individual analysis visits will be evaluated using the logistic 
regression model with treatment group and randomization strata as factors and weight as a 
covariate.  In addition, to evaluate the robustness of ACR response over time, a GEE model 
will be fitted that includes analysis visit and the treatment group-by-analysis visit interaction 
as factors.  An exchangeable covariance structure will be assumed for the GEE model fitted 
for ACR response variable.   
HAQ-DI over time 
Between-treatment differences in the change from baseline in HAQ-DI will be evaluated 
using an ANCOVA model with treatment group and randomization strata as factors,  weight 
and baseline DAS28 score as covariates. The significance of the treatment effect for 
secukinumab regimens at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate 
analysis visits. 
HAQ-DI response over time will be evaluated in the same fashion as ACR response over time 
i.e. using logistic regression.  Baseline HAQ-DI score and randomization strata will be used 
as a covariate. 
Changes in DAS28 over time 
Between-treatment differences in the change from baseline in DAS28-CRP will be evaluated 
using an ANCOVA model with treatment group and randomization strata as factors, weight 
and baseline DAS28-CRP score as  covariates.   For sensitivity, a repeated measures 
ANCOVA will be used with treatment group, randomization strata, analysis visit, and 
treatment group by analysis visit interaction as factors and baseline DAS28-CRP score and 
weight as covariates. An unstructured covariance structure will be assumed for this model.  
The significance of the treatment effect for secukinumab regimens at different analysis visits 
will be determined from the pairwise comparisons performed between secukinumab regimens 
and placebo at the appropriate analysis visits.   
DAS28 remission, low disease activity at Week 24 and over time 
DAS28 remission is defined as a DAS28-CRP index score less than 2.6.  Low disease activity 
is defined as DAS28-CRP index less than or equal to 3.2  The proportion of subjects meeting 
these response criteria at Week 24 will be evaluated using a logistic regression model with 
treatment group and , randomization strata as factors, weight and baseline DAS28-CRP score 
as covariates. 
If a subject discontinues from the study prior Week 24 or meets the criteria for early escape 
due to pre-defined response criteria, the subject will be classified as being a non-responder 
and will be classified as having not been in DAS28-CRP remission.  If measurements are 
available at the two previous timepoints prior to Week 24 and the subject was classified as a 
responder then the subject will be classified as a responder at Week 24. 
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The Week 24 results will be confirmed by a GEE model which incorporates analysis visit and 
the treatment group-by-analysis visit interaction as factors and assumes an exchangeable 
covariance structure 
EULAR response at Week 24 and over time 
Based on the EULAR response criteria (good responder, moderate responder, and non-
responder) as determined based on the value of DAS28-CRP achieved and the magnitude of 
change from baseline. Between-treatment differences in EULAR response at Week 24 will be 
evaluated using a proportional odds regression model with treatment group and randomization 
strata as factor , weight and baseline DAS28-CRP score as covariates. Frequency tables will 
also be presented to show the response rate over time up to Week 24 and Week 52, as 
appropriate. 
Changes in tender joint counts over time 
For the change in tender joint counts, since evidence from the literature would suggest that the 
changes from baseline are normally distributed (van Vollenhoven 2003), between-treatment 
differences in the change in tender joint counts will be evaluated using an ANCOVA model 
with treatment group and randomization strata as factors,  weight and baseline tender joint 
counts as  covariates. The significance of the secukinumab treatment effect at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo  at the appropriate analysis visits. 
Change in swollen joint counts over time 
For the change in swollen joint counts, since evidence from the literature would suggest that 
the changes from baseline are normally distributed (van Vollenhoven 2003), Between-
treatment differences in the change in swollen joint counts will be evaluated using an 
ANCOVA model with treatment group and randomization strata as factors,  weight and 
baseline swollen joint counts as  covariates.  The significance of the secukinumab treatment 
effect at different analysis visits will be determined from the pairwise comparisons performed 
between secukinumab regimens and placebo  at the appropriate analysis visits. 
Change in Patient’s global assessment in disease activity 
For the change in patient’s global assessment, since evidence from the literature would 
suggest that the changes from baseline are normally distributed (van Voellenhoven 2003), 
between-treatment differences in the change in patient’s global assessment will be evaluated 
using an ANCOVA model with treatment group and randomization strata as factors,  weight 
and baseline patient’s global assessment VAS score as  covariates.  The significance of the 
secukinumab treatment effect at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate 
analysis visits. 
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Change in Physician’s global assessment in disease activity 
For the change in physician’s global assessment in disease activity, since evidence from the 
literature would suggest that the changes from baseline are normally distributed (van 
Vollenhoven 2003), between-treatment differences in the change in physician’s global 
assessment will be evaluated using an ANCOVA model with treatment group and  
randomization strata as factors,  weight and baseline physician’s global assessment VAS score 
as  covariates. The significance of the secukinumab treatment effect at different analysis visits 
will be determined from the pairwise comparisons performed between secukinumab regimens 
and placebo   at the appropriate analysis visits. 
Change in PsA Pain 
For the change in PsA pain, since evidence from the literature would suggest that the changes 
from baseline are normally distributed (van Vollenhoven 2003), between-treatment 
differences in the change in PsA pain will be evaluated using an ANCOVA model with 
repeated measures with treatment group and  randomization strata as factors, weight and 
baseline pain VAS as covariates. The significance of the secukinumab treatment effect at 
different analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo  at the appropriate analysis visits. 
Change in erythroycyte sedimentation rate (ESR) 
For the change in ESR, since evidence from the literature would suggest that the changes from 
baseline are normally distributed (van Vollenhoven 2003), between-treatment differences in 
the change in ESR will be evaluated using an ANCOVA model with treatment group and 
randomization strata, as factors,  weight and baseline ESR as  covariates.  The significance of 
the secukinumab treatment effect at different analysis visits will be determined from the 
pairwise comparisons performed between secukinumab regimens and placebo at the 
appropriate analysis visits. 
Change in high-sensitivity C-reactive protein (hsCRP) 
For the change in hsCRP, since evidence from the literature would suggest that the data is not 
normally distributed (Huffman 2006), analysis will be performed on the loge ratio of the 
treatment value vs. baseline value (calculated by dividing the post-baseline value by the 
baseline value and then applying the loge transformation) to normalize the distribution of 
hsCRP at each analysis visit. Between-treatment differences in the change in hsCRP relative 
to baseline will be evaluated using an ANCOVA model with treatment group and 
randomization strata, as factors and weight loge baseline hsCRP as covariates.  The 
significance of the secukinumab treatment effect at different analysis visits will be determined 
from the pairwise comparisons performed between secukinumab regimens and placebo   at the 
appropriate analysis visits. In addition, the 2-sided 95% confidence intervals obtained from 
the model will be back transformed to the original scale. 
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PASI 75 response and IGA 
PASI 75 response and IGA over time will be evaluated for those subjects in whom the 
assessment occurred (which is planned to be a subset of the FAS).  The binary variable will be 
evaluated in the same fashion as ACR response, i.e. a logistic regression model with treatment 
and and randomization strata as factors and weight as a covariate. 
Missing data will be handled via LOCF. 
mNAPSI 
The mNAPSI scores range from 0-140 for all finger and toenails. The mNAPSI score will be 
evaluated for those subjects in whom the assessment occurred (which is planned to be a subset 
of the FAS) and summarized by treatment group.  Treatments will be compared using 
ANCOVA with treatment regimen and randomization strata as factors and baseline score and 
weight as covariates. 
LDI 
LDI measures the dactylitis and the scores will be summarized by treatment group.  In 
addition, a parametric or non-parametric ANCOVA will be used to compare the treatment 
groups using treatment regimen and randomization strata as factors and baseline LDI and 
weight as covariates.  
LEI 
The LEI will be summarized by treatment group.  In addition, a parametric or non-parametric 
ANCOVA will be used to compare the treatment groups using treatment regimen and 
randomization strata as factors and baseline LDI and weight as covariates. 
9.5.3 Safety variables 
Adverse events 
Treatment emergent adverse events (events started after the first dose of study treatment or 
events present prior to the first dose of study treatment but increased in severity based on 
preferred term) will be summarized.  
AEs will be summarized by presenting, for each treatment group, the number and percentage 
of subjects having any AE, having an AE in each primary system organ class and having each 
individual AE (preferred term). Summaries will also be presented for AEs by severity and for 
study treatment related AEs. If a subject reported more than one adverse event with the same 
preferred term, the adverse event with the greatest severity will be presented. If a subject 
reported more than one adverse event within the same primary system organ class, the subject 
will be counted only once with the greatest severity at the system organ class level, where 
applicable. Serious adverse events will also be summarized. 
These summaries will be presented separately by study period.   
As appropriate, the incidence of AEs will be presented per 100 patient years of exposure.  
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Separate summaries will be provided for death, serious adverse event, other significant 
adverse events leading to discontinuation and adverse events leading to dose adjustment 
(including study treatment discontinuation). 
A graphical display of relative frequencies within system organ classes and relative risks, as 
appropriate, will be presented. 
For AEs of special interest (e.g. infections), time-to-event analysis will be performed, as 
appropriate. Results will be tabulated and the Kaplan-Meier estimates for the cumulative rate 
will be plotted. 
When adjudication is required of major cardiovascular events (MACE), a summary of those 
types of events as reported by the investigator and confirmed by adjudication will be 
provided. 
Laboratory data 
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, serum chemistry and urinalysis). Descriptive summary statistics for the change 
from baseline to each study visit will be presented. These descriptive summaries will be 
presented by test group, laboratory test and treatment group. Change from baseline will only 
be summarized for subjects with both baseline and post baseline.  
For each parameter, the maximum change from baseline within each study period will be 
evaluated analogously.  
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal 
laboratory ranges will be used to evaluate whether a particular laboratory test value was 
normal, low, or high for each visit value relative to whether or not the baseline value was 
normal, low, or high. These summaries will be presented by laboratory test and treatment 
group. Shifts will be presented by visit as well as for most extreme values post-baseline. 
Immunogenicity 
Summary statistics will be provided for the percent of subjects with immunogenicity. If 
appropriate, shift tables will also be presented. 
Vital signs 
Analysis of the vital sign measurements using summary statistics for the change from baseline 
for each post-baseline visit will be performed. These descriptive summaries will be presented 
by vital sign and treatment group. Change from baseline will only be summarized for subjects 
with both baseline and post-baseline values. 
ECG 
Summary statistics will be presented for ECG variables by visit and treatment group.  
Qualitative changes will be summarized. 
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9.5.4 Health-related Quality of Life 
The PsAQoL will be evaluated for FAS subjects where data are available.  All Health-related 
Quality of Life will be evaluated based on FAS. 
EQ-5D 
The EQ-5D is a questionnaire with 5 questions (regarding mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression) each with three categories (no problem, moderate 
problem, severe problems) and a health state assessment from 0 (worst possible health state) 
to 100 (best possible health state). The number and percentage of subjects in each of the three 
categories for each question will be presented by visit and treatment group. Chi-square tests 
may be used to compare treatments.  
 Summary statistics will be shown for the health state assessment by visit and treatment group. 
The change from baseline at each timepoint will be compared amongst treatments using 
ANCOVA 
SF-36 
The following variables will be evaluated:  
• SF-36 domain scores. 
• SF-36 domain score responders (Improvements of ≥ 5 points and ≥ 10 points will be used 
as measures of clinically important differences (MCIDs) in SF-36 domain scores: 
• Type I responders (improvement of ≥ 5 points in ≥ 6 domains) 
• Type II responders (improvement of ≥ 10 points in ≥ 3 domains) 
• SF-36 PCS and MCS scores. 
• SF-36 PCS and MCS score responders (MCIDs of ≥ 2.5 points and ≥ 5 points will be used 
for analysis purposes):    
• Type I responders (improvement of ≥ 2.5 points) 
• Type II responders (improvement of ≥ 5 points). 
ANCOVA will be carried out to estimate treatment differences for SF-36 domain scores and 
SF-36 summary scores. The ANCOVA model will consider treatment group and 
randomization strata as factors, weight and baseline score as  covariates. Contrasts will be 
tested at a two-sided 5% level of significance. 
In the responder analyses, treatment groups will be compared with respect to response to 
treatment using a logistic regression model with treatment and randomization strata as factors,  
weight and baseline SF-36 summary score as covariates. Odds ratios with corresponding 95% 
confidence intervals will be estimated in addition. 
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FACIT-Fatigue 
Between-treatment differences in the change in FACIT-Fatigue total score will be evaluated 
using an ANCOVA model with treatment group, randomization strata as factors,  weight and 
baseline FACIT-Fatigue total score as covariates.  The significance of the treatment effect for 
secukinumab regimens at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate 
analysis visits. 
Dermatology Life Quality Index  
The DLQI will be evaluated for those subjects in whom the assessment occurred (which is 
planned to be a subset of the FAS).  The DLQI measures functional disability of subjects with 
dermatological disorders that are greater than 18 years of age and had been utilized as a 
relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials.  The 
DLQI is a simple, validated, self-administered 10-item questionnaire.  The instrument 
contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and 
school, personal relationships, treatment).  For the DLQI, each question will be answered with 
the following response: “not at all,” “a little,” “a lot,” or “very much”.  Seven scores will be 
derived from the DLQI: the total score of each of the six dimensions as well as the total score 
over all items. The higher the score, the more quality of life is impaired.  
For each of the seven scores the percentage change from baseline will be derived. Summary 
statistics will be provided for absolute values as well as for the percentage change by visit and 
treatment group. 
The absolute value and the percentage change from baseline of DLQI total score will be 
analyzed with the Van-Elteren test using type-II weights, for all pairwise comparisons 
between secukinumab treatment groups versus control(s). The Van-Elteren test will be 
performed at each visit. Language of the questionnaire and geographical region and body 
weight stratum will be the strata adjusted for in the Van-Elteren test. In addition, stratified 
Hodges-Lehmann estimates for the median as well as confidence intervals will be derived for 
the absolute values and percentage change to baseline for each treatment group as well as for 
all pairwise comparisons between secukinumab treatment groups versus placebo. 
It is understood that conclusions obtained from the confidence intervals of these estimates 
(mean or Hodges-Lehmann estimates for the median) will not be completely consistent with 
the testing results (Van-Elteren test) which constitute the key analysis for drawing 
conclusions. 
In addition, summary statistics will be provided for number of subjects achieving DLQI 0 or 
1. Secukinumab treatment groups will be compared to placebo by means of Fisher’s exact 
test. 
PsAQoL 
The PsA quality of life (PsAQoL) questionnaire contains 20 individual yes/no questions 
where the total score is determined by the number of questions that received a “yes” response.  
Thus, a higher score reflects a poorer quality of life.  Descriptive statistics (mean, median, 
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standard deviation, minimum, maximum) will be presented  for each treatment group for the 
total score for all analysis visits including baseline and the change from baseline for all post-
randomization visits.  In addition, the number and percentage of subjects who responded yes 
and no to each questions will be presented by treatment group and analysis visit.  Shift tables 
showing the changes in individual questions will also be presented, as appropriate between-
treatment differences will be analyzed via ANCOVA. 
WPAI-GH 
The WPAI-GH has four main outcomes and they are expressed in percentages. Descriptive 
statistics (mean, median, standard deviation, minimum, maximum) will be presented for each 
treatment group for the four outcomes including baseline and the change from baseline for all 
post-randomization visits will be summarized by treatment.  Between-treatment differences 
may be analyzed via ANCOVA. 
9.5.5 Pharmacokinetics 
All subjects with concentration data will be included in the pharmacokinetic data analysis. 
Pharmacokinetic variables 
The following pharmacokinetic parameter will be determined: Cmin,ss. Individual 
concentrations will be listed. 
Biofluid concentrations will be expressed in µg/ml. All concentrations below the limit of 
quantification or missing data will be labeled as such in the concentration data listings. 
Concentrations below the Limit of Quantification will be treated as zero in summary statistics 
for concentration data only. 
Cmin,ss will be determined using Phoenix. 
During modeling of the pharmacokinetics of secukinumab, the broad principles outlined in the 
FDA Guidance for Industry: Population Pharmacokinetics will be followed. 
Statistical methods for pharmacokinetic analyses 
All completed subjects with quantifiable PK measurements of secukinumab will be included 
in the PK data analysis. Serum concentrations will be expressed in mass per volume units. All 
concentrations below the limit of quantification or missing data will be labeled as such in the 
concentration data listings. PK concentrations will be summarized by visit and treatment 
group. In addition to mean, standard deviation, coefficient of variation, median and quartiles, 
the geometric mean and geometric coefficient of variation and n(log) will be presented. 
9.5.6 Pharmacogenetics 
The exploratory pharmacogenetic studies are designed to investigate the association between 
genetic factors (genotypes) and clinical assessments (phenotypes) which are collected during 
the clinical trial. Without prior evidence of a strong association, a number of possible 
associations are evaluated with exploratory analyses.  A range of statistical tests (chi-square 
tests, ANCOVAs, linear and logistic regression) are used for the analyses.  Additional data, 
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from subsequent clinical trials, are often needed to confirm associations.  Alternatively, if the 
numbers of subjects enrolled in the study are too small to complete proper statistical analyses, 
these data may be combined, as appropriate, with those from other studies to enlarge the data 
set for analysis.   
9.5.7 Biomarkers 
Soluble marker panel studies investigate differences in the level of expression of proteins or 
peptides between individuals in a given biofluid.  The goal of such studies is to allow the 
identification of potential protein or peptide biomarkers of drug action or disease, and to 
better understand the associated underlying molecular mechanisms.  By applying statistical 
analysis methods (e.g. principal component analysis) between subject groups, distinct study 
time points, or between study groups from other clinical trials, it may be possible to identify 
patterns which are associated with disease state or response to drug treatment.  However, the 
exact type of data analysis method will depend on the type of data obtained in the study and 
thus the analysis of this data will be data driven. 
9.5.8 PK/PD 
An indirect response model, driven by study treatment concentration, will be used to 
characterize the time course of efficacy response. Further details of the modeling approach 
will be specified in a modeling plan. 
9.6 Sample size calculation 
A 5% two-sided type I error rate will used to control for type I error.  Two secukinumab doses 
will be tested versus placebo with respect to the primary endpoint (ACR20 response at Week 
24), thus the type-I-error will be split to 2.5% two-sided for each comparison. Sample sizes 
will be based on this type I error assumption. 
In this study population a placebo response rate of about 10% to 15% after 12 to 16 weeks 
were reported (Kavanaugh 2009) and (Mease 2005) for the naive population.  The response 
rate of 15% will be assumed for the TNFα inhibitor naïve population and 10% for the TNFα 
inhibitor IR-population.  Based on the weighted average, the overall placebo rate is expected 
to be 13.5%.   
The response on secukinumab is expected to be 50% in the TNFα inhibitor naïve population 
and 40% in the TNFα inhibitor IR-population.  Based on the weighted average, the overall 
rate on a dose of secukinumab is expected to be 47%. 
For the primary endpoint, ACR20 in the TNFα inhibitor naïve population, 140 subjects per 
group would yield approximately 99% power to detect a treatment difference of 35% 
(Fisher’s exact test, PASS 2002). 
In order to satisfy health authority requirements in the US, the same comparison will also be 
compared using a more stringent type I error (0.125%).  Despite the smaller risk for type I 
error in this analysis, the study still maintains 99% power to detect the treatment difference of 
35%. 
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9.7 Power for analysis of key secondary variables 
Power for secondary variables was calculated using a two-sided 2.5% type I error. With an 
assumed placebo rate of 13.5% and secukinumab 47%, the study is over 99% powered to 
detect a treatment difference of ACR20 in the full FAS population, assuming 200 TNFα 
inhibitor naive subjects per treatment arm (Fisher’s exact test, PASS 2002). A standard 
deviation of approximately 0.5 has been observed for the change from baseline in HAQ-DI in 
golimumab and adalimumab trials in psoriatic arthritis.  A 0.3 treatment difference is 
considered clinically relevant.  Using those assumptions, the study has approximately over 
99% power to detect a difference between secukinumab and placebo (NQuery Advisor 6.01), 
assuming 140 TNFα inhibitor naïve subjects per arm. 
For structural endpoint, historical data (adalimumab) in this population showed a standard 
deviation of 1.2 on active drug and 2.4 on placebo at week 26.  Using the standard deviations 
above and a clinically meaningful difference of 0.6, there is 70% power to show statistically 
significant differences between secukinumab (pooled 280 TNFα inhibitor naive subjects) and 
placebo (140 TNFα inhibitor naive subjects).  Individual comparisons between secukinumab 
and placebo would have 66% power (Satterthwaite t-test, PASS 2002). 
Reference data for major clinical response was not found for this population.  However, it is 
commonly evaluated in rheumatoid arthritis.  In arthritis, an active and placebo response of 
approximately 10% and 2% has been observed (Cimzia© (certolizumab), Orencia© (abatacept) 
labels).  With 140 subjects per treatment arm, the study would be approximately 48% power 
to show a difference in this variable for TNFα inhibitor naïve subjects. 
9.8 Interim Analysis 
The primary efficacy analysis will be performed after all subjects have completed Week 52 
assessment. 
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10 Ethical considerations 
10.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 
21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid 
down in the Declaration of Helsinki. 
10.2 Informed consent procedures 
Eligible subjects may only be included in the study after providing written (witnessed, where 
required by law or regulation), IRB/IEC-approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative of the subject. 
In cases where the subject’s representative gives consent, the subject should be informed 
about the study to the extent possible given his/her understanding. If the subject is capable of 
doing so, he/she should indicate assent by personally signing and dating the written informed 
consent document or a separate assent form. Informed consent must be obtained before 
conducting any study-specific procedures (i.e. all of the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the subject source 
documents.  
Novartis will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory requirements and is 
considered appropriate for this study. Any changes to the proposed consent form suggested by 
the investigator must be agreed to by Novartis before submission to the IRB/IEC, and a copy 
of the approved version must be provided to the Novartis monitor after IRB/IEC approval. 
Women of child bearing potential should be informed that taking the study treatment may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the subject will not reliably comply, they 
should not be entered in the study. 
The study includes an optional pharmacogenetic component which requires a separate 
signature if the subject agrees to participate.  It is required as part of this protocol that the 
Investigator presents this option to the subject.  The process for obtaining consent should be 
exactly the same as described above for the main informed consent.  
Declining to participate in these pharmacogenetic assessments will in no way affect the 
subject’s ability to participate in the main research study.  
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In the event that Novartis wants to perform testing on the samples that are not described in 
this protocol, additional Institutional Review Board and/or ethics committee approval will be 
obtained. 
10.3 Responsibilities of the investigator and IRB/IEC 
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board (IRB/IEC) before study start. A signed and dated statement that the protocol and 
informed consent have been approved by the IRB/IEC must be given to Novartis before study 
initiation. Prior to study start, the investigator is required to sign a protocol signature page 
confirming his/her agreement to conduct the study in accordance with these documents and all 
of the instructions and procedures found in this protocol and to give access to all relevant data 
and records to Novartis monitors, auditors, Novartis Clinical Quality Assurance 
representatives, designated agents of Novartis, IRBs/IECs/REBs, and regulatory authorities as 
required. If an inspection of the clinical site is requested by a regulatory authority, the 
investigator must inform Novartis immediately that this request has been made. 
10.4 Publication of study protocol and results 
Novartis assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this trial will be either submitted for publication 
and/or posted in a publicly accessible database of clinical trial results. 
11 Protocol adherence 
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
trial to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the conduct of the study this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR. 
11.1 Protocol Amendments 
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC. Only 
amendments that are required for subject safety may be implemented prior to IRB/IEC 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety of any subject 
included in this study, even if this action represents a deviation from the protocol. In such 
cases, Novartis should be notified of this action and the IRB/IEC at the study site should be 
informed within 10 working days. 
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13 Appendices 
13.1 Appendix 1: Clinically notable laboratory values and vital signs 
Safety Analyses:  Expanded Limits and Notable Criteria 
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests. 
Clinically notable values will be forwarded to Novartis at the same time that they are sent to 
investigators. 
 Final Harmonization 
  Notable Criteria 
Laboratory Variable  Standard Units SI Units 
LIVER FUNCTION AND RELATED VARIABLES 
SGOT (AST)  >3 x ULN >3 x ULN 
SGPT (ALT)  >3 x ULN >3 x ULN 
Bilirubin  >2 x ULN >2 x ULN 
Alkaline phosphatase  >2.5 x ULN >2.5 x ULN 
    
RENAL FUNCTION, METABOLIC AND ELECTROLYTE VARIABLES 
Creatinine (serum)  >50 % above baseline1) >50 % above baseline1) 
Potassium  <3.0 mEq/L 
>6.0 mEq/L 
<3 mmol/L 
>6 mmol/L 
Sodium  <115 mEq/L 
>160 mEq/L 
<115 mmol/L 
>160 mmol/L 
1) The baseline serum creatinine value is the pre-treatment serum creatinine level, which is defined as the 
 creatinine level measured at screening (Visit 1). 
HEMATOLOGY VARIABLES 
Hemoglobin:  20 g/L decrease from baseline 
Platelet count:  <Lower Limit of Normal (LLN) 
White blood cell count: <0.8 x LLN 
Neutrophils:  <0.9 x LLN 
Eosinophils:  >1.1 x ULN 
Lymphocytes:  >1.1 x ULN 
Protein urine dipstick: ++ 
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13.2 Appendix 2: The classification criteria for psoriatic arthritis 
(CASPAR)  
To meet the ClASsification of Psoriatic ARthritis (CASPAR) criteria for diagnosis of 
psoriatic arthritis according to Taylor et al 2006, a subject must have inflammatory articular 
disease (joint, spine or entheseal) and at least 3 points from the following 5 categories: 
1. Evidence of current psoriasis, a personal history of psoriasis, or a family history of 
psoriasis (2 points)  
• Current psoriasis is defined as psoriatic skin or scalp disease present today as judged 
by a rheumatologist or dermatologist.†  
• A personal history of psoriasis is defined as a history of psoriasis that may be 
obtained from a patient, family physician, dermatologist, rheumatologist, or other 
qualified health care provider.  
• A family history of psoriasis is defined as a history of psoriasis in a first- or second-
degree relative according to patient report. 
2. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis 
observed on current physical examination (1 point)  
3. A negative test result for the presence of rheumatoid factor by any method except latex        
(1 point)  
4. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis 
recorded by a rheumatologist (1 point)  
5. Radiographic evidence of juxta-articular new bone formation appearing as ill-defined 
ossification near joint margins (but excluding osteophyte formation) on plain radiographs 
of the hand or foot (1 point) 
Total score: _______   
(The CASPAR criteria eCRF will autopopulate the total number of points of the CASPAR 
criteria met by the subject.  If the total score ≥ 3, the subject meets CASPAR criteria for PsA 
diagnosis.) 
† Current psoriasis is assigned a score of 2; all other features are assigned a score of 1 
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13.3 Appendix 3: American College of Rheumatology (ACR) Measures 
and Criteria of Response 
Number of tender joints 
Seventy-eight joints (78) are scored as either tender or not tender: 8 distal interphalangeal, 10 
proximal interphalangeal and 20 metacarpophalangeal joints of the hands, the 10 
metatarsophalangeal and 10 proximal interphalangeal joints of the feet, the 2 wrists, 2 elbows, 
2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 temporomandibular, 2 hip, 2 knee, 2 
talo-tibial, and 2 mid-tarsal joints.  
Joint tenderness is to be scored present (1) or absent (0).  
Number of swollen joints 
Joints are to be scored as either swollen (1) or not swollen (0). The 76 joints to be examined 
for swelling are the same as those examined for tenderness, however excluding both hip 
joints. 
Patient's assessment of PsA pain 
On a 100 mm non-anchored visual analog scale, from no pain to unbearable pain. 
Patient's global assessment of disease activity 
On a 100 mm non-anchored visual analog scale, from no arthritis activity to maximal arthritis 
activity, after the question "Considering all the ways your arthritis affects you, draw a line on 
the scale for how well you are doing". 
Physician's global assessment of disease activity 
On a 100 mm non-anchored visual analog scale, from no arthritis activity to maximal arthritis 
activity. 
Patient's assessment of physical function 
Health Assessment Questionnaire – HAQ-DI© 
ACR20/50/70* 
A patient will be considered as improved according the ACR20 criteria* if she/he has at least 
20 % improvement in 
• the two following measures: 
o Tender joint count, 
o Swollen joint count. 
• and at least 3 of the following 5 measures: 
o Patient's assessment of pain, 
o Patient's global assessment of disease activity, 
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o Physician's global assessment of disease activity, 
o Health Assessment Questionnaire (HAQ©) score, 
o C-reactive protein (CRP)/Erythrocyte Sedimentation Rate (ESR). 
ACR50 = 50 % improvement in at least 3 of the 5 measures and 50 % improvement in the 
swollen and tender joint count. 
ACR70 = 70 % improvement in at least 3 of the 5 measures and 70 % improvement in the 
swollen and tender joint count. 
Reference: (Felson 1995)  
13.4 Appendix 4: The Psoriatic Arthritis Response Criteria (PsARC) 
The PsARC represent a composite measure of psoriatic arthritis disease severity and include 
the following 4 measures: 
1. Patient global assessment of disease activity (improvement of 1 on a 5-point Likert 
scale is required for a response) 
2. Physician global assessment of disease activity (improvement of 1 on a 5-point Likert 
scale is required fro a response) 
3. Join pain (reduction of 30% or more in total score, assessing either 68 or 78 joints, 
using a 4-point scale is required for a response) 
4. Join swelling (reduction of 30% or more in total score, assessing either 68 or 78 joints, 
using a 4-point scale is required for a response) 
In order to be a ‘PsARC responder’ patients must achieve improvement in 2 of the above 
mentioned 4 measures, one of which must be joint pain or swelling, without worsening in any 
of the 4 measures. 
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13.5 Appendix 5: Disease Activity Score (DAS) 
The Disease Activity Score (DAS) is a combined index to measure the disease activity in 
patients with RA. It has been extensively validated for its use in clinical trials in combination 
with the EULAR response criteria. 
Evaluation of response to a treatment can be made much easier and more objective using the 
DAS. Just assess the number of swollen and tender joints and measure the ESR. The DAS will 
provide you with a number between 0 and 10, indicating how active the disease is at this 
moment. Recently the DAS-CRP has been developed. The C-reactive protein (CRP) may be 
used as an alternative to ESR in the calculation of the DAS or the DAS28. 
Using the DAS, several thresholds have been developed for high disease activity, low disease 
activity or remission. Also, response criteria have been developed based on the DAS, so when 
the DAS of a patient is measured at two time-points (e.g. before the start of a treatment and 
after 3 months), the patients clinical response can be assessed. 
The DAS in the clinical trials 
Comparing the DAS28 from one patient on two different time-points, it is possible to define 
improvement or response. The EULAR response criteria are defined as follows: 
 
Present 
DAS28 
DAS28 improvement 
>1.2 0.6 - 1.2 <0.6 
<3.2 good response moderate response no response 
3.2 - 5.1 moderate response 
moderate 
response no response 
>5.1 moderate response no response no response 
Both the thresholds for high and low disease activity and remission and the abovementioned 
improvement criteria should give you a feel how to interpret your DAS28 scores. 
In order to calculate the DAS28, information about the following disease variables is needed: 
• The number of swollen joints and tender joints should be assessed using 28-joint count 
(tender28 and swollen28) 
• The erythrocyte sedimentation rate (ESR) should be measured in mm/hour. 
• The patient’s general health (GH) or global disease activity measured on a Visual 
Analogue Scale (VAS) of 100 mm (both are useable for this purpose) must be obtained. 
Using this data, the DAS28 can be calculated using the following formula: 
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH 
The DAS28 provides you with a number on a scale from 0 to 10 indicating the current activity 
of the rheumatoid arthritis of your patient. A DAS28 above 5.1 means high disease activity 
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whereas a DAS28 below 3.2 indicates low disease activity. Remission is achieved by a 
DAS28 lower than 2.6 (comparable to the ARA remission criteria). 
Disease Activity Scores using C-reactive protein 
C-reactive protein (CRP) may be used as an alternative to ESR in the calculation of the DAS 
or DAS28, using the formulas below. CRP is a more direct measure of inflammation than 
ESR, and it is more sensitive to short-term changes (Kushner 1991). CRP production is 
associated with radiological progression in RA (Van Leeuwen 1993), and is considered at 
least as valid as ESR to measure RA disease activity (Mallya 1982, Wolfe 1997). Another 
advantage of determination of CRP is that waiting time for the laboratory result is shorter and 
that in case of multicenter studies a central laboratory can be used. 
The following formulas to calculate the DAS28 using CRP (mg/L) give good estimations of 
the original DAS28 values on a group level. DAS28-4(crp) = 0.56*sqrt(TJC28) + 
0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 
TJC28: 28 Tender joint count; SJC28: 28 Swollen joint count; CRP: C-reactive protein; GH: 
General Health on a 100mm. Visual Analogue Scale. 
It is strongly advised to adhere either to ESR or to CRP determinations. 
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13.6 Appendix 6: The Psoriasis Area and Severity Index (PASI) 
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their 
response to therapy. The PASI produces a numeric score that can range from 0 to 72. The 
severity of disease is calculated as follows. In the PASI system, the body is divided into 4 
regions: the head (h), trunk (t), upper extremities (u), and lower extremities (l), which account 
for 10%, 30%, 20% and 40% of the total BSA, respectively. Each of these areas is assessed 
separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The 
scoring system for the signs of the disease (erythema, induration, and scaling) are: 0 = none, 1 
= slight, 2 = moderate, 3 = severe, and 4 = very severe. The scale for estimating the area of 
involvement for psoriatic lesions is outlined below. 
0 = no involvement 
1 = 1% to 9% involvement 
2 = 10% to 29% involvement 
3 = 30% to 49% involvement 
4 = 50% to 69% involvement 
5 = 70% to 89% involvement 
6 = 90% to 100% involvement 
To help with the area assessments, the following conventions should be noted: 
• the neck is considered part of the head 
• the axillae and groin are part of the trunk 
• the buttocks are part of the lower extremities 
The PASI formula is: 
PASI = 0.1 (Eh + Ih + Sh) Ah + 0.3 (Et + It + St) At + 0.2 (Eu + Iu + Su) Au + 0.4 (El + Il + 
Sl) Al 
where E = erythema, I = induration, S = scaling, and A = area 
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13.7 Appendix 7: The modified Nail Psoriasis Severity Index (mNAPSI) 
Modified NAPSI Instructions 
This tool will ask you to assess each nail abnormality for each of a subject’s nails. If you 
question which grade to give, your answer should be the lower of the grades. Three features or 
groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) of each 
fingernail will be graded on a scale from 0 to 3, according to the directions below. Four 
features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) will 
be graded as either present or absent for each fingernail. After you have viewed all the nails of 
a subject, consider all aspects of all of the subject’s nails and place a mark on the visual 
analog scale giving a global assessment of their nails. 
1. Onycholysis: Separation of the nail plate from the nail bed. The separatedpart of the nail is 
opaque and can have white, yellow, or greenish tinge. If there is a piece of nail missing, 
estimate where the nail normally would have ended at the end of the nail bed, and count that 
missing part as involved in onycholysis. 
Oil-drop (salmon patch) dyschromia: Reddish-brown discoloration under the nail plate. 
Onycholysis and oil-drop dyschromia are considered together. When looking at the nail, 
combine the total percentage area of the nail that is affected by either and use that combined 
total to score the nail. 
 
Score Percent of nail with onycholysis or oil-drop dyschromia present 
0 No onycholysis or oil drop dyschromia present 
1 1–10% of the nail has onycholysis or oil-drop dyschromia 
2 11–30% of the nail has onycholysis or oil-drop dyschromia 
3 > 30% of the nail has onycholysis or oil-drop dyschromia 
 
2. Pitting: Small, sharply defined depressions in the nail surface. Pits are discrete 
abnormalities (“ice-pick-like”). If there is nail plate crumbling that is confluent with pits, do 
not score for pits. If the pits are separate from crumbling, they may be scored regardless of 
whether crumbling is present or not. 
 
Score Number of pits 
0 0 
1 1–10 
2 11–49 
3 > 50 
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3. Nail plate crumbling: Crumbling or fragmentation of friable nail plate which may be 
associated with confluent pitting. Crumbling involves alteration of the nail plate surface. 
Horizontal ridging of the nail, “wave-like” appearance, and horizontal lines are all features of 
crumbling. 
 
Score Percent of nail with crumbling present 
0 No crumbling 
1 1–25% of the nail has crumbling 
2 26–50% of the nail has crumbling 
3 > 50% of the nail has crumbling 
 
The next 4 abnormalities are scored only by their presence or absence. A score of 1 indicates 
present and a score of zero indicates not present. 
1. Leukonychia: White spots in the nail plate due to psoriasis in the mid matrix. Leukonychia 
are just color changes. If it appears that there is depression or irregularity to the nail surface, 
this may be pitting or crumbling, not leukonychia. If the leukonychia is adjacent to, or 
confluent with crumbling or pits, it is counted as part of the crumbling or pitting and not as a 
separate abnormality. 
2. Splinter hemorrhages: Small, longitudinal, linear, dark brown hemorrhage under the 
fingernail. 
3. Nail bed hyperkeratosis: Thickened keratin in the nail bed. 
4. Red spots in the lunula: Small pink or red macules in the lunula. 
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13.8 Appendix 8: Standard reference table for the LDI 
 
Table – hands (in cm) 
Digit Men Women 
Thumb 7.0 5.8 
Index 6.3 5.4 
Middle 6.3 5.4 
Ring 5.9 5.0 
Little 5.2 4.4 
 
Table – feet (in cm) 
Digit Men Women 
Central toe 8.2 7.2 
Second 5.2 4.6 
Middle 5.0 4.4 
Fourth 5.0 4.4 
Little 5.2 4.5 
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13.9 Appendix 9: Guidelines for administering PRO questionnaires 
Before trial begin 
Study coordinators should familiarize themselves with the PRO questionnaire(s) in the trial 
and identify any items where a subject’s response might highlight issues of potential concern. 
For example, one question in the SF-36 asks ‘How much of the time in the past 4 weeks- have 
you felt downhearted and blue?’ If a subject responds ‘most or all of the time’, then the study 
coordinator should inform the study investigator. 
Before completion 
• Subjects should be provided with the correct questionnaire 
• At the appropriate visits, and 
• In the appropriate language 
 Subjects should have adequate space and time to complete the forms 
 Subjects should be provided with a firm writing surface (such as a table or a clip board) 
and a pencil 
 Questionnaire should be administered before the clinical examination 
During completion 
 Administrator may clarify the questions but should not influence the response 
 Only one response for each question 
 Subjects should initial and date the last page of the questionnaires 
 Also see ‘Addressing Problems and Concerns’ 
After completion 
 Check for completeness and not for content* 
 Check for multiple responses that were made in error 
 Data should be transcribed from the completed questionnaire to the appropriate screen on 
the e-CRF 
 File completed questionnaire in the subject study files 
*However, any response which may directly impact or reflect the subject’s medical 
condition (e.g. noting of depression) should be communicated by the study coordinator to 
the investigator). 
Addressing Problems and Concerns 
Occasionally a subject may have concerns or questions about the questionnaires administered. 
Guidance related to some of the most common concerns and questions are given below. 
The subject does not want to complete the questionnaire(s) 
Tell the subject that completion of the questionnaire(s) is voluntary. The goal is to better 
understand the physical, mental, and social health problems of subjects. Emphasize that this 
This document (090095a88362b521 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 5/12/2011 2:47:40 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by Ambs Petra in Basel at Thu, May 12, 2011 16:41:36 CEST
Novartis Confidential Page 101 
Clinical Trial Protocol  Protocol No. CAIN457F2306 
 
 
information is as important as any of the other medical information, and that the 
questionnaire(s) is simple to complete. Suggest that the questionnaire(s) may be different 
from anything the respondent has filled in the past. If the subject still declines, retrieve the 
questionnaires. Record the reason for the decline, and thank the subject. 
The subject is too ill or weak to complete the questionnaire(s) 
In these instances, the coordinator may obtain subject responses by reading out loud each 
question, followed by the corresponding response categories, and entering the subject’s 
response. No help should be provided to the subject by any person other than the designated 
study coordinator. The coordinator should not influence subject responses. The study 
coordinator cannot translate the question into simpler language and has to be read verbatim. 
The subject wants someone else to complete the questionnaire(s) 
In no case should the coordinator or anyone other than the subject provide responses to the 
questions. Unless specified in the study protocol proxy data are not an acceptable substitute 
for subject self-report. Subjects should be discouraged from asking a family member or friend 
for help in completing a questionnaire. 
The subject does not want to finish completing the questionnaire(s) 
If non-completion is a result of the subject having trouble understanding particular items, ask 
the subject to explain the difficulty. Re-read the question for them verbatim, but do not 
rephrase the question. If the respondent is still unable to complete the questionnaire, accept it 
as incomplete. Thank the subject. 
The subject is concerned that someone will look at his/her responses 
Emphasize that all responses are to be kept confidential. Point out that their names do not 
appear anywhere on the questionnaire, so that their results will be linked with an ID number 
and not their name. Tell the subject that his/her answers will be pooled with other subjects’ 
answers and that they will be analyzed as a group rather than as individuals. Tell the subject 
that completed forms are not routinely shared with treating staff, and that their responses will 
only be seen by you (to check for completeness), and possibly the investigator. Any response 
which may directly impact on or reflect their medical condition (e.g. noting of severe 
depression) will be communicated by the coordinator to the physician. 
The subject asks the meaning of a question/item 
While completing the questionnaire, some subjects might ask the meaning of specific items so 
that they can better understand and respond. If this happens, assist the subject by rereading the 
question for them verbatim. If the subject asks to interpret the meaning of an item, do not try 
to explain it, but suggest that he/she use his/her own interpretation of the question. Subjects 
should answer the questions based on what they think the questions mean. 
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Glossary of terms 
 
Assessment A procedure used to generate data required by the study 
Control treatment A study treatment used as a comparator to reduce assessment bias, 
preserve blinding of investigational treatment, assess internal study 
validity, and/or evaluate comparative effects of the investigational 
treatment
Enrollment Point/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)
Inadequate response to TNFα  Active disease despite stable treatment with anti-TNFa for at least 3 months at a stable dose or for at least one dose in the case of lack of 
tolerance 
Investigational treatment The study treatment whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is synonymous 
with “investigational new treatment.”
Medication number A unique identifier on the label of each study treatment package in studies 
that dispense study treatment using an IVR system 
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.
Phase A major subdivision of the study timeline; begins and ends with major 
study milestones such as enrollment, randomization, completion of 
treatment, etc. 
Premature patient withdrawal Point/time when the patient exits from the study prior to the planned 
completion of all study treatment administration and assessments; at this 
time all study treatment administration is discontinued and no further 
assessments are planned
Randomization number A unique identifier assigned to each randomized patient, corresponding to 
a specific treatment arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when 
study treatment was discontinued whichever is later 
Study treatment Any treatment administered to the patient as part of the required study 
procedures; includes investigational treatment and any control drugs
Study treatment discontinuation Point/time when patient permanently stops taking study treatment for any 
reason; may or may not also be the point/time of premature patient 
withdrawal
Subject number A number assigned to each patient who enrolls in the study. When 
combined with the center number, a unique identifier is created for each 
patient in the study. 
Variable Information used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at specified timepoints
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Amendment 3  
Amendment rationale 
This protocol amendment is primarily issued for the following reasons: 
• To expand the statistical hierarchy (primary plus ranked secondary variables) to include 
more endpoints which are relevant to determining the overall therapeutic value of a 
therapy for PsA. These endpoints include but are not limited to PASI75, PASI90, DAS28-
CRP, HAQ-DI, SF-36, dactylitis and enthesitis. Psoriatic arthritis (PsA) is a multifaceted 
chronic disabling disease that can present as different clinical phenotypes: peripheral 
arthritis, axial disease, skin and nail disease, dactylitis, and enthesitis, and hence defining 
outcome measures has been a challenge. Traditionally endpoints for PsA studies focused 
only on peripheral arthritis endpoints relevant for rheumatoid arthritis. However recently 
there has been additional interest by Health Authorities and the scientific community in 
endpoints specific/more relevant for such patients (PRO e.g. SF36) and overall extra, skin 
related endpoints (PASI 75/90), dactylitis and enthesitis, hence these have been added in 
the proposed amendment hierarchy. Recent labels for Ustekinumab (Stelara), working on 
the same pathway as secukinumab, approved in Nov 2013 mentions skin related endpoints 
(PASI 90), dactylitis and enthesitis. Prior to finalizing original protocol for 
CAIN457F2306 there were no new approved therapies with this in the label. Thus the 
endpoints at that time were based on then existing knowledge. Thus it is critical that we 
align our analyses and endpoints with new precedence and hence the emerging demands 
of the field. The additional hierarchical considerations do not add any new assessments for 
patients; all this data is being collected already, we are only now reorganizing the 
hierarchy of secondary endpoints in line with new knowledge 
• In addition, the analysis is changed to include all subjects in Full Analysis Set (FAS) 
which includes TNFα inhibitor naïve as well as TNFα inhibitor inadequate responders 
(TNF-IR) rather than focusing only on the subset of subjects who are TNFα inhibitor 
naïve, as the FAS would be more representative of the general population of PsA patients. 
There were no new therapies approved when original protocol for CAIN457F2306 was 
written and thus TNFα inhibitor naïve patients were target population in line with the then 
existing labels/indications. The shift from TNFα inhibitor naïve to FAS, to increase the 
generalizability of the study findings is also in keeping with the recently approved 
Ustekinumab label that has also been studied in mixed population of both TNFα inhibitor 
naïve as well as TNF-IR patients. 
• As the primary endpoint is at Week 24 and the analysis will be carried out after all 
subjects have completed Week 52 visit, there is no longer a need for the sponsor to be 
blinded past this time point. The conduct of the interim analysis was revised in line with 
this. However, sites and subjects will remain blinded until all subjects complete study to 
ensure an unbiased assessment of the two different secukinumab doses. 
• To mention only women of child bearing potential will undergo routine urine pregnancy 
tests (UPT). Thus this excludes postmenopausal women apart from sterile women from 
undergoing frequent UPT. This has been amended to avoid unnecessary UPT burden for 
women with confirmed menopause (defined as per section 4.2). 
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None of the changes made are due to safety concerns and none of the changes have an impact 
on the conduct of the trial or alter in any way the treatment of study subjects. 
At the time of this amendment, enrollment into the study was complete with 606 subjects 
randomized but the data remained blinded as database lock has not occurred. 
Changes to the protocol 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font deletions and red underlined for insertions. 
The wording of various sub-sections to “Study objectives” (Section 2), “Study design (Section 
3.1), “Interim analysis” (section 3.5), “Treatment arms (Section 5.2), “Treatment blinding” 
(Section 5.4), “Efficacy” (Section 6.4), “Pregnancy and assessment of fertility” (Section 
6.5.8), “Data analysis” (Section 9) and Appendix 3 and have been amended to reflect the 
rationale given above. 
Additionally, this protocol amendment includes the correction of typographical and 
formatting errors and editorial changes for increased clarity of the text. Consequently, changes 
were implemented throughout the protocol. 
None of the changes described in this amended protocol are made due to newly emerged 
safety considerations.  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities as required. 
Summary of previous amendments 
Amendment 2 (18-Dec-2012) 
Amendment rationale 
This protocol amendment is issued to update sections of the data analysis plan, specifically to 
update how missing values are handled. The guidance language for study treatment 
interruptions and discontinuation has been clarified. The notable laboratory values and 
guidance for subject observation post study treatment administration have been aligned with 
the wording used in all current secukinumab arthritis studies. None of the changes made are 
due to safety concerns and none of the changes have impact on the conduct of the trial or alter 
in any way the treatment of study subjects. 
Changes to the protocol 
The wording of various sub-sections to “Data analysis” (Section 9) have been amended to 
reflect the rationale given above. 
Additionally, this protocol amendment includes the correction of typographical and 
formatting errors, and clarification of the wording in certain sections.  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities. 
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The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol. 
Amendment 1 (04-Aug-2011) 
Amendment rationale 
This protocol amendment is issued to clarify discrepancies in the protocol. However, none of 
the changes has an impact for the conduct of the trial or the patient’s treatment. 
Changes to the protocol 
Wording on the subject number for re-screened subject was removed. Subject will be tracked 
using a unique subject identifier, that will be applied within the database but not visible for 
the investigator and therefore the sentence was misleading. 
The section ‘Serum biomarkers related to targeted pathway’ had been included as a subsection 
of ‘Pharmacogenetics,’ but Serum biomarkers should be a separate section This is now 
corrected. Furthermore, a Sample Log for serum biomarkers is now included in this section. 
Additionally, we took the opportunity of this protocol amendment to correct typographical 
and formatting errors, and to clarify certain wordings. 
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Protocol synopsis 
Title of study: A randomized, double-blind, placebo-controlled, multicenter study of 
secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, 
tolerability and long term efficacy up to 2 years in patients with active psoriatic 
arthritis 
Purpose and rationale: The purpose of this 2 year study is to demonstrate efficacy 
on signs and symptoms of psoriatic arthritis and to assess the long term safety, 
tolerability and efficacy on joint/bone structure of secukinumab given as intravenous 
(i.v.) loading doses, followed by sub-cutaneous (s.c.) injections of two dose levels of 
secukinumab versus placebo in subjects with active PsA. Efficacy at Week 24 will be 
assessed based on signs and symptoms according to the American College of 
Rheumatology response criteria (ACR 20 response), whereas long term efficacy will 
be based on joint/bone structural preservation (X-ray) and physical function (HAQ-DI), 
as well as skin assessment for psoriasis signs. Treatment will continue up to 2 years 
to assess inhibition of joint damage and physical function. 
Objectives: 
Primary objective: To demonstrate the efficacy of secukinumab 75 or 150 mg at 
Week 24 is superior to placebo in subjects with active PsA based on the proportion of 
subjects achieving an ACR20 response. 
Secondary objectives: To demonstrate that: 
1. The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo 
based on the proportion of subjects achieving a PASI75 response in the subgroup 
of subjects who have ≥3% skin involvement with psoriasis. 
2. The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo 
based on the proportion of subjects achieving a PASI90 response in the subgroup 
of subjects who have ≥3% skin involvement with psoriasis. 
3. The improvement (change) from baseline on secukinumab 75 or 150 mg is 
superior to placebo for the DAS28-CRP at Week 24. 
4. The improvement (change) from baseline on secukinumab 75 or 150 mg is 
superior to placebo for the SF36-PCS at Week 24. 
5. The improvement (change) from baseline on secukinumab 75 or 150 mg is 
superior to placebo for the HAQ-DI at Week 24. 
6. The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo 
based on the proportion of subjects achieving an ACR50 response. 
7. The improvement (change) from baseline to Week 24 on secukinumab pooled 
regimen (75 mg and 150 mg s.c.) is superior to placebo for joint/bone structural 
damage (van der Heijde modified total Sharp score). 
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8. The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 
is superior to placebo based on the proportion of subjects with dactylitis in the 
subset of subjects who have dactylitis at baseline. 
9. The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 
is superior to placebo based on the proportion of subjects with enthesitis in the 
subset of subjects who have enthesitis at baseline. 
10. The improvement (change) from baseline to Week 24 on secukinumab 75 or 150 
mg is superior to placebo for joint/bone structural damage (van der Heijde 
modified total Sharp score). 
11. The overall safety and tolerability of each secukinumab regimen compared to 
placebo as assessed by vital signs, clinical laboratory values, ECG and adverse 
events monitoring 
Population: The study population will consist of a representative group of 
rheumatoid factor (RF) and anti-CCP negative subjects at least 18 years of age, 
fulfilling the CASPAR criteria and must have active psoriatic arthritis. Subjects 
included must report active disease despite current or previous NSAID, DMARD 
and/or TNFα inhibitor therapy. 
Concomitant therapy with MTX (≤25 mg/week) will be acceptable, if dose and route of 
administration have been stable for at least four weeks prior to the randomization visit. 
Subjects must have signs of skin manifestations of psoriasis, defined by at least one 
psoriatic plaque of ≥2 cm diameter (but not in armpits, or chest between breasts, or 
groin) or nail changes consistent with psoriasis or documented history of plaque 
psoriasis. 
Subjects cannot be re-screened more than once. A new Informed Consent Form 
must be signed for each screening 
This is a multinational study and it is expected that subjects will be enrolled at 
approximately 150 sites. About 850 subjects will be screened for approximately 600 
subjects to be randomized). A screening failure rate of 30 % and post-randomization 
dropout rate of 25 % is anticipated. Enrollment will stop as soon as the target number 
of randomized subjects is reached.  
Inclusion/Exclusion criteria:  
Inclusion criteria: 
Subjects eligible for inclusion in this study have to fulfill all of the following criteria: 
1. Male or non-pregnant, non-lactating female subjects at least 18 years of age 
2. Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 
months with moderate to severe PsA who must have at Baseline ≥3 tender joints 
out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each) 
3. Rheumatoid factor and anti-CCP antibodies negative 
4. Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2 cm 
diameter (but not in intertriginous areas such as armpits, or chest between 
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breasts, or groin) or nail changes consistent with psoriasis or documented history 
of plaque psoriasis 
Exclusion criteria: 
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study: 
1. Chest X-ray with evidence of ongoing infectious or malignant process, obtained 
within 3 months of screening and evaluated by a qualified physician 
2. Subjects who have previously been treated with more than 3 different TNFα 
inhibitors (investigational or approved) 
3. Subjects taking high potency opioid analgesics (e.g., methadone, hydromorphone, 
or morphine) 
4. Subjects who have ever received biologic immunomodulating agents except for 
those targeting TNFα, investigational or approved  
5. Previous exposure to secukinumab or any other biologic drug directly targeting IL-
17 or IL-17 receptor  
6. Previous treatment with any cell-depleting therapies including but not limited to 
anti-CD20, investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, 
anti-CD19) 
Investigational and reference therapy: At baseline, eligible subjects will be 
randomized to one of the following three treatment arms in a ratio of 1:1:1. 
• Group 1: secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then 
secukinumab 75 mg s.c. starting at Week 8 and injected every 4 weeks 
• Group 2: secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then 
secukinumab 150 mg s.c. starting at Week 8 and injected every 4 weeks 
• Group 3: Placebo i.v. at BSL, Weeks 2 and 4 then placebo s.c. starting at 
Weeks 8 and 12. 
At Week 16 (Visit 8), all subjects will be classified as responders ( ≥ 20% 
improvement from baseline in both tender and swollen joint counts) or non-
responders and will be re-assigned/re-randomized at Week 16 by the IRT to receive 
double-blind treatment up to 2 years, as follows: 
• Subjects on placebo (Group 3) who are non-responders will be re-randomized 
to receive secukinumab 75 mg s.c. or 150 mg s.c. (1:1) every 4 weeks 
• Subjects on placebo (Group 3) who are responders will continue to receive 
secukinumab placebo every 4 weeks until Week 24. At Week 24, these 
subjects will receive secukinumab 75 mg s.c. or 150 mg s.c. (1:1) every 4 
weeks regardless of responder status (as dictated by the re-randomization). 
Study design: This pivotal study uses a double-blind, randomized, parallel-group, 
placebo-controlled design. A screening (SCR) period running 4 weeks before 
randomization will be used to assess eligibility followed by a treatment period of 2 
years. 
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At Week 24, efficacy of secukinumab treatment will be assessed based on an ACR20 
response. 
Subjects who complete the 2 year study may be eligible to enter a planned extension 
trial. 
Efficacy assessments:  
• ACR 20, 50, 70  
• PsARC response 
• Disease Activity Score-CRP(DAS28-CRP) and EULAR response criteria 
• HAQ-DI 
• Progression of structural damage by X-ray – van der Heijde total modified Sharp 
score and subscores 
• Leeds Enthesitis Index (LEI)  
• Leeds Dactylitis Index (LDI) and dactylitis count 
• Psoriasis Area and Severity Index (PASI) 
• Investigator’s Global Assessment (mod 2011) for overall psoriatic disease 
• Target lesion assessment 
• Modified Nail Psoriasis Severity Index (mNAPSI) 
• MRI on hands (incl. wrist) (at selected centers and in TNFα inhibitor naïve 
subjects with a swollen wrist)  
• Quality of Life, fatigue, utilities and work productivity (SF-36 v2 Acute Form, 
FACIT-Fatigue, DLQI, PsAQoL, EQ-5D, WPAI-GH) 
Other assessments:  
• Safety and tolerability: Evaluation of all AEs and SAEs including injection site 
reactions, vital signs, ECGs and laboratory assessments 
• Anti-secukinumab antibodies 
• Smoking history 
• Pharmacokinetics 
• Soluble plasma protein markers related to targeted pathway and cardiovascular 
risk markers 
• Exploratory: pharmacogenetics 
• ANA, anti-dsDNA antibodies, anti-CCP antibodies,  
Data analysis:  
The primary endpoint in the study is ACR20 at Week 24 for all subjects. Secondary 
objectives will be to compare secukinumab to placebo according to a sequential 
testing procedure and include PASI75 response, PASI90 response, change from 
baseline in DAS28-CRP, change from baseline in SF-36-PCS, ACR50 response, 
change from baseline in van der Heijde modified total Sharp score, presence of 
dactylitis and enthesitis. Safety analyses will include summaries of adverse events, 
laboratory measurements, ECGs and vital signs. 
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1 Introduction 
1.1 Background 
Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease belonging to 
the spectrum of conditions commonly referred to as spondyloarthritides (SpA). The scientific 
community is split over the question whether to view these conditions together or consider 
them as separate entities (Nash 2005). For example, inflammatory back pain associated with 
psoriasis fit two classifications (1) AS with psoriasis or (2) psoriatic spondylitis (Gladman 
2007). However, while diverse in their clinical presentations, common environmental as well 
as genetic factors associated with susceptibility to SpA are suspected (Turiewicz 2007). This 
latter notion was recently corroborated by findings in a large-scale single nucleotide 
polymorphism (SNP) scan study, where IL23R variants that were previously linked to 
Crohn`s disease and psoriasis (diseases that may both co-exist with spondyloarthritides) 
conferred risk to developing ankylosing spondylitis (Barrett 2008). Together, a common 
pathway including the IL-23/IL-17 axis may play a role in seronegative SpAs including 
psoriatic arthritis. 
Psoriatic arthritis is a frequent chronic immune-mediated disease encompassing a spectrum of 
overlapping clinical entities (Moll and Wright 1973). About 10 - 40% of patients with 
psoriasis suffer from PsA. Recent efforts were aimed at defining more stringent classification 
criteria for standardized recruitment into clinical trials (Taylor 2006). PsA is associated with 
significant morbidity and disability, and thus constitutes a major socioeconomic burden. It is 
not only more common but also more severe than previously thought (Gladman 2004). The 
majority of patients will have psoriasis prior the associated arthritis occurs and will be under 
treatment for their skin disease. NSAIDs are used for musculoskeletal pain symptoms. 
Traditional disease modifying anti-rheumatic drugs (DMARDs) include methotrexate (MTX), 
sulfasalazine, cyclosporine, and leflunomide and are inadequate for a number of patients 
because these drugs only partially control established disease (Mease 2008).  
Several lines of evidence support the notion of prominent T cell involvement in the 
pathogenesis of PsA. Memory CD4+ and CD8+ cells are present in skin lesions as well as the 
inflamed synovium that express activation markers and have characteristics of oligoclonal 
expansion. (Curran 2004, Tassiulas 1999) Clinical trials demonstrated efficacy of T cell 
targeted therapy in PsA (cyclosporine A, CTLA4 Ig, alefacept). TNF blocking therapy was 
successfully introduced to the treatment of patients with PsA (Mease 2000). Despite these 
efforts, an unmet clinical need exists for patients with PsA for better disease control and long 
term prevention of structural damage beyond mere abrogation of inflammatory processes. In 
addition, current treatment options for patients with intolerance or an inadequate response to 
anti-TNF-α agents are limited. 
IL-17 antagonism represents a novel therapeutic approach aimed at interference with the 
chronic inflammatory process by selectively targeting the predominant proinflammatory 
cytokine of the helper T17 cell subset. Additional effects of anti-IL17 on bone homoeostasis 
via RANKL and IL-1, upstream of TNFα, can be inferred from animal studies (Koenders 
2005). Assuming a potential role of TH17 cells in the inflammatory infiltrate in PsA, it can be 
speculated that locally disturbed homeostasis of osteoclastogenic and osteoblastogenic 
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mechanisms characteristic of PsA might be affected by IL-17 blockade. Such effects may be 
additive or synergistic to anti-TNF, and thus may provide a therapeutic advancement to 
prevent structural damage in PsA. 
Secukinumab (AIN457) is a high-affinity fully human monoclonal anti-human antibody that 
neutralizes IL-17A activity. IL-17A is the key cytokine in the newly discovered TH17 
pathway which is thought to be an important mediator of autoimmunity. Neutralization of IL-
17A has strong pre-clinical and clinical target validation and documentation of efficacy in a 
proof of concept study (CAIN457A2101) and a phase II study (CAIN457F2201) in 
Rheumatoid Arthritis (RA). IL-17A has been shown to play a pivotal direct pathogenetic role 
in both inflammatory and destructive joint tissue manifestations of RA and has direct effects 
on matrix metalloprotease (MMP) activation and stimulation of osteoclast-mediated bone 
resorption (Stamp 2004; Witowski 2004; Moseley 2003). Interim analysis of all 42 subjects 
enrolled in the PsA PoC study CAIN457A2206 who completed week 6, together with 
preliminary data from the later time points up to week 16, suggest that a clinically meaningful 
response for signs and symptoms is induced as early as 2 weeks after start of secukinumab 
treatment, with further improvement up to week 6 and maintenance of response up to week 16. 
Therefore, treatment with secukinumab may also reduce loss of cartilage and erosion of bone 
in PsA and may result in improvement of symptoms and functional joint manifestations in 
afflicted patients. Furthermore, In a completed proof of concept study (CAIN457A2102), the 
effects of secukinumab administered at 3 mg/kg as a single intravenous infusion were 
compared with that of placebo in thirty-six subjects with active chronic plaque-type psoriasis. 
The study demonstrated efficacy at the 4- week endpoint and continuous efficacy at 12 weeks 
based on Psoriasis Area and Severity Index (PASI) and Investigator’s Global Assessment mod 
2009 (IGA mod 2011) endpoints.  
To date, over 2,000 subjects with a variety of diseases and healthy volunteers have been 
enrolled into completed and ongoing studies with secukinumab, and over 1,400 subjects have 
been newly exposed to secukinumab at single and multiple doses ranging from 0.3 mg/kg to 
10 mg/kg intravenous (i.v.) and 25 mg to 300 mg subcutaneous (s.c.).  Of these, over 300 
subjects have been continued on secukinumab through enrollment into extension trials. In 
total, 333 RA and 61 PsA subjects have been enrolled into trials with secukinumab. Full 
safety results including all reported adverse events are currently available for eight studies 
(across autoimmune indications) that have been completed. These show comparable numbers 
of adverse events in subjects treated with secukinumab compared to placebo without 
indication of any specific organ toxicity. Please refer to the Investigator Brochure for a more 
detailed review of the pre-clinical and clinical information on secukinumab. 
1.2 Purpose  
The purpose of this study is to demonstrate at Week 24 the efficacy and assess the safety of 
secukinumab given as intravenous (i.v.) loading doses, followed by sub-cutaneous (s.c.) 
injections of 2 dose levels of secukinumab versus placebo in subjects with active PsA. At 
Week 24, efficacy will be assessed based on improvement in signs and symptoms according 
to the American College of Rheumatology response criteria (ACR20 response), whereas long 
term efficacy up to 2 years will be based on joint/bone structure preservation (X-ray) and 
improvement in physical function (HAQ-DI), as well as skin and nail improvement for 
psoriasis signs. 
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Data from this study are aimed at supporting a global submission of the psoriatic arthritis 
indication. 
2 Study objectives 
2.1 Primary objectives 
To demonstrate the efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo 
in subjects with active PsA based on the proportion of subjects achieving an ACR20 response. 
2.2 Secondary objectives 
The secondary objectives of the study are to demonstrate: 
1. The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving a PASI75 response in the subgroup of subjects who have 
≥3% skin involvement with psoriasis. 
2. The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving a PASI90 response in the subgroup of subjects who have 
≥3% skin involvement with psoriasis. 
3. The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the DAS28-CRP at Week 24. 
4. The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the SF36-PCS at Week 24. 
5. The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the HAQ-DI at Week 24. 
6. The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving an ACR50 response. 
7. The improvement (change) from baseline to Week 24 on secukinumab pooled regimen (75 
mg and 150 mg s.c.) is superior to placebo for joint/bone structural damage (van der 
Heijde modified total Sharp score). 
8. The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 is 
superior to placebo based on the proportion of subjects with dactylitis in the subset of 
subjects who have dactylitis at baseline. 
9. The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 is 
superior to placebo based on the proportion of subjects with enthesitis in the subset of 
subjects who have enthesitis at baseline. 
10. The improvement (change) from baseline to Week 24 on secukinumab 75 or 150 mg is 
superior to placebo for joint/bone structural damage (van der Heijde modified total Sharp 
score). 
11. The overall safety and tolerability of each secukinumab regimen compared to placebo as 
assessed by vital signs, clinical laboratory values, ECG and adverse events monitoring 
2.3 Exploratory Objectives 
To evaluate the efficacy of secukinumab at week 24 and other time points in subjects with 
active PsA, as applicable, on:  
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1. Structural progression as measured by the erosion and joint space narrowing (van der 
Heijde modified Sharp sub scores), proportion of subjects with no structural progression, 
and maintenance of effect over time  
2. ACR20, ACR50, ACR70, PASI75, PASI90, PsARC response criteria, EULAR reponse 
criteria, low disease activity (DAS28 ≤3.2), disease remission (DAS28 <2.6), Major 
Clinical Response (MCR; any continuous six-month period of ACR70 response), and 
HAQ-DI response.  
3. Change from baseline over time in DAS28-CRP, SF36-PCS, SF36-MCS, HAQ-DI score, 
ACR components, IGA mod 2011, Dactylitis count, LDI, LEI, mNAPSI, WPAI-GH, 
FACIT-Fatigue, PsAQoL, DLQI, EQ-5D-3L up to 2 years.  
4. Proportion of subjects achieving Minimal Disease Activity ( 5 of the following 7 criteria: 
≤1 tender joint, ≤1 swollen joint, PASI ≤1 or IGA mod 2011 ≤1, patient assessment of 
pain (VAS) ≤15, patient global assessment of disease (VAS) ≤20, HAQ-DI ≤0.5, tender 
entheseal points ≤1). 
In addition, the following will be explored: 
5. The development of immunogenicity against secukinumab 
6. The Pharmacokinetic/Pharmacodynamic (PK/PD) relationship of secukinumab. 
7. Pharmacogenetic assessments to examine whether individual genetic variation in genes 
relating to drug metabolism, PsA and the drug target pathway confer differential response 
to secukinumab 
8. Identification of potential biomarkers associated with treatment response to secukinumab 
or possibly correlating with the severity or progression of PsA, and impact of 
secukinumab on cardiovascular surrogate biomarkers. 
9. To measure the effect of secukinumab on joint/bone structure preservation using MRI 
measurements (modified RAMRIS and JSN score). 
3 Investigational plan 
3.1 Study design 
This pivotal phase III study uses a double-blind, randomized, parallel-group, placebo 
controlled design. A screening period running up to 4 weeks before randomization will be 
used to assess eligibility followed by a treatment period of two years. At baseline (BSL), 
subject whose eligibility is confirmed will be randomized to one of three treatment groups:  
• Group 1: Secukinumab i.v. (10mg/kg) at BSL, Weeks 2 and 4, then secukinumab 75 mg 
s.c. starting at Week 8 and injected every 4 weeks  
• Group 2: Secukinumab i.v. (10mg/kg) at BSL, Weeks 2 and 4, then secukinumab 150 mg 
s.c. starting at Week 8 and injected every 4 weeks 
• Group 3: Placebo i.v. at BSL, Weeks 2 and 4, then placebo s.c. starting at Week 8 and 
Week 12.  
The subjects will be stratified according to being either TNFα inhibitor incomplete responders 
(IR) or TNFα inhibitor naïve subjects. 30% of subjects are planned to be TNFα inhibitor 
inadequate responders to ensure a representative subject population for the assessment of 
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efficacy and safety. Thus, it is planned to randomize approximately180 TNFα inhibitor IR 
subjects and 420 TNFα inhibitor naïve subjects. 
At Week 16 (Visit 8), all subjects will be classified as responders ( ≥20% improvement from 
baseline in both tender and swollen joint counts) or non-responders. Subjects who were 
randomized to placebo at baseline will be re-randomized by the Interactive Response 
Technology (IRT) to receive double blind treatment up to 2 years, as follows (see Figure 3-1): 
¾ Subjects on secukinumab placebo (Group 3) who are responders will remain on 
placebo until week 24. At Week 24, these subjects will receive either secukinumab 75 
or 150 mg every 4 weeks (as dictated by the re-randomization). 
¾ Subjects on secukinumab placebo (Group 3) who are non-responders will be re-
randomized (1:1) at Week 16 to receive either secukinumab 75 mg or 150 mg s.c. 
every 4 weeks. 
Rescue medication will not be allowed until Week 24. However, subjects deemed not to be 
benefiting from the study treatment by the investigator or for any reason on their own accord 
will be free to discontinue participation in the study at any time. 
Subjects who complete the study may be eligible to enter a planned extension trial. 
A Follow-up visit is to be done 12 weeks after last study treatment administration for subjects 
who early terminated the study or for subjects who completed the study but do not enter the 
extension study. 
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Figure 3-1 Study Design 
8 16 24 48Week -4 to BSL 32 40 56 100 104524
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Escape treatment: 75mg  or 150mg AIN457 (1:1)
Group 1
AIN457 i.v. loading 
followed by 75 mg s.c.
n = 200
Group 2
AIN457 i.v. loading 
followed by 150 mg s.c.
n = 200
Group 3
Placebo i.v. 
followed by placebo s.c.
n = 200
F112
NR
Randomization 
AIN457 administration (s.c.)
Placebo to AIN457 administration (s.c.)
Non-responder (<20% reduction in TJC and/or SJC)
AIN457 10 mg/kg administration (i.v.)
Placebo to AIN457 administration (i.v.)
 
3.2 Rationale of study design 
The double-blind, randomized, parallel-group placebo controlled design used in this study is 
aligned with Phase III trials of other biologics and is in accordance with EMA guidelines 
(EMA 2003). The treatment duration of the placebo group is kept short and the group will be 
re-assigned to active treatment at the end of the primary endpoint analysis. The blinding is 
maintained beyond the primary endpoint so as to ensure reliable efficacy and safety measures. 
The regular assessments of disease activity ensures that subjects who are experiencing 
worsening of disease in any of the treatment groups can exit the study upon their own wish or 
based on the advice of the investigator at any time. Long term treatment data up to two years 
are being generated to demonstrate long-term efficacy and to support the safety database in 
this population. 
3.3 Rationale of dose/regimen, duration of treatment 
The dosing rationale for psoriatic arthritis (PsA) and ankylosing spondylitis (AS) relies upon 
the dose-efficacy relationship data obtained in the proof of concept (PoC) studies in 
Rheumatoid Arthritis (RA) (CAIN457A2101), in Ankylosing Spondylitis (AS) 
(CAIN457A2209) and in PsA (CAIN457A2206) along with data from the RA dose ranging 
trial (CAIN457F2201). 
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Interim analysis of all 42 subjects enrolled in study CAIN457A2206 (dosed with i.v. 
2 x 10mg/kg) who completed Week 6, together with preliminary data from the later time 
points up to Week 16, suggest that a clinically meaningful response is induced as early as 2 
weeks after start of secukinumab treatment, with further improvement up to Week 6 and 
maintenance of response up to Week 16. 
Evidence to support a similar dose-efficacy relationship for secukinumab across the arthritides 
(RA, AS and PsA) is substantiated by existing evidence which indicates a degree of 
commonality in the pathways leading to joint damage in these chronic inflammatory diseases 
and a comparatively similar acute phase response and cytokine profile in the pathogenesis of 
the diseases. In further support of common inflammatory pathways all three conditions are 
responsive to both anti-IL17 and anti-TNFα therapy. 
In the RA PoC study (CAIN457A2101), two doses of secukinumab 10 mg/kg i.v. 
administered at BSL and Week 3, achieved an ACR20 of 46% at Week 6 and 54% at Week 
16 compared to a placebo response of 27% and 31% respectively at these time points. In 
contrast fixed doses of secukinumab administered at BSL and then every 4 weeks at 75, 150 
and 300 mg in the RA Ph II study (CAIN457F2201) achieved an ACR20 of 48%, 40% and 
39% at Week 8 and 50%, 47% and 54% at Week 16. However, placebo responses in this trial 
were 24% at Week 8 and 36% at Week 16. Thus the i.v. regimen employed in the PoC trial 
resulted in a 19% improvement in ACR20 over placebo at Week 6 and 23% at Week 16 
(Figure 3-2). The fixed monthly doses of secukinumab at 75, 150 mg and 300 mg resulted in 
24%, 16% and 15% improvement in ACR20 over placebo at Week 8 and 14%, 11% and 18% 
respectively at Week 16 (Figure 3-2). These data suggest that early high doses of 
secukinumab lead to increased efficacy in the first 8 weeks. Based upon these data currently 
planned Phase III studies in RA will be employing an i.v. loading regimen induction therapy 
with 10 mg/kg secukinumab administered at BSL, 2 and 4 followed by monthly secukinumab 
s.c. at either 75 mg or 150 mg.  
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Figure 3-2 Placebo corrected ACR20 over time comparing two doses of 
secukinumab 10 mg/kg i.v. at BSL and 3 (CAIN457A2101) to fixed s.c. 
doses of secukinumab every 4 weeks (CAIN457F2201) 
 
To define the optimal dose for maintenance ACR, DAS28 and HAQ efficacy parameters were 
considered based on study CAIN457F2201. Data available from this study up to 24 weeks 
indicates that efficacy responses can be maintained or improved with the proposed monthly 
doses of 75 or 150 mg s.c. 
The efficacy data from the RA study CAIN457F2201 showed that at Week 24 in the overall 
population as originally randomized ACR20 responses were 38 % for 25 mg, 57% for 75 mg, 
58% for 150 mg and 51% for 300 mg. Non-responders in the 25 and 75 mg dose had received 
1 dose of 150mg at Week 20 and non-responders in the 150 mg group had received one dose 
of 300 mg at Week 20. Subjects in the 300 mg cohort remained on 300 mg. Subjects switched 
from placebo to 150 mg after week 16 attained a 56% ACR 20 response by Week 24. These 
data indicate that 25 mg has similar efficacy to placebo and that 75 mg and 150 mg provided 
the best efficacy.  
Both 75 mg and 150 mg s.c. dosed every 4 weeks in maintenance are proposed based on the 
totality of the data from CAIN457F2201 for phase III for the following reasons: 
1) To ensure optimal assessment of efficacy potential for ACR responses using 2 effective s.c. 
doses used in phase II. 
2) To ensure that subjects with increased inflammatory burden (i.e. high CRP) receive 
adequate doses of secukinumab as there is indication that they may require >75 mg. 
3) To assess in a sufficient subject population if subjects with increased body weight require 
higher doses than 75 mg of secukinumab. 
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4) To assess the effect of secukinumab on structural benefit of the two proposed doses to see 
if there is a differential between these doses on this endpoint (to date no joint structure data is 
available for secukinumab). 
5) The availability of longer term safety data for 75, 150 and 300 mg administered s.c. every 4 
weeks (CAIN457F2201, CAIN457C2303). 
3.4 Rationale for choice of comparator 
A placebo arm up to the primary endpoint at Week 24 is included in this study. Due to the 
nature of the disease and the outcome measures used (ACR20 criteria) a placebo arm is 
necessary to obtain reliable efficacy measurements. The continuation of the placebo group up 
to the primary endpoint at Week 24 can be supported from an ethical standpoint. Moreover 
the inclusion of a placebo group is in accordance with health authority guidelines, including 
(FDA 1999/ EMA 2003). 
3.5 Purpose and timing of interim analyses/design adaptations 
The Week 52 analysis will be performed after all subjects have completed the Week 52 visit. 
For this analysis, all subjects will have completed the assessments related to the primary and 
key secondary objectives. Subsequent to the Week 52 analysis, the final analysis will be 
conducted after all subjects complete the study. Additional analyses may be performed to 
support heath authority interactions, as necessary. 
The investigators, site personnel and monitors will continue to remain blinded to the treatment 
each subject received until the end of the trial. The X-Ray and MRI interpretation will be 
performed by an imaging service provider and readers will be blinded to the treatment as well 
as visit information. 
4 Population 
The study population will consist of a representative group of RF and anti-CCP negative 
subjects at least 18 years of age, fulfilling the CASPAR criteria (see Appendix 2) and must 
have active PsA. Subjects included must have active disease despite current or previous 
NSAID, DMARD and / or TNFα inhibitor therapy. 
Concomitant therapy with MTX (≤25 mg/week) will be acceptable, if dose and route of 
administration have been stable for at least four weeks prior to the randomization visit. 
Subjects must have signs of skin manifestations of psoriasis, defined by at least one psoriatic 
plaque of ≥2 cm diameter (but not in armpits, or chest between breasts, or groin) or nail 
changes consistent with psoriasis or a documented history of plaque psoriasis. 
This is a multinational study and it is expected that subjects will be enrolled at approximately 
150 sites. About 850 subjects will be screened for approximately 600 subjects to be 
randomized). 
A screening failure rate of 30 % and post-randomization drop-out rates of 20% at 1 year and 
25% at 2 years are anticipated. Enrollment will stop as soon as the target number of 
randomized subjects is reached. 
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Subjects may only be re-screened once. A new Informed Consent Form must be signed for 
each screening. 
4.1 Inclusion criteria 
Subjects eligible for inclusion in this study have to fulfill all of the following criteria: 
1. Subject must be able to understand and communicate with the investigator and be able 
to comply with the requirements of the study and must give a written, signed and dated 
informed consent before any study assessment is performed 
2. Male or non-pregnant, non-lactating female subjects at least 18 years of age 
3. Diagnosis of PsA classified by CASPAR criteria (see Appendix 2) and with symptoms 
for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 
tender joints out of 78 and ≥3 swollen joints out of 76 (dactylitis of a digit counts as 
one joint each) 
4. RF and anti-CCP antibodies negative 
5. Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2 cm 
diameter (but not in intertriginous areas such as armpits, or chest between breasts, or 
groin) or nail changes consistent with psoriasis or a documented history of plaque 
psoriasis 
6. Subjects with PsA should have been on NSAIDs for at least 4 weeks prior to 
randomization with inadequate control of symptoms or intolerant to NSAIDs 
7. Subjects who are regularly taking NSAIDs as part of their PsA therapy are required to 
be on a stable dose for at least 2 weeks before study randomization and should remain 
on a stable dose up to Week 24 
8. Subjects taking corticosteroids must be on a stable dose of ≤10 mg/day prednisone or 
equivalent for at least 2 weeks before randomization and should remain on a stable 
dose up to Week 24 
9. Subjects taking MTX (≤ 25 mg/week) are allowed to continue their medication if the 
dose is stable for at least 4 weeks before randomization and should remain on a stable 
dose throughout the study  
10. Subjects on MTX must be on folic acid supplementation at randomization 
11. Subjects who are on a DMARD other than MTX must discontinue the DMARD 
28 days prior to randomization except for leflunomide, which has to be discontinued 
for 8 weeks prior to randomization unless a cholestyramine washout has been 
performed 
12. Subjects who have been on a TNFα inhibitor must have experienced an inadequate 
response to previous or current treatment with a TNFα inhibitor given at an approved 
dose for at least 3 months or have stopped treatment due to safety/tolerability 
problems after at least one administration of a TNFα inhibitor 
13. Subjects who have previously been treated with TNFα inhibitors (investigational or 
approved) will be allowed entry into study after appropriate wash-out period prior to 
randomization: 
a. 4 weeks for Enbrel® (etanercept) – with a terminal half-life of 102 ± 30 hours (s.c. 
route) 
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b. 8 weeks or longer for Remicade® (infliximab) – with a terminal half-life of 8.0-9.5 
days (i.v. infusion) 
c. 10 weeks or longer for Humira® (adalimumab) – with a terminal half-life of 10-20 
days (average 2 weeks) (s.c. route) 
d. 10 weeks or longer for Simponi® (golimumab) – with a terminal half-life of 11-14 
days 
e. 10 weeks or longer for Cimzia® (certolizumab) – with a terminal half-life of 
approx. 14 days 
4.2 Exclusion criteria 
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study: 
1. Subjects taking high potency opioid analgesics (e.g., methadone, hydromorphone, or 
morphine) 
2. Subjects who have ever received biologic immunomodulating agents except for those 
targeting TNFα, investigational or approved  
3. Subjects who have previously been treated with more than 3 different TNFα inhibitors 
(investigational or approved) 
4. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or 
IL-17 receptor  
5. Use of any investigational drug and/or devices within 4 weeks of randomization or 5 half-
lives of the investigational drug, whichever is longer 
6. Ongoing use of prohibited psoriasis treatments / medications (e.g., topical corticosteroids, 
UV therapy) at randomization. The following wash out periods need to be observed: 
a. Oral or topical retinoids 4 weeks 
b. Photochemotherapy (e.g. PUVA) 4 weeks 
c. Phototherapy (UVA or UVB) 2 weeks  
d. Topical treatments (except in face, scalp and genital area during screening, only 
corticosteroids with mild to moderate potency) 2 weeks 
7. Any intramuscular or intravenous corticosteroid treatment within 4 weeks before 
randomization 
8. Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before 
randomization 
9. Previous treatment with any cell-depleting therapies including but not limited to anti-
CD20 and investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-
CD19) 
10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a 
female after conception and until the termination of gestation, confirmed by a positive 
hCG laboratory test  
11. Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, unwilling to use effective contraception during the study and for 16 
weeks after stopping treatment. Effective contraception is defined as either: 
a. Barrier method: Condom or Occlusive cap (diaphragm or cervical/vault caps) with 
spermicides (where available).  
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Spermicides alone are not a barrier method of contraception and should not be used 
alone 
The following methods are considered more effective than the barrier method and are also 
acceptable: 
b. Total abstinence: When this is in line with the preferred and usual lifestyle of the 
subject  [Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception] 
c. Female sterilization: have had a surgical bilateral oophorectomy (with or without 
hysterectomy) or tubal ligation at least six weeks before taking study treatment. In 
case of oophorectomy alone, only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment 
d. Male partner sterilization. [For female subjects on the study, the vasectomized male 
partner should be the sole partner for that subject] 
e. Use of established oral, injected or implanted hormonal methods of contraception, 
intrauterine device (IUD) or intrauterine system (IUS) 
NOTE: Women are considered post-menopausal and not of child bearing potential if they 
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous 
amenorrhea as defined by the central lab FSH and/or estradiol levels. 
12. Active ongoing inflammatory diseases other than PsA that might confound the evaluation 
of the benefit of secukinumab therapy as judged by the investigator 
13. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, 
infectious or gastrointestinal conditions or the management thereof which in the opinion 
of the investigator places the subject at unacceptable risk for participation in an 
immunomodulatory therapy 
14. Significant medical diseases / problems, including but not limited to the following: 
Uncontrolled hypertension (≥160/95 mmHg), congestive heart failure [New York Heart 
Association status of class III or IV], uncontrolled diabetes, or very poor functional status 
unable to perform self-care 
15. History of clinically significant liver disease or liver injury as indicated by abnormal liver 
function tests such as SGOT (AST), SGPT (ALT), alkaline phosphatase, or serum 
bilirubin. The Investigator should be guided by the following criteria: 
a. Any single parameter may not exceed 2 x upper limit of normal (ULN). A single 
parameter elevated up to and including 2 x ULN should be re-checked once more as 
soon as possible, and in all cases, at least prior to randomization, to rule out lab error 
b. If the total bilirubin concentration is increased above 2 x ULN, total bilirubin should 
be differentiated into the direct and indirect reacting bilirubin. In any case, serum 
bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L) 
16. History of renal trauma, glomerulonephritis, or subjects with one kidney only, or a 
creatinine level exceeding 1.5 mg/dl (132.6 µmol/L) at screening 
17. Screening total WBC count <3,000/µl, or platelets <100,000/µl or neutrophils <1,500/µl 
or hemoglobin <8.5 g/dl (85 g/L) 
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18. Active systemic infections during the last two weeks (exception: common cold) prior to 
randomization 
19. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis 
infection as defined by either a positive PPD skin test (the size of induration will be 
measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5mm or 
according to local practice/guidelines) or a positive QuantiFERON TB-Gold test as 
indicated in the assessment schedule (see Table 6-1). Subjects with a positive test may 
participate in the study if further work up (according to local practice/guidelines) 
establishes conclusively that the subject has no evidence of active tuberculosis. If presence 
of latent tuberculosis is established then treatment according to local country guidelines 
must have been initiated  
20. Chest X-ray with evidence of ongoing infectious or malignant process, obtained within 3 
months of screening and evaluated by a qualified physician 
21. Known infection with HIV, hepatitis B or hepatitis C at screening or randomization 
22. History of lymphoproliferative disease or any known malignancy or history of malignancy 
of any organ system within the past 5 years (except for basal cell carcinoma or actinic 
keratoses that has been treated with no evidence of recurrence in the past 3 months, 
carcinoma in situ of the cervix or non-invasive malignant, colon polyps that have been 
removed) 
23. Current severe progressive or uncontrolled disease which in the judgment of the clinical 
investigator renders the subject unsuitable for the trial 
24. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability or lack of access to veins) 
25. Any medical or psychiatric condition which, in the Investigator’s opinion, would preclude 
the participant from adhering to the protocol or completing the study per protocol 
26. Donation or loss of 400 mL or more of blood within 8 weeks before dosing 
27. History or evidence of ongoing alcohol or drug abuse, within the last six months before 
randomization 
28. Plans for administration of live vaccines during the study period or 6 weeks prior 
randomization 
No additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible subjects. 
5 Treatment 
5.1 Investigational and control treatment 
The appearance of the lyophilized cake for secukinumab 150 mg Powder for Solution is 
slightly different from secukinumab placebo to 150 mg Powder for Solution.  Also, the caps 
for the vials of secukinumab 150 mg powder and secukinumab placebo are different colors.  
Therefore, in order to maintain the blind in the study, an unblinded pharmacist or unblinded 
qualified site personnel will be appointed at site to prepare the study treatment. 
Novartis will supply the following study treatments: 
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• Investigational Treatment: Secukinumab  
Secukinumab 150 mg Powder for Solution for s.c. injection or i.v. infusion is provided in 
glass vials each containing 150 mg secukinumab as lyophilized cake. Secukinumab 
150 mg vials are labeled as AIN457 150 mg. The vials contain a 20% overfill to allow a 
complete withdrawal of the labeled amount of secukinumab. The 150 mg Powder for 
Solution is used to prepare both the 75 mg and the 150 mg dose. 
• Reference Therapy: Secukinumab placebo (for s.c. injection):  
Secukinumab placebo to 150 mg Powder for Solution for s.c. injection is provided in glass 
vials as lyophilized cake. Secukinumab placebo vials are labeled as AIN457 placebo. Each 
vial contains a mixture of inactive excipients, matching the composition of the 
secukinumab 150 mg Powder for Solution.  
Reference therapy (Secukinumab placebo for i.v. infusion): 100 mL 0.9% NaCl solution is to 
be used as placebo for i.v. secukinumab, and is to be provided locally. 
The supply will be open label. 
For detailed instructions for storage, handling, reconstitution and administration of all study 
treatments, please refer to the pharmacist manual. 
5.2 Treatment arms 
At baseline, eligible subjects will be randomized to one of the following 3 treatment arms in a 
ratio of 1:1:1: 
• Group 1: Secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4, then secukinumab 75 mg 
s.c. starting at Week 8 and injected every 4 weeks 
• Group 2: Secukinumab i.v. (10 mg/kg) at BSL, Weeks 2 and 4, then secukinumab 150 mg 
s.c. starting at Week 8 and injected every 4 weeks 
• Group 3: Placebo i.v. at BSL, Weeks 2 and 4, then placebo s.c. starting at Week 8 and 
Week 12. 
At Week 16 (Visit 8), all subjects will be classified as responders (≥20% improvement from 
baseline in both tender and swollen joint counts) or non-responders. Subjects who were 
randomized to placebo at baseline will be re-randomized by the Interactive Response 
Technology (IRT) to receive double blind treatment up to two years, as follows (see Figure 3-
1): 
• Subjects on placebo (Group 3) who are responders will remain on placebo until week 24. 
At Week 24, these subjects will receive either secukinumab 75 or 150 mg every 4 weeks, 
regardless of responder status (as dictated by the re-randomization). 
• Subjects on placebo (Group 3) who are non-responders will be re-randomized (1:1) at 
Week 16 to receive either secukinumab 75 mg or 150 mg s.c. every 4 weeks. 
5.3 Treatment assignment 
At baseline (Visit 2), all eligible subjects will be randomized via the Interactive Response 
Technology (IRT) to one of the treatment arms. The IRT can be contacted via the Interactive 
Voice Response System (IVRS) or interactive web response system (IWRS). The investigator 
or his/her delegate will contact the IRT after confirming that the subject fulfills all the 
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inclusion criteria and does not fulfill any exclusion criterion.  The IRT will assign a 
randomization number to the subject, which will be used to link the subject to a treatment arm 
and will specify unique medication numbers for the first packages of study treatment to be 
prepared for the subject. The unique medication number will be communicated to the 
unblinded pharmacist or unblinded qualified site personnel. The randomization number will 
not be communicated to any of the site staff including the unblinded pharmacist or unblinded 
qualified site personnel. However, the unblinded pharmacist/unblinded qualified site 
personnel will know what treatment the subject is receiving due to the open-label packaging 
of the study treatments and the fact that he/she will prepare the study treatment to be 
administered to the subject by the blinded site personnel.  
At Visit 8 (Week 16), the IRT will also ask for the subject’s responder status (responder/non-
responder).  The IRT will not generate the medication number of the vial(s) to be 
administered for Week 16 if the subject’s responder status is missing. IRT will only 
communicate to the caller the medication numbers, not the randomization number.  
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A 
subject randomization list will be produced by the IRT provider using a validated system that 
automates the random assignment of subject numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by or under the 
responsibility of Novartis Drug Supply Management using a validated system that automates 
the sequential assignment of medication numbers to study treatment packs containing each of 
the study treatments.  
Randomization will be stratified according to being either TNFα IR or TNFα inhibitor naïve 
subjects. 30% of subjects should be TNFα inhibitor IR to ensure a representative subject 
population for the assessment of efficacy and safety. It is planned to randomize approximately 
180 TNFα inhibitor IR subjects and 420 TNFα inhibitor naïve subjects. 
The randomization scheme for subjects will be reviewed and approved by a member of the 
Novartis Audit Readiness, Validation and Randomization Group within IIS IA&R (Integrated 
Information Science Integrated Analytics and Reporting). 
5.4 Treatment blinding 
This is a double-blind, randomized treatment trial. Subjects, investigator staff (with the 
exception of the unblinded pharmacist), persons performing the assessments, and data 
analysts will remain blinded to the identity of the treatment from the time of randomization 
until database lock, using the following methods: (1) Randomization data are kept strictly 
confidential until the time of unblinding, and will not be accessible by anyone else involved in 
the study with the exception of the bioanalyst, the Novartis unblinded monitors and for the 
preparation of the study treatment, an independent, unblinded pharmacist/nurse/physician or 
authorized personnel at the investigator’s site who will prepare the study treatment for 
subjects. (2) The identity of the secukinumab/placebo treatments will be concealed by the use 
of study treatments in form of syringes or i.v. infusion bags filled with reconstituted 
secukinumab/placebo solutions that are identical in appearance, but the actual secukinumab or 
placebo vials with lyophilisate will be supplied “open-label.” 
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The independent, unblinded pharmacist/nurse/physician or authorized personnel will make 
sure that no other person will have access to the treatment and treatment administration 
documentation. 
The bioanalyst will have access to the randomization list to facilitate analysis of the PK/PD 
and immunogenicity samples (i.e. to avoid the unnecessary analysis of placebo samples). 
Whenever needed or requested by the clinical team, the bioanalyst will share information 
from PK measurements before clinical database lock in a blinded fashion with the 
pharmacokineticist.  
The independent, unblinded pharmacist/nurse/physician or authorized personnel will contact 
the IRT after randomization to receive the treatment assignment information. He/she will then 
prepare the study treatment. The independent, unblinded pharmacist/nurse/physician or 
authorized personnel will contact the IRT again at each visit between V4 and V29 to get the 
treatment assignment information for the subject. 
The X-Ray and MRI interpretations performed by central Imaging CRO personnel will not be 
disclosed to investigators, site personnel, subjects and monitors during the trial. 
The week 52 analysis will be performed after all subjects have completed the assessments at 
Week 52. Data analysts will not be blinded after Week 52 database lock. Summary results 
may be shared internally and externally, however individual unblinded subject data will not be 
disclosed. A final database lock will occur when all subjects have completed the study. 
Unblinding will only occur in the case of subject emergencies (see Section 5.5.10). 
5.5 Treating the subject 
5.5.1 Subject numbering 
Each subject is uniquely identified in the study by a combination of his/her center number and 
subject number. The center number is assigned by Novartis to the investigative site. After the 
subject has signed the ICF, the investigator or his/her staff will contact the IRT and provide 
the requested identifying information for the subject. At each site, the first subject is assigned 
subject number 1, and subsequent subjects are assigned consecutive numbers (e.g. the second 
subject is assigned subject number 2, the third subject is assigned subject number 3). Once 
assigned to a subject, a subject number will not be reused. If the subject fails to be 
randomized for any reason, the IRT must be notified within 2 days and the reason for not 
being randomized will be entered on the Screening Phase Disposition Form. The appropriate 
eCRF(s) should also be completed. 
Subjects can only be re-screened once and will receive a new subject number after they have 
been re-consented. Subjects who are mis-randomized cannot be re-screened. 
5.5.2 Dispensing the study treatment 
At each visit that treatment is dispensed, an independent, unblinded 
pharmacist/nurse/physician or authorized personnel will identify the study treatment vials to 
administer to the subject by interacting with the IRT and obtaining the medication numbers 
This document (090095a8850576db in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 12/6/2013 3:37:39 PM, signing status at this time:  Completed (1 of 1 signatures) 
Approved for report publication by Patekar Manmath in Hyderabad at Fri, Dec 06, 2013 21:07:15 IST
Novartis Confidential Page 35 
Amended Protocol Version v03 Clean  Protocol No. CAIN457F2306 
 
for the s.c. injection or infusion. The unblinded pharmacist/nurse/physician or authorized 
personnel may contact the IRT to review the treatment assignment of a subject at any time. 
Immediately before preparing the treatment for administration to the subject, the unblinded 
pharmacist/nurse/physician or authorized personnel will document which treatment has been 
prepared in the source documents, Pharmacist Log, Drug Preparation Form for Unblinded 
Personnel, Pharmacist Drug Dispensing Form, containing that subject’s unique subject 
number. 
The study treatment packaging has a 2-part label. A unique medication number is printed on 
each part of this label which corresponds to a vial to be used (active or placebo). Immediately 
before preparation of the study treatment, the unblinded pharmacist/nurse/physician or 
authorized site personnel will detach the outer part of the label from the packaging and affix it 
to the source document (Drug Label Form) for that subject’s unique subject number. 
5.5.3 Supply, storage and tracking of study treatment 
Study treatment will be supplied to each study site by Novartis as open labeled bulk 
medication. 
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly, and kept in a secured location to which only the unblinded 
pharmacist/nurse/physician or authorized personnel has access. Upon receipt, all study 
treatment should be stored according to the instructions specified on the drug labels. Clinical 
supplies are to be dispensed and administered only in accordance with the protocol. 
Secukinumab lyophilisate (150 mg active/placebo) must be stored in a locked refrigerator at 
2-8°C and must be carefully controlled in accordance with regulations governing 
investigational medicinal products and local regulations. 
Medication labels will be in the local language and comply with the legal requirements of 
each country. They will include storage conditions for the drug, but no information about the 
subject except for the medication number. 
The unblinded pharmacist/nurse/physician or authorized personnel must maintain an accurate 
record of the shipment and dispensing of study treatment in a drug accountability log. 
Monitoring of drug accountability will be performed by the unblinded field monitor during 
site visits and at the completion of the trial.  
At the conclusion of the study, and as appropriate during the course of the study, the 
pharmacist will return all used, partly used and unused study treatment, packaging, drug labels, 
as well as the empty vials and a copy of the completed drug accountability log to the Novartis 
monitor or to the Novartis address provided in the investigator folder at each site. 
Destruction of the unused drug should be done according to local requirements and after 
approval Novartis by clinical team. 
5.5.4 Instructions for prescribing and taking study treatment 
Study treatment will be administered s.c. or by i.v. infusion throughout the study by a blinded 
nurse/physician or blinded authorized site personnel only. Dose levels of 10 mg/kg for i.v. and 
either 75 mg or 150 mg s.c. of secukinumab or placebo will be administered. 
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Before administration to the subject, the study treatment will have to be prepared by an 
unblinded pharmacist/nurse or authorized site personnel appointed at the study site as outlined 
in the Pharmacist Manual.  The unblinded pharmacist/nurse or authorized site personnel must 
not have any contact with the subject and must not be involved in any of the study 
assessments. The syringes or infusion bags with the ready-to-use study treatment solution 
prepared will be provided by the unblinded pharmacist/nurse or authorized personnel to the 
blinded investigator or assigned site staff, who will inject or infuse the subject during the 
study visit. 
Detailed instructions on the preparation and administration of the study treatment will be 
described in the Pharmacist Manual and provided to each site. 
Dosing should occur in the morning in order to coordinate sample collection times for PK 
assessments (see Section 6.6.3).. Once the infusion process or the s.c. injection has been 
completed, and the condition of the subject is deemed stable by the investigator or designated 
healthcare professional, the subject can be discharged. 
The first study treatment administration will occur at BSL (Visit 2) after all study scheduled 
assessments have been performed (and inclusion/exclusion criteria confirmed) and only after 
the scheduled blood samples have been drawn.  
At BSL, Week 2 and Week 4 subjects will receive study treatment i.v. starting at Week 8 
subjects will receive study treatment as s.c. injections every 4 weeks. 
At study visits when pre-dose blood samples have to be drawn (Table 6-1), the study 
treatment will be injected to the subject only after the blood samples have been taken. 
At Week 1 (Visit3), Week 104 (visit 30) and during the follow-up period (Visit F112), no 
study treatment will be administered.  
All study treatments assigned to the subject during the study will be recorded in the IRT. 
The subject should be instructed to contact the investigator if he/she is unable for any reason 
to attend the study visit as scheduled. 
All dates and times of injections and infusions administered to the subject during the study 
must be recorded on the Dosage administration record eCRF. All injections and infusions 
prepared by the pharmacist should be documented in the Source Documents for Pharmacy 
Drug Handling. 
5.5.4.1 Preparation of secukinumab solution and secukinumab placebo 
solution for s.c. injection or infusion 
The vials containing the lyophilisate will be appropriately diluted in order to attain the correct 
dosage. For full details, refer to the Pharmacist Manual. 
5.5.4.2 Administration 
For i.v. administration 
Secukinumab active/placebo should be administered i.v. using only the materials (infusion 
bags, infusion lines and in-line filter) specified in writing by the sponsor and as outlined in the 
pharmacist manual. 
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The entire diluted secukinumab solution in 100 mL of 0.9% NaCl solution or 100 mL of 0.9% 
NaCl solution for placebo doses should be administered (please see pharmacist manual for 
details of administration).  
For s.c. administration 
Secukinumab active/placebo should be administered using a 27Gx0.5`` needle (1 injection of 
1 mL per visit) as outlined in the pharmacist manual. 
The investigator or designee should administer the study treatment by rotating body sites 
(thighs, arms and abdomen).  
5.5.4.3 After reconstitution 
From a microbiological point of view, the secukinumab Solution and secukinumab Placebo 
Solution for s.c. injection or for i.v. infusion, either reconstituted lyophilisate in vial, infusion 
bag or into the administration syringe, should be used immediately. 
If study treatment preparation has been performed under aseptic conditions, the secukinumab 
Solution and secukinumab Placebo Solution for s.c. injection or for infusion might be stored 
at 2-8°C for no longer than 24 hours. The standing time of 24 hours is defined as the time 
from the first lyophilisate vial has been pierced until end of s.c. injection or infusion. If the 
solution is not used within the timeframe given in the Pharmacist Manual, it should be kept at 
2 - 8 °C, and allowed to come to room temperature before administration (for further details, 
please refer to the Pharmacist Manual). 
Chemical and physical in-use stability of the secukinumab Solution and secukinumab Placebo 
Solution for s.c. injection or infusion, either reconstituted lyophilisate in vial, infusion bag or 
administration syringe, has been demonstrated for up to 24 hours at 2 to 8°C.  
Any unused product or waste material should be disposed of in accordance with local 
requirements. 
5.5.5 Permitted dose adjustments and interruptions of study treatment 
Study treatment dose adjustments are not permitted. Study treatment interruption is also not 
permitted with the following exceptions: 
Study treatment interruption is permitted if, in the opinion of the investigator, a subject is 
deemed to be placed at a significant safety risk unless dosing is temporarily interrupted. In 
such cases study treatment should be interrupted only during the time that this risk is present 
and ongoing. Study treatment can be started again at the next scheduled visit after resolution 
of the safety risk. 
The effect of secukinumab on live vaccines is unknown; therefore live vaccines should not be 
administered during participation in the study. In case a live vaccine has been administered 
due to a medical urgency, study treatment should be interrupted for at least 12 weeks. 
Any study treatment interruption must be recorded on the corresponding eCRF(s). 
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5.5.6 Rescue medication 
Rescue medication is defined as any new therapeutic intervention or a significant change to 
ongoing therapy made because a subject is experiencing either no benefit from participation in 
the trial or worsening/exacerbation of their disease. Rescue medication must not be used 
before completion of Visit 10 (Week 24). Please see Sections 5.5.7 and Section 5.5.8 for 
details. 
Any use of rescue medication must be recorded on the corresponding Prior and Concomitant 
Medications eCRF. 
5.5.7 Concomitant treatment 
The investigator should instruct the subject to notify the study site about any new medications 
(including over-the-counter drugs, calcium and vitamins) he/she takes after the subject is 
enrolled into the study. All medications (other than study treatment) and significant non-drug 
therapies (including physical therapy and blood transfusions) administered after the subject 
starts treatment with study treatment must be listed on the corresponding eCRF. The reason 
and the name of the drug should be listed. 
Guidelines for the use of specific medications are provided below: 
Methotrexate 
Subjects on MTX have to be treated with stable treatment of MTX (≤25 mg/week) for at least 
4 weeks before randomization and maintained stable throughout the treatment period.  
Folic acid  
Subjects on MTX must be taking folic acid supplementation before randomization and during 
the trial to minimize the likelihood of MTX associated toxicity. Folic acid supplementation 
should not be taken on the same day than MTX intake. 
Leflunomide wash-out with cholestyramine 
In case of leflunomide treatment, a drug wash-out of 8 weeks has to be performed. However, 
another wash-out procedure might be considered. Cholestyramine could be given orally to 
wash-out the drug at a dose of 8 g t.i.d. Cholestyramine reduced plasma levels of the active 
leflunomide metabolite by approximately 40 % in 24 hours and by 49 % to 65 % in 48 hours 
in three healthy volunteers. The administration of cholestyramine is recommended in subjects 
who require a drug elimination procedure. If a subject receives the therapy of 8 g t.i.d. for 11 
days, he/she could be safely randomized 4 weeks after the beginning of this 11-day period. 
Systemic corticosteroids 
Treatment with systemic corticosteroids will be allowed if the dose was stable for at least 2 
weeks before randomization and maintained stable throughout the study period. A maximum 
dosage of 10 mg equivalent of daily prednisone will be allowed. 
Corticosteroid dose reductions are permitted after Week 24. However, for any dose reductions 
after Week 24, the corticosteroid dose should not be reduced more than 1 mg prednisone 
equivalent every 4 weeks. 
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Intra-articular corticosteroids are not permitted within 4 weeks prior to baseline and up to 
week 24. After week 24, no more than 1 joint per 24-week period may be injected. No single 
injection should exceed 40 mg of triamcinolone (or equivalent) and the total dose of intra-
articular corticosteroid may not exceed 80 mg of triamcinolone (or equivalent) during any 52-
week period. Injection of intra-articular steroids is not permitted within 8 weeks prior to 
Weeks 24, 52, and 104. 
However, any change in the dose of oral corticosteroids during the trial should be recorded on 
the corresponding eCRF. 
Non-steroidal anti-inflammatory drugs (NSAIDs) (COX-1 or COX-2 inhibitors), 
low strength opioids and acetaminophen/paracetamol 
Subjects on regular use of NSAIDs or paracetamol/acetaminophen should be on stable dose 
for at least 2 weeks before randomization to allow inclusion and during the treatment period. 
Subjects taking NSAIDs, low strength opioids, or paracetamol/acetaminophen PRN within the 
2 weeks before randomization can continue to do so after randomization, however, they have 
to refrain from any intake during at least 24 hours before a visit with disease activity 
assessment. 
However, any change of the NSAIDs, opioids, or paracetamol/acetaminophen treatment 
during the trial should be recorded on the corresponding eCRF. 
5.5.8 Prohibited treatment 
Use of the treatments listed in Table 5-1 is NOT allowed after the start of the washout period. 
Live vaccines should not be given until 12 weeks after last study treatment administration. 
Table 5-1 Prohibited treatment 
Prohibited treatments Washout period   
(before randomization)
Biological immunomodulating agents > 3 different TNFα 
inhibitors 
Never 
Etanercept 
Infliximab 
Adalimumab, golimumab, certolizumab 
 
 
4 weeks 
8 weeks 
10 weeks 
Unstable dose of MTX 4 weeks 
Other DMARD (except MTX) 4 weeks  
Leflunomide  8 weeks  
Leflunomide with Cholestyramine washout 4 weeks 
Unstable dose of NSAIDs (COX1 or COX2 inhibitors) 2 weeks 
Systemic corticosteroids > 10 mg prednisone equivalent  2 weeks 
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Prohibited treatments Washout period   
(before randomization)
Intra-articular steroid  injections up to Week 24 4 weeks 
Oral or topical retinoids 4 weeks 
Photochemotherapy (e.g. PUVA) 4 weeks 
Phototherapy (UVA or UVB) 2 weeks 
Topical skin treatments (except in face, scalp and genital area 
during screening, only corticosteroids with mild to moderate 
potency) 
2 weeks 
Any investigational treatment or participation in any 
interventional trial 
4 weeks or 5 half-lives 
(whichever is longer)  
Analgesics other than paracetamol/acetaminophen and low 
strength opioids PRN 
4 weeks 
Live vaccinations up to Week 24 6 weeks 
 
5.5.9 Discontinuation of study treatment and premature subject withdrawal 
Study treatment must be discontinued and the subject withdrawn from the trial if the 
investigator determines that continuing it would result in a significant safety risk for that 
subject. The following circumstances require study treatment discontinuation: 
• Withdrawal of informed consent 
• Emergence of the following adverse events: 
• Any severe or serious adverse event that is not compatible with administration of 
study treatment, including adverse events that require treatment with an unacceptable 
co-medication up to Week 24 
• Onset of lymphoproliferative disease or any malignancy except for treated basal cell 
carcinoma, treated actinic keratoses, treated in situ carcinoma of the cervix or non-
invasive malignant colon polyps which are being or have been removed. 
• Life threatening infection 
• Any laboratory abnormalities that in the judgment of the investigator are clinically 
significant and are deemed to place the subject at a safety risk for continuation in the study 
(A general guidance on clinically notable laboratory values is provided in Appendix 1.) 
• Pregnancy 
• Use of the following medication(s): 
• Any biologic immunomodulating agent except secukinumab 
• Any other protocol deviation that results in a significant risk to the subject’s safety 
In case of undue safety risk for the subject, the subject should discontinue study treatment at 
the discretion of the investigator.  
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In addition to these requirements for study treatment discontinuation, the investigator should 
discontinue study treatment for a given subject if, on balance, he/she thinks that continuation 
would be detrimental to the subject’s well-being. 
For subjects who discontinue study treatment a Dosage Administration Record eCRF should 
be completed, giving the date and primary reason for stopping study treatment. Then, all 
Week 104 assessments must be performed on the day of study treatment discontinuation or as 
early as possible after study treatment discontinuation ; and the follow up visit should be 
performed (F112).  
The appropriate personnel from the site and Novartis will assess whether study treatment 
should be discontinued for any subject whose treatment code has been broken inadvertently 
for any reason. 
The investigator must also contact the IRT to register the subject’s discontinuation from study 
treatment. 
Subjects may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they state an intention to withdraw, or fail to return for visits, or 
become lost to follow up for any other reason. 
If premature withdrawal occurs for any reason, the investigator must determine the primary 
reason for a subject’s premature withdrawal from the study and record this information on the 
Study completion eCRF.  
The investigator should ensure that the subject returns for an end of study visit (week 104) 4 
weeks after last study treatment, and a follow-up visit (F112) 12 weeks after last study 
treatment. Even if the subject is not willing to come back for all assessments, every effort 
should be made to collect the scheduled X-ray assessments. 
For subjects who are lost to follow-up (i.e. those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), the investigator should 
show "due diligence" by documenting in the source documents steps taken to contact the 
subject, e.g. dates of telephone calls, registered letters, etc. 
Subjects who are prematurely withdrawn from the study will not be replaced. 
5.5.10 Emergency unblinding of treatment assignment 
Emergency unblinding should only be undertaken when it is essential to treat the subject 
safely and efficaciously. Most often, study treatment discontinuation and knowledge of the 
possible treatment assignments are sufficient to treat a study subject who presents with an 
emergency condition. Emergency code breaks are performed using the IRT. When the 
investigator contacts the system to unblind a subject, he/she must provide the requested 
subject identifying information and confirm the necessity to unblind the subject. The 
investigator will then receive details of the study treatment for the specified subject and a fax 
or email confirming this information. The system will automatically inform the Novartis 
monitor for the site and the Clinical Trial Head that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the IRT in case of emergency. The investigator will inform the subject how to contact 
his/her backup in cases of emergency when he/she is unavailable. The investigator will 
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provide protocol number, study treatment name if available, subject number, and instructions 
for contacting the local Novartis CPO (or any entity to which it has delegated responsibility 
for emergency code breaks) to the subject in case emergency unblinding is required at a time 
when the investigator and backup are unavailable. 
Study treatment must be discontinued after emergency unblinding. 
5.5.11 Study completion and post-study treatment 
A subject will be considered to have completed the study if he/she received a maximum of 
100 weeks of study treatment and upon completion of all the scheduled study assessments and 
procedures up to and including Week 112. 
Information on the subject’s completion or discontinuation of the study and the reason for 
discontinuation of the study will be recorded on the appropriate Study Phase Completion 
eCRF page. 
Study Completion evaluations must also be performed when a subject prematurely withdraws 
from the study for whatever reason. 
The investigator must provide follow-up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care. This care may 
include initiating another treatment outside of the study as deemed appropriate by the 
investigator. This treatment may be any non-biologic DMARD. In case of a biologic 
treatment, a waiting period of 3 months is recommended before initiating the treatment. 
5.5.12 Early study termination 
The study can be terminated at any time for any reason by Novartis. Should this be necessary, 
the subject should be seen as soon as possible and treated as described in Section 6 for a 
prematurely withdrawn subject. The investigator may be informed of additional procedures to 
be followed in order to ensure that adequate consideration is given to the protection of the 
subject’s interests. The investigator will be responsible for informing IRBs and/or ECs of the 
early termination of the trial. 
6 Visit schedule and assessments 
Table 6-1 lists all of the assessments and indicates with an “X” the visits when they are 
performed. 
Subjects should be seen for all visits on the designated day or as closely as possible to the 
original planned visit schedule. For all infusion visits (Visits 2, 4 and 5), study treatment 
should not be administered within less than 1 week after the previous infusion. Starting at 
Visit 6 (Week 8), subjects should not receive study treatment within less than 2 weeks after 
the previous administration. 
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Table 6-1 Assessment schedule 
 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128 
Week ≤-4 BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Informed consent / 
optional PG informed 
consent 
X                              
 
Inclusion/Exclusion 
criteria 
X X                              
Relevant medical history/ 
current medical condition 
X                               
Cardiovascular medical 
history  X                             
 
Psoriasis/psoriatic arthritis 
medical history and 
previous 
psoriasis/psoriatic arthritis 
therapies 
X X                             
 
Smoking history  X                              
Demography X                               
Physical Exam1 X X X X X X X X X X X X X X X X X  X  X  X  X  X  X X X 
Height X                               
Weight X X        X       X        X     X X 
Vital signs X X X X X X X X X X X X X X X X X  X  X  X  X  X  X X X 
PPD skin test2 or 
QuantiFERON TB-Gold 
test 
X                              
 
Rheumatoid factor (RF) X                               
Anti-CCP antibodies X         X       X             X  
Chest X-ray3 X                               
ECG (central)  X      X         X             X  
Randomization  X      X4  X4                      
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 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128 
Week ≤-4 BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Administration of i.v. 
study treatment 
 X  X X                           
Administration of s.c. 
study treatment      X X X X X X X X X X X X X X X X X X X X X X X X  
 
Prior medication X X                              
Hematology, blood 
chemistry, local urinalysis 
X X X X X X X X X X X X  X   X  X  X  X  X  X   X X 
Serum pregnancy test X                               
Urine pregnancy test  X   X  X X  X  X  X   X  X  X  X  X  X   X X 
Con medication/non drug 
therapy  
 Update as necessary throughout the study 
Adverse Events/SAE5 
(including injection site 
reaction & infections) 
 Update as necessary throughout the study 
MRI (swollen hand/wrist; 
TNF-naïve subjects 
only)12  
 X     X   X                    X14 
 
X-Ray (hands/wrists + 
feet) 
 X      X9  X10       X             X11  
ANA  X        X       X             X  
Anti-dsDNA  X        X       X             X  
Immunogenicity  X        X       X             X X 
PK assessments (at 
predose) 
 X   X   X  X       X             X X 
Tender & Swollen joint 
counts (TJC78 / SJC76) X X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
Patient’s assessment of PsA 
pain (VAS scale)  
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
Patient’s global assessment 
of disease activity (VAS 
scale) 
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
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 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128 
Week ≤-4 BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Physician’s global 
assessment of disease 
activity (VAS scale) 
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
Health Assessment 
Questionnaire (HAQ-DI) 
 X X X X X X X X X X X X X X X X  X  X  X  X  X   X  
High sensitivity C-
Reactive protein (hsCRP) X X X X X X X X X X X X X X X X X  X  X  X  X  X   X X 
Erythrocyte 
Sedimentation Rate (ESR) 
X X X X X X X X X X X X X X X X X  X  X  X  X  X   X X 
Leeds Dactylitis Index X X  X X X X X  X  X  X   X  X  X  X  X  X   X  
Leeds Enthesitis Index X X  X X X X X  X  X  X   X  X  X  X  X  X   X  
PASI (only if  ≥ 3% of 
BSA at BSL) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
IGA (only if  ≥ 3% of 
BSA at BSL) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
Target Lesion Score 
(TLS; only if target lesion 
with ≥ 2cm diameter) 
 X X X X X X X  X  X  X   X  X  X  X  X  X   X  
mNAPSI (only in subjects 
with nail involvement)  X X X X X X X  X  X  X   X  X  X  X  X  X   X  
WPAI-GH  X      X  X       X             X  
SF-36 Acute Form v2   X   X X X X  X       X             X  
FACIT-Fatigue v4  X   X X X X  X       X             X  
PsAQoL  X   X X X X  X       X             X  
EQ-5D v3L  X   X X X X  X       X             X  
DLQI (only if  ≥ 3% of 
BSA at BSL)  X   X X X X  X       X             X  
Lipids6  X    X  X  X       X      X       X  
Cardiovascular panel  X      X  X       X             X  
Serum biomarkers related 
to targeted pathway 
 X        X       X             X  
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 SCR Treatment Period 1 Treatment Period 2 Follow
-up 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 F1128 
Week ≤-4 BSL 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 
10413/ 
Disc. 
Subj. 
112 
Pharmacogenetics7  X                              
Treatment Period 1 
Completion Form13 
                X               
Treatment Period 2 
Completion Form                              X 
 
Follow-up period 
Completion Form 
                              X 
1 These assessments are source documentation only and will not be entered into the eCRF 
2 The PPD skin test can be performed at any time during the screening period but it has to be read within 72 hrs and before randomization 
3 A chest X-ray is required if it was not performed and evaluated within 3 months before screening 
4 Subjects will be re-assigned/re-randomized to new treatment groups based on their responder status and the treatment group to which they were randomized at Visit 2 
5 AEs/SAEs occurring after the subject has provided informed consent must be reported 
6 Samples must be obtained fasting 
7 Pharmacogenetic sample should only be collected after separate Informed Consent Form (ICF) is signed 
8 Follow-up visit to be done 12 weeks after last study treatment administration for subjects who terminated the study early or for subjects who completed the study but do not enter the 
extension study 
9 X-rays only taken for subjects who are non-responder at Week 16 (only achieving < 20% reduction in both, TJC and SJC) 
10 X-rays only taken for subjects who are responder at Week 16 (achieving ≥ 20% reduction in both, TJC and SJC) 
11 Subjects who discontinue will have their X-rays taken only if more than 60 days have elapsed since their last X-rays 
12 Subjects who undergo the MRI assessments need to be TNFα inhibitor naïve and should have a swollen wrist at baseline; the more swollen wrist should be scanned; if both hands are 
equally swollen, the dominant hand should be scanned 
13 In case of premature discontinuation, assessments to be done 4 weeks after last study treatment administration. In case of premature discontinuation before Week 52, the Treatment Phase I 
Completion Form must also be completed. 
14 Only for subjects participating in the MRI sub-study who discontinue before or at week 24 
.
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6.1 Information to be collected on screening failures 
Subjects may discontinue from the study prior to entering the treatment period. Those subjects 
are considered screening failures. 
If a subject discontinues before entering the double-blind treatment period at BSL, IRT must 
be notified within 2 days and the reason for not being randomized will be entered on the 
Screening Phase Disposition eCRF. In addition only the following eCRFs should be 
completed: Demography eCRF, Informed Consent eCRF, Inclusion/Exclusion eCRF, and the 
AE eCRF should be completed for any SAEs that occurred during the screening period. 
6.2 Demographics/other baseline characteristics 
Subject demographic and baseline characteristic data to be collected on all subjects and 
recorded in the eCRF include: 
• Date of birth, age, sex, race, ethnicity and source of subject referral 
• Relevant PsA/Psoriasis and general medical history/current medical condition data 
until the start of study treatment , such as date of diagnosis of PsA/Psoriasis, previous 
PsA/Psoriasis therapies with the status of TNFα inhibitor naïve or IR, cardiovascular 
medical history, and smoking history 
Whenever possible, diagnoses and not symptoms will be recorded. 
6.3 Treatment exposure and compliance 
All dates and times of study treatment administration will be recorded on the appropriate 
Dosage Administration Record eCRF. 
Drugs administered prior to start of treatment and other drugs continuing or started during the 
study treatment period will be entered in the Prior/Concomitant medications/significant non-
drug therapies eCRF. Compliance is expected to be 100% (unless temporary interruption is 
needed for safety reasons as described in Section 5.5.5) since study treatment will be 
administered by the investigator or site staff. Compliance will also be assessed by a Novartis 
monitor using vial counts and information provided by the unblinded 
pharmacist/nurse/physician or authorized site personnel 
6.4 Efficacy 
• ACR 20, 50 and 70  
• PsARC response 
• Disease Activity Score-CRP (DAS28-CRP) and EULAR response criteria 
• HAQ-DI© 
• Leeds Enthesitis Index (LEI) 
• Leeds Dactylitis Index (LDI) and dactylitis count 
• Progression of  structural damage by X-ray (hands/wrists and feet) – van der Heijde 
modified total Sharp score and subscores (erosion and joint space narrowing score) 
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• MRI of hand/wrist (in a subgroup of TNFα inhibitor naïve subjects at selected clinical 
sites only) 
• Psoriasis Area and Severity Index (PASI) 
• IGA (mod 2011) 
• Target lesion Score 
• Modified Nail Psoriasis Severity Index (mNAPSI) 
• Swollen Joint Count (SJC)/Tender Joint Count (TJC) 
• Patient’s assessment of pain intensity (VAS scale) 
• Patient’s global assessment of disease activity (VAS scale) 
• Physician’s global assessment of disease activity (VAS scale) 
• Erythrocyte Sedimentation Rate (ESR) and high sensitivity C-Reactive Protein (hsCRP) 
6.4.1 American College of Rheumatology (ACR) response 
The primary efficacy variable is the clinical response to treatment according to ACR20 
individual improvement in disease activity at Week 24. A subject is defined as an ACR20 
responder if, and only if, the following three conditions hold (See Appendix 3): 
1. they have a ≥ 20% improvement in the number of tender joints (based on 78 joints) 
2. they have a ≥ 20% improvement in the number of swollen joints (based on 76 joints) 
3. they have a ≥ 20% improvement in three of the following five domains 
• Patient Global Assessment (measured on a VAS scale, 0-100) 
• Physician Global Assessment (measured on a VAS scale, 0-100) 
• Patient’s assessment of PsA pain (measured on a VAS scale, 0-100) 
• Disability (HAQ-DI© score) 
• Acute phase reactant (hsCRP or ESR)  
Additionally, Major Clinical Response (continuous six-month period of ACR70 response) 
will be assessed as a key secondary objective at week 52 
6.4.1.1 Tender 78 joint count and swollen 76 joint count 
Joint counts will be performed at scheduled visits as indicated in Table 6-1, by the 
independent assessor(s) who must be well trained and part of the site personnel. Whenever 
possible, the same evaluator should perform these assessments at all visits. 
The 78 joints assessed for tenderness include the 2 temporomandibular, 2 sternoclavicular, 2 
acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 2 first carpometacarpal, 10 
metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 
the 2 hip, 2 knee, 2 talo-tibial, 2 mid-tarsal, 10 metatarsophalangeal, 10 proximal 
interphalangeal, and 8 distal interphalangeal joints of the feet. All of these except for the hips 
are assessed for swelling. Joint tenderness and swelling are to be graded present (1) or absent 
(0). Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive 
result for swollen joint count. Dactylitis of a digit in the foot or hand counts as one tender and 
swollen joint.  
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Data is recorded for tender and swollen joints (right or left side), i.e. a box (no, yes or not 
applicable) needs to be ticked for all joints. The total number of tender and swollen joints 
(right and left) will be automatically calculated in the eCRF. 
6.4.1.2 Patient’s assessment of PsA pain intensity 
The patient’s assessment of pain will be performed using 100 mm visual analog scale (VAS) 
ranging from “no pain” to “unbearable pain” after the question “Please indicate with a 
vertical mark ( | ) through the horizontal line the most pain you had from your psoriatic 
arthritis today”. 
6.4.1.3 Patient’s global assessment of disease activity 
The patient’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from ”very good” to ”very poor”, after the question "Considering all the ways 
psoriatic arthritis affects you, please indicate with a vertical mark ( | ) through the horizontal 
line how well you are doing today”.  
6.4.1.4 Physician’s global assessment of disease activity 
The physician’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from no disease activity to maximal disease activity, after the question "Considering 
all the ways the disease affects your patient, draw a line on the scale for how well his or her 
condition is today”. To enhance objectivity, the physician must not be aware of the specific 
patient’s global assessment of disease activity, when performing his own assessment on that 
patient. 
6.4.1.5 HAQ-DI 
The HAQ-DI is a key secondary efficacy endpoint for this study. The HAQ-DI© was 
developed by Stanford University and is one of the most widely used measures to assess the 
long-term influence of chronic disease on a subject's level of functional ability and activity 
restriction. The disability assessment component of the HAQ, the HAQ-DI, assesses a 
subject's level of functional ability and includes questions of fine movements of the upper 
extremity, locomotor activities of the lower extremity, and activities that involve both upper 
and lower extremities. There are 20 questions in eight categories of functioning including 
dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each 
item asks over the past week "Are you able to …" perform a particular task. Each item is 
scored on a 4-point scale from 0 to 3, representing normal (normal, no difficulty [0]), some 
difficulty (1), much difficulty (2), and unable to do (3).  
The purpose of the HAQ-DI in this study is to assess the functional ability of subjects with 
PsA. 
Patient reported outcomes (PROs) will be collected using the digital pen technology. Details 
relating to the administration of all PROs are provided in Appendix 9. 
6.4.1.6 High Sensitivity C-reactive protein (hsCRP) 
Blood for this assessment will be obtained in order to identify the presence of inflammation, 
to determine its severity, and to monitor response to treatment. 
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Since the results of this test may unblind study personnel, results from the central lab will be 
provided for screening and baseline only. The hsCRP results from samples collected during 
the treatment period will be revealed following database lock only. 
6.4.1.7 Erythrocyte sedimentation rate (ESR) 
Blood for ESR, which is helpful in diagnosing inflammatory diseases and is used to monitor 
disease activity and response to therapy, will be obtained at scheduled visits (see Table 6-1). 
6.4.2 DAS28 and EULAR response 
The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR 
or CRP and the Patient Global Assessment. A DAS28 score > 5.1 implies active disease, ≤ 3.2 
low disease activity, and < 2.6 remission. EULAR response criteria are based on DAS28 
status in combination with DAS28 improvements. 
6.4.3 PsARC response 
A subject is defined as a PsARC responder if, and only if, they have an improvement in two 
of the following four factors (with at least one factor being a joint count) and no worsening in 
the remaining factors 
• Patient global assessment (0-100 mm VAS scale, improvement defined as decrease of 
at least 20 mm) 
• Physician global assessment (0-100 mm VAS scale, improvement defined as decrease 
of at least 20 mm) 
• Tender 78-joint count (improvement defined as decrease of at least 30%) 
• Swollen 76-joint count (improvement defined as decrease of at least 30%) 
6.4.4 Radiographic assessments 
Separate radiographs of each hand/wrist (PA) and each foot (AP) will be taken at baseline, 
Week 24, 52, and 104. Bone erosion, joint space narrowing (JSN), and total radiographic 
scores will be determined using a PsA modified van der Heijde‐Sharp (vdH‐S) scoring 
method (van der Heijde 2005)  that includes the second through fifth distal interphalangeal 
(DIP) joints of each hand. Erosions (0–5 in the hands and 0–10 in the feet) and JSN (0–4) will 
be graded separately in six wrist joints, all metacarpal phalangeal, proximal interphalangeal, 
and DIP joints of each hand, and the first interphalangeal joint and all metatarsal phalangeal 
joints for each foot. The total radiographic score (hands and feet combined) ranges from 0 to 
528, with higher scores indicating more articular damage. The maximum total erosion score is 
360. The maximum total JSN score is 168.   
The change in the Van der Heijde modified Sharp score is calculated against the baseline 
value. Radiologists will be trained on the X-ray acquisition and further details will be 
provided in a manual for the radiologists, e.g. joint placement and beam positioning.  
In case of analogue X-rays films, the original film will be sent to the central reading CRO and 
will undergo quality control and will be digitized. Standard film and cassettes will be 
provided to all centers that do not produce digital X-rays. In case of digital equipment, sites 
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need to confirm minimum requirements with the imaging CROs Digital X-rays will be 
transferred electronically.  
In case of insufficient quality, the center will be advised and trained on any quality issues 
prior to the repeat X-ray and to keep any repeat X-rays to a minimum. 
Subjects who are non-responder at Week 16 (not achieving a ≥20% improvement from 
baseline in both TJC and SJC) will have their hands/wrists and feet X-rays taken at this visit 
(Week 16).  Subjects who are responder at Week 16 (≥20% improvement from baseline in 
both tender and swollen joint counts) will have their hands/wrists and feet X-rays taken at 
Week 24. Subjects who discontinue study treatment before the end of the trial, hands/wrists 
and feet X-rays will be taken at the time of study treatment discontinuation. However, if the 
radiograph performed at time of early discontinuation of study treatment is less than 60 days 
to a prior X-ray, it does not need to be performed. Likewise, if a scheduled X-ray at Week 24, 
52, or 104 is scheduled less than 60 days after any prior hands/wrists and feet X-rays, it does 
not need to be performed. All following X-rays will be performed as scheduled.  
The readings of the X-rays and the scoring will be performed centrally. Complete X-ray 
procedures will be defined in an Imaging Manual provided to the centers by an Imaging CRO 
designated by Novartis. 
6.4.5 Magnetic Resonance Imaging (MRI) 
MRI will be performed in a subgroup of approximately 90 subjects with at least one swollen 
wrist at baseline (approx. 30 subjects/treatment arm) at selected sites. The hand with the more 
swollen wrist should be chosen (determined at baseline by the investigator). If both wrists are 
equally affected, the dominant hand/wrist should be chosen. The site should ensure that the 
same hand/wrist selected at baseline will be scanned at the following visits. Subjects with any 
contraindications to MRI (e.g.: pacemakers, aneurysm clips, artificial heart valves, ear 
implants, metal fragments, foreign objects in the eyes, skin or body or severe claustrophobia) 
or to gadolinium injections (e.g. allergic or adverse reactions to gadolinium, estimated 
glomerular filtration rate below 60 mL/1.73 m2 (based on MRD formula)) should not perform 
an MRI evaluation.  
MRIs will be performed at BSL, Week 12 and Week 24 using a whole body MRI system. For 
subjects participating in the MRI sub-study who discontinue before or at week 24, a MRI will 
be performed at the time of discontinuation. The MRI assessment will require gadolinium 
contrast agent injections. MRI machines should have a field strength of 1.5 Tesla. The MRI 
protocol and required sequences will be described in the imaging acquisition manual.  
The readings of the scan and the scoring will be performed centrally. Readers will be blinded 
to clinical information and to the sequence of the images. The MRIs will be scored according 
to a modified OMERACT RAMRIS system (Ostergaard 2010) for erosions, bone marrow 
edema (BME), and synovitis. In addition, JSN will be scored (Peterfy 2010).  
6.4.6 Psoriasis Area and Severity Index (PASI) 
The PASI assessment will be conducted for subjects in whom at least 3% of the body surface 
area (BSA) was affected by psoriatic skin involvement at baseline (Visit 2). The PASI 
assesses the extent of psoriasis on four body surface areas (head, trunk and upper and lower 
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limbs) and the degree of plaque erythema, scaling and thickness. A PASI score (Fredriksson 
and Pettersson 1978, Weisman 2003, Gottlieb 2005) will be derived as indicated in Table 6-2.  
The head, trunk, upper limbs and lower limbs are assessed separately for erythema, thickening 
(plaque elevation, induration), and scaling (desquamation).  The average degree of severity of 
each sign in each of the four body regions is assigned a score of 0-4.  The area covered by 
lesions on each body region is estimated as a percentage of the total area of that particular 
body region.  Further practical details help the assessment: 
1. The neck is assessed as part of the head. 
2. The axillae and groin are assessed as part of the trunk. 
3. The buttocks are assessed as part of the lower limbs. 
4. When scoring the severity of erythema, scales should not be removed. 
Table 6-2 The PASI scoring system 
Body  
region 
Erythema (E) 
 
Thickening 
(plaque elevation,
induration, I) 
Scaling 
(desquamation) 
(D) 
Area score 
(based on true 
area %, A)* 
Head  (H)** 0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Trunk,   
(T)*** 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Upper  
limbs (U) 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Lower  
limbs  
(L)**** 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
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* Percentage (not score) of body region (not whole body) affected will be entered in the eCRF 
**Neck is assessed as part of the Head (H) body region. 
***Axillae and groin are assessed as part of the Trunk (T) body region. 
****Buttocks are assessed as part of the Lower limbs (L) body region. 
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the PASI score is calculated 
using the formula: 
PASI = 0.1(EH+IH+DH)AH + 0.2(EU+IU+DU)AU + 0.3(ET+IT+DT)AT + 0.4(EL+IL+DL)AL 
The keys for the letters are provided in Table 6-2. 
PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a 
theoretic maximum of 72.0. The investigator is only responsible for collecting the components 
or scoring signs and total regional area. More information is provided in Appendix 6.  
6.4.7 Investigator’s Global Assessment (IGA mod 2011) 
IGA mod 2011 will be conducted for overall psoriatic disease as indicated in Table 6-3 for 
subjects in whom at least 3% of the body surface area (BSA) was affected by psoriatic skin 
involvement at baseline (Visit 2).  It is recommended that the same evaluator conducts the 
assessment throughout the study wherever possible. 
The IGA mod 2011 rating scale for overall psoriatic disease is shown in Table 6-3. 
The IGA mod 2011 scale has been developed based on a previous version of the scale used in 
secukinumab phase II psoriasis studies in collaboration with health authorities in particular the 
FDA. The explanations/descriptions of the points on the scale have been improved to ensure 
appropriate differentiation between the points. 
The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease 
state at the time of the assessments, and does not attempt a comparison with any of the 
subject’s previous disease states, whether at baseline or at a previous visit.  
The IGA mod 2011 score will be recorded in the eCRF. 
Table 6-3 The IGA mod 2011 rating scale 
Score Short Description Detailed Description 
0 Clear No signs of psoriasis. Post-inflammatory hyperpigmentation may be present. 
1 Almost clear Normal to pink coloration of lesions; no thickening; no to minimal focal scaling. 
2 Mild Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling. 
3 Moderate Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling. 
4 Severe 
Bright to deep dark red coloration; severe thickening with 
hard edges; severe / coarse scaling covering almost all or 
all lesions. 
Note:  Involvement of nails is not part of the assessment. 
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Based on this scale, a subject will be considered as IGA 0 or 1 responder if the subject 
achieves a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to 
baseline. 
6.4.8 Target lesion score (TLS) 
The Target Lesion Score will be done for subjects enrolled in the study having a psoriatic 
target lesion that is at least 2 cm in diameter identified at baseline (Visit 2). At the visits 
indicated in Table 6-1, this target lesion will be scored for erythema, scaling, and thickness, 
each on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). The 
parameter scores will be summed automatically in the eCRF, giving a score ranging from 0 to 
12. 
6.4.9 Modified Nail Psoriasis Severity Index (mNAPSI) 
The mNAPSI is an instrument to assess psoriatic nail involvement in subjects with PsA and 
nail psoriasis. It will be collected only in subjects with psoriatic nail involvement. The 
modifications on the original NAPSI to create the mNAPSI were made by rheumatologists, 
with dermatologists’ input, as a tool for clinical trials. The creators’ goal was to develop a tool 
to assess disease severity and response to treatment in clinical trials, keeping in mind that the 
assessor in a clinical trial most likely would not be a trained dermatologist (Cassel 2007). 
More information is provided in Appendix 7. 
6.4.10 Leeds Dactylitis Index (LDI) 
The Leeds Dactylitis Index (LDI) (Helliwell 2005) basic measures the ratio of the 
circumference of the affected digit to the circumference of the digit on the opposite hand or 
foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of 
circumference is multiplied by a tenderness score, using a modification of LDI which is a 
binary score (1 for tender, 0 for non-tender). If both sides are considered involved, or the 
circumference of the contralateral digit cannot be obtained, the number will be compared to 
data provided in the standard reference tables (see Appendix 8). This modification is referred 
to as LDI basic and will be applied in this study. The LDI requires a finger circumference 
gauge or a tape measure to measure digital circumference. 
Dactylitis count 
The dactylitis count is the number of fingers and toes with dactylitis, with a range of 0-20.  
Presence of dactylitis 
If dactylitis is present with any finger or toe, the subject is counted as a subject with dactylitis. 
6.4.11 Leeds Enthesitis Index (LEI) 
LEI is a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral 
epicondyle humerus L + R, proximal achilles L + R and medial condyle femur L + R. 
Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 
sites, for an overall score range of 0–6. Higher count represents greater enthesitis burden.  
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In this study, the lateral condyle femur L + R data were collected erroneously instead of 
required medial condyle femur L + R. Therefore, a 4-site LEI (LEI-4) will be calculated with 
the four correct sites: lateral epicondyle humerus L + R, proximal achilles L + R.  
Presence of enthesitis 
If enthesitis is present with any of the 4 sites (lateral epicondyle humerus L + R, proximal 
achilles L + R), the subject is counted as a subject with enthesitis. 
6.4.12 Appropriateness of efficacy assessments  
The efficacy outcome measures used in this study are the standard measures used across many 
psoriatic arthritis trials and they are required for regulatory filing. 
6.5 Safety 
• Evaluation of all AEs and SAEs including injection site reactions, ECGs, physical 
examination, vital signs and laboratory assessments 
• Assessment of anti-secukinumab antibody development (immunogenicity) 
6.5.1 QuantiFERON TB-Gold test or PPD skin test 
Either a QuantiFERON TB-Gold test or a PPD skin test must be performed at screening, 
Subjects with a positive test may only participate in the study if further work up (according to 
local practice/guidelines) establishes conclusively that the subject has no evidence of active 
tuberculosis. If presence of latent tuberculosis is established then treatment according to local 
country guidelines must have been initiated. 
QuantiFERON TB-Gold test 
• A QuantiFERON TB-Gold test is to be performed at screening (Visit 1) and the results to 
be known prior to randomization to determine the subject’s eligibility for the trial. The test 
will be used to screen the subject population for latent tuberculosis infection.  
• The test will be performed by the central laboratory. Details on the collection, processing 
and shipment of samples and reporting of results by the central laboratory are provided in 
the laboratory manual. 
PPD skin test 
• A PPD skin test is to be performed at screening and read before randomization to 
determine the subject’s eligibility for the trial. The test dose is bioequivalent to 5 
tuberculin units of standard PPD injected intradermally usually into the volar surface of 
the forearm. The site is cleansed and the PPD extract is then injected into the most 
superficial layer under the skin. If given correctly, the injection should raise a small wheal 
of about 5 mm, which resolves within 10-15 minutes. 
Because the reaction (induration) will take 48-72 hours to develop, the subjects must return to 
the investigators’ site within that time for a proper evaluation of the injection site. This will 
determine whether the subject has had a significant reaction to the PPD test. A reaction is 
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measured in millimeters of induration (hard swelling) at the site. A PPD skin induration 
≥5 mm (or according to local practice/guidelines) is interpreted as a positive result 
6.5.2 Physical examination 
A physical examination will be performed at scheduled visits as indicated in Table 6-1. 
Significant findings that are present before the subject has signed the Informed Consent Form 
must be included in the relevant medical history eCRF. Significant findings made after the 
subject has signed the Informed Consent Form which meet the definition of an AE must be 
recorded in the Adverse Event case report form. It will include the examination of general 
appearance, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological systems. 
6.5.3 Vital signs 
6.5.4 Height and weight 
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing) (both without shoes) will be measured. 
If possible, body weight assessments should be performed by the same study site staff 
member using the same scale throughout the study. 
6.5.5 Electrocardiogram (ECG) 
A standard 12-lead ECG will be performed at visits as indicated in Table 6-1.  
All ECGs must be performed on the ECG machines provided for the study. 
All ECGs will be independently reviewed. Instructions for the collection and transmission of 
the ECGs to the independent reviewer will be provided in the ECG investigator manual. 
Clinically relevant abnormalities should be recorded on the relevant Medical History/Current 
Medical Conditions eCRF for the baseline ECG.  
Clinically relevant abnormalities noted after the baseline ECG should be reported as AEs (see 
Section 7). 
6.5.6 Local tolerability (injection site reactions) 
The local tolerability at the site of s.c. injection will be assessed in the case of any local 
reaction, until this has disappeared. 
The assessment of pain, redness, swelling, induration, hemorrhage and itching will be 
performed by a physician and will be recorded on the Adverse Event eCRF, including the 
severity (none, mild, moderate, severe) and the duration. 
6.5.7 Laboratory evaluations 
A central laboratory will be used in this study. All laboratory tests should be conducted at the 
central laboratory except for ESR and urinalysis/urine pregnancy tests. Central laboratory 
information, including collection, shipment of samples and reporting of results, may be found 
in the laboratory manual. For the identification of notable values, see Appendix 1. All subjects 
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with laboratory tests containing clinically significant abnormal values are to be followed until 
the values return to normal ranges or until a valid reason, other than drug related AE, is 
defined. 
6.5.7.1 Hematology 
Hemoglobin, platelet, red blood cell (RBC), white blood cell (WBC) and differential white 
blood cell counts will be measured at scheduled visits.  
6.5.7.2 Clinical chemistry 
Serum chemistries will include glucose, urea, creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, 
total protein, albumin, and uric acid. 
6.5.7.3 Lipid panel 
A lipid profile including High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), 
cholesterol and triglycerides will be measured from a fasting blood sample. 
6.5.7.4 Cardiovascular panel 
A cardiovascular profile including lipoprotein (a), apolipoprotein B, apolipoprotein A-1, and 
adiponectin will be measured from a blood sample. 
6.5.7.5 Urinalysis 
Dipsticks will be provided by the central laboratory to the sites for local urinalysis 
assessments. The urinalysis results for standard parameters such as protein, glucose, blood 
and WBCs will be recorded in the appropriate eCRF page. 
6.5.8 Pregnancy and assessments of fertility 
Secukinumab must not be given to pregnant women; therefore effective methods of birth 
control must be used for women of child-bearing potential (see exclusion criteria definitions, 
Section 4.2). 
A serum β-hCG test will be performed in all women at Visit 1 (screening). All women of 
child bearing potential (WOCBP) at screening will have local urine pregnancy tests as 
indicated in Table 6-1. A positive urine pregnancy test requires immediate interruption of 
study treatment until serum β-hCG is performed and found to be negative. If positive, the 
subject must be discontinued from the trial. 
6.5.9 Tolerability of secukinumab 
Tolerability will be assessed by adverse events, laboratory values, injection site reaction and 
immunogenicity. 
6.5.10 Additional parameters 
Blood will be obtained for ANA, anti-dsDNA antibodies, anti-CCP antibodies, and 
Rheumatoid Factor (RF) at scheduled visits as indicated in Table 6-1.  
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6.5.11 Immunogenicity 
Blood samples for immunogenicity (anti-secukinumab antibodies) will be taken pre-dose at 
the scheduled timepoints as indicated in Table 6-1. In addition, if a subject discontinues from 
the study at any timepoint, he/she will needs to provide a sample at the last visit. 
The actual sample collection date and exact time will be entered on the Immunogenicity blood 
collection eCRF. Sampling problems will be noted in the Comments section of the eCRF.  
All blood samples will be taken by either direct venipuncture or an indwelling cannula 
inserted in a forearm vein. 
A laboratory manual will be provided to the investigators with detailed information on sample 
collection, handling and shipment. 
Tubes and preprinted labels will be provided by the central lab to the sites. 
Analytical Method 
An electrochemiluminescence method will be used for the detection of potential anti-
secukinumab antibody formation. The detailed method description to assess immunogenicity 
will be described in the bioanalytical raw data of the study and in the respective Bioanalytical 
Data Report (BDR). 
Table 6-4 IG sample log 
Visit Week IG Sample number 
2 0 301 
10 24 302 
17 52 303 
30 104 304 
F112 112 305 
6.5.12 Appropriateness of safety measurements 
The safety measures used in this study are reliable and relevant standard measures for a 
biologic in PsA. The specific focus on infection rates in addition to the other safety measures 
ensures the ability to deliver data on a critical safety endpoint for this class of therapy. A 
Chest X-ray at screening is performed to rule out the presence of a pulmonary malignancy or 
infectious process, in particular tuberculosis. The radiation exposure that results from these X-
ray measurements is not necessary for medical care but is intended for research purposes only. 
The total amount of radiation from all X-ray measurements performed in this study (1 safety 
chest X-ray, 3-4 X-rays of hands/wrists and feet) is estimated to be around 1 mS over 104 
weeks, and is approximately equivalent to a uniform whole body exposure of 26 weeks of 
exposure to natural background radiation.  For effective radiation doses under 3 mSv (300 
mrem), the risk is considered to be "minimal". Therefore, the radiation exposure in this study 
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involves minimal risk and is necessary to obtain the research information desired and ensure 
reliable safety measures before the treatment with a biologic. 
The safety assessments selected are standard for this indication/patient population. 
6.6 Other assessments 
• Quality of Life questionnaire/ Patient reported outcomes (PROs) 
• Pharmacokinetics 
• Pharmacogenetics 
• Serum biomarkers related to targeted pathway 
6.6.1 Quality of Life questionnaires/Patient Reported Outcomes (PROs) 
The impact of PsA on various aspects of subjects’ health-related quality of life (HRQoL) will 
be assessed using the following validated instruments: 
• HAQ-DI (see Section 6.4.1.5) 
• SF-36 v2 (Acute form) 
• EQ-5D 
• FACIT-Fatigue 
• PsAQoL 
• DLQI 
All questionnaires will be available, where possible, in the local languages of the participating 
countries and should be completed by subjects before they see the study physician. The 
subject should be given sufficient space and time to complete the questionnaire. 
Responses will be collected on digital paper to allow the use of a digital pen.  Only the 
original digital paper provided can be used for the digital pens (i.e. these pages must not be 
photocopied). 
All questionnaires will be completed in the respondent’s local language. The study 
coordinator should check the questionnaires for completeness and encourage the subject to 
complete any missing responses. The original questionnaires will be kept with the subject’s 
file as the source document. 
Completed questionnaires should be reviewed and assessed by the investigator, before the 
clinical examination, for responses which may indicate potential AEs or SAEs. This 
assessment should be documented in the source records. If AEs or SAEs are confirmed the 
investigator should record the events as per instructions given in the relevant section of the 
protocol (see Section 7). 
Guidelines for administering the PRO questionnaires can be found in Appendix 9. 
6.6.1.1 SF-36 Version 2 (Acute Form) 
The Short Form Health Survey (SF-36) is a widely used and extensively studied instrument to 
measure health-related quality of life among healthy subjects and patients with acute and 
chronic conditions. It consists of eight subscales that can be scored individually: Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-
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Emotional, and Mental Health (Ware 1993). Two overall summary scores, the Physical 
Component Summary (PCS) and the Mental Component Summary (MCS) also can be 
computed (Ware 1994). The SF-36 has proven useful in monitoring general and specific 
populations, comparing the relative burden of different disease, differentiating the health 
benefits produced by different treatments, and in screening individual subjects. 
The purpose of the SF-36 in this study is to assess the HRQoL of subjects. Given the acute 
nature of this disease, version 2, with a 1-week recall period, will be used in this study.  
6.6.1.2 EQ-5D 
The EQ-5D is a widely used, self-administered questionnaire designed to assess health status 
in adults. The measure is divided into two distinct sections. The first section includes one item 
addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and 
anxiety/depression). Subjects rate each of these items from "no problem," "some problem," or 
"extreme problem." A composite health index is then defined by combining the levels for each 
dimension. The second section of the questionnaire measures self-rated (global) health status 
utilizing a vertically oriented visual analogue scale where 100 represents the "best possible 
health state" and 0 represents the "worst possible health state." Respondents are asked to rate 
their current health by placing a mark along this continuum. The recall period is "today," and 
the questionnaire requires approximately 5 to 10 minutes to complete. 
The EQ-5D contains six items designed to assess health status in terms of a single index value 
or health utility score. One of the strengths of the EQ-5D approach is that it allows 
"weighting" by the subject of particular health states and the generation of subject utilities. 
Published weights are available that allow for the creation of a single summary health utility 
score. Overall scores range from 0 to 1, with lower scores representing a higher level of 
dysfunction.  
The purpose of the EQ-5D in this study is to assess the health status of subjects. 
6.6.1.3 FACIT-Fatigue 
The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue©) is a 13-
item questionnaire (Cella 1993; Yellen 1997) that assesses self-reported fatigue and its impact 
upon daily activities and function. 
The purpose of FACIT-Fatigue© in this study is to assess the impact of fatigue on subjects 
with PsA. 
6.4.5.1. PsAQoL 
The PsAQoL is a 20-item questionnaire designed to assess the impact of PsA and its treatment 
on quality of life. Each item of the questionnaire is in the form of a simple statement to which 
subjects indicate whether or not the statement is true for them at that moment. 
The theoretical basis for the PsAQoL is the needs-based model of QoL which argues that 
disease-related impairment and disability influences a person’s ability to meet his or her needs. 
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6.6.1.4 DLQI 
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability 
index designed to assess health-related quality of life in adult subjects with skin diseases such 
as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994).  The measure is self-
administered and includes domains of daily activities, leisure, personal relationships, 
symptoms and feelings, treatment, and work/school.  The measure is widely used: it has been 
tested across 32 different skin conditions and is available in multiple languages.  The recall 
period is the past week, and the instrument requires 1 to 2 minutes for completion. 
Each item has four response categories ranging from 0 (not at all) to 3 (very much).  “Not 
relevant” is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 
questions.  Scores range from 0 to 30, and higher scores indicate greater health-related quality 
of life impairment.  Additionally, each subscale of the DLQI may be analyzed separately. 
6.6.1.5 Work Productivity and Activity Impairment (WPAI-GH) 
The Work Productivity and Activity Impairment (WPAI-GH) questionnaire is an instrument 
to measure impairments in both paid work and unpaid work. It measures absenteeism, 
presenteeism as well as the impairments in unpaid activity because of health problem during 
the past seven days. The WPAI-GH consists of six questions:  
1 = currently employed 
2 = hours missed due to health problems  
3 = hours missed other reasons  
4 = hours actually worked  
5 = degree health affected productivity while working (VAS)  
6 = degree health affected productivity in regular unpaid activities (VAS)  
The recall period for the questions 2 to 6 is seven days. Four main outcomes can be generated 
from the WPAI-GH and expressed in percentages.  
1. percent work time missed due to health for those who were currently employed  
2. percent impairment while working due to health for those who were currently 
employed and actually worked in the past seven days  
3. percent overall work impairment due to health  for those who were currently employed  
4. percent activity impairment due to health for all respondents 
6.6.2 Pharmacokinetics 
Pharmacokinetic (PK) samples will be obtained for all subjects, and secukinumab 
concentrations will be assessed in serum. The PK samples will be collected pre-dose at 
scheduled visits as indicated in Table 6-1. 
All blood samples will be drawn by direct venipuncture in a forearm vein. 
The actual sample collection date and exact time will be entered on the PK blood collection 
summary eCRF. Sampling problems will be noted in the Comments section of the eCRF. 
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The bioanalyst will receive a copy of the randomization schedule to facilitate analysis of the 
PK samples. The bioanalyst will provide the samples’ concentration data to the team under 
blinded conditions. Both the site’s unblinded pharmacist and bioanalyst will keep this 
information confidential until clinical database lock. 
PK sample handling, labeling and shipment instructions 
Laboratory manuals will be provided by the central laboratory with detailed information on 
sample collection, sample handling and shipment. 
Tubes and labels will be provided by the central laboratory with study/sample type 
information pre-printed on the label. 
Table 6-5 PK sample log 
Visit Week Time Sample 
number 
PK collection 
number 
2 0 0 (pre-dose) 1 1 
5 4 672 h (pre-dose) 2 1 
8 16 2688 h (pre-dose) 3 1 
10 24 4032 h (pre-dose) 4 1 
17 52 8736 h (pre-dose) 5 1 
30 104 17472 h (anytime) 6 1 
F112 112 18816 h (anytime) 7 1 
Analytical methods 
An ELISA method will be used for bioanalytical analysis of secukinumab in serum, with an 
anticipated lower limit of quantification (LLOQ) of 80 ng/mL. The detailed method 
description to assess secukinumab concentration will be described in the bioanalytical raw 
data of the study and in the respective Bioanalytical Data Report (BDR). 
6.6.3 Pharmacogenetics 
The pharmacogenetic endpoints are exploratory and are not intended to be used for regulatory 
judgments pertaining to the safety or efficacy of the investigational treatment. However, these 
data may be considered for voluntary submission, consistent with applicable regulatory 
guidance on this topic, in order to develop the knowledge base necessary to establish the 
validity of new genomic biomarkers. 
This study includes an optional exploratory pharmacogenetic assessment which requires 
signature of a separate informed consent if the subject agrees to participate. The identity of the 
subject will not be revealed. It is required as part of this protocol that the Investigator presents 
these options to the subject. 
Exploratory pharmacogenetics studies are planned as a part of this study with the objectives of 
identifying inherited genetic factors that may (1) predict response to treatment with 
secukinumab, (2) predict relative susceptibility to drug-drug interactions, (3) predict genetic 
predisposition to side effects, or (4) be related to PsA and could also predict response to 
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treatment with secukinumab. We hope to develop a better understanding how subjects with 
PsA respond to secukinumab. 
The genetic markers (or polymorphisms) that may be studied that relate to the etiology of PsA 
include HLA C*0602 alleles. Polymorphisms in genes that relate to the mechanism of action 
may include the nonsynonymous polymorphisms in IL17A (S141S, R134R), IL17A receptor 
(V367A, Q562P) and related genes. 
Despite continuing advances in genetics research, not all of the polymorphisms relevant to 
drug metabolism, drug action and PsA have been identified. Therefore, additional 
polymorphisms will be added within the restricted scope of these studies as described above. 
In addition, recent advances in genotyping technologies have made genome-wide association 
(GWA) studies possible.  GWA studies may also be undertaken within the restricted scope of 
these studies as described above. 
At all study sites, one optional blood sample will be collected in subjects for 
pharmacogenetics assessment at baseline (Visit 2) as indicated in Table 6-1. 
Lab manuals will be provided with detailed information on sample collection, handling, and 
shipment. The actual sample collection date must be entered on the central lab assessment 
eCRF. 
Any DNA derived from the sample that remains after analysis may be stored for up to 15 
years to address scientific questions related to secukinumab or PsA. 
Table 6-6 PG sample log 
Visit Week PG Sample 
number 
mL 
2 0 1301 10 
Sample analytical methods: 
Covance Central Laboratory Services is using the Qiagen Autopure Extraction Robot for 
Genomic DNA Extraction from EDTA Whole Blood.  Genotyping will be conducted by the 
Genomic and Genetic Applications (GGA) Cambridge laboratory utilizing Taqman endpoint 
detection sequencing or real-time PCR-based techniques. 
6.6.4 Serum biomarkers related to targeted pathway 
Biomarkers are objectively measured and evaluated indicators of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention (Biomarkers 
Definitions Working Group 2001). This search for biomarkers of disease and drug response 
will involve an integrated molecular approach examining genetic and serum protein profiles. 
These exploratory assessments aim to identify potential markers of response and/or loss of 
response, and to characterize molecular mechanisms of treatment with secukinumab. 
Any biomarker samples may be stored for up to 20 years (depending on local regulations) to 
research scientific questions related to secukinumab, PsA and related diseases with a potential 
involvement of IL-17A. The material can be destroyed on subject’s request at any time point. 
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Details on the collections, handling and shipment of the samples to the central laboratory will 
be provided to investigators in the laboratory manual. 
Any results from these exploratory biomarker assessments will be reported separately. 
Serum biomarkers related to systemic inflammation, bone and joint metabolism and 
cardiovascular risk will be measured. The final selection of analytes will be driven by assay 
availability, new information from the public domain, results obtained in other secukinumab 
clinical studies, as well as by hypotheses generated by other exploratory biomarker 
assessments. In addition, selected markers exploring the effect of secukinumab treatment on 
co-morbidities may be assessed. 
Table 6-7 Serum biomarker sample log 
Visit Week Time Volume (mL) SB Sample 
number 
SB collection 
number 
2 0 pre-dose 2 601 1 
10 24 pre-dose 2 602 1 
17 52 pre-dose 2 603 1 
30 104 anytime 2 604 1 
Blood collection and processing:  
At all study sites, blood samples will be collected for soluble serum markers pre-dose at the 
scheduled timepoints as indicated in Table 6-1. 
All blood samples will be taken by either direct venipuncture or an indwelling cannula 
inserted in a forearm vein. Samples should then be processed and shipped as detailed in the 
laboratory manual. 
The actual sample collection date will be entered on the corresponding eCRF. Sampling 
problems will be noted in the Comments section of the eCRF. 
7 Safety monitoring 
7.1 Adverse events 
An adverse event is the appearance or worsening of any undesirable sign, symptom, or 
medical condition occurring after the subject has signed the Informed Consent Form even if 
the event is not considered to be related to study treatment. Medical conditions/diseases 
present before the subject has signed the Informed Consent Form are only considered adverse 
events if they worsen after the subject has signed the Informed Consent Form. Abnormal 
laboratory values or test results constitute adverse events only if they induce clinical signs or 
symptoms, are considered clinically significant, or require therapy. 
The occurrence of adverse events should be sought by non-directive questioning of the subject 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by the subject during or between visits or through physical examination, laboratory test, or 
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other assessments. All adverse events must be recorded on the Adverse Events CRF with the 
following information: 
1. the severity grade (mild, moderate, severe) 
2. its relationship to the study treatment(s) (suspected/not suspected) 
3. its duration (start and end dates or if continuing at final exam) 
4. whether it constitutes a serious adverse event (SAE) 
An SAE is defined as an event which: 
• is fatal or life-threatening  
• results in persistent or significant disability/incapacity 
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
• routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition 
• elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since the start of study treatment 
• treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission  
• social reasons and respite care in the absence of any deterioration in the subject’s 
general condition 
• is medically significant, i.e. defined as an event that jeopardizes the subject or may require 
medical or surgical intervention to prevent one of the outcomes listed above 
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2. 
All adverse events should be treated appropriately. Action taken with study treatment should 
include one of the following: none, dose adjusted, temporarily interrupted, permanently 
discontinued, unknown or not applicable. Additionally, information must be provided whether 
a concomitant medication or non-drug therapy was given. The action taken to treat the 
adverse event should be recorded on the Adverse Event CRF.  
 Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently, if 
necessary) of any changes in severity, the suspected relationship to the study treatment, the 
interventions required to treat it, and the outcome. 
Information about common side effects already known about the investigational treatment can 
be found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Investigator Notifications (IN). This information will be included in the subject 
informed consent and should be discussed with the subject during the study as needed. 
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7.2 Serious adverse event reporting 
To ensure subject safety, every SAE (regardless of suspected causality) occurring after the 
subject has signed the Informed Consent Form and until 12 weeks after last administered dose 
of study treatment or 30 days after the subject has stopped study participation (whichever is 
later) must be reported to Novartis within 24 hours of learning of its occurrence.  
Any SAEs experienced after this period should only be reported to Novartis if the investigator 
suspects a causal relationship to the study treatment.  
Recurrent episodes, complications, or progression of the initial SAE must be reported as 
follow-up to the original episode, regardless of when the event occurs. This report must be 
submitted within 24 hours of the investigator receiving the follow-up information. An SAE 
that is considered completely unrelated to a previously reported one should be reported 
separately as a new event. 
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form. The investigator must assess the relationship of any SAE to study treatment, complete 
the SAE Report Form in English, and send the completed, signed form by fax within 24 hours 
to the local Novartis Drug Safety and Epidemiology Department (DS&E). The telephone and 
telecopy number of the contact persons in the local department of DS&E, specific to the site, 
are listed in the investigator folder provided to each site. The original copy of the SAE Report 
Form and the fax confirmation sheet must be kept with the case report form documentation at 
the study site. 
Follow-up information is sent to the same person to whom the original SAE Report Form was 
sent, using a new SAE Report Form stating that this is a follow-up to the previously reported 
SAE and giving the date of the original report. The follow-up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the subject continued or withdrew from study participation.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is 
thought to be related to the Novartis study treatment, a Drug Safety and Epidemiology 
Department associate may urgently require further information from the investigator for 
Health Authority reporting. Novartis may need to issue an IN to inform all investigators 
involved in any study with the same drug that this SAE has been reported. Suspected 
Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per national regulatory requirements in participating countries. 
7.3 Pregnancies 
To ensure subject safety, each pregnancy in a subject on study treatment must be reported to 
Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up 
to determine outcome, including spontaneous or voluntary termination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the local Novartis DS&E Department. Pregnancy follow-up should be recorded 
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on the same form and should include an assessment of the possible relationship to the 
Novartis study treatment of any pregnancy outcome. Any SAE experienced during pregnancy 
must be reported on the SAE Report Form. 
7.4 Data monitoring and adjudication committees 
Data monitoring committee 
A data monitoring committee (DMC) will review the safety data of this trial at regular 
intervals. Details regarding the DMC process will be available in the relevant secukinumab 
DMC charter. 
Adjudication committee 
An independent adjudication committee consisting of external experts may be used to monitor 
specific safety events, including, but potentially not limited to clinically significant cardio- 
and cerebro-vascular events. The events will be blindly reviewed and adjudicated as they 
occur during the conduct of the trial.  
Details regarding the adjudication process will be available in the relevant secukinumab 
Adjudication Committee charter. 
8 Data review and database management 
8.1 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and (e)CRFs with the investigators and their staff. 
During the study, the field monitor will visit the site regularly to check the completeness of 
subject records, the accuracy of entries on the (e)CRFs, the adherence to the protocol and to 
Good Clinical Practice (GCP), the progress of enrollment, and to ensure that study treatment 
is being stored, dispensed, and accounted for according to specifications. Key study personnel 
must be available to assist the field monitor during these visits. 
The investigator must maintain source documents for each subject in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on (e)CRFs must be traceable to these source documents in the 
subject’s file. The investigator must also keep the original informed consent form signed by 
the subject (a signed copy is given to the subject). 
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the (e)CRF entries. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and the recording of data that will be used for all primary and safety 
variables. Additional checks of the consistency of the source data with the (e)CRFs are 
performed according to the study-specific monitoring plan. No information in source 
documents about the identity of the subjects will be disclosed. 
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8.2 Data collection 
Designated investigator staff will enter the data required by the protocol into the OC/RDC 
system. Designated investigator site staff will not be given access to the system until they 
have been trained.  
Automatic validation procedures within the system check for data discrepancies during and 
after data entry and, by generating appropriate error messages, allow the data to be confirmed 
or corrected online by the designated investigator site staff. The Investigator must certify that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copies of the subject data for archiving at the 
investigational site.  
8.3 Database management and quality control 
Novartis staff review the data entered into the eCRFs by investigational staff for completeness 
and accuracy and instruct the site personnel to make any required corrections or additions. 
Queries are sent to the investigational site using an electronic data query. Designated 
investigator site staff is required to respond to the query and confirm or correct the data. If the 
electronic query system is not used, a paper Data Query Form will be faxed to the site. Site 
personnel will complete and sign the faxed copy and fax it back to Novartis staff who will 
make the correction to the database. The signed copy of the Data Query Form is kept at the 
investigator site. 
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employs the Anatomical Therapeutic Chemical (ATC) classification 
system. Medical history/current medical conditions and adverse events will be coded using 
the Medical dictionary for regulatory activities (MedDRA) terminology. 
Laboratory samples will be processed centrally and the results will be sent electronically to 
Novartis. 
ECG readings will be processed centrally and the results will be sent electronically to 
Novartis.  
Subjects will use a digital pen to enter PRO data. The system will be supplied by a vendor 
who will also manage the database. The data will be processed centrally and the results will 
be transferred electronically to the Novartis database. 
Randomization codes and data about all study treatment dispensed to the subject will be 
tracked using an IRT system. The system will be supplied by a vendor, who will also manage 
the database. The database will be sent electronically to Novartis (or a designated CRO). 
Each occurrence of a code break via IRT will be reported to the clinical team and monitor.  
The code break functionality will remain available until study shut down or upon request of 
Novartis. 
Pharmacogenetic and exploratory biomarkers samples 
To maximize confidentiality, all samples and the information associated with the samples will 
be double-coded to prevent the exposure of the subject’s information and identity. This 
double-coding process allows Novartis to go back and destroy the sample at the subject’s 
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request.  In addition, sample information is stored in one secured database while genetic data 
is stored in an independent secured database. 
The use of pharmacogenetics to search for biomarkers of disease and drug action is 
exploratory. Any results from this pharmacogenetic study will not be placed in the subject’s 
medical records. 
9 Data analysis 
Summary statistics for continuous variables include N, mean, standard deviation, minimum, 
lower quartile, median, upper quartile, and maximum. For binary or discrete variables the 
absolute number of subjects in each category and relative frequencies will be provided. 
Unless otherwise specified, p-values will be presented as 2-sided p-values and the type I error 
rate (alpha) will be 5%. 
Inferential efficacy comparisons with placebo will generally focus on the first 24-weeks of 
treatment unless otherwise specified (e.g. Major clinical response). 
Efficacy and safety data for the placebo-controlled period (or the entire treatment period as 
appropriate) will be presented by the following 3 treatment groups.  Subjects may be included 
in more than one treatment group for some analyses (e.g. exposure-adjusted adverse events 
over the entire treatment period).  These treatment groups represent the regimens subjects will 
be eligible to be randomized to. 
Group 1: Secukinumab regimen 1: secukinumab i.v. (10mg/kg) at BSL, Week 2 and 4 then 
secukinumab 75 mg s.c. starting at Week 8 every 4 weeks. 
Group 2: Secukinumab regimen 2: secukinumab i.v. (10mg/kg)  at BSL, Week 2 and 4 then 
secukinumab 150 mg s.c. starting at Week 8 every 4 weeks. 
Group 3: Placebo regimen: Placebo i.v. at BSL, Week 2 and 4 then placebo s.c. starting at 
Week 8 every 4 weeks. 
Note that the treatment groups above for a subject may differ depending on the time period of 
the analysis and whether one assesses the subject for efficacy or safety (see Section 9.1 for 
details). 
Data may also be presented by a combination of the ‘original’ and ‘switch’ treatment groups.   
These treatment groups represent the treatment combinations the subjects experience over the 
course of the entire trial in case of rescue or re-randomization. 
9.1 Analysis sets 
The following analysis sets will be used in this trial: 
Randomized set: The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis-randomized subjects (mis-randomized in IRT) will be 
excluded from the randomized set. 
Mis-randomized subjects are defined as those subjects who were mistakenly randomized into 
the IVR prior to the site confirming all eligibility criteria had been met and to whom no study 
medication was given. Mis-randomized subjects are treated as screen failures. 
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Full analysis set (FAS): The FAS will be comprised of all subjects from the randomized set 
to whom study treatment has been assigned. Following the intent-to-treat principle, subjects 
will be analyzed according to the treatment assigned to at randomization, but actual stratum, if 
stratified randomization is used. 
Safety set: The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period. Subjects will be analyzed according to treatment received. 
9.2 Subject demographics and other baseline characteristics 
Summary statistics will be presented for continuous demographic and baseline characteristic 
variables for each treatment group and for all subjects in the randomized set. The number and 
percentage of subjects in each category will be presented for categorical variables for each 
treatment group and all subjects. 
The randomized treatment groups will be summarized by the following demographic 
variables: 
• Gender, age, race, ethnicity, weight, height, and BMI 
Baseline disease characteristics will also be compared for the following variables: 
• TNFα history (naive or inadequate responder), ACR components,  number of prior 
biologic PsA therapies, dose of methotrexate or other DMARD at randomization 
Medical history 
Any significant prior or active medical condition at the time of signing informed consent will 
be coded using the MedDRA dictionary. These medical conditions will be summarized by 
primary system organ class and preferred term. 
To establish a baseline level of cardiovascular risk, the number and percentage of subjects 
with pre-solicited cardiovascular risk factors will be summarized by treatment group. The 
number of cardiovascular risk factors that each subject has will also be summarized by 
treatment group. If it is unknown whether or not a subject currently or previously experienced 
a specific cardiovascular risk factor, it will be assumed that cardiovascular risk factor did not 
occur for that subject. 
9.3 Treatments (study treatment, rescue medication, other 
concomitant therapies, compliance) 
Study treatment 
The analysis of study treatment data will be based on the safety set.  The number of active and 
placebo injections and infusions received will be presented by treatment group. 
The duration of exposure to study treatment will also be summarized by treatment group. In 
addition, the number and percentage of subjects with cumulative exposure levels (e.g. any 
exposure, ≥ 1 week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
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Duration of exposure is defined as the time from first dose of study treatment to the time of 
treatment switch (for subjects who switch treatment) or end of treatment period. For subjects 
who discontinue this will be the last visit in the corresponding treatment period. 
Prior and concomitant medication 
Prior and concomitant medications will be summarized in separate tables by treatment group. 
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of randomized 
study treatment and the date of the last study visit will be a concomitant medication, including 
those which were started pre-baseline and continued into the period where study treatment is 
administered. 
Medications will be presented in alphabetical order, by Anatomical Therapeutic Classification 
(ATC) codes and grouped by anatomical main group. Tables will show the overall number 
and percentage of subjects receiving at least one treatment of a particular ATC code and at 
least one treatment in a particular anatomical main group. 
Significant prior and concomitant non-drug therapies and procedures will be summarized by 
primary system organ class and MedDRA preferred term. 
The number and percentage of subjects receiving prior and concomitant psoriatic arthritis 
therapy will be presented by randomized treatment group as well as the reasons for stopping 
their therapies (primary lack of efficacy, secondary lack of efficacy, lack of tolerability, other) 
and the total duration of exposure to psoriatic arthritis therapies previously. 
9.4 Analysis of the primary variable(s) 
Details of the testing strategy including primary and secondary endpoints are provided in 
Section 9.5.1. 
9.4.1 Variable 
The primary efficacy variable will be ACR20 response at Week 24. The analysis of the 
primary efficacy variable will be based on the FAS. Primarily, CRP will be used instead of 
ESR to calculate ACR response; ESR will only be used in the event CRP is missing. 
9.4.2 Statistical model, hypothesis, and method of analysis 
The statistical hypothesis for ACR20 being tested is that there is no difference in the 
proportion of subjects fulfilling the ACR20 criteria at Week 24 in any of the secukinumab 
regimens versus placebo regimen. 
Let pj denote the proportion of ACR20 responders at Week 24 for treatment regimens j, j=0, 1, 
2, where 
• 0 corresponds to placebo regimen, 
• 1 corresponds to secukinumab 75 mg s.c., 
• 2 corresponds to secukinumab 150 mg s.c., 
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In statistical terms, Hj: pj = p0, HAj: pj ≠ p0, for the jth secukinumab regimen, i.e. 
H1: secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 
H2: secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 
The primary endpoint of ACR20 at Week 24 will be analyzed via logistic regression with 
treatment and TNF-alpha inhibitor status as factors and weight as a covariate. Odds ratios will 
be computed for comparisons of secukinumab regimens versus placebo regimen utilizing the 
logistic regression model fitted.   
For subjects meeting the criteria for early escape at Week 16, their ACR20 will be set to non-
response at Week 24.  This applies for all three treatment regimens in order to minimize bias. 
9.4.3 Handling of missing values/censoring/discontinuations 
Missing data for ACR20 response and other binary efficacy variables (e.g. ACR50, ACR70, 
HAQ-DI response, etc.) for data up to 1-year (week 52) will be handled as follows: 
1. Subjects who drop out of the trial for any reason will be considered non-responders from 
the time they drop out through week 52. 
2. Subjects who do not have the required data to compute ACR response (i.e. tender and 
swollen joint counts and at least three of the five ACR core set variables) at baseline and 
at the specific time point will be classified as non-responders. 
Continuous variables (e.g. ACR components, DAS, etc.) will be analyzed using a mixed-
effects repeated measures model (MMRM) which is valid under the missing at random 
(MAR) assumption.  For analyses of these parameters, if all post-baseline values are missing 
then these missing values will not be imputed and this subject will be removed from the 
analysis of the corresponding variable, i.e. it might be that the number of subjects providing 
data to an analysis is smaller than the number of subjects in the FAS. 
Data collected after Week 52 will be presented as ‘observed case’; i.e. all available data for 
each time point will be included in the analyses. 
In general, the handling of data for subjects who meet rescue criteria at Week 16 will be 
handled in the following fashion:   
• For binary endpoints, subjects will be considered as non-responders.   This will be done 
for all treatment regimens in order to minimize bias.  
• For continuous endpoints, the goal of the analyses would be to estimate what would have 
happened if the subjects had stayed on the original treatment.  Thus, the data collected 
after the subject switches to secukinumab will be treated as missing for placebo subjects 
and will be analyzed using a mixed-effects repeated measures model (MMRM) which is 
valid under the missing at random (MAR) assumption. For secukinumab subjects, the 
actual values will be used in the analysis. 
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9.4.4 Supportive analyses 
Sensitivity analyses and supportive analyses will be conducted in order to provide evidence 
that the results seen from the primary analysis are robust. These analyses will center on the 
deviations in model assumptions, and the treatment of missing data. 
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ACR20 response at Week 24 will also be evaluated using a non-parametric 
regression (Koch et. al 1998) model with the same independent variables as the logistic 
regression model 
The impact of missing data on the analysis results will be assessed as well by repeating the 
logistic regression model using ways to handle missing data. These may include, but are not 
limited to: 
• Multiple imputation 
• Observed data analysis 
9.5 Analysis of secondary variables 
9.5.1 Secondary variables 
Testing strategy 
The following primary and secondary hypotheses will be included in the sequential testing 
strategy, and type-I-errors will be set such that a family-wise type-I-error of 5% is kept:  
Primary objective (as described in Section 9.4): 
H1: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24 
H2: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24  
Secondary objectives: 
H3: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to PASI75 
response at Week 24 in the subgroup of subjects who have ≥3% skin involvement with 
psoriasis 
H4: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to PASI75 
response at Week 24 in the subgroup of subjects who have ≥3% skin involvement with 
psoriasis 
H5: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to PASI90 
response at Week 24 in the subgroup of subjects who have ≥3% skin involvement with 
psoriasis 
H6: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to PASI90 
response at Week 24 in the subgroup of subjects who have ≥3% skin involvement with 
psoriasis 
H7: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for DAS28-CRP at Week 24 
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H8: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for DAS28-CRP at Week 24 
H9: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for SF36-PCS at Week 24 
H10: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for SF36-PCS at Week 24 
H11: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for HAQ-DI at Week 24 
H12: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for HAQ-DI at Week 24 
H13: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to ACR50 
response at Week 24 
H14: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to ACR50 
response at Week 24 
H15: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo 
regimen with respect to structural damage (van der Heijde modified total Sharp score) at 
week 24 
H16: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo 
regimen with respect to presence of dactylitis at Week 24 in the subset of subjects who 
have dactylitis at baseline 
H17: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo 
regimen with respect to presence of enthesitis at Week 24 in the subset of subjects who 
have enthesitis at baseline 
H18: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24 
H19: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24  
The graphical approach of (Bretz 2009) for sequentially rejective testing procedures is used to 
illustrate the testing strategy: 
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Figure 9-1 Testing strategy 
 
 
The family-wise error will be set to α=5% and it will be controlled with the proposed 
hierarchical testing strategy.  With this hierarchical testing approach, the hypotheses will be 
separated into two families, hypotheses H1 ~ H14 will be the first family and hypotheses H15 ~ 
H19 will be the second family. The second family hypotheses will be tested only when all 
hypotheses in the first family have been rejected.  Each of the hypotheses (H1 and H2) for the 
primary objective (based on signs and symptoms at week 24) for each secukinumab regimen 
versus placebo will be tested simultaneously at α/2. If at least one of H1 and/or H2 are/is 
rejected, then H3 and/or H4, respectively, is tested. If at least one of H3 and/or H4 is rejected, 
the hypothesis H5 and/or H6, is tested, respectively. Similar process applies until H13 and H14. 
Once all hypotheses within the first family for a secukinumab regimen are rejected, then the 
respective α/2 can be passed on to the other regimen’s hypotheses within the family, if they 
are not already rejected at α/2. Only when all H1 ~ H14 are rejected, the objective on joint 
structure endpoint at Week 24 for testing pooled secukinumab doses versus placebo (H15) will 
be tested at α. If H15 is rejected, then H16 is tested at α. Similarly if H16 is rejected, then H17 is 
tested at α. If these pooled hypotheses are all rejected, then hypotheses concerning individual 
regimens of secukinumab versus placebo (H18 and H19) can be tested for a particular regimen 
at α/2. Once the hypothesis of structure damage for a secukinumab regimen is rejected, then 
the respective α/2 can be passed on to the other regimen’s hypothesis, if it is not already 
rejected at α/2. Of note, in the description above, rejection of a hypothesis refers to rejection 
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of the two-sided hypothesis; however the level of a rejected hypothesis is only passed on 
according to the graphical procedure for the test of another hypothesis if the treatment effect 
is in favor of secukinumab. 
PASI 75 and PASI 90 response 
PASI 75 response and PASI 90 at Week 24 will be evaluated for those subjects in whom the 
assessment occurred due to sufficient skin involvement (at least 3% BSA affected with 
psoriasis) (which is planned to be a subset of the FAS).  These binary variables will be 
evaluated in the same fashion as ACR response, i.e. a logistic regression model with treatment 
and randomization strata as factors and weight as a covariate. 
Changes in DAS28-CRP 
Between-treatment differences in the change from baseline in DAS28-CRP will be compared 
by means of a mixed model repeated measures (MMRM) with treatment regimen, analysis 
visit, and TNF-alpha inhibitor status as factors, and weight and baseline as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
SF-36 PCS 
The analysis of SF-36 is described in Section 9.5.4. 
Physical function (HAQ-DI) 
Between-treatment differences in the change in HAQ-DI will be evaluated using a mixed 
effect repeated measures model (MMRM) with treatment regimen, analysis visit and TNF-
alpha inhibitor status as factors, and weight and baseline HAQ-DI score as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
ACR50 at Week 24 
Response at Week 24 to ACR50 in the FAS will be evaluated using a logistic regression 
model with treatment and randomization stratum (TNFα status -naive or IR) as factors and 
weight as a covariate. 
Joint/bone structural damage at Week 24 
The change at Week 24 from baseline van der Heijde total modified Sharp score will be 
evaluated using a non-parametric ANCOVA model with treatment regimen and TNF-alpha 
inhibitor status as factors, and weight and baseline van der Heijde total modified Sharp score 
as covariates. The pooled secukinumab regimens (75 mg s.c. and 150 mg s.c.) will be 
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compared to placebo, then each of the secukinumab regimens will be compared versus the 
placebo regimen via pairwise comparisons. 
For subjects who meet the criteria for early escape at Week 16 and subjects who discontinue 
the study prior to Week 24, linear extrapolation will be used to impute the value at Week 24.  
If baseline or all post-baseline total modified Sharp score/s is/are missing for a subject, the 
subject will be excluded from the analyses. 
Dactylitis at Week 24 
Presence of dactylitis at Week 24 in the subset of subjects who have dactylitis at baseline will 
be evaluated using a logistic regression model with treatment and randomization stratum 
(TNFα status -naive or IR) as factors and weight as a covariate. 
Enthesitis at Week 24 
Presence of enthesitis at Week 24 in the subset of subjects who have enthesitis at baseline will 
be evaluated using a logistic regression model with treatment and randomization stratum 
(TNFα status -naive or IR) as factors and weight as a covariate. 
9.5.2 Exploratory efficacy variables 
All the following exploratory efficacy variables will be analyzed on the FAS for all applicable 
analysis visits unless otherwise specified. 
• HAQ-DI response 
• Major clinical response by Week 52 and 104 
• Joint/bone structural damage at Week 52 and 104 
• Evidence of no disease progression at Week 24, 52 and 104 
• PsARC, ACR20/50/70 response over time 
• DAS28 remission, low disease activity, EULAR response at Week 24 and over time 
• Minimal disease activity 
• ACR components 
o Changes in tender joint counts over time 
o Change in swollen joint counts over time 
o Change in Patient’s global assessment in disease activity 
o Change in Physician’s global assessment in disease activity 
o Change in PsA Pain 
o Change in HAQ-DI over time 
o Change in erythrocyte sedimentation rate (ESR) 
o Change in high-sensitivity C-reactive protein (hsCRP) 
• PASI 75, PASI 90, and IGA 0/1 response over time 
• Target lesion score 
• mNAPSI 
• LDI and dactylitis count 
• LEI-4 
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Between-treatment comparisons for binary variables in the FAS population (e.g PsARC, 
ACR20, etc.) at individual analysis visits will be evaluated using a logistic regression model 
with treatment and TNF-alpha inhibitor status as factors and baseline score (if appropriate) 
and weight as covariates. 
Continuous variables (e.g. change from baseline in PsA pain) will be evaluated using a mixed-
effect model repeated measures (MMRM) with treatment regimen, TNF-alpha inhibitor status, 
and analysis visit as factors and weight and baseline score as continuous covariates.  
Treatment by analysis visit and baseline by analysis visit will be included as interaction terms 
in the model.  An unstructured covariance structure will be assumed for this model.  The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo at the appropriate analysis visits. Variables such as hsCRP whose distribution is not 
anticipated to be normal will be transformed and analyzed on the loge scale. 
Joint/bone structural damage at Week 52 and 104 
Observed joint/bone structure data at Week 52 will be compared between subjects randomized 
at baseline to secukinumab regimen (pooled from 2 secukinumab regimens) and placebo 
followed by secukinumab regimen. The change from baseline to Week 52 will be evaluated 
using a non-parametric ANCOVA model utilized for Week 24 and including randomization 
strata as a covariate. 
As sensitivity analysis, for subjects with missing modified Sharp score values at Week 52, 
their Week 52 value will be imputed by linear extrapolation from baseline, Week 16 and 
Week 24, and at subject discontinuation visit (if subject discontinued prior to Week 52) to 
Week 52. 
Summary statistics of observed data at Week 52 will be provided for each treatment regimens: 
secukinumab 75 mg, secukinumab 150 mg, placebo escape or switch to secukinumab 75 mg 
at Week 16 or 24, placebo escape or switch to secukinumab 150 mg at Week 16 or 24. 
Summary statistics include mean, standard deviation, minimum, lower quartile, median, upper 
quartile and maximum. 
Observed Joint/bone structure data at Week 104 will be summarized by treatment group. In 
addition, the change from week 52 will also be summarized within treatment regimen. 
Evidence of no disease progression at Week 24, 52 and 104 
The proportion of subjects without disease progression will be defined as those subjects who 
have a change in van der Heijde total modified Sharp score at Week 24 relative to baseline ≤ 0.  
The proportion of subjects without disease progression at Week 24 will be evaluated using a 
logistic regression model with treatment group and randomization strata, as factors, weight 
and baseline van der Heijde total modified Sharp score as covariates. 
The proportion of subjects without disease progression at Week 52 and 104 will be evaluated 
in the same manner.  At week 104, the proportion of subjects with disease progression from 
week 52 will also be examined. 
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EULAR response at Week 24 and over time 
Based on the EULAR response criteria (good responder, moderate responder, and non-
responder) as determined based on the value of DAS28-CRP achieved and the magnitude of 
change from baseline, between-treatment differences in EULAR response at Week 24 and 
other analysis visits will be evaluated using a proportional odds regression model with 
treatment group and randomization strata as factors and weight and baseline DAS28-CRP 
score as covariates. Frequency tables will also be presented to show the response rate over 
time up to Week 24 and Week 52, as appropriate. 
Magnetic Resonance Imaging 
MRI Analysis will be based on the subjects who have MRI performed at selected centers. 
The change in synovitis between Week 24 and baseline will be evaluated using a 
nonparametric ANCOVA model with treatment regimen as a factor, weight and baseline 
erosion score as covariates. Pair-wise comparison versus placebo will be made for each of the 
secukinumab regimens. Tenosynovitis, periarticular inflammation, bone edema/osteitis, bone 
erosion, bone proliferation, and joint space narrowing will be evaluated in the same manner. 
For subjects with missing data at Week 24, linear extrapolation will be used to impute missing 
data. In order to minimize bias, the extrapolation will use baseline and week 12. Change from 
baseline will be summarized by analysis visit with summary statistics including mean, 
standard deviation, minimum, lower quartile, median, upper quartile and maximum. 
LEI-4 
In this study, the lateral condyle femur L + R data were collected instead of required medial 
condyle femur L + R. Therefore, a 4-site LEI (LEI-4, i.e. score with the four correct sites: 
lateral epicondyle humerus L + R and proximal achilles L + R) will be summarized by 
treatment group and visit. Change from baseline in the 4-site LEI will be analyzed using a 
nonparametric ANCOVA model with treatment regimen and randomization strata as factors, 
weight and baseline score as covariates. Pair-wise comparison versus placebo will be made 
for each of the secukinumab regimens by visit. 
9.5.3 Safety variables 
Adverse events 
Treatment emergent adverse events (events started after the first dose of study treatment or 
events present prior to the first dose of study treatment but increased in severity based on 
preferred term) will be summarized. 
AEs will be summarized by presenting, for each treatment group, the number and percentage 
of subjects having any AE, having an AE in each primary system organ class and having each 
individual AE (preferred term). Summaries will also be presented for AEs by severity and for 
study treatment related AEs. If a subject reported more than one adverse event with the same 
preferred term, the adverse event with the greatest severity will be presented. If a subject 
reported more than one adverse event within the same primary system organ class, the subject 
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will be counted only once with the greatest severity at the system organ class level, where 
applicable. Serious adverse events will also be summarized. 
These summaries may be presented separately by study periods. 
As appropriate, the incidence of AEs will be presented per 100 patient years of exposure. 
Separate summaries will be provided for death, serious adverse event, and other significant 
adverse events leading to discontinuation. 
A graphical display of relative frequencies within system organ classes and relative risks, as 
appropriate, will be presented. 
When adjudication is required of major cardiovascular events (MACE), a summary of those 
types of events as reported by the investigator and confirmed by adjudication will be provided. 
Laboratory data 
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, serum chemistry and urinalysis). Descriptive summary statistics for the change 
from baseline to each study visit will be presented. These descriptive summaries will be 
presented by test group, laboratory test and treatment group. Change from baseline will only 
be summarized for subjects with both baseline and post baseline. 
For each parameter, the maximum change from baseline within each study period will be 
evaluated analogously. 
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal 
laboratory ranges will be used to evaluate whether a particular laboratory test value was 
normal, low, or high for each visit value relative to whether or not the baseline value was 
normal, low, or high. These summaries will be presented by laboratory test and treatment 
group. Shifts will be presented by visit as well as for most extreme values post-baseline. 
Immunogenicity 
A listing of immunogenicity (anti-AIN457 antibodies) will be provided. 
Vital signs 
Analysis of the vital sign measurements using summary statistics for the change from baseline 
for each post-baseline visit will be performed. These descriptive summaries will be presented 
by vital sign and treatment group. Change from baseline will only be summarized for subjects 
with both baseline and post-baseline values. 
ECG 
Summary statistics will be presented for ECG variables by visit and treatment group.  
Qualitative changes will be summarized. 
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9.5.4 Health-related Quality of Life 
The PsAQoL will be evaluated for FAS subjects where data are available.  All Health-related 
Quality of Life will be evaluated based on FAS. 
EQ-5D 
The number and percentage of subjects in each of the three categories for each question will 
be presented by visit and treatment group. 
Summary statistics will be shown for the health state assessment by visit and treatment group. 
For the change in EQ-5D overall health state (VAS), between-treatment differences in the 
change in EQ-5D overall health state (VAS) will be evaluated using a mixed effect repeated 
measures model (MMRM) with treatment group, analysis visit and TNF-alpha inhibitor status 
as factors and baseline EQ-5D overall health state (VAS) and weight as continuous covariates. 
Treatment by analysis visit and baseline EQ-5D overall health state (VAS) by analysis visit 
will be included as interaction terms in the model. An unstructured covariance structure will 
be assumed for the model. The significance of the treatment effects for secukinumab regimens 
at different analysis visits will be determined from the pairwise comparisons performed 
between secukinumab regimens and placebo at the appropriate analysis visits. 
SF-36 
The following variables will be evaluated: 
o SF-36 domain scores. 
o SF-36 PCS and MCS scores. 
o SF-36 PCS responder (improvement of ≥ 2.5 points, Lubeck 2004) 
Between-treatment differences in the change from baseline for SF-36 summary scores 
(PCS/MCS) will be evaluated using a mixed effect repeated measures model (MMRM) with 
treatment group, analysis visit and TNF-alpha inhibitor status as factors and baseline SF-36 
score and weight as continuous covariates. Treatment by analysis visit and baseline SF-36 
score by analysis visit will be included as interaction terms in the model. An unstructured 
covariance structure will be assumed for the model. The significance of the treatment effects 
for secukinumab regimens at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate 
analysis visits. 
In the responder analyses, treatment groups will be compared with respect to response to 
treatment using a logistic regression model with treatment and TNF-alpha inhibitor status as 
factors, baseline SF-36 summary score and weight as covariates. Odds ratios with 
corresponding 95% confidence intervals will be estimated in addition. 
Individual SF-36 domain scores will be summarized. 
FACIT-Fatigue 
Between-treatment differences in the change from baseline for FACIT-Fatigue scores will be 
evaluated using a mixed effect repeated measures model (MMRM) with treatment group, 
analysis visit and TNF-alpha inhibitor status as factors and baseline and weight as continuous 
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covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
Dermatology Life Quality Index  
Between-treatment differences in the change from baseline for DLQI will be evaluated using a 
mixed effect repeated measures model (MMRM) with treatment group, analysis visit and 
TNF-alpha inhibitor status as factors and baseline and weight as continuous covariates. 
Treatment by analysis visit and baseline by analysis visit will be included as interaction terms 
in the model. An unstructured covariance structure will be assumed for the model. The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo at the appropriate analysis visits. 
PsAQoL 
Between-treatment differences in the change from baseline for PsAQoL scores will be 
evaluated using a mixed effect repeated measures model (MMRM) with treatment group, 
analysis visit and TNF-alpha inhibitor status as factors and baseline and weight as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
WPAI-GH 
Summary statistics will be shown for the WPAI-GH assessment by visit and treatment group. 
9.5.5 Pharmacokinetics 
All subjects with concentration data will be included in the pharmacokinetic data analysis. 
Pharmacokinetic variables 
The following pharmacokinetic parameter will be determined: Cmin,ss. Individual 
concentrations will be listed. 
Biofluid concentrations will be expressed in µg/ml. All concentrations below the limit of 
quantification or missing data will be labeled as such in the concentration data listings. 
Concentrations below the Limit of Quantification will be treated as zero in summary statistics 
for concentration data only. 
Cmin,ss will be determined using Phoenix. 
During modeling of the pharmacokinetics of secukinumab, the broad principles outlined in the 
FDA Guidance for Industry: Population Pharmacokinetics will be followed. 
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Statistical methods for pharmacokinetic analyses 
All completed subjects with quantifiable PK measurements of secukinumab will be included 
in the PK data analysis. Serum concentrations will be expressed in mass per volume units. All 
concentrations below the limit of quantification or missing data will be labeled as such in the 
concentration data listings. PK concentrations will be summarized by visit and treatment 
group. In addition to mean, standard deviation, coefficient of variation, median and quartiles, 
the geometric mean and geometric coefficient of variation and n(log) will be presented. 
9.5.6 Pharmacogenetics 
The exploratory pharmacogenetic studies are designed to investigate the association between 
genetic factors (genotypes) and clinical assessments (phenotypes) which are collected during 
the clinical trial. Without prior evidence of a strong association, a number of possible 
associations are evaluated with exploratory analyses.  A range of statistical tests (chi-square 
tests, ANCOVAs, linear and logistic regression) are used for the analyses.  Additional data, 
from subsequent clinical trials, are often needed to confirm associations.  Alternatively, if the 
numbers of subjects enrolled in the study are too small to complete proper statistical analyses, 
these data may be combined, as appropriate, with those from other studies to enlarge the data 
set for analysis. 
9.5.7 Biomarkers 
Soluble marker panel studies investigate differences in the level of expression of proteins or 
peptides between individuals in a given biofluid. The goal of such studies is to allow the 
identification of potential protein or peptide biomarkers of drug action or disease, and to 
better understand the associated underlying molecular mechanisms.  By applying statistical 
analysis methods (e.g. principal component analysis) between subject groups, distinct study 
time points, or between study groups from other clinical trials, it may be possible to identify 
patterns which are associated with disease state or response to drug treatment. However, the 
exact type of data analysis method will depend on the type of data obtained in the study and 
thus the analysis of this data will be data driven. 
9.5.8 PK/PD 
An indirect response model, driven by study treatment concentration, will be used to 
characterize the time course of efficacy response. Further details of the modeling approach 
will be specified in a modeling plan. 
9.6 Sample size calculation 
The original power calculations used in the protocol have been updated to incorporate more 
recent published data in the PsA population.  In addition, the statistical hierarchy (primary 
plus ranked secondary variables) was expanded to include more endpoints important in the 
treatment of psoriatic arthritis patients.  No adjustment was made to the sample size as a result 
of the updated power calculations; the original sample size of N=200 per treatment regimen 
was retained. The adjustments to the power calculations and the statistical hierarchy were 
done before the unblinding of the trial in order to prevent bias. 
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A 5% two-sided type I error rate will used to control for type I error.  Two secukinumab doses 
will be tested versus placebo with respect to the primary endpoint (ACR20 response at Week 
24), thus the type-I-error will be split to 2.5% two-sided for each comparison. Sample sizes 
will be based on this type I error assumption. 
A placebo response rate of about 25% after 24 weeks was reported for the TNFα inhibitor 
naive population in the PSUMMIT I study (McInnes et al 2013), and 15% was reported for 
the TNFα inhibitor IR population in the PSUMMIT II study (Ritchlin et al 2013).  Based on 
the weighted average, the overall placebo rate is expected to be 22%. 
The response on secukinumab is expected to be 55% in the TNFα inhibitor naïve population 
and 35% in the TNFα inhibitor IR-population.  Based on the weighted average, the overall 
rate on a dose of secukinumab is expected to be 49%. 
For the primary endpoint, ACR20 in the overall population, 200 subjects per group would 
yield approximately 99% power to detect a treatment difference in the response rates between 
the secukinumab regimens and placebo with the above assumptions (Fisher’s exact test, 
nQuery 7.0). 
9.7 Power for analysis of secondary variables 
Power for secondary variables was calculated using a two-sided 2.5% type I error. With an 
assumed placebo rate of 7.6% and secukinumab 58.1%, the study is over 99% powered to 
detect a treatment difference of PASI75 in the full FAS population, assuming 135 subjects per 
treatment arm (Fisher’s exact test, nQuery 7.0). Similarly, with an assumed placebo rate of 
5% and secukinumab 44%, the study is over 99% powered to detect a treatment difference of 
PASI90 in the full FAS population, assuming 135 subjects per treatment arm. It is assumed 
that about 67.5% of enrolled patients have ≥3% skin involvement with psoriasis. Assumptions 
of PASI75 and PASI90 rates are based on PSUMMIT I and II studies (McInnes et al 2013 and 
Ritchlin et al 2013). 
A between-treatment difference of 1.31 and standard deviation of 1.34 has been observed for 
the change from baseline in DAS28-CRP in Golimumab (Kavanaugh et al 2009) for the TNFα 
inhibitor naïve population. Assuming the difference is half in the TNFα inhibitor IR 
population, the overall population has a between-treatment difference of 1.12. With these 
assumptions, the study has approximately over 99% power to detect a difference between 
secukinumab and placebo (Two group t-test, nQuery Advisor 7.0), assuming 200 subjects per 
arm. 
A standard deviation of approximately 10.1 and a between-treatment difference of 6.32 has 
been observed for the change from baseline at week 24 in SF36-PCS in Ustekinumab trial 
(McInnes et al 2013). Using those assumptions, the study has approximately 99% power to 
detect a difference between secukinumab and placebo (Two group t-test, NQuery Advisor 7.0), 
assuming 200 subjects per arm. 
A standard deviation of approximately 0.5 and a between-treatment difference of 0.25 has 
been observed for the change from baseline at week 24 in HAQ-DI in Ustekinumab trial 
(McInnes et al 2013; Ritchlin et al 2012; Ritchlin et al 2013). Using those assumptions, the 
study has approximately 99% power to detect a difference between secukinumab and placebo 
(Two group t-test, NQuery Advisor 7.0), assuming 200 subjects per arm. 
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With an assumed placebo rate of 7.4% (McInnes et al 2013; Ritchlin et al 2012; Ritchlin et al 
2013) and secukinumab 25.5%, the study is over 99% powered to detect a between-treatment 
difference of ACR50 in the full FAS population, assuming 200 subjects per treatment arm 
(Fisher’s exact test, nQuery 7.0). 
For structural endpoint, historical data (adalimumab) showed a standard deviation of 1.2 on 
active treatment and 2.4 on placebo at week 26, and a between-treatment difference of 0.6 for 
the TNFα inhibitor naïve population (Mease et al 2005). Assuming the between-treatment 
difference is half in the TNFα inhibitor IR population, the overall population has a between-
treatment difference of 0.51. Using the above assumptions, there is 80% power to show 
statistically significant differences between secukinumab (pooled 400 subjects) and placebo 
(200 subjects). Individual comparisons between secukinumab and placebo would have 66% 
power (Satterthwaite t-test, nQuery 7.0). 
For the presence of dactylitis at Week 24 in the subset of subjects who have dactylitis at 
baseline, with an assumed placebo rate of 76% (McInnes et al 2013) and secukinumab 57%, 
there is about 89% power to show statistically significant difference between secukinumab 
(pooled 200 subjects) and placebo (100 subjects), assuming 50% subjects have dactylitis at 
baseline (Fisher’s exact test, nQuery 7.0). 
For the presence of enthesitis at Week 24 in the subset of subjects who have enthesitis at 
baseline, with an assumed placebo rate of 81% (McInnes et al 2013) and secukinumab 65%, 
there is about 87% power to show statistically significant difference between secukinumab 
(pooled 240 subjects) and placebo (120 subjects), assuming 60% subjects have enthesitis at 
baseline (Fisher’s exact test, nQuery 7.0). 
9.8 Interim Analysis 
The Week 52 analysis will be performed after all subjects have completed the Week 52 visit. 
For this analysis, all subjects will have completed the assessments related to the primary and 
secondary objectives. Thus, no adjustment will be made to the type I error rate for this 
analysis and an interim clinical study report will be produced. 
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10 Ethical considerations 
10.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 
21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid 
down in the Declaration of Helsinki. 
10.2 Informed consent procedures 
Eligible subjects may only be included in the study after providing written (witnessed, where 
required by law or regulation), IRB/IEC-approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative of the subject. 
In cases where the subject’s representative gives consent, the subject should be informed 
about the study to the extent possible given his/her understanding. If the subject is capable of 
doing so, he/she should indicate assent by personally signing and dating the written informed 
consent document or a separate assent form. Informed consent must be obtained before 
conducting any study-specific procedures (i.e. all of the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the subject source 
documents. 
Novartis will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory requirements and is 
considered appropriate for this study. Any changes to the proposed consent form suggested by 
the investigator must be agreed to by Novartis before submission to the IRB/IEC, and a copy 
of the approved version must be provided to the Novartis monitor after IRB/IEC approval. 
Women of child bearing potential should be informed that taking the study treatment may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the subject will not reliably comply, they 
should not be entered in the study. 
The study includes an optional pharmacogenetic component which requires a separate 
signature if the subject agrees to participate. It is required as part of this protocol that the 
Investigator presents this option to the subject. The process for obtaining consent should be 
exactly the same as described above for the main informed consent. 
Declining to participate in these pharmacogenetic assessments will in no way affect the 
subject’s ability to participate in the main research study. 
In the event that Novartis wants to perform testing on the samples that are not described in 
this protocol, additional Institutional Review Board and/or ethics committee approval will be 
obtained. 
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10.3 Responsibilities of the investigator and IRB/IEC 
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board (IRB/IEC) before study start. A signed and dated statement that the protocol and 
informed consent have been approved by the IRB/IEC must be given to Novartis before study 
initiation. Prior to study start, the investigator is required to sign a protocol signature page 
confirming his/her agreement to conduct the study in accordance with these documents and all 
of the instructions and procedures found in this protocol and to give access to all relevant data 
and records to Novartis monitors, auditors, Novartis Clinical Quality Assurance 
representatives, designated agents of Novartis, IRBs/IECs/REBs, and regulatory authorities as 
required. If an inspection of the clinical site is requested by a regulatory authority, the 
investigator must inform Novartis immediately that this request has been made. 
10.4 Publication of study protocol and results 
Novartis assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this trial will be either submitted for publication 
and/or posted in a publicly accessible database of clinical trial results. 
11 Protocol adherence 
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
trial to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the conduct of the study this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR. 
11.1 Protocol Amendments 
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC. Only 
amendments that are required for subject safety may be implemented prior to IRB/IEC 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety of any subject 
included in this study, even if this action represents a deviation from the protocol. In such 
cases, Novartis should be notified of this action and the IRB/IEC at the study site should be 
informed within 10 working days. 
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13 Appendices 
13.1 Appendix 1: Clinically notable laboratory values and vital signs 
Safety Analyses:  Expanded Limits and Notable Criteria 
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests. 
Clinically notable values will be forwarded to Novartis at the same time that they are sent to 
investigators. 
 Final Harmonization 
  Notable Criteria 
Laboratory Variable  Standard Units SI Units 
LIVER FUNCTION AND RELATED VARIABLES 
SGOT (AST)  >3 x ULN >3 x ULN 
SGPT (ALT)  >3 x ULN >3 x ULN 
Bilirubin  >2 x ULN >2 x ULN 
Alkaline phosphatase  >2.5 x ULN >2.5 x ULN 
    
RENAL FUNCTION, METABOLIC AND ELECTROLYTE VARIABLES 
Creatinine (serum)  >2 x ULN1) >2 x ULN1) 
1) The baseline serum creatinine value is the pre-treatment serum creatinine level, which is defined as the 
 creatinine level measured at screening (Visit 1). 
HEMATOLOGY VARIABLES 
Hemoglobin:  ≥20 g/L decrease from baseline 
Platelet count:  <100x10E9/L 
White blood cell count: <0.8 x LLN 
Neutrophils:  <0.9 x LLN 
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13.2 Appendix 2: The classification criteria for psoriatic arthritis 
(CASPAR)  
To meet the ClASsification of Psoriatic ARthritis (CASPAR) criteria for diagnosis of 
psoriatic arthritis according to Taylor et al 2006, a subject must have inflammatory articular 
disease (joint, spine or entheseal) and at least 3 points from the following 5 categories: 
1. Evidence of current psoriasis, a personal history of psoriasis, or a family history of 
psoriasis (2 points)  
• Current psoriasis is defined as psoriatic skin or scalp disease present today as judged 
by a rheumatologist or dermatologist.†  
• A personal history of psoriasis is defined as a history of psoriasis that may be 
obtained from a patient, family physician, dermatologist, rheumatologist, or other 
qualified health care provider. 
• A family history of psoriasis is defined as a history of psoriasis in a first- or second-
degree relative according to patient report. 
2. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis 
observed on current physical examination (1 point)  
3. A negative test result for the presence of rheumatoid factor by any method except latex        
(1 point)  
4. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis 
recorded by a rheumatologist (1 point)  
5. Radiographic evidence of juxta-articular new bone formation appearing as ill-defined 
ossification near joint margins (but excluding osteophyte formation) on plain radiographs 
of the hand or foot (1 point) 
Total score: _______   
(The CASPAR criteria eCRF will auto-populate the total number of points of the CASPAR 
criteria met by the subject.  If the total score ≥ 3, the subject meets CASPAR criteria for PsA 
diagnosis.) 
† Current psoriasis is assigned a score of 2; all other features are assigned a score of 1 
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13.3 Appendix 3: American College of Rheumatology (ACR) Measures 
and Criteria of Response 
Number of tender joints 
Seventy-eight joints (78) are scored as either tender or not tender: 8 distal interphalangeal, 10 
proximal interphalangeal, 10 metacarpophalangeal and 2 first carpometacarpal joints of the 
hands, 8 distal interphalangeal, 10 metatarsophalangeal and 10 proximal interphalangeal joints 
of the feet, the 2 wrists, 2 elbows, 2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 
temporomandibular, 2 hip, 2 knee, 2 talo-tibial, and 2 mid-tarsal joints.  
Joint tenderness is to be scored present (1) or absent (0).  
Number of swollen joints 
Joints are to be scored as either swollen (1) or not swollen (0). The 76 joints to be examined 
for swelling are the same as those examined for tenderness, however excluding both hip joints. 
Patient's assessment of PsA pain 
On a 100 mm non-anchored visual analog scale, from no pain to unbearable pain. 
Patient's global assessment of disease activity 
On a 100 mm non-anchored visual analog scale, from no arthritis activity to maximal arthritis 
activity, after the question "Considering all the ways your arthritis affects you, draw a line on 
the scale for how well you are doing". 
Physician's global assessment of disease activity 
On a 100 mm non-anchored visual analog scale, from no arthritis activity to maximal arthritis 
activity. 
Patient's assessment of physical function 
Health Assessment Questionnaire – HAQ-DI© 
ACR20/50/70* 
A patient will be considered as improved according the ACR20 criteria* if she/he has at least 
20 % improvement in 
• the two following measures: 
o Tender joint count, 
o Swollen joint count. 
• and at least 3 of the following 5 measures: 
o Patient's assessment of pain, 
o Patient's global assessment of disease activity, 
o Physician's global assessment of disease activity, 
o Health Assessment Questionnaire (HAQ©) score, 
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o C-reactive protein (CRP)/Erythrocyte Sedimentation Rate (ESR). 
ACR50 = 50 % improvement in at least 3 of the 5 measures and 50 % improvement in the 
swollen and tender joint count. 
ACR70 = 70 % improvement in at least 3 of the 5 measures and 70 % improvement in the 
swollen and tender joint count. 
Reference: (Felson 1995) 
13.4 Appendix 4: The Psoriatic Arthritis Response Criteria (PsARC) 
The PsARC represent a composite measure of psoriatic arthritis disease severity and include 
the following 4 measures: 
1. Patient global assessment of disease activity (improvement of 1 on a 5-point Likert 
scale is required for a response) 
2. Physician global assessment of disease activity (improvement of 1 on a 5-point Likert 
scale is required for a response) 
3. Join pain (reduction of 30% or more in total score, assessing either 68 or 78 joints, 
using a 4-point scale is required for a response) 
4. Join swelling (reduction of 30% or more in total score, assessing either 68 or 78 joints, 
using a 4-point scale is required for a response) 
In order to be a ‘PsARC responder’ patients must achieve improvement in 2 of the above 
mentioned 4 measures, one of which must be joint pain or swelling, without worsening in any 
of the 4 measures. 
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13.5 Appendix 5: Disease Activity Score (DAS) 
The Disease Activity Score (DAS) is a combined index to measure the disease activity in 
patients with RA. It has been extensively validated for its use in clinical trials in combination 
with the EULAR response criteria. 
Evaluation of response to a treatment can be made much easier and more objective using the 
DAS. Just assess the number of swollen and tender joints and measure the ESR. The DAS will 
provide you with a number between 0 and 10, indicating how active the disease is at this 
moment. Recently the DAS-CRP has been developed. The C-reactive protein (CRP) may be 
used as an alternative to ESR in the calculation of the DAS or the DAS28. 
Using the DAS, several thresholds have been developed for high disease activity, low disease 
activity or remission. Also, response criteria have been developed based on the DAS, so when 
the DAS of a patient is measured at two time-points (e.g. before the start of a treatment and 
after 3 months), the patients clinical response can be assessed. 
The DAS in the clinical trials 
Comparing the DAS28 from one patient on two different time-points, it is possible to define 
improvement or response. The EULAR response criteria are defined as follows: 
 
Present 
DAS28 
DAS28 improvement 
>1.2 0.6 - 1.2 <0.6 
<3.2 good response moderate response no response 
3.2 - 5.1 moderate response 
moderate 
response no response 
>5.1 moderate response no response no response 
Both the thresholds for high and low disease activity and remission and the abovementioned 
improvement criteria should give you a feel how to interpret your DAS28 scores. 
In order to calculate the DAS28, information about the following disease variables is needed: 
• The number of swollen joints and tender joints should be assessed using 28-joint count 
(tender28 and swollen28) 
• The erythrocyte sedimentation rate (ESR) should be measured in mm/hour. 
• The patient’s general health (GH) or global disease activity measured on a Visual 
Analogue Scale (VAS) of 100 mm (both are useable for this purpose) must be obtained. 
Using this data, the DAS28 can be calculated using the following formula: 
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH 
The DAS28 provides you with a number on a scale from 0 to 10 indicating the current activity 
of the rheumatoid arthritis of your patient. A DAS28 above 5.1 means high disease activity 
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whereas a DAS28 below 3.2 indicates low disease activity. Remission is achieved by a 
DAS28 lower than 2.6 (comparable to the ARA remission criteria). 
Disease Activity Scores using C-reactive protein 
C-reactive protein (CRP) may be used as an alternative to ESR in the calculation of the DAS 
or DAS28, using the formulas below. CRP is a more direct measure of inflammation than 
ESR, and it is more sensitive to short-term changes (Kushner 1991). CRP production is 
associated with radiological progression in RA (Van Leeuwen 1993), and is considered at 
least as valid as ESR to measure RA disease activity (Mallya 1982, Wolfe 1997). Another 
advantage of determination of CRP is that waiting time for the laboratory result is shorter and 
that in case of multicenter studies a central laboratory can be used. 
The following formulas to calculate the DAS28 using CRP (mg/L) give good estimations of 
the original DAS28 values on a group level. DAS28-4(crp) = 0.56*sqrt(TJC28) + 
0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 
TJC28: 28 Tender joint count; SJC28: 28 Swollen joint count; CRP: C-reactive protein; GH: 
General Health on a 100mm. Visual Analogue Scale. 
It is strongly advised to adhere either to ESR or to CRP determinations. 
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13.6 Appendix 6: The Psoriasis Area and Severity Index (PASI) 
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their 
response to therapy. The PASI produces a numeric score that can range from 0 to 72. The 
severity of disease is calculated as follows. In the PASI system, the body is divided into 4 
regions: the head (h), trunk (t), upper extremities (u), and lower extremities (l), which account 
for 10%, 30%, 20% and 40% of the total BSA, respectively. Each of these areas is assessed 
separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The 
scoring system for the signs of the disease (erythema, induration, and scaling) are: 0 = none, 1 
= slight, 2 = moderate, 3 = severe, and 4 = very severe. The scale for estimating the area of 
involvement for psoriatic lesions is outlined below. 
0 = no involvement 
1 = 1% to 9% involvement 
2 = 10% to 29% involvement 
3 = 30% to 49% involvement 
4 = 50% to 69% involvement 
5 = 70% to 89% involvement 
6 = 90% to 100% involvement 
To help with the area assessments, the following conventions should be noted: 
• the neck is considered part of the head 
• the axillae and groin are part of the trunk 
• the buttocks are part of the lower extremities 
The PASI formula is: 
PASI = 0.1 (Eh + Ih + Sh) Ah + 0.3 (Et + It + St) At + 0.2 (Eu + Iu + Su) Au + 0.4 (El + Il + 
Sl) Al 
where E = erythema, I = induration, S = scaling, and A = area 
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13.7 Appendix 7: The modified Nail Psoriasis Severity Index (mNAPSI) 
Modified NAPSI Instructions 
This tool will ask you to assess each abnormality for each of a subject’s fingernails. If you 
question which grade to give, your answer should be the lower of the grades. Three features or 
groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) of each 
fingernail will be graded on a scale from 0 to 3, according to the directions below. Four 
features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula) will 
be graded as either present or absent for each fingernail. After you have viewed all the 
fingernails of a subject, consider all aspects of all of the subject’s fingernails and place a mark 
on the visual analog scale giving a global assessment of their fingernails. 
1. Onycholysis: Separation of the nail plate from the nail bed. The separated part of the nail is 
opaque and can have white, yellow, or greenish tinge. If there is a piece of nail missing, 
estimate where the nail normally would have ended at the end of the nail bed, and count that 
missing part as involved in onycholysis. 
Oil-drop (salmon patch) dyschromia: Reddish-brown discoloration under the nail plate. 
Onycholysis and oil-drop dyschromia are considered together. When looking at the nail, 
combine the total percentage area of the nail that is affected by either and use that combined 
total to score the nail. 
 
Score Percent of nail with onycholysis or oil-drop dyschromia present
0 No onycholysis or oil drop dyschromia present 
1 1–10% of the nail has onycholysis or oil-drop dyschromia 
2 11–30% of the nail has onycholysis or oil-drop dyschromia 
3 > 30% of the nail has onycholysis or oil-drop dyschromia 
 
2. Pitting: Small, sharply defined depressions in the nail surface. Pits are discrete 
abnormalities (“ice-pick-like”). If there is nail plate crumbling that is confluent with pits, do 
not score for pits. If the pits are separate from crumbling, they may be scored regardless of 
whether crumbling is present or not. 
 
Score Number of pits 
0 0 
1 1–10 
2 11–49 
3 > 50 
 
3. Nail plate crumbling: Crumbling or fragmentation of friable nail plate which may be 
associated with confluent pitting. Crumbling involves alteration of the nail plate surface. 
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Horizontal ridging of the nail, “wave-like” appearance, and horizontal lines are all features of 
crumbling. 
 
Score Percent of nail with crumbling present 
0 No crumbling 
1 1–25% of the nail has crumbling 
2 26–50% of the nail has crumbling 
3 > 50% of the nail has crumbling 
 
The next 4 abnormalities are scored only by their presence or absence. A score of 1 indicates 
present and a score of zero indicates not present. 
1. Leukonychia: White spots in the nail plate due to psoriasis in the mid matrix. Leukonychia 
are just color changes. If it appears that there is depression or irregularity to the nail surface, 
this may be pitting or crumbling, not leukonychia. If the leukonychia is adjacent to, or 
confluent with crumbling or pits, it is counted as part of the crumbling or pitting and not as a 
separate abnormality. 
2. Splinter hemorrhages: Small, longitudinal, linear, dark brown hemorrhage under the 
fingernail. 
3. Nail bed hyperkeratosis: Thickened keratin in the nail bed. 
4. Red spots in the lunula: Small pink or red macules in the lunula. 
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13.8 Appendix 8: Standard reference table for the LDI 
 
Table – hands (in cm) 
Digit Men Women 
Thumb 7.0 5.8 
Index 6.3 5.4 
Middle 6.3 5.4 
Ring 5.9 5.0 
Little 5.2 4.4 
 
Table – feet (in cm) 
Digit Men Women 
Central toe 8.2 7.2 
Second 5.2 4.6 
Middle 5.0 4.4 
Fourth 5.0 4.4 
Little 5.2 4.5 
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13.9 Appendix 9: Guidelines for administering PRO questionnaires 
Before trial begin 
Study coordinators should familiarize themselves with the PRO questionnaire(s) in the trial 
and identify any items where a subject’s response might highlight issues of potential concern. 
For example, one question in the SF-36 asks ‘How much of the time in the past 4 weeks- have 
you felt downhearted and blue?’ If a subject responds ‘most or all of the time’, then the study 
coordinator should inform the study investigator. 
Before completion 
• Subjects should be provided with the correct questionnaire 
• At the appropriate visits, and 
• In the appropriate language 
• Subjects should have adequate space and time to complete the forms 
• Subjects should be provided with a firm writing surface (such as a table or a clip board) 
and the digital pen 
• Questionnaire should be administered before the clinical examination 
During completion 
• Administrator may clarify the questions but should not influence the response 
• Only one response for each question 
• Subjects should initial and date the last page of the questionnaires 
• Also see ‘Addressing Problems and Concerns’ 
After completion 
• Check for completeness and not for content* 
• Check for multiple responses that were made in error 
• Data should be transcribed from the completed questionnaire to the appropriate screen on 
the e-CRF 
• File completed questionnaire in the subject study files 
*However, any response which may directly impact or reflect the subject’s medical 
condition (e.g. noting of depression) should be communicated by the study coordinator to 
the investigator). 
Addressing Problems and Concerns 
Occasionally a subject may have concerns or questions about the questionnaires administered. 
Guidance related to some of the most common concerns and questions are given below. 
The subject does not want to complete the questionnaire(s) 
Tell the subject that completion of the questionnaire(s) is voluntary. The goal is to better 
understand the physical, mental, and social health problems of subjects. Emphasize that this 
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information is as important as any of the other medical information, and that the 
questionnaire(s) is simple to complete. Suggest that the questionnaire(s) may be different 
from anything the respondent has filled in the past. If the subject still declines, retrieve the 
questionnaires. Record the reason for the decline, and thank the subject. 
The subject is too ill or weak to complete the questionnaire(s) 
In these instances, the coordinator may obtain subject responses by reading out loud each 
question, followed by the corresponding response categories, and entering the subject’s 
response. No help should be provided to the subject by any person other than the designated 
study coordinator. The coordinator should not influence subject responses. The study 
coordinator cannot translate the question into simpler language and has to be read verbatim. 
The subject wants someone else to complete the questionnaire(s) 
In no case should the coordinator or anyone other than the subject provide responses to the 
questions. Unless specified in the study protocol proxy data are not an acceptable substitute 
for subject self-report. Subjects should be discouraged from asking a family member or friend 
for help in completing a questionnaire. 
The subject does not want to finish completing the questionnaire(s) 
If non-completion is a result of the subject having trouble understanding particular items, ask 
the subject to explain the difficulty. Re-read the question for them verbatim, but do not 
rephrase the question. If the respondent is still unable to complete the questionnaire, accept it 
as incomplete. Thank the subject. 
The subject is concerned that someone will look at his/her responses 
Emphasize that all responses are to be kept confidential. Point out that their names do not 
appear anywhere on the questionnaire, so that their results will be linked with an ID number 
and not their name. Tell the subject that his/her answers will be pooled with other subjects’ 
answers and that they will be analyzed as a group rather than as individuals. Tell the subject 
that completed forms are not routinely shared with treating staff, and that their responses will 
only be seen by you (to check for completeness), and possibly the investigator. Any response 
which may directly impact on or reflect their medical condition (e.g. noting of severe 
depression) will be communicated by the coordinator to the physician. 
The subject asks the meaning of a question/item 
While completing the questionnaire, some subjects might ask the meaning of specific items so 
that they can better understand and respond. If this happens, assist the subject by rereading the 
question for them verbatim. If the subject asks to interpret the meaning of an item, do not try 
to explain it, but suggest that he/she use his/her own interpretation of the question. Subjects 
should answer the questions based on what they think the questions mean. 
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1 Introduction 
Data will be analyzed by Novartis according to the data analysis section 9 of the clinical study 
protocol.  That statistical methodology is described below and any deviations from the 
protocol are documented. Additional detailed information regarding the analysis methodology 
is contained in the Appendix section. 
2 Study Objectives 
The primary objective is to demonstrate the efficacy of secukinumab 75 or 150 mg at Week 
24 is superior to placebo in patients with active PsA based on the proportion of patients 
achieving an ACR20 response in the entire study population. 
The secondary objectives of the study are to demonstrate: 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving a PASI75 response in the subgroup of subjects who have 
≥3% skin involvement. 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving a PASI90 response in the subgroup of subjects who have 
≥3% skin involvement. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the DAS28-CRP at Week 24 in the entire study population. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the SF36-PCS at Week 24 in the entire study population. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the HAQ-DI at Week 24 in the entire study population. 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving an ACR50 response in the entire study population. 
• The improvement (change) from baseline to Week 24 on secukinumab pooled regimen (75 
mg and 150 mg s.c.) is superior to placebo for joint/bone structural damage (van der 
Heijde modified total Sharp score) in the entire study population. 
• The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 is 
superior to placebo based on the proportion of subjects with dactylitis in the subset of 
subjects who have dactylitis at baseline. 
• The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 is 
superior to placebo based on the proportion of subjects with enthesitis in the subset of 
subjects who have enthesitis at baseline. 
• The improvement (change) from baseline to Week 24 on secukinumab 75 or 150 mg is 
superior to placebo for joint/bone structural damage (van der Heijde modified total Sharp 
score) in the entire study population. 
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Furthermore, additional aspects of efficacy, safety and tolerability of secukinumab will be 
investigated. 
3 Data presentation 
Summary statistics for continuous variables will include N, mean, standard deviation, 
minimum, lower quartile, median, upper quartile, maximum. Summary statistics for discrete 
variables will be presented in contingency tables and will include absolute and relative 
frequencies. 
If not otherwise specified, p-values and confidence intervals will be two-sided. 
Unless otherwise stated, the level of significance will be set to 5% (two-sided, family-wise 
type-I-error). 
Data analyses will be presented by treatment regimen.  Efficacy and safety data for the 
placebo-controlled period will be presented by the following 3 treatment groups. Subjects 
may be included in more than one treatment group for some analyses (e.g. exposure-adjusted 
adverse events over the entire treatment period). These treatment groups represent the 
regimens subjects will be eligible to be randomized to for the first 24 weeks of the study. 
• Secukinumab regimen 1: secukinumab i.v. (10mg/kg) at BSL, Week 2 and Week 4 
then secukinumab 75 mg s.c. starting at Week 8 and injected every 4 weeks 
• Secukinumab regimen 2: secukinumab i.v. (10mg/kg) at BSL, Week 2 and Week 4 
then secukinumab 150 mg s.c. starting at Week 8 and injected every 4 weeks 
• Placebo regimen: Placebo i.v. at BSL, Week 2 and Week 4 then placebo s.c. starting at 
Week 8 and injected every 4 weeks  
Note that the treatment groups above for a subject may differ depending on the time period of 
the analysis and whether one assesses the subject for efficacy or safety (see Section 4.2 for 
details).  
Comparative efficacy data 
Comparative efficacy analyses (i.e. inferential efficacy comparisons with placebo or active 
comparator) will focus on the time period when both active drug and the placebo are given in 
a manner suitable for making comparisons (e.g. double-blind).  For AIN457F2306 this is the 
first 24-weeks of treatment.  Comparative efficacy will be performed based on the FAS 
population using the randomized treatment.   After week 24, the active secukinumab regimens 
will be compared using confidence intervals on the FAS population using treatment sequence. 
Efficacy data following rescue/re-randomization 
Data will also be presented after Week 24, by a combination of the ‘original’ and ‘switch’ 
treatment groups and will be referred to as treatment sequence. These treatment sequences 
represent the treatment combinations the subjects experience over the course of the entire trial 
in case of rescue or re-randomization. 
All listings will be presented by treatment sequence. 
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4 Subjects and treatments 
4.1 Analysis Sets 
The following analysis sets will be used for the data analysis.  
Randomized set: The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis-randomized subjects (mis-randomized in IWRS/IVRS/IXRS) 
will be excluded from the randomized set.   
Mis-randomized subjects are defined as those subjects who were mistakenly randomized into 
the IVR prior to the site confirming all eligibility criteria had been met and to whom no study 
medication was given.  Mis-randomized patients are treated as screen failures.   
Full analysis set (FAS): The FAS will be comprised of all subjects from the randomized set 
to whom study treatment has been assigned. Following the intent-to-treat principle, subjects 
will be analyzed according to the treatment assigned to at randomization, but actual stratum, if 
stratified randomization is used.  
Safety set: The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period. Subjects will be evaluated according to treatment received. 
4.2 Treatment groups 
The summaries by treatment will be performed by the randomized treatment or treatment 
sequence.  For some safety summaries (e.g. exposure-adjusted) the ‘switch’ treatment may be 
summarized separately 
• Randomized treatment: 
• AIN457 10 mg/kg - 75 mg  
• AIN457 10 mg/kg - 150 mg  
• Placebo     
• Treatment sequence: 
• AIN457 10 mg/kg - 75 mg  
• AIN457 10 mg/kg - 150 mg  
• Placebo (non-responder) - AIN457 75 mg 
• Placebo (non-responder) - AIN457 150 mg 
• Placebo (responder) - AIN457 75 mg 
• Placebo (responder) - AIN457 150 mg 
• Switch treatments (for placebo patients who cross-over): 
• AIN457 75 mg no load  
• AIN457 150 mg no load 
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5 Subgroup definitions 
The primary endpoint(s) and secondary endpoints will be evaluated for TNF-alpha inhibitor 
status.  
6 Assessment windows, baseline and post baseline 
definitions, missing data handling 
Baseline and post-baseline definitions 
In general, a baseline value refers to the last measurement made prior to administration of the 
first dose of study treatment. A post-baseline value refers to a measurement taken after the 
first dose of study treatment.  
Analysis visit windows 
Analysis visit windows will be used for the data that is summarized by visit; they are based on 
the study evaluation schedule and comprise a set of days around the nominal visit day. For 
any assessment, there are protocol defined scheduled visits around which analysis visit 
windows were created to cover the complete range of days within the study.  The analysis 
visit windows and rules for dealing with multiple measurements within the windows are 
described in the Appendix. 
 
7 Subject disposition, background and demographic 
characteristics 
7.1 Subject disposition 
The number of subjects screened will be presented. In addition, the reasons for screen failures 
will be provided. The number and percentage of subjects in the randomized set who 
completed the study periods and who discontinued the study prematurely (including the 
reason for discontinuation) will be presented at the end of each treatment period (Week 52 
and Week 104), if appropriate, for each treatment group and all subjects. 
The number and percentage of patients who meet the rescue criteria at week 16 will be 
presented. 
For each protocol deviation (PD), the number and percentage of subjects for whom the PD 
applies will be tabulated. 
7.2 Background and demographic characteristics 
The following common background and demographic variables, if collected, will be analyzed 
in all studies: 
Continuous variables: 
o Age (which is derived from date of birth and the screening assessment date) 
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o Height 
o Weight 
o Body mass index (BMI) = (body weight in kilograms) / (height in meters)2 
Categorical variables: 
o Age categories (<65 years, 65 years and older, 75 years and older) 
o Gender 
o Race 
o Ethnicity 
The following disease specific baseline characteristics and history of disease will be 
summarized as well: 
• TNFα history (naive or inadequate responder), ACR components, number of prior 
biologic PsA therapies, MTX use (yes or no) and dose at baseline, time since first 
diagnosis of PsA, and psoriasis involvement (proportion of patients with psoriasis of 
hands and feet, psoriasis of the nail, and target lesion diameter). 
Unless otherwise specified, summary statistics will be presented for continuous variables for 
each treatment group and for all subjects (total) in the randomized set. The number and 
percentage of subjects in each category will be presented for categorical variables for each 
treatment group and all subjects (total) in the randomized set.  
 
8 Medical history 
Any condition entered on the Relevant medical history / current medical conditions CRF will 
be coded using the MedDRA dictionary. They will be summarized by system organ class 
(SOC) and preferred term (PT) of the MedDRA dictionary. Summaries for cardiovascular 
medical history and psoriasis history will be provided as well. 
Smoking history will be summarized by treatment group. 
Chest x-ray (screening) results will be listed. 
Unless otherwise specified, analyses will be based on the randomized set. 
9 Study medication 
The analysis of study treatment data will be based on the safety set. The number of active and 
placebo infusions and injections will be summarized by treatment group. The duration of 
exposure to study treatment will also be summarized by treatment group. In addition, the 
number and percentage of subjects with cumulative exposure levels (e.g. any exposure, ≥ 1 
week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
Duration of exposure will be defined as the time from first dose of study treatment to the time 
of treatment switch (for subjects who switch treatment) or end of treatment period (whichever 
is first). For subjects who discontinue, this will be the subject’s last visit in the corresponding 
treatment period.  
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Duration of exposure (years) = duration of exposure (days) / 365.25 
Duration of exposure (100 subject years) = duration of exposure (years) / 100 
The analyses of duration of exposure described above will be done for the entire study 
treatment period. 
10 Concomitant medication 
Prior and concomitant medications will be summarized in separate tables by treatment group. 
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of randomized 
study treatment and the date of the last study visit will be a concomitant medication, including 
those which were started pre-baseline and continued into the period where study treatment is 
administered. 
Medications will be presented in alphabetical order, by Anatomical Therapeutic Classification 
(ATC) codes and grouped by anatomical main group. Tables will show the overall number 
and percentage of subjects receiving at least one treatment of a particular ATC code and at 
least one treatment in a particular anatomical main group. 
Significant prior and concomitant surgeries and procedures will be summarized by primary 
system organ class and MedDRA preferred term. 
The number and percentage of subjects receiving prior and concomitant psoriatic arthritis 
therapy will be presented by randomized treatment group as well as the reasons for stopping 
their therapies (primary lack of efficacy, secondary lack of efficacy, lack of tolerability, other) 
and the total duration of exposure to psoriatic arthritis therapies previously. 
Prior or concomitant medication will be identified by comparing recorded or imputed start 
and end dates of medication taken to the reference start date. Further rules will be given in 
RAP Module 8. 
11 Efficacy evaluation 
11.1 Description of efficacy variables 
ACR 20/50/70 
ACR20 is a binary response variable defined for each subject. A subject will be considered a 
responder according to ACR20 criteria if he/she has at least (i.e., ≥): 
• 20% improvement from baseline in tender 78-joint count 
• 20% improvement from baseline in swollen 76-joint count 
• 20% improvement from baseline in at least 3 of the following 5 measures: 
o Patient’s assessment of PsA pain (VAS 100 mm) 
o Patient’s global assessment of PsA disease activity (VAS 100 mm) 
o Physician’s global assessment of PsA disease activity (VAS 100 mm) 
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o Patient self-assessed disability (Health Assessment Questionnaire [HAQ©] 
score) 
o Acute phase reactant (C-reactive protein [hsCRP]) or Erythrocyte 
sedimentation rate (ESR). 
In the definition above, the baseline value refers to the last measurement made prior to 
administration of the first dose of study treatment.  
The primary endpoint is the proportion of subjects achieving ACR20 at Week 24. Primarily, 
CRP will be used to calculate ACR response: ESR will only be used in the event CRP is 
missing. 
ACR50 and ACR70 are defined in the same way as ACR20 by replacing the 20% with 50% 
and 70% improvement from baseline, respectively.  
ACRn represents the percent improvement on the continuous scale and from ACRn one can 
directly calculate ACR20, ACR50, and ACR70 using the appropriate cutoffs. This variable is 
defined as: 
 ACRn = min (x1, x2, x3), where  
x1 = % improvement from baseline in tender 68-joint count 
x2 = % improvement from baseline in swollen 66-joint count 
and x3 = 3rd largest value of x4, x5, x6, x7, x8 where,  
x4 = % improvement from baseline in Patient’s assessment of PsA pain (VAS 100 
mm) 
x5 = % improvement from baseline in Patient’s global assessment of PsA disease 
activity (VAS 100 mm) 
x6 = % improvement from baseline in Physician’s global assessment of PsA disease 
activity (VAS 100 mm) 
x7 = % improvement from baseline in Patient self-assessed disability (Health 
Assessment Questionnaire [HAQ©] score) 
x8 = % improvement from baseline in Acute phase reactant (C-reactive protein 
[hsCRP]) or Erythrocyte sedimentation rate (ESR) 
ACRn can be computed even if up to two values of x4, x5, x6, x7, x8 are missing. ACRn, 
theoretically, can not be computed, if one or both of x1, x2 is/are missing OR more than three 
values of x4, x5, x6, x7, x8 are missing.  
Health Assessment Questionnaire - Disability Index (HAQ-DI) 
The Health Assessment Questionnaire (HAQ©) was developed by Stanford University and is 
one of the most widely used measures to assess the long-term influence of chronic disease on 
a subject's level of functional ability and activity restriction. The disability assessment 
component of the HAQ (Health Assessment Questionnaire – Disability Index), the HAQ-DI, 
assesses a subject's level of functional ability and includes questions of fine movements of the 
upper extremity, locomotor activities of the lower extremity, and activities that involve both 
upper and lower extremities. There are 20 questions in eight categories of functioning 
including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem 
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of each item asks over the past week "Are you able to …" perform a particular task. Each item 
is scored on a 4-point scale from 0 to 3, representing normal (normal, no difficulty [0]), some 
difficulty [1], much difficulty [2], and unable to do [3].  
Scoring for the eight functional categories and overall disability index scoring will be 
performed as follows:  
There are eight categories; first score within each category:  
 Dressing and Grooming, includes items 1 and 2  
 Arising, includes items 3 and 4  
 Eating, includes items 5, 6 and 7  
 Walking, includes items 8 and 9  
 Hygiene, includes items 10, 11, and 12  
 Reach, includes items 13 and 14  
 Grip, includes items 15, 16 and 17  
 Activities, includes items 18, 19, and 20 
The score for each category will be the single response within the category with the highest 
score (greatest difficulty). For example, in the "Eating" category, there are two answers (one 
for each item). If "Cut your food with a knife or fork" is marked as "3" and "Lift a full cup or 
glass to your mouth" is marked as "0", then the score for the "Eating" category would be "3" 
(the response indicating the greatest difficulty within the category). If a component question is 
left blank or the response is too ambiguous to assign a score, then the score that that category 
will be determined by the remaining completed question(s). However, if any "aids or devices" 
and/or "help from another person" items at the bottom of each page are checked, the category 
to which they apply will be adjusted upward to "2". If the basic score is already "2" or "3", 
the score remains unchanged. "Aids or devices" and "help from another person" can only 
change a category's score to "2"; they do not change the score to a "1" or a "3". 
The score for the disability index will be the mean of the eight category scores. If more than 
two of the categories, or 25%, are missing, scale will not be scored. Otherwise, divide the sum 
of the categories by the number of answered categories. The higher score indicates greater 
disability. 
HAQ-DI response is defined by an improvement of at least 0.3 score points compared to 
baseline. 
Joint/bone structural damage 
The primary score for analyses will be total van der Heijde modified Sharpe (vdH-S) score 
(van der Heijde 1999), but the erosion score and joint space narrowing score will be analyzed 
in similar fashion. 
Erosions will be assessed each hand (20 locations per hand) and each foot (6 locations per 
foot). The maximum erosion score is 200 for all 40 hand locations, and 120 for all 12 feet 
locations. Thus, the total possible erosion score is 320.  
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Joint space narrowing (JSN) will be assessed in each hand (20 locations per hand) and foot (6 
locations per foot). The maximum score is 160 for all 40 hand joints, and 48 for all 12 feet 
joints. Thus, the total possible JSN score is 208.  
Pencil-in-cup: Osteolysis of the proximal phalanx and the base of the distal phalanx resulting 
in a pencil like proximal phalanx covered by cup like base of the distal phalanx. Pencil-in-cup 
will be scored as “P” where applicable.  
Gross Osteolysis: Osteolysis of the phalanx resulting in a loss of the normal joint structure, 
usually accompanied by shortening of the length of the phalanx. Gross osteolysis will be 
scored as “G” where applicable.  
If a joint or bone is not visible (e.g. poor film quality, missing imaging, severe misalignment, 
flexion deformity, dislocation) at the timepoint, the individual joint or bone will be coded as 
Not Visible (N).  
If radiographs at the timepoint show a joint or bone with surgical fusion, replacement 
(prosthesis), or amputation, then the joint or bone will be scored Surgically Modified (S).  
To obtain the total vdH-S score, scores for erosions and JSN in both the hands and feet will be 
added together. Any “P” or “G” will be considered the maximal score for the feature (erosions 
and JSN) per location in the calculation of the total vdH-S score. Any “N” or “S” will be 
considered null in the calculation of the total vdH-S score. The range of scores is 0 ~ 528. 
If the scores are missing for some locations, let ES denote the erosion score and JSNS denote 
the joint space narrowing score, the total score will be calculated as follows: 
12*avg(feet ES) + 12*avg(feet JSNS) + 40*avg(hands ES) + 40*avg(hands JSNS) 
Major clinical response 
Major clinical response is defined as continuous six-months of ACR70 response for a subject. 
DAS28, low disease activity and remission  
The Disease Activity Score (DAS) is a combined index to measure the disease activity in 
patients with RA. It has been extensively validated for its use in clinical trials in combination 
with the EULAR response criteria. 
The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, CRP 
or ESR, and the Patient Global Assessment. A DAS28 score > 5.1 implies active disease, ≤ 
3.2 low disease activity, and < 2.6 remission. 
The following 28 joints will be assessed for tenderness and swelling: metacarpophalangeal 
IV(10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow(2), 
shoulders (2), and knees (2). 
The following formulas can be used to calculate the DAS28 with CRP (mg/L) or ESR 
(mm/hour).  
DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 
DAS28-ESR = 0.56*sqrt(tender28) + 0.28*sqrt(swollen28) + 0.70*ln(ESR) + 0.014*PGA 
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TJC28: 28 Tender joint count; SJC28: 28 Swollen joint count; CRP: C-reactive protein; 
PGA: Patient Global Assessment 
If any component measurement is missing, DAS28 will be missing. 
DAS28-CRP will be primary for analysis; DAS-ESR will be secondary. 
DAS28-CRP (or ESR) remission is defined as a DAS28-CRP (or ESR) index score less than 
2.6. Low disease activity is defined as DAS28-CRP (or ESR) index less than or equal to 3.2.  
EULAR response 
Using the DAS, several thresholds have been developed for high disease activity, low disease 
activity or remission. Also response criteria have been developed based on the DAS, so when 
the DAS of a patient is measured at two time-points (e.g. before the start of a treatment and 
after 3 months), the patients clinical response can be assessed. 
Comparing the DAS28-CRP (or ESR) from one patient on two different time-points, it is 
possible to define improvement or response. The EULAR response criteria are defined as 
follows: 
Table 11-1 EULAR response criteria 
Present DAS28 
DAS28 improvement 
 
>1.2 0.6 - 1.2 <0.6 
< 3.2 good response moderate response no response 
3.2 - 5.1 moderate response moderate response no response 
>5.1 moderate response no response no response 
Both the thresholds for high and low disease activity and remission and the above mentioned 
improvement criteria should give a feel how to interpret your DAS28 scores. 
Minimal disease activity  
A subject will be considered a responder of minimal disease activity (MDA, see Coates 2010) 
if he/she achieves at least 5 of the following 7 items: 
• ≤ 1 tender joint count 
• ≤ 1 swollen joint count  
• PASI  ≤ 1 or IGA ≤ 1 
• patient pain VAS ≤ 15  
• patient global VAS ≤ 20  
• HAQ-DI ≤ 0.5 
• tender entheseal points ≤ 1 
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ACR Components 
Tender 78 joint count and swollen 76 joint count  
The 78 joints assessed for tenderness include the 2 temporomandibular, 2 sternoclavicular, 2 
acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 2 first carpometacarpal, 10 
metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 
the 2 hip, 2 knee, 2 talo-tibial, 2 mid-tarsal, 10 metatarsophalangeal, 10 proximal 
interphalangeal, and 8 distal interphalangeal joints of the feet. All of these except for the hips 
are assessed for swelling. Joint tenderness and swelling are to be graded present (1) or absent 
(0). Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive 
result for swollen joint count. Dactylitis of a digit in the foot or hand counts as one tender and 
swollen joint. 
If the number of joints for which data were available (e.g., T) is less than 78/76 for the 
tender/swollen joint assessment, the number of tender/swollen joints (e.g., t) will be scaled up 
proportionately (i.e., 78*t/T or 76*t/T for tender or swollen joint count).   
Patient’s assessment of PsA Pain 
The patient’s assessment of pain will be performed using 100 mm visual analog scale (VAS) 
ranging from “no pain” to “unbearable pain” after the question “Please indicate with a 
vertical mark ( | ) through the horizontal line the most pain you had from your psoriatic 
arthritis today”. 
Patient’s global assessment of PsA disease activity 
The patient’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from ”very good” to ”very poor”, after the question "Considering all the ways 
psoriatic arthritis affects you, please indicate with a vertical mark ( | ) through the horizontal 
line how well you are doing today”.  
Physician’s global assessment of PsA disease activity 
The physician’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from no disease activity to maximal disease activity, after the question "Considering 
all the ways the disease affects your patient, draw a line on the scale for how well his or her 
condition is today”. To enhance objectivity, the physician must not be aware of the specific 
patient’s global assessment of disease activity, when performing his own assessment on that 
patient. 
Erythrocyte sedimentation rate (ESR) 
Blood for ESR, which is helpful in diagnosing inflammatory diseases and is used to monitor 
disease activity and response to therapy, will be obtained at scheduled visits. 
High-sensitivity C-reactive protein (hsCRP) 
Blood for this assessment will be obtained in order to identify the presence of inflammation, 
to determine its severity, and to monitor response to treatment. Since the results of this test 
may unblind study personnel, results from the central lab will be provided for screening and 
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baseline only. The hsCRP results from samples collected during the treatment period will be 
revealed following database lock only. 
Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) will be performed in a subgroup of subjects with at least 
one swollen wrist at baseline at selected sites.  The independent reviewers shall perform MRI 
assessments according to the modified PsAMRIS scoring method (Ostergaard, Mikkel et al 
2009). Assessments will be performed on the hand with the more swollen wrist determined at 
baseline by the investigator. If both wrists are equally affected, the dominant hand/wrist will 
be chosen. The MRIs will be scored for the following assessments: 
• Synovitis 
• Tenosynovitis 
• Periarticular inflammation 
• Bone edema/osteitis 
• Bone erosion 
• Bone proliferation 
• Joint space narrowing 
Synovitis is defined as an area in the synovial compartment that shows greater than normal 
postgadolinium enhancement of a thickness greater than the estimated width of the normal 
synovium. A total of 17 locations in the hand and wrist will be evaluated for synovitis. 
Synovitis will be assessed on a scale of 0-3 for each location. The maximum possible score 
for synovitis is 51. 
Tenosynovitis is defined as an area with signal characteristics that show greater than normal 
water content or greater than normal post-gadolinium enhancement adjacent to a tendon, in an 
area with tendon sheath. A total of 14 hand locations and 10 wrist regions will be evaluated 
for tenosynovitis. Synovitis will be assessed on a scale of 0-3 for each location. The 
maximum possible score for tenosynovitis in the hand and wrist is 72. 
Periarticular inflammation is defined as an area with signal characteristics that show greater 
than normal water content or greater than normal post-gadolinium enhancement at 
extraarticular sites including the periosteum and the entheses (not including tendon sheaths as 
this is defined as tenosynovitis). A total of 28 locations in the hand will be evaluated for 
periarticular inflammation. Periarticular inflammation will be assessed on a scale of 0-2 for 
each location. The maximum possible score for periarticular inflammation in the hand is 56. 
MRI edema/osteitis is defined as a lesion, that may occur alone or surrounding an erosion or 
other bone abnormalities, within the trabecular bone, often with ill-defined margins and signal 
characteristics consistent with increased water. A total of 43 locations will be evaluated for 
bone edema/osteitis.Bone edema/osteitis is scored on a scale of 0-3 based on the proportion of 
estimated originally noneroded bone involved. The maximum possible score for bone 
edema/osteitis is 129. 
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MRI bone erosion is defined as a sharply marginated bone lesion, with correct juxta-articular 
localization and typical signal characteristics, with a cortical break seen in at least one plane. 
A total of 43 locations will be evaluated for bone erosions. Each bone is scored on a scale of 
0-10. The maximum possible score for bone erosions is 430. 
Bone proliferation is defined as an abnormal bone formation in the periarticular region such as 
at the entheses and across the joint. A total of 14 joints will be evaluated for bone proliferation. 
Bone proliferation will be assessed on a scale of 0-2 for each location. The maximum possible 
score for Bone proliferation is 28. 
Joint space narrowing (JSN) is defined as the reduction in joint space. JSN is scored on a scale 
of 0-4 based on the amount of narrowing present in a given joint. The maximum possible 
score for JSN in all 29 hand joints is 116. 
If a joint or bone is not visible (e.g. poor image quality, missing imaging, severe misalignment, 
flexion deformity, dislocation, ankylosis of >50% of articular surface [for erosion score only]) 
at the timepoint, the individual joint or bone will be coded as Not Visible (N). If MRIs at the 
timepoint show a joint or bone with surgical fusion, replacement (prosthesis), or amputation, 
then the joint or bone will be scored Surgically Modified (S).To obtain the total score per 
feature, any “N” or “S” will be considered null in the calculation. 
The score per feature will be calculated as the sum of scores from all available locations per 
feature. 
PsARC response 
A subject is defined as a PsARC responder if, and only if, they have an improvement in two 
of the following four factors (with at least one factor being a joint count) and no worsening in 
the remaining factors 
• Patient global assessment (0-100 mm VAS scale, improvement defined as decrease of at 
least 20 mm) 
• Physician global assessment (0-100 mm VAS scale, improvement defined as decrease of 
at least 20 mm) 
• Tender 78-joint count (improvement defined as decrease of at least 30%) 
• Swollen 76-joint count (improvement defined as decrease of at least 30%) 
PsARC response won’t be calculated if any of the four components are missing. 
Leeds Enthesitis Index (LEI) 
LEI is a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral 
epicondyle humerus L + R, proximal achilles L + R and medial condyle femur L + R. 
Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 
sites, for an overall score range of 0–6. Higher count represents greater enthesitis burden.  
In this study, the lateral condyle femur L + R data were collected instead of required medial 
condyle femur L + R. Therefore, a 4-site LEI (LEI-4) will be calculated with the four correct 
sites: lateral epicondyle humerus L + R, proximal achilles L + R. If measures are missing for 
any of these four sites, the LEI-4 won’t be calculated. 
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Presence of enthesitis 
If enthesitis is present with any of the 4 sites (lateral epicondyle humerus L + R, proximal 
achilles L + R), the patient is counted as a patient with enthesitis. 
Leeds Dactylitis Index (LDI) 
The LDI measures the ratio of the circumference of the affected digit to the circumference of 
the digit on the opposite hand or foot: a minimum difference of 10% is used to define a 
dactylitic digit. If both sides are considered involved, a table of normative values is used to 
provide the comparison. The ratio of circumference is multiplied by a tenderness score, 
originally based on the Ritchie index (graded 0–3), but a later modification amended this to a 
binary score (0 for nontender, 1 for tender) — this later modification is referred to as the LDI 
basic, and is adopted in this study. For each dactylitic digit, the final score is: 
[{(A/B) - 1} * 100 ] * C, 
where A is circumference of involved digit, B circumference of opposite (unaffected or from 
reference) and C is tenderness (0 or 1 in this case). The results from each digit with dactylitis 
are then summed to produce a final score. Only involved digits are assessed. 
Dactylitis count 
The dactylitis count is the number of fingers and toes with dactylitis, with a range of 0-20.  
Presence of dactylitis 
If dactylitis is present with any finger or toe, the patient is counted as a patient with dactylitis. 
Psoriasis Area and Severity Index (PASI) 
The PASI assessment will be conducted for subjects in whom at least 3% of the body surface 
area (BSA) was affected by psoriatic skin involvement at baseline (Visit 2). The PASI 
assesses the extent of psoriasis on four body surface areas (head, trunk and upper and lower 
limbs) and the degree of plaque erythema, scaling and thickness. A PASI score will be 
derived as indicated in Table 11-2. The head, trunk, upper limbs and lower limbs are assessed 
separately for erythema, thickening (plaque elevation, induration), and scaling (desquamation). 
The average degree of severity of each sign in each of the four body regions is assigned a 
score of 0-4. The area covered by lesions on each body region is estimated as a percentage of 
the total area of that particular body region. Further practical details help the assessment: 
1. The neck is assessed as part of the head. 
2. The axillae and groin are assessed as part of the trunk. 
3. The buttocks are assessed as part of the lower limbs. 
4. When scoring the severity of erythema, scales should not be removed. 
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Table 11-2 The PASI scoring system 
Body  
region 
Erythema (E) 
 
Thickening 
(plaque elevation,
induration, I) 
Scaling 
(desquamation) 
(D) 
Area score 
(based on true 
area %, A)* 
Head  (H)** 0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Trunk,   
(T)*** 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Upper  
limbs (U) 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Lower  
limbs  
(L)**** 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Percentage (not score) of body region (not whole body) affected will be entered in the eCRF 
**Neck is assessed as part of the Head (H) body region. 
***Axillae and groin are assessed as part of the Trunk (T) body region. 
****Buttocks are assessed as part of the Lower limbs (L) body region. 
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the PASI score is calculated 
using the formula: 
PASI = 0.1(EH+IH+DH)AH + 0.2(EU+IU+DU)AU + 0.3(ET+IT+DT)AT + 0.4(EL+IL+DL)AL 
The keys for the letters are provided in Table 11-2. 
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PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a 
theoretic maximum of 72.0. The total score comes from eCRF. 
IGA mod 2011 
IGA mod 2011 will be conducted for overall psoriatic disease for subjects in whom at least 
3% of the body surface area (BSA) was affected by psoriatic skin involvement at baseline. It 
is recommended that the same evaluator conducts the assessment throughout the study 
wherever possible. 
The IGA mod 2011 rating scale for overall psoriatic disease is displayed in Table 11-3. 
Table 11-3 The IGA mod 2011 rating scale 
Score Short Description Detailed Description 
0 Clear No signs of psoriasis. Post-inflammatory hyperpigmentation may be present. 
1 Almost clear Normal to pink coloration of lesions; no thickening; no to minimal focal scaling. 
2 Mild Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling. 
3 Moderate Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling. 
4 Severe 
Bright to deep dark red coloration; severe thickening with 
hard edges; severe / coarse scaling covering almost all or 
all lesions. 
Note:  Involvement of nails is not part of the assessment. 
The IGA mod 2011 scale has been developed based on a previous version of the scale used in 
secukinumab phase II psoriasis studies in collaboration with health authorities in particular the 
FDA. The explanations/descriptions of the points on the scale have been improved to ensure 
appropriate differentiation between the points. 
The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease 
state at the time of the assessments, and does not attempt a comparison with any of the 
subject’s previous disease states, whether at baseline or at a previous visit. 
Based on this scale, subjects will be considered as IGA mod 2011 0 or 1 responder if they 
achieve a score of 0 or 1 and improve by at least 2 points on the IGA scale compared to 
baseline. 
Target lesion score (TLS) 
The Target Lesion Score will be done for subjects enrolled in the study having a psoriatic 
target lesion that is at least 2 cm in diameter identified at baseline. At specified visits this 
target lesion will be scored for erythema, scaling, and thickness, each on a scale of 0 to 4 (0 = 
none, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). The parameter scores will be 
summed automatically in the eCRF, giving a score ranging from 0 to 12. 
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Modified Nail Psoriasis Severity Index (mNAPSI) 
The mNAPSI is an instrument to assess psoriatic nail involvement in subjects with PsA and 
nail psoriasis. It will be collected only in subjects with psoriatic nail involvement. The 
modifications on the original NAPSI to create the mNAPSI were made by rheumatologists, 
with dermatologists’ input, as a tool for clinical trials. The creators’ goal was to develop a tool 
to assess disease severity and response to treatment in clinical trials, keeping in mind that the 
assessor in a clinical trial most likely would not be a trained dermatologist. The mNAPSI 
scores range from 0-130 for all finger nails. The total mNAPSI score will be calculated as the 
sum of all the scores from available nails.  
11.2 Description of Health-related Quality of Life Endpoints 
SF-36 
The Short Form Health Survey (SF-36) is a widely used and extensively studied instrument to 
measure health-related quality of life among healthy subjects and patients with acute and 
chronic conditions. It consists of eight subscales that can be scored individually: Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- 
Emotional, and Mental Health. Two overall summary scores, the Physical Component 
Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The SF-
36 has proven useful in monitoring general and specific populations, comparing the relative 
burden of different disease, differentiating the health benefits produced by different treatments, 
and in screening individual patients.  
FACIT - Fatigue  
The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue©) is a 13- 
item questionnaire that assesses self-reported fatigue and its impact upon daily activities and 
function. 
Subjects respond to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = 
somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 
2 weeks. The scale score is computed by summing the item scores, after reversing those items 
that are worded in the negative direction. Numbering the questions from 1 to 13, it is evident 
that questions 7 and 8 are worded in the positive direction (4 indicates a desirable response) 
and all other questions are worded in the negative directions (4 indicates an undesirable 
response). Thus, it is necessary to reverse the responses for questions 7 and 8 (i.e. original 
response of 0 gets mapped to 4, 1=3, 2=2, 3=1, and 4=0) for scoring purposes. 
When there are missing item scores, the subscale score was computed by summing the non-
missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by 
the number of non-missing items (i.e. normalizing the results). The latter rule applied only 
when at least half of the items (seven or more) are non-missing.  
FACT Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue 
(Cella D et al., 2004). 
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EuroQol 5D (EQ-5D) 
The EQ-5D is a widely used, self-administered questionnaire designed to assess health status 
in adults. The measure is divided into two distinct sections. The first section includes one item 
addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and 
anxiety/depression). Subjects rate each of these items from "no problem," "some problem," or 
"extreme problem." A composite health index is then defined by combining the levels for each 
dimension. The second section of the questionnaire measures self-rated (global) health status 
utilizing a vertically oriented visual analogue scale where 100 represents the "best possible 
health state" and 0 represents the "worst possible health state." Respondents are asked to rate 
their current health by placing a mark along this continuum. The recall period is "today," and 
the questionnaire requires approximately 5 to 10 minutes to complete. 
The EQ-5D contains six items designed to assess health status in terms of a single index value 
or health utility score. One of the strengths of the EQ-5D approach is that it allows 
"weighting" by the patient of particular health states and the generation of patient utilities. 
Published weights are available that allow for the creation of a single summary health utility 
score. Overall scores range from 0 to 1, with lower scores representing a higher level of 
dysfunction.  
PsAQoL 
The PsA quality of life (PsAQoL) questionnaire contains 20 individual yes/no questions 
where the total score is determined by the number of questions that received a “yes” response. 
A higher score reflects a poorer quality of life.  
The PsAQoL score will not be calculated if more than 4 questions are missing. Otherwise, 
divide the number of ‘yes’ by the number of answered questions, multiply by 20.  
Dermatology Life Quality Index (DLQI) 
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability 
index designed to assess health-related quality of life in adult subjects with skin diseases such 
as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes 
domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, 
and work/school. The measure is widely used: it has been tested across 32 different skin 
conditions and is available in multiple languages. The recall period is the past week, and the 
instrument requires 1 to 2 minutes for completion. 
Each item has four response categories ranging from 0 (not at all) to 3 (very much). “Not 
relevant” is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 
questions. Scores range from 0 to 30, and higher scores indicate greater health-related quality 
of life impairment. If two or more questions are left unanswered, the total score will not be 
calculated. 
Work Productivity and Activity Impairment - General Health (WPAI-GH) 
The Work Productivity and Activity Impairment (WPAI-GH) questionnaire is an instrument 
to measure impairments in both paid work and unpaid work. It measures absenteeism, 
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presenteeism as well as the impairments in unpaid activity because of health problem during 
the past seven days. The WPAI-GH consists of six questions: 
1 = currently employed 
2 = hours missed due to health problems 
3 = hours missed other reasons 
4 = hours actually worked 
5 = degree health affected productivity while working (VAS) 
6 = degree health affected productivity in regular unpaid activities (VAS) 
The recall period for the questions 2 to 6 is seven days.  
Four main outcomes can be generated from the WPAI-GH and expressed in percentages by 
multiplying the following scores by 100:  
1) percent work time missed due to health = Q2/(Q2 + Q4) for those who were currently 
employed;  
2) percent impairment while working due to health = Q5/10 for those who were currently 
employed and actually worked in the past seven days;  
3) percent overall work impairment due to health Q2/(Q2 + Q4) + ((1 - Q2/(Q2 + Q4)) × 
(Q5/10)) for those who were currently employed; 
4) percent activity impairment due to health Q6/10 for all respondents.  
For those who missed work and did not actually work in the past seven days, the percent 
overall work impairment due to health will be equal to the percent work time missed due to 
health. 
11.3 Handling of missing data 
Missing data 
Missing data for ACR20 response and other binary efficacy variables for data up to 1-year 
(Week 52) will be handled as follows: 
1. Subjects who drop out of the trial for any reason will be considered non-responders from 
the time they drop out through Week 52. 
2. Subjects who do not have the required data to compute ACR20 response at baseline and at 
the specific time point will be classified as non-responders. 
Patients who were unblinded prior to the scheduled timepoint will be considered non-
responders from the time of unblinding up to the end of the placebo-controlled period (Week 
24). The primary analysis will use the non-responder imputation.  
Continuous variables (e.g. ACR20 components) will be analyzed using a mixed-effects 
repeated measures model (MMRM) which is valid under the missing at random (MAR) 
assumption.  As such, single-point imputation of missing data will not be performed (e.g. 
LOCF).  For analyses of these parameters, if all post-baseline values are missing then these 
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missing values will not be imputed and this subject will be removed from the analysis of the 
corresponding variable, i.e. it might be that the number of subjects providing data to an 
analysis is smaller than the number of subjects in the FAS. 
Data post-rescue 
In general, the handling of data for subjects who are rescued at Week 16 will be handled in 
the following fashion (up to Week 24):  
• For binary endpoints, subjects will be considered non-responders.   This will be done for 
all treatment regimens in order to minimize bias.  
• For continuous endpoints, the goal of the analyses would be to estimate what would have 
happened if the patients had stayed on the original treatment.  Thus, the data collected 
after the patient switches to secukinumab will be treated as missing for placebo patients 
and will be analyzed using a mixed-effects repeated measures model (MMRM) which is 
valid under the missing at random (MAR) assumption.  For secukinumab patients, the 
actual values will be used in the analysis. 
Data collected after Week 52 will generally be presented as ‘observed case’; i.e. all available 
data for each time point will be included in the analyses. 
11.4 Analysis of Primary variable 
The primary efficacy variable will be ACR20 response at Week 24. The analysis of the 
primary efficacy variable will be based on the FAS. Primarily, CRP will be used instead of 
ESR to calculate ACR response; ESR will only be used in the event CRP is missing.   
Statistical analysis 
The statistical hypothesis for ACR20 being tested is that there is no difference in the 
proportion of subjects fulfilling the ACR20 criteria at Week 24 in any of the secukinumab 
regimens versus placebo regimen. 
Let pj denote the proportion of ACR20 responders at Week 24 for treatment regimens j, j=0, 1, 
2, where  
• 0 corresponds to placebo regimen, 
• 1 corresponds to secukinumab 75 mg s.c., 
• 2 corresponds to secukinumab 150 mg s.c., 
In statistical terms, Hj: pj = p0, HAj: pj ≠ p0, for the jth secukinumab regimen, i.e. 
H1: secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24  
H2: secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24  
The primary endpoint of ACR20 at Week 24 will be analyzed via logistic regression with 
treatment and TNF-alpha inhibitor status as factors and weight as a covariate.  Odds ratios 
will be computed for comparisons of secukinumab regimens versus placebo regimen utilizing 
the logistic regression model fitted.   
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For subjects meeting the criteria for early escape at Week 16, their ACR20 will be set to non-
response at Week 24.  This applies for all three treatment regimens in order to minimize bias. 
Supportive analyses 
Sensitivity analyses and supportive analyses will be conducted in order to provide evidence 
that the results seen from the primary analysis are robust.  These analyses will center on the 
deviations in model assumptions, and the treatment of missing data. 
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ACR20 response at Week 24 will also be evaluated using a non-parametric 
regression (Koch et. al 1998) model with the same independent variables as the logistic 
regression model.  In addition, further logistic regression models may be conducted which 
explore the impact of other baseline or disease characteristics on response.  Treatment by 
factor interactions will be explored. 
The impact of missing data on the analysis results will be assessed as well by repeating the 
logistic regression model using ways to handle missing data.  These may include, but are not 
limited to: 
• Multiple imputation 
• Observed data analysis 
11.5 Analysis of secondary variables 
The secondary efficacy variables include:  
• response to treatment at Week 24 according to the PASI75 criteria in the subgroup of 
subjects who have ≥3% skin involvement 
• response to treatment at Week 24 according to the PASI90 criteria in the subgroup of 
subjects who have ≥3% skin involvement 
• change from baseline in DAS28-CRP at Week 24 in the FAS 
• change in SF-36 PCS from baseline at Week 24 in the FAS 
• change in HAQ-DI from baseline at Week 24 in the FAS 
• response to treatment at Week 24 according to the ACR50 criteria in the FAS 
• change from baseline in mTSS at Week 24 pooled secukinumab regimen vs placebo in the 
FAS 
• presence of dactylitis at Week 24 pooled secukinumab regimen vs placebo in the subset of 
subjects who have dactylitis at baseline 
• presence of enthesitis at Week 24 pooled secukinumab regimen vs placebo in the subset of 
subjects who have enthesitis at baseline 
• change from baseline in mTSS at Week 24 individual secukinumab regimen vs placebo in 
the FAS 
Testing strategy to control type I error 
The following hypotheses will be included in the testing strategy, and type-I-errors will be set 
such that a family-wise type-I-error of 5% is kept: 
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Primary objectives: 
H1: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to ACR20 
response at Week 24  
H2: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to ACR20 
response at Week 24  
Secondary objectives: 
H3: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to PASI75 
response at Week 24  
H4: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to PASI75 
response at Week 24  
H5: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to PASI90 
response at Week 24  
H6: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to PASI90 
response at Week 24  
H7: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for DAS28-CRP at Week 24  
H8: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for DAS28-CRP at Week 24   
H9: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for SF36-PCS at Week 24  
H10: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for SF36-PCS at Week 24   
H11: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for HAQ-DI at Week 24  
H12: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for HAQ-DI at Week 24   
H13: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to ACR50 
response at Week 24  
H14: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to ACR50 
response at Week 24  
H15: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to structural damage (van der Heijde modified total Sharp score) at week 24  
H16: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to presence of dactylitis at Week 24  
H17: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to presence of enthesitis at Week 24  
H18: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24 
H19: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24  
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The graphical approach of (Bretz 2009) for sequentially rejective testing procedures is used to 
illustrate the testing strategy: 
Figure 11-1 Testing strategy 
 
 
The family-wise error will be set to α=5% and it will be controlled with the proposed 
hierarchical testing strategy.  With this hierarchical testing approach, the hypotheses will be 
separated into two families, hypotheses of signs and symptoms (H1 ~ H14) will be the first 
family and hypotheses of structure damage (H15 ~ H19) will be the second family. The second 
family hypotheses will be tested only when all hypotheses in the first family have been 
rejected.  Each of the hypotheses (H1 and H2) for the primary objective (based on signs and 
symptoms at week 24) for each secukinumab regimen versus placebo will be tested 
simultaneously at α/2. If at least one of H1 and/or H2 are/is rejected, then H3 and/or H4, 
respectively.  If at least one of H3 and/or H4 is rejected, the hypothesis H5 and/or H6, is tested, 
respectively. Similar process applies until H13 and H14. Once all hypotheses within the first 
family for a secukinumab regimen are rejected, then the respective α/2 can be passed on to the 
other regimen’s hypotheses within the family, if they are not already rejected at α/2. Only 
when all H1 ~ H14 are rejected, the objective on joint structure endpoint at Week 24 for testing 
pooled secukinumab doses versus placebo (H15) will be tested at α. If H15 is rejected, then H16 
is tested at α. Similarly if H16 is rejected, then H17 is tested at α. If these pooled hypotheses are 
all rejected, then hypotheses concerning individual regimens of secukinumab versus placebo 
(H18 and H19) can be tested for a particular regimen at α/2. Once the hypothesis of structure 
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damage for a secukinumab regimen is rejected, then the respective α/2 can be passed on to the 
other regimen’s hypothesis, if it is not already rejected at α/2.  Of note, in the description 
above, rejection of a hypothesis refers to rejection of the two-sided hypothesis; however the 
level of a rejected hypothesis is only passed on according to the graphical procedure for the 
test of another hypothesis if the treatment effect is in favor of secukinumab. 
PASI 75 and PASI 90 response 
PASI 75 response and PASI 90 at Week 24 will be evaluated for those subjects in whom the 
assessment occurred (which is planned to be a subset of the FAS).  These binary variables will 
be evaluated in the same fashion as ACR response, i.e. a logistic regression model with 
treatment and randomization strata as factors and weight as a covariate. 
Changes in DAS28-CRP  
Between-treatment differences in the change from baseline in DAS28-CRP will be compared 
by means of a mixed model repeated measures (MMRM) with treatment regimen, analysis 
visit, and TNF-alpha inhibitor status as factors, and weight and baseline as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits.  
SF-36 PCS 
Between-treatment differences in the change in SF-36 PCS will be evaluated using a mixed 
effect repeated measures model (MMRM).  Treatment group, analysis visit and TNF-alpha 
inhibitor status as factors and baseline SF-36 score and weight as continuous covariates. 
Treatment by analysis visit and baseline SF-36 score by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
Physical function (HAQ-DI)  
Between-treatment differences in the change in HAQ-DI will be evaluated using a mixed 
effect repeated measures model (MMRM) with treatment regimen, analysis visit and TNF-
alpha inhibitor status as factors, and weight and baseline HAQ-DI score as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits.  
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ACR50 at Week 24  
Response at Week 24 to ACR50 in the FAS will be evaluated using a logistic regression 
model with treatment and randomization stratum (TNFα status -naive or IR) as factors and 
weight as a covariate.     
Joint/bone structural damage at Week 24 
The change at Week 24 from baseline van der Heijde total modified Sharp score will be 
evaluated using a non-parametric ANCOVA model with treatment regimen and TNF-alpha 
inhibitor status as factors, and weight and baseline van der Heijde total modified Sharp score 
as covariates. The pooled secukinumab regimens (75 mg s.c. and 150 mg s.c.) will be 
compared to placebo, then each of the secukinumab regimens will be compared versus the 
placebo regimen via pairwise comparisons. 
For subjects who meet the criteria for early escape at Week 16 and subjects who discontinue 
the study prior to Week 24, linear extrapolation will be used to impute the value at Week 24.  
In order to minimize bias, the extrapolation will use baseline and all post-baseline data up to 
the point the subject meets criteria for early escape treatment, or discontinues the study.  If 
baseline or all post-baseline total modified Sharp score/s is/are missing for a subject, the 
subject will be excluded from the analyses.  
Dactylitis at Week 24  
Presence of dactylitis at Week 24 in the subset of subjects who have dactylitis at baseline will 
be evaluated using a logistic regression model with treatment and randomization stratum 
(TNFα status -naive or IR) as factors and weight as a covariate.  
Enthesitis at Week 24  
Presence of enthesitis at Week 24 in the subset of subjects who have enthesitis at baseline will 
be evaluated using a logistic regression model with treatment and randomization stratum 
(TNFα status -naive or IR) as factors and weight as a covariate.  
11.6 Analysis of exploratory variables 
All the following exploratory efficacy variables will be analyzed on the FAS for all applicable 
analysis visits unless otherwise specified.  
• HAQ response 
• Major clinical response by Week 52 and 104 
• Joint/bone structural damage at Week 52 and 104 
• Evidence of no disease progression at Week 24, 52 and 104 
• PsARC, ACR20/50/70 response over time 
• DAS28 remission, low disease activity, EULAR response at Week 24 and over time 
• Minimal disease activity 
• ACR components 
o Changes in tender joint counts over time 
o Change in swollen joint counts over time 
o Change in Patient’s global assessment in disease activity 
o Change in Physician’s global assessment in disease activity 
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o Change in PsA Pain 
o Change in HAQ-DI over time 
o Change in erythrocyte sedimentation rate (ESR) 
o Change in high-sensitivity C-reactive protein (hsCRP) 
• PASI 75, PASI 90, and IGA response over time 
• Target lesion score 
• mNAPSI 
• LDI and dactylitis count 
• LEI-4 
Between-treatment comparisons for binary variables in the FAS population (e.g PsARC, 
ACR20, etc.) at individual analysis visits will be evaluated using a logistic regression model 
with treatment and TNF-alpha inhibitor status as factors and baseline score (if appropriate) 
and weight as covariates.   
Continuous variables (e.g. change from baseline in PsA pain) will be evaluated using a mixed-
effect model repeated measures (MMRM) with treatment regimen, TNF-alpha inhibitor status, 
and analysis visit as factors and weight and baseline score as continuous covariates.  
Treatment by analysis visit and baseline by analysis visit will be included as interaction terms 
in the model.  An unstructured covariance structure will be assumed for this model.  The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo at the appropriate analysis visits. Variables such as hsCRP whose distribution is not 
anticipated to be normal will be transformed and analyzed on the loge scale. 
Joint/bone structural damage at Week 52 and 104 
Observed joint/bone structure data at Week 52 will be compared between subjects randomized 
at baseline to secukinumab regimen (pooled from 2 secukinumab regimens) and placebo 
followed by secukinumab regimen. The change from baseline to Week 52 will be evaluated 
using a non-parametric ANCOVA model utilized for Week 24 and including randomization 
strata as a covariate.   
As sensitivity analysis,  for subjects with missing modified Sharp score values at Week 52, 
their Week 52 value will be imputed by linear extrapolation from baseline, Week 16 and 
Week 24, and at subject discontinuation visit (if subject discontinued prior to Week 52) to 
Week 52. 
Summary statistics of observed data at Week 52 will be provided for each treatment regimens: 
secukinumab 75 mg,  secukinumab 150 mg, placebo escape or switch to secukinumab 75 mg 
at Week 16 or 24, placebo escape or switch to secukinumab 150 mg at Week 16 or 24. 
Summary statistics include mean, standard deviation, minimum, lower quartile, median, upper 
quartile and maximum. 
Observed Joint/bone structure data at Week 104 will be summarized by treatment group.  In 
addition, the change from week 52 will also be summarized within treatment regimen. 
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Evidence of no disease progression at Week 24, 52 and 104 
The proportion of subjects without disease progression will be defined as those subjects who 
have a change in van der Heijde total modified Sharp score at Week 24 relative to baseline ≤ 0.  
The proportion of subjects without disease progression at Week 24 will be evaluated using a 
logistic regression model with treatment group and randomization strata, as factors, weight 
and baseline van der Heijde total modified Sharp score as covariates. 
The proportion of subjects without disease progression at Week 52 and 104 will be evaluated 
in the same manner.  At week 104, the proportion of subjects with disease progression from 
week 52 will also be examined. 
EULAR response at Week 24 and over time 
Based on the EULAR response criteria (good responder, moderate responder, and non-
responder) as determined based on the value of DAS28-CRP achieved and the magnitude of 
change from baseline, between-treatment differences in EULAR response at Week 24 and 
other analysis visits will be evaluated using a proportional odds regression model with 
treatment group and randomization strata as factors and weight and baseline DAS28-CRP 
score as covariates. Frequency tables will also be presented to show the response rate over 
time up to Week 24 and Week 52, as appropriate. 
Magnetic Resonance Imaging 
MRI Analysis will be based on the patients who have MRI performed at selected centers. 
The change in synovitis between Week 24 and baseline will be evaluated using a 
nonparametric ANCOVA model with treatment regimen as a factor, weight and baseline 
erosion score as covariates. Pair-wise comparison versus placebo will be made for each of the 
secukinumab regimens. Tenosynovitis, periarticular inflammation, bone edema/osteitis, bone 
erosion, bone proliferation, and joint space narrowing will be evaluated in the same manner. 
For subjects with missing data at Week 24, linear extrapolation will be used to impute missing 
data. In order to minimize bias, the extrapolation will use baseline and week 12. Change from 
baseline will be summarized by analysis visit with summary statistics including mean, 
standard deviation, minimum, lower quartile, median, upper quartile and maximum. 
LEI-4 
The 4-site LEI (i.e. score with the four correct sites: lateral epicondyle humerus L + R and 
proximal achilles L + R) will be summarized by treatment group and visit. Change from 
baseline in the 4-site LEI will be analyzed using a nonparametric ANCOVA model with 
treatment regimen and randomization strata as factors, weight and baseline score as covariates. 
Pair-wise comparison versus placebo will be made for each of the secukinumab regimens by 
visit.  
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11.7 Analysis of Health-related Quality of life variables 
PsAQoL 
Between-treatment differences in the change from baseline for PsAQoL scores will be 
evaluated using a mixed effect repeated measures model (MMRM) with treatment group, 
analysis visit and TNF-alpha inhibitor status as factors and baseline and weight as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
SF-36 
The following variables will be evaluated: 
• SF-36 domain scores. 
• SF-36 PCS and MCS scores. 
• SF-36 PCS responder (improvement of ≥ 2.5 points, Lubeck 2004) 
Between-treatment differences in the change from baseline for SF-36 summary scores 
(PCS/MCS) will be evaluated using a mixed effect repeated measures model (MMRM).  
Treatment group, analysis visit and TNF-alpha inhibitor status as factors and baseline SF-36 
score and weight as continuous covariates. Treatment by analysis visit and baseline SF-36 
score by analysis visit will be included as interaction terms in the model. An unstructured 
covariance structure will be assumed for the model. The significance of the treatment effects 
for secukinumab regimens at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate 
analysis visits. 
In the responder analyses, treatment groups will be compared with respect to response to 
treatment using a logistic regression model with treatment and TNF-alpha inhibitor status as 
factors, baseline SF-36 summary score and weight as covariates. Odds ratios with 
corresponding 95% confidence intervals will be estimated in addition.   
Individual SF-36 domain scores will be summarized. 
FACIT-Fatigue 
Between-treatment differences in the change from baseline for FACIT-Fatigue scores will be 
evaluated using a mixed effect repeated measures model (MMRM) with treatment group, 
analysis visit and TNF-alpha inhibitor status as factors and baseline and weight as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
Novartis Confidential Page 38 
RAP Module 3 25-Nov-2013 (9:51) AIN457F2306 
 
EuroQol 5D (EQ-5D) 
The number and percentage of subjects in each of the three categories for each question will 
be presented by visit and treatment group.  
Summary statistics will be shown for the health state assessment by visit and treatment group.  
For the change in EQ-5D overall health state (VAS), between-treatment differences in the 
change in EQ-5D overall health state (VAS) will be evaluated using a mixed effect repeated 
measures model (MMRM) with treatment group, analysis visit and TNF-alpha inhibitor status 
as factors and baseline EQ-5D overall health state (VAS) and weight as continuous covariates. 
Treatment by analysis visit and baseline EQ-5D overall health state (VAS) by analysis visit 
will be included as interaction terms in the model. An unstructured covariance structure will 
be assumed for the model. The significance of the treatment effects for secukinumab regimens 
at different analysis visits will be determined from the pairwise comparisons performed 
between secukinumab regimens and placebo at the appropriate analysis visits. 
Dermatology Life Quality Index (DLQI) 
Between-treatment differences in the change from baseline for DLQI will be evaluated using a 
mixed effect repeated measures model (MMRM) with treatment group, analysis visit and 
TNF-alpha inhibitor status as factors and baseline and weight as continuous covariates. 
Treatment by analysis visit and baseline by analysis visit will be included as interaction terms 
in the model. An unstructured covariance structure will be assumed for the model. The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo at the appropriate analysis visits. 
WPAI-GH 
Summary statistics will be shown for the WPAI-GH assessment by visit and treatment group. 
 
12 Pharmacokinetic evaluations (change / add PD, PK/PD, 
Biomarkers, as needed) 
12.1 Pharmacokinetics 
All completed subjects with quantifiable pharmacokinetic (PK) measurements of 
secukinumab will be included in the pharmacokinetic data analysis. Serum concentrations will 
be expressed in mass per volume units. All concentrations below the limit of quantification as 
well as missing data will be labeled as such in the concentration data listings. PK 
concentrations will be summarized by visit and treatment group. In addition to mean, standard 
deviation (SD), coefficient of variation (CV), median and quartiles, the geometric mean and 
geometric coefficient of variation (CV) and n(log) will be presented. The formula for deriving 
the geometric mean and CV (%) is as following:  
• CV (%) = (SD/mean)*100, 
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• geometric mean=exp( (sum of log transformed data) / number of non-missing data points 
after log transformation), 
• geometric CV = sqrt( exp( variance of log-transformed data)-1)*100. 
In addition, sample number, concentration, sample date, sample time at pre-dose and minutes 
pre-dose will be listed by treatment sequence. 
Values below lower limit of quantification/below detection limit will be imputed by 0. 
Pharmacokinetic data of the study treatment will be analyzed with a population-
pharmacokinetic mixed effects model. The analysis will be based on a pooled data set, 
including pharmacokinetic samples from previous studies. The modeling approach will be 
further detailed in a modeling plan. Results will be reported separately. 
12.2 Pharmacogenetics 
The exploratory pharmacogenetic studies are designed to investigate the association between 
genetic factors (genotypes) and clinical assessments (phenotypes) which are collected during 
the clinical trial. Without prior evidence of a strong association, a number of possible 
associations will be evaluated with exploratory analyses.  A range of statistical tests (chi-
square tests, analysis of covariance (ANCOVA), linear and logistic regression) will be used 
for the analyses.  Additional data, from subsequent clinical trials, are often needed to confirm 
associations.  Alternatively, if the numbers of subjects enrolled in the study are too small to 
complete proper statistical analyses, these data may be combined, as appropriate, with those 
from other studies to enlarge the data set for analysis. 
Results will be reported separately. 
12.3 Biomarkers 
Soluble marker panel studies investigate differences in the level of expression of proteins or 
peptides between individuals in a given biofluid.  The goal of such studies is to allow the 
identification of potential protein or peptide biomarkers of drug action or disease, and to 
better understand the associated underlying molecular mechanisms.  By applying statistical 
analysis methods (e.g. principal component analysis) between subject groups, distinct study 
time points, or between study groups from other clinical trials, it may be possible to identify 
patterns which are associated with disease state or response to drug treatment.  However, the 
exact type of data analysis method will depend on the type of data obtained in the study and 
thus the analysis of this data will be data driven. 
Results will be reported separately. 
12.4 PK/PD 
Exploratory analysis to investigate the correlation between the PK data and efficacy outcomes 
will be performed. 
An indirect response model, driven by study treatment concentration, will be used to 
characterize the time course of efficacy response. Further details of the modeling approach 
will be specified in a modeling plan. Results will be reported separately. 
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13 Safety evaluation 
Summaries may be performed separately for initial (Week 1-16) and entire treatment periods.  
Week 16 is chosen due to the fact that placebo patients may be rescued as early as week 16. 
Use of data up to and including the last visit before rescue provides and unbiased comparison 
between AIN and placebo; data collected beyond week 16 are included in analyses which 
summarize the entire treatment period.  The analyses of the follow-up period will be limited to 
summaries for treatment-emergent adverse events, serious adverse events and risks based on 
adverse events.  
Safety analyses will be performed on treatment received or actual treatment as described 
below: 
The actual treatment or treatment received for summaries of safety data will differ to the 
treatment assigned at randomization only if a subject received the wrong treatment during the 
entire study. 
For those subjects who received not the treatment randomized, i.e. who received erroneously 
the wrong treatment at least once, an additional AE listing will be prepared displaying which 
events occurred after the treatment errors. 
13.1 Adverse events 
The crude incidence of treatment emergent adverse events (i.e. events started after the first 
dose of study treatment or events present prior to the first dose of study treatment but 
increased in severity based on preferred term) will be summarized by primary system organ 
class and preferred term. Confidence intervals for the crude rate will be derived as described 
in Section 18.2.4.1. In addition, exposure time-adjusted rates (incidence rate as well as event 
rate) including 95% confidence intervals will be provided for the entire treatment period (see 
Section 18.2.5.1) to adjust for differences in exposure.  A graphical display of the crude 
incidence rates and exposure-adjusted rates within system organ classes will be presented for 
all AEs and serious AEs. 
The most common adverse events reported (≥ 1 % in any group for each preferred term in the 
SOC-PT table or ≥ 1 % in any group for each SMQ table) will be presented in descending 
frequency according to its incidence in total secukinumab group (combining all secukinumab 
treatment groups) starting from the most common event. Summaries (crude incidences only) 
will also be presented for AEs by severity and for study treatment related AEs. If a particular 
AE ‘severity’ is missing, this variable will be listed as missing and treated as missing in 
summaries. If a subject reported more than one adverse event with the same preferred term, 
the adverse event with the greatest severity will be presented. If a subject reported more than 
one adverse event within the same primary system organ class, the subject will be counted 
only once with the greatest severity at the system organ class level, where applicable.  
A graphical display of the crude rates or exposure adjusted incidence rates within system 
organ classes will be presented as follows: For all AEs regardless of severity and seriousness, 
the point estimate (i.e. relative frequency for evaluation of initial treatment and exposure 
adjusted incidence for evaluation of entire treatment) within system organ classes will be 
presented graphically with system organ class on the y-axis. This figure will consist of two 
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panels: i) point estimate of AEs, ii) point estimate of serious AEs. The placebo group will be 
displayed with a bar whereas dots will be used for secukinumab treatment groups. For the 
exposure adjusted incidences a linear scale will be used on the x-axes.  
Additional plots will be provided showing point estimates and confidence intervals on the left 
panel and numeric values of point estimate and confidence interval on the right panel of the 
figure. This will be done separately for all AEs and all SAEs. 
Separate summaries will be provided for adverse events suspected to be related to study drug, 
deaths, serious adverse events, and adverse events leading to discontinuation and adverse 
events leading to dose adjustment. 
Adverse events will also be reported separately by SMQ according to MedDRA, using a 
narrow search.  The MedDRA version used for reporting the study will be described in a 
footnote. 
Follow-up period summaries will be done for all subjects in follow-up who do not go on to 
the extension study (completers and early discontinuations).  
A listing of non-treatment emergent adverse events will be done.  These adverse events 
occurred before the first dose of the study treatment.  The crude incidence rate will be 
provided without treatment information. 
Algorithms for date imputations will be provided in RAP M8. 
For SAEs occurred during screening a listing will be prepared for all subjects screened 
including screening failures. 
An overview of the safety analyses and which will be performed for each analysis period is 
described in Table 13-1. 
Table 13-1 Overview of analyses on some safety endpoints 
Analysis 
period 
AEs & SAEs AEs by 
severity 
Study drug 
related AEs 
AEs-SMQ Risk Notables for 
(vitals/ 
ECG), lab 
criteria 
Day 1 – 
Week 16 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
Day 1 – 
Week 24 
• exposure 
time 
adjusted 
incidence* 
     
Entire 
Treatment 
(up to week 
104) 
 
• crude 
incidence 
• exposure 
time 
adjusted 
incidence* 
• crude 
incidence 
 
• crude 
incidence 
 
• exposure 
time 
adjusted 
incidence 
• crude 
incidence 
• exposure 
time 
adjusted 
incidence 
• crude 
incidence 
 
follow-up 
(week 104 to 
112) 
• crude 
incidence 
   • crude 
incidence  
 
*Exposure-adjusted incidence rates will be done at the PSOC for AE and SAE and Level 1 for Risks and SMQ 
analyses 
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13.2  Laboratory data 
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, chemistry and urinalysis). In addition to the individual laboratory parameters the 
ratios “total cholesterol / HDL” and “apolipoprotein B / apolipoprotein A1” will be derived 
and summarized. 
For urinalysis, frequency tables will be presented. 
Descriptive summary statistics for the change from baseline to each study visit will be 
presented. These descriptive summaries will be presented by laboratory test and treatment 
group. Change from baseline will only be summarized for subjects with both baseline and 
post baseline values and will be calculated as: 
change from baseline = post baseline value – baseline value 
For each parameter, the maximum change (maximum decrease and maximum increase) from 
baseline, if appropriate for each study phase, will be analyzed analogously.  
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal 
laboratory ranges will be used to evaluate whether a particular laboratory test value was 
normal, low, or high for each visit value relative to whether or not the baseline value was 
normal, low, or high. If appropriate, the shifts to the most extreme laboratory test value within 
a treatment phase (either initial or entire) will be presented as well (including category “high 
and low”). These summaries will be presented by laboratory test and treatment group. 
The following laboratory parameters will be analyzed with respect to numerical Common 
Terminology Criteria for Adverse Events (CTCAE) grades, given in Table 13-2: hemoglobin, 
platelets, white blood cell count, neutrophils, lymphocytes, creatinine, total bilirubin (TBL), 
gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), glucose, cholesterol, triglycerides (TG). 
These summaries will be split into hematology and chemistry for study level reports and the 
pooled summary of clinical safety. 
Table 13-2 CTCAE grades for laboratory parameters to be analyzed 
CTCAE v4.0 Term Grade 1    Grade 2    Grade 3    Grade 4    
HGB decreased 
(Anemia) <LLN – 100 g/L <100 – 80 g/L <80 g/L  
Platelet count 
decreased <LLN – 75.0 x10e9 /L <75.0 - 50.0 x10e9 /L <50.0 – 25.0 x10e9 /L <25.0 x 10e9 /L 
White blood cell 
decreased <LLN - 3.0 x 10e9 /L <3.0 - 2.0 x 10e9 /L <2.0 - 1.0 x 10e9 /L <1.0 x 10e9 /L 
Neutrophil count 
decreased <LLN - 1.5 x 10e9 /L <1.5 - 1.0 x 10e9 /L <1.0 - 0.5 x 10e9 /L <0.5 x 10e9 /L 
Lymphocyte count 
decreased <LLN - 0.8 x 10e9/L <0.8 - 0.5 x 10e9 /L 
 
<0.5 - 0.2 x 10e9 /L <0.2 x 10e9 /L 
Creatinine increased* 
 
>1 - 1.5 x baseline;  
>ULN - 1.5 x ULN 
>1.5 - 3.0 x baseline; 
>1.5 - 3.0 x ULN 
>3.0 baseline;  
>3.0 - 6.0 x ULN >6.0 x ULN 
TBL increased >ULN - 1.5 x ULN >1.5 - 3.0 x ULN >3.0 - 10.0 x ULN >10.0 x ULN 
GGT increased >ULN - 2.5 x ULN >2.5 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
ALT increased >ULN - 3.0 x ULN >3.0 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
AST increased >ULN - 3.0 x ULN >3.0 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
ALP increased >ULN - 2.5 x ULN >2.5 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
Glucose increased 
(Hyperglycemia )  
  
>ULN - 8.9 mmol/L >8.9 - 13.9 mmol/L >13.9 - 27.8 mmol/L >27.8 mmol/L 
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CTCAE v4.0 Term Grade 1    Grade 2    Grade 3    Grade 4    
Glucose decreased 
(Hypoglycemia) <LLN - 3.0 mmol/L <3.0 - 2.2 mmol/L <2.2 - 1.7 mmol/L <1.7 mmol/L 
Cholesterol high >ULN - 7.75 mmol/L >7.75 - 10.34 mmol/L >10.34 - 12.92 mmol/L >12.92 mmol/L 
Hypertriglyceridemia 1.71 - 3.42 mmol/L >3.42 - 5.7mmol/L >5.7 - 11.4 mmol/L >11.4 mmol/L 
*Note: for “creatinine increased” the baseline criteria do not apply 
Shift tables will be presented comparing baseline laboratory result (CTCAE grade) with the 
worst results (expressed in CTCAE grade) during the treatment phase (either initial or entire) 
analyzed. Of note, baseline will be defined as last assessment prior to first dosing in initial 
treatment phase. Subjects with abnormal laboratory values will be listed and values outside 
the normal ranges will be flagged. 
Summaries for newly occurring or worsening clinically notable lipid abnormalities will also 
be provided cumulatively for each of the following parameters and categories: 
• HDL: 
• <=LLN 
• <0.8 x LLN 
• LDL, cholesterol, triglycerides: 
• >=ULN  
• >1.5 x ULN  
• >2.5 x ULN 
Newly occurring or worsening liver enzyme abnormalities will also be summarized based on 
the event criteria given in Table 13-3: 
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Table 13-3 Liver-related events 
Parameter Criterion 
ALT >3xULN; >5xULN; >8xULN;>10xULN, >20xULN 
AST >3xULN; >5xULN; >8xULN >10xULN; >20xULN 
ALT or AST >3xULN; >5xULN; >8xULN >10xULN; >20xULN 
TBL >1.5xULN, >2xULN, >3xULN, 
ALP >2xULN, >3xULN. >5xULN 
ALT or AST & 
TBL 
ALT or AST>3xULN & TBL >2xULN; 
ALT or AST >5xULN & TBL >2xULN; 
ALT or AST >8xULN & TBL >2xULN; 
ALT or AST >10xULN & TBL >2xULN 
ALP & TBL ALP >3xULN & TBL >2xULN 
ALP >5xULN & TBL >2xULN 
ALT or AST & 
TBL & ALP 
ALT or AST>3xULN & TBL >2xULN & ALP <2xULN (Hy’s Law) 
Note: elevated ALP may suggest obstruction as a consequence of gall bladder or 
bile duct disease; ALP may also be increased in malignancy. FDA therefore terms 
Hy’s Law cases as indicators of pure hepatocellular injury. This does not mean 
that cases of ALT or AST >3xULN & TBL >2xULN & ALP ≥2xULN may not result 
in severe DILI. 
Notes: 
1) In studies which enroll subjects with pre-existing liver disease, baseline LFT may be increased 
above ULN; in such a case it is meaningful to add the condition “and worse than baseline” to the 
abnormality criteria 
For a combined criterion to be fulfilled, all conditions have to be fulfilled on the same visit. 
The criteria are not mutually exclusive, e.g. a subject with ALT = 6.42xULN is counted for 
ALT >3xULN and ALT>5x ULN. 
Individual subject data listings will be provided for subjects with abnormal laboratory data. 
Data of subjects with newly occurring or worsening liver enzyme abnormalities will be listed 
in an additional listing. 
13.3  Vital signs 
Analysis in vital sign measurement using descriptive summary statistics for the change from 
baseline for each post-baseline visit will be performed. These descriptive summaries will be 
presented by vital sign and treatment group. Change from baseline will only be summarized 
for subjects with both baseline and post-baseline values and will be calculated as: 
change from baseline = post-baseline value – baseline value 
The number and percentage of subjects with newly occurring notable vital signs will be 
presented. Criteria for notable vital sign abnormalities are provided in Table 13-4 below. 
Table 13-4 Criteria for notable vital sign abnormalities 
Vital sign (unit) Notable abnormalities 
Systolic blood pressure (mmHg) >= 140 mmHg or < 90 mmHg 
Diastolic blood pressure (mmHg) >=90 mmHg or <60 mmHg 
Pulse (bpm) > 100 bpm or <60 bpm 
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13.4   Electrocardiogram (ECG) 
The following quantitative variables will be summarized: ventricular rate, RR interval, PR 
interval, QRS duration, QT interval, and corrected QT interval (QTc). Both Bazett (QTcB) 
and Fridericia (QTcF) corrections will be presented for QTc.  
QTc will be summarized by computing the number and percentage of subjects (including 95% 
confidence intervals for pooled analyses, e.g. DMC or SCS) with: 
• QTc > 500 msec  
• QTc > 480 msec 
• QTc > 450 msec 
• QTc changes from baseline > 30 msec 
• QTc changes from baseline > 60 msec 
• PR > 250 msec 
Summary statistics will be presented for ECG variables by visit and treatment group. 
In addition, shift tables comparing baseline ECG interpretation (normal, abnormal, not 
available, total) with the worst on-study interpretation (normal, abnormal, not available, total) 
will be provided. 
A listing of all newly occurring or worsening abnormalities will be provided, as well as a by-
subject listing of all quantitative ECG parameters.   
13.5   Immunogenicity 
A listing of immunogenicity (anti-AIN457 antibodies) will be provided. 
13.6   Compound specific safety evaluation 
Safety topics of interest, such as risks defined in the Safety Profiling Plan, Risk Management 
Plan or topics of interest regarding signal detection or routine analysis are defined in the 
Program Case Retrieval Sheet that is stored in CREDI at the path Cabinets/CREDI 
Projects/A/AIN457A/Integrated Medical Safety. 
The crude incidence and exposure-adjusted incidence rates for potential compound and class-
related risks and routine risks will be summarized. In addition, listings will be provided 
presenting which subjects experienced which risk. 
Important note: For the evaluation of SPP risks primary and secondary system organ classes 
of the MedDRA dictionary will be considered. 
14 Sample size calculation 
The original power calculations used in the protocol have been updated to incorporate more 
recent published data in the PsA population.  In addition, the statistical hierarchy (primary 
plus ranked secondary variables) was expanded to include more endpoints important in the 
treatment of psoriatic arthritis patients.  No adjustment was made to the sample size as a result 
of the updated power calculations; the original sample size of N=200 per treatment regimen 
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was retained.  The adjustments to the power calculations and the statistical hierarchy were 
done before the unblinding of the trial in order to prevent bias. 
A 5% two-sided type I error rate will be used to control for type I error.  Two secukinumab 
doses will be tested versus placebo with respect to the primary endpoint (ACR20 response at 
Week 24), thus the type-I-error will be split to 2.5% two-sided for each comparison. Sample 
sizes will be based on this type I error assumption. 
A placebo response rate of about 25% after 24 weeks was reported for the TNFα inhibitor 
naive population in the PSUMMIT I study (McInnes et al 2013), and 15% was reported for 
the TNFα inhibitor IR population in the PSUMMIT II study (Ritchlin et al 2013).  Based on 
the weighted average, the overall placebo rate is expected to be 22%. 
The response on secukinumab is expected to be 55% in the TNFα inhibitor naïve population 
and 35% in the TNFα inhibitor IR-population.  Based on the weighted average, the overall 
rate on a dose of secukinumab is expected to be 49%. 
For the primary endpoint, ACR20 in the overall population, 200 subjects per group would 
yield approximately 99% power to detect a treatment difference of 27% (Fisher’s exact test, 
nQuery 7.0). 
15 Power for analysis of secondary variables 
Power for secondary variables was calculated using a two-sided 2.5% type I error. With an 
assumed placebo rate of 7.6% and secukinumab 58.1%, the study is over 99% powered to 
detect a treatment difference of PASI75 in the full FAS population, assuming 135 subjects per 
treatment arm (Fisher’s exact test, nQuery 7.0). Similarly, with an assumed placebo rate of 
5% and secukinumab 44%, the study is over 99% powered to detect a treatment difference of 
PASI90 in the full FAS population, assuming 135 subjects per treatment arm. It is assumed 
that about 67.5% of enrolled patients have ≥3% skin involvement. Assumptions of PASI75 
and PASI90 rates are based on PSUMMIT I and II studies (McInnes et al 2013 and Ritchlin et 
al 2013). 
A difference of 1.31 and standard deviation of 1.34 has been observed for the change from 
baseline in DAS28-CRP in Golimumab (Kavanaugh et al 2009) for the TNFα inhibitor naïve 
population. Assuming the difference is half in the TNFα inhibitor IR population, the overall 
population has a difference of 1.12. With these assumptions, the study has approximately over 
99% power to detect a difference between secukinumab and placebo (Two group t-test, 
nQuery Advisor 7.0), assuming 200 subjects per arm.  
A standard deviation of approximately 10.1 and a treatment difference of 6.32 has been 
observed for the change from baseline at week 24 in SF36-PCS in Ustekinumab trial 
(Mclnnes et al 2013). Using those assumptions, the study has approximately 99% power to 
detect a difference between secukinumab and placebo (Two group t-test, NQuery Advisor 7.0), 
assuming 200 subjects per arm. 
A standard deviation of approximately 0.5 and a treatment difference of 0.25 has been 
observed for the change from baseline at week 24 in HAQ-DI in Ustekimumab trial (McInnes 
et al 2013; Ritchlin et al 2012; Ritchlin et al 2013). Using those assumptions, the study has 
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approximately 99% power to detect a difference between secukinumab and placebo (Two 
group t-test, NQuery Advisor 7.0), assuming 200 subjects per arm. 
With an assumed placebo rate of 7.4% (McInnes et al 2013 and Ritchlin et al 2013) and 
secukinumab 25.5%, the study is over 99% powered to detect a treatment difference of 
ACR50 in the full FAS population, assuming 200 subjects per treatment arm (Fisher’s exact 
test, nQuery 7.0). 
For structural endpoint, historical data (adalimumab) showed a standard deviation of 1.2 on 
active treatment and 2.4 on placebo at week 26, and a difference of 0.6 for the TNFα inhibitor 
naïve population. Assuming the difference is half in the TNFα inhibitor IR population, the 
overall population has a difference of 0.51. Using the above assumptions, there is 80% power 
to show statistically significant differences between secukinumab (pooled 400 subjects) and 
placebo (200 subjects).  Individual comparisons between secukinumab and placebo would 
have 66% power (Satterthwaite t-test, nQuery 7.0). 
For the presence of dactylitis at Week 24 in the subset of patients who have dactylitis at 
baseline, with an assumed placebo rate of 76% (McInnes et al 2013) and secukinumab 57%, 
there is about 89% power to show statistically significant difference between secukinumab 
(pooled 200 subjects) and placebo (100 subjects), assuming 50% patients have dactylitis at 
baseline (Fisher’s exact test, nQuery 7.0).   
For the presence of enthesitis at Week 24 in the subset of patients who have enthesitis at 
baseline, with an assumed placebo rate of 81% (McInnes et al 2013) and secukinumab 65%, 
there is about 87% power to show statistically significant difference between secukinumab 
(pooled 240 subjects) and placebo (120 subjects), assuming 60% patients have enthesitis at 
baseline (Fisher’s exact test, nQuery 7.0).   
16 Interim Analysis 
The Week 52 analysis will be performed after all subjects have completed the Week 52 visit. 
For this analysis, all subjects will have completed the assessments related to the primary and 
secondary objectives. Thus, no adjustment will be made to the type I error rate for this 
analysis and an interim clinical study report will be produced. 
17 DMC 
A project-level DMC will monitor the trials’ progress for unexpectedly large differences in 
toxicity between treatment groups on a regular basis or per the request of the DMC. Details 
regarding the reasons for the DMC and the grounds for stopping/continuing studies, as well as 
the DMC procedures are provided in the project-level DMC charter. 
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18 Appendix 
18.1 Visit Windows 
When visit windows are used, all visits will be re-aligned, i.e., they will be mapped into one 
of the visit windows. E.g., if the Week 4 visit of a subject is delayed and occurs on Day 46 
instead of on Day 29, say, it will be re-aligned to visit window Week 8. In the case of major 
deviations from the visit schedule, or due to unscheduled visits, several assessments of a 
subject may fall in a particular visit window (either scheduled or unscheduled). Statistical 
approaches to handle multiple assessments in a given visit window are specified below.  
Of note, subjects are allowed to have gaps in visits.  All data collected will be displayed in 
listings.  
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Table 18-1 Analysis visit windows  
Analysis 
Visit 
Target 
Day 
Analysis 
Visit 
Window  
Group1 Group2 Group3 Group4 Group5 Group6 Group7 Group8 Group9 Group10 
Baseline 1 Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* 
Week 1 8 2-11 2-11 2-11     2-11    
Week 2 15 12-22  12-22  12-22     2-22  12-22    
Week 4 29 23-43  23-43  23-43    2-71 23-43  23-43 2-43   
Week 8 57 44-71  44-71  44-71     44-71  44-71 44-71  2-85   
Week 12 85 72-99 72-99 72-99 2-127   72-99 72-99 72-99   
Week 16 113 100-127 100-127 100-127  2-141 72-141 100-141 100-141 100-141 86-141 2-239 
Week 20 141 128-155 128-155 128-155         
Week 24 169 156-183 156-183 156-183 128-449 142-267 142-267 142-197 142-197 142-267 142-267  
Week 28 197 184-211 184-211 184-211         
Week 32 225 212-239 212-239 212-253    198-253 198-253    
Week 36 253 240-267 240-267          
Week 40 281 268-295 268-295 254-323    254-323 254-323    
Week 44 309 296-323 296-323          
Week 48 337 324-351 324-351          
Week 52 365 352-379 352-393 324-393  268-547 268-547 324-393 324-393 268-547 268-449 240-547 
Week 56 393 380-407           
Week 60 421 408-435 394-449 394-449    394-449 394-449    
Week 64 449 436-463           
Week 68 477 464-491 450-505 450-505    450-505 450-505    
Week 72 505 492-519           
Week 76 533 520-547 506-561 506-561    506-561 506-561  450-631  
Week 80 561 548-575           
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Week 84 589 576-603 562-617 562-617    562-617 562-617    
Week 88 617 604-631           
Week 92 645 632-659 618-687 618-687    618-687 618-687    
Week 96 673 660-687           
Week 100 701 688-715           
Week 104 729 716-743 688-743 688-743 450-743 548-743 548-743 688-743 688-743 548-743 632-743 548-743 
Group1: ACR components, Vital signs 
Group2: Hematology, blood chemistry, urinalysis 
Group3: MRI  
Group4: X-Ray, WPAI-GH 
Group5: PK 
Group6: Presence of enthesitis, LEI, presence of dactylitis, LDI, dactylitis count 
Group7: PASI, IGA, TLS, mNAPSI 
Group8: SF-36, FACIT, PsAQoL, EQ-5D, DLQI 
Group9: Lipids 
Group10: ECG 
* The first administration of randomized study treatment (first dose) is defined as 1. 
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The following rules are used to determine the window for an applicable visit post baseline: 
“Lower limit” = “upper limit of prior applicable visit” + 1. “Upper limit” = “target day of 
current visit” + integer part of (“target day of next applicable visit” – “target day of current 
visit”)/2. Lower limit of the first applicable visit is always Day 2. 
The mapping described above applies to all visits (not just scheduled visits).  Repeat and/or 
unscheduled visits (which will be numbered in the database according to new NCDS 
standards) will be mapped for analysis purposes in the same way as scheduled visits.  This 
leaves the possibility, then, for multiple measurements within an analysis window.  The 
following conventions will be used to determine the appropriate measurement to be 
summarized in the event of multiple measurements within a visit window. 
Table 18-2 Rules for flagging variables 
Timing of measurement Type of data Rule 
Baseline All data The last measurement made prior to administration of the first dose of 
study treatment – note this may include measurements taken on the day 
of randomization (e.g. lab). If a patient did not receive any dose of study 
treatment then the randomization date will be used. 
Post-baseline efficacy All data • For visits without switch of treatment in the window, the measurement 
closest to the target will be used. In the event two measurements are 
taken equally apart (e.g. 1 before target date and 1 after) the first one 
will be used.  
• For visits during which the patient switches from placebo to AIN the 
following will be done based on whether or not the patient met the 
rescue criteria: 
o If the analysis visit window is <= week 16(for non-responders) or 
week 24 (for responders), then:  
 If available, the closest measurement to the target 
date which is ON or BEFORE the switch date will be 
used (i.e. the closest measurement to target which is 
on placebo). 
 If there are no data on or before the switch then the 
closest measurement to the target date after the 
switch will be used. 
o If the analysis visit window is > week 16(for non-responders) or 
week 24 (for responders), then  
 If available, the closest measurement to the target 
date which is AFTER the switch date will be used (i.e. 
the closest measurement to target which is on AIN). 
 If there are no data AFTER the switch then the closest 
measurement to the target date before the switch will 
be used. 
Post-baseline safety Summary visit 
information (e.g. lab, 
ECG, etc.) 
• For visits without switch of treatment in the window, the measurement 
closest to the target will be used. In the event two measurements are 
taken equally apart (e.g. 1 before target date and 1 after) the first one 
will be used.  
• For visits during which the patient switches from placebo to AIN the 
following will be done based on whether or not the patient met the 
rescue criteria: 
o If the analysis visit window is <= week 16(for non-responders) or 
week 24 (for responders), then:  
 If available, the closest measurement to the target 
date which is ON or BEFORE the switch date will be 
used (i.e. the closest measurement to target which is 
on placebo). 
 If there are no data on or before the switch then the 
closest measurement to the target date after the 
switch will be used. 
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Timing of measurement Type of data Rule 
o If the analysis visit window is > week 16(for non-responders) or 
week 24 (for responders), then  
 If available, the closest measurement to the target 
date which is AFTER the switch date will be used (i.e. 
the closest measurement to target which is on AIN). 
 If there are no data AFTER the switch then the closest 
measurement to the target date before the switch will 
be used. 
Post-baseline safety  Notable 
abnormalities (e.g. 
lab) 
The most extreme measurement in the window will be used.  Note this 
means a patient can have a notably high and notably low measurement 
within a window.  
18.2 Statistical methodology and assumptions 
18.2.1 Analysis of continuous data 
18.2.1.1 Summary statistics for continuous data 
Summary statistics (including N, mean, standard deviation, minimum, lower quartile, median, 
upper quartile, maximum) will be provided for continuous data by visit and treatment group.  
18.2.1.2 Mixed-effects repeated measures model 
Endpoints with continuous data type expected to be normally distributed (e.g, DAS28) will be 
analyzed using a mixed-effects repeated measures model (MMRM) with treatment regimen, 
randomization strata, and analysis visit as factors and weight and baseline as continuous 
covariates. Confidence intervals for the difference between each dose of secukinumba and 
placebo will be calculated.  
SAS code for MMRM: 
Proc mixed data= das28 covtest; 
Class trt stratum; 
Model response= trt weight stratum baseline/ s; 
Repeated /type=un subject=patientid r; 
Run; 
18.2.1.3 Non-parametric analysis of covariance 
A non-parametric ANCOVA model (Koch 1998) will be used for the endpoints that are not 
normally distributed, e.g. X-ray, MRI, et. ctrl. 
2-stage SAS code for non-parametric ANCOVA: 
1) Proc glm data=xray; 
by stratum; 
Model response= weight baseline/ s; 
Output out=results residual=resid; 
Run; 
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2) proc freq data=tmp;  *tmp is the data “results” combined with strata and trt information; 
Tables strata*trt*resid/cmh; 
Run; 
18.2.2 Analysis of binary (and categorical) data 
18.2.2.1 Summary statistics for binary and categorical data 
Summary statistics for discrete variables will be presented in contingency tables and will 
include count and frequency in each category. If applicable, confidence intervals will be 
derived as well based on the score method including continuity correction [Newcombe 
(1998)]: 
With z as (1-alpha/2)-quantile of the standard normal distribution (SAS: z=PROBIT(1-
alpha/2), n  as total number of subjects (i.e. number of subjects in the denominator), and p as 
estimated crude incidence (number of subjects with event / n ) it is pq −=1  
Then the lower limit is 
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For binary response variables (e.g. for ACR20/50/70, HAQ-DI responder, PASI 75, IGA 
response) the placebo-adjusted response rates including 95% confidence interval will be 
derived.  
SAS code for risk difference: 
Proc freq data=acr order=formatted;  
Tables response*trt/ riskdiff; 
Run; 
(Note the response value should be sorted with ‘1’ ahead of ‘0’.) 
Fisher’s exact test will be applied to rare events (e.g., MCR), pairwise treatment group 
comparisons to placebo or active controls. 
SAS code for Fisher’s exact test: 
Proc freq data=mcr order=formmatted; 
Tables response*trt/Fisher; 
Run; 
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Figures will be provided for primary and secondary variables, with means and 95% 
confidence intervals displayed across time for all the treatment groups. 
18.2.2.2 Logistic regression 
Certain binary outcome variables, e.g. response outcomes, will be evaluated using a logistic 
regression model with treatment regimen, weight, stratum if applicable. Odds ratios will be 
computed for comparisons of AIN457 regimens versus control(s) utilizing the logistic 
regression model fitted.  
SAS code for logistic regression: 
Proc logistic data=acr descending; 
Class trt stratum; 
Model response=trt weight stratum; 
Run; 
To assess potential region effect for the primary variables or key secondary variables, a 
logistic regression model will be fitted with treatment, region, weight, stratum if applicable, 
treatment-by-region interaction as explanatory variables. If p < 0.100 for the treatment-by-
region interaction, then, further exploratory analysis will be done (tabular and/or graphical 
methods) to look for a possible explanation of the differences observed across regions. 
18.2.3 Multiple Imputation 
A multiple imputation will be performed based on MAR by treatment group for baseline 
weight, baseline and post-baseline of each parameter for visits up to the primary time point 
(Week 24) using Markov Chain Monte Carlo (MCMC) method with EM algorithm. 
Impute the missing values 100 times (NIMPUTE) with a seed=457<studycode> as shown 
below: 
proc mi data= min= max= out=imp minmaxiter=10000000 nimpute=100 seed=4572306; 
            by trt; 
            var weight_base var1_base var1_week1-var1_week24; 
            mcmc chain=multiple initial=em;   
run; 
If needed repeat for each component necessary to calculate the final score, e.g. as follows:  
proc mi data=imp min=<min of scale> max=<max of scale> out=imp2 minmaxiter=100000 
nimpute=1 seed=4572306; 
            by trt _imputation_; 
            var weight_base var2_base var2_week1-var2_week24; 
            mcmc chain=multiple initial=em;   
run; 
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The score can now be is calculated based on the complete data. MIANALYZE will then be 
performed with the contrast estimate and the corresponding standard error.  These are derived 
using GENMOD as shown below: 
proc genmod data = imp2; 
   by _imputation_; 
class trt strata; 
   model var = trt base_wgt strata / link=logit dist=bin; 
   lsmeans trt / diff; 
   estimate 'AIN457 75mg mg vs Placebo' trt 1 -1 0; 
   estimate 'AIN457 150mg mg vs Placebo' trt 1 0 -1; 
   ods output Estimates=imp_est lsmeans=imp_lsm diffs=imp_lsm_diff; 
run; 
The estimates and the standard errors of imputed parameter will then be combined by 
applying Rubin’s rules for multiple imputed data sets. 
proc mianalyze data=imp_est; 
 by label; 
modeleffects LBetaEstimate; 
   stderr StdErr; 
   ods output ParameterEstimates=mi_res; 
run; 
18.2.4 Crude incidence and related risk estimates  
18.2.4.1 Crude incidence and 100*(1-α)% confidence interval 
For n subjects, each at risk to experience a certain event with probability π, the crude 
incidence is estimated as p=x/n, where x is the number of subjects with the event. 
Absolute and relative frequencies will be displayed as well as 95% confidence interval for the 
relative frequency based on the score method including continuity correction (Newcombe 
1998).  
With z  as (1-α/2)-quantile of the standard normal distribution (SAS: z=PROBIT(1-alpha/2), 
n  as total number of subjects (i.e. number of subjects in the denominator), and p as estimated 
crude incidence (number of subjects with event / n ) it is pq −=1 . 
Then the lower limit is 
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and the upper limit is 
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Note: if p = 0 then L = 0  and if p = 1 then U = 1. 
If appropriate, an exact 100*(1-α)% confidence interval (Clopper-Pearson 1934) will be 
obtained by using the SAS procedure PROC FREQ with the EXACT BINOMIAL statement. 
However, the confidence interval derived via the score method including continuity correction 
will be the default in safety analyses. 
18.2.4.2 Odds ratio and 100*(1-α)% confidence interval 
For an investigational drug group with n1 subjects at risk, independent from the control group 
(e.g. placebo or comparator) with n0 subjects at risk,  of whom x1 and x0 experience a certain 
event with probability π1 and π0 respectively, the odds ratio is estimated as 
)1/(
)1/(
00
11
pp
pp
−
−
  with p1= x1/n1 and p0=x0/n0.  A conditional exact 100*(1-α)% confidence 
interval will be obtained by using the SAS procedure PROC FREQ with statement EXACT 
OR. 
18.2.4.3 Risk difference and 100*(1-α)% confidence interval 
For an investigational drug group with n1 subjects at risk, independent from the control group 
(e.g. placebo or comparator) with n0 subjects at risk, of whom x1 and x0 experience a certain 
event, the risk difference is estimated as p1-p0 with p1= x1/n1 and p0=x0/n0.  
Exact unconditional confidence limits for the risk difference will be obtained with SAS 
procedure PROC FREQ and option RISKDIFF in the TABLES statement, specifying the 
RISKDIFF option also in the EXACT statement.   
18.2.5 Exposure adjusted incidence rate and related risk estimates 
18.2.5.1 Exposure adjusted incidence rate and 100*(1-α)% confidence interval 
It will be assumed that for each of n subjects in a clinical trial the time tj (j=1,...,n) to the first 
occurrence of a certain event is observed, or if the event was not experienced, the (censored) 
time to the end of the observation period. The sequence of first occurrences of an event will 
be modeled to follow approximately a Poisson process with constant intensity θ. The rate 
parameter θ will be estimated as λ=D/T, where ∑
=
=
n
j
jtT
1
 and D is the number of subjects 
with at least one event. Conditionally on T, an exact 100*(1-α)% confidence interval for a 
Poisson variable with parameter θT and observed value D can be obtained based on (Garwood, 
1936), from which an exact 100*(1-α)% confidence interval for D/T will be derived as 
follows (Sahai, 1993; Ulm, 1990): 
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Lower confidence limit   
T
c
L D2,2/
5.0 α
=  for D>0, 0 otherwise, 
Upper confidence limit 
T
c
U D 22,2/1
5.0 +−
=
α  
where kc ,α  is the αth quantile of the Chi-square distribution with k degrees of freedom. 
The example below shows how this should be handled for cases where subjects switch 
treatment.  In particular for summarizing ‘Any AIN’ as a group, one should take into 
consideration the sequence of treatments while calculating exposure time for subjects.   
Table 18-3 Examples for calculating exposure time for incidence rates (IR) 
1st 
treatment 
1st  exposur
e 
2nd 
treatment 
2nd 
exposure 
Event days (in 
terms of study 
day) 
Exposure for IR 
Placebo 100 days 150 mg  200 days 50 (1st trt) 
110 (10 days 
into 2nd trt) 
Placebo:  50 days 
(event) 
150 mg:  10 days 
(event) 
Any AIN:  10 days 
(event) 
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1 Introduction 
Data will be analyzed by Novartis according to the data analysis section 9 of the clinical study 
protocol.  That statistical methodology is described below and any deviations from the 
protocol are documented. Additional detailed information regarding the analysis methodology 
is contained in the Appendix section. 
2 Study Objectives 
The primary objective is to demonstrate the efficacy of secukinumab 75 or 150 mg at Week 
24 is superior to placebo in patients with active PsA based on the proportion of patients 
achieving an ACR20 response in the entire study population. 
The secondary objectives of the study are to demonstrate: 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving a PASI75 response in the subgroup of subjects who have 
≥3% skin involvement. 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving a PASI90 response in the subgroup of subjects who have 
≥3% skin involvement. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the DAS28-CRP at Week 24 in the entire study population. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the SF36-PCS at Week 24 in the entire study population. 
• The improvement (change) from baseline on secukinumab 75 or 150 mg is superior to 
placebo for the HAQ-DI at Week 24 in the entire study population. 
• The efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo based on the 
proportion of subjects achieving an ACR50 response in the entire study population. 
• The improvement (change) from baseline to Week 24 on secukinumab pooled regimen (75 
mg and 150 mg s.c.) is superior to placebo for joint/bone structural damage (van der 
Heijde modified total Sharp score) in the entire study population. 
• The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 is 
superior to placebo based on the proportion of subjects with dactylitis in the subset of 
subjects who have dactylitis at baseline. 
• The efficacy of secukinumab pooled regimen (75 mg and 150 mg s.c.) at Week 24 is 
superior to placebo based on the proportion of subjects with enthesitis in the subset of 
subjects who have enthesitis at baseline. 
• The improvement (change) from baseline to Week 24 on secukinumab 75 or 150 mg is 
superior to placebo for joint/bone structural damage (van der Heijde modified total Sharp 
score) in the entire study population. 
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Furthermore, additional aspects of efficacy, safety and tolerability of secukinumab will be 
investigated. 
3 Data presentation 
Summary statistics for continuous variables will include N, mean, standard deviation, 
minimum, lower quartile, median, upper quartile, maximum. Summary statistics for discrete 
variables will be presented in contingency tables and will include absolute and relative 
frequencies. 
If not otherwise specified, p-values and confidence intervals will be two-sided. 
Unless otherwise stated, the level of significance will be set to 5% (two-sided, family-wise 
type-I-error). 
Data analyses will be presented by treatment regimen.  Efficacy and safety data for the 
placebo-controlled period will be presented by the following 3 treatment groups. Subjects 
may be included in more than one treatment group for some analyses (e.g. exposure-adjusted 
adverse events over the entire treatment period). These treatment groups represent the 
regimens subjects will be eligible to be randomized to for the first 24 weeks of the study. 
• Secukinumab regimen 1: secukinumab i.v. (10mg/kg) at BSL, Week 2 and Week 4 
then secukinumab 75 mg s.c. starting at Week 8 and injected every 4 weeks 
• Secukinumab regimen 2: secukinumab i.v. (10mg/kg) at BSL, Week 2 and Week 4 
then secukinumab 150 mg s.c. starting at Week 8 and injected every 4 weeks 
• Placebo regimen: Placebo i.v. at BSL, Week 2 and Week 4 then placebo s.c. starting at 
Week 8 and injected every 4 weeks  
Note that the treatment groups above for a subject may differ depending on the time period of 
the analysis and whether one assesses the subject for efficacy or safety (see Section 4.2 for 
details).  
Comparative efficacy data 
Comparative efficacy analyses (i.e. inferential efficacy comparisons with placebo or active 
comparator) will focus on the time period when both active drug and the placebo are given in 
a manner suitable for making comparisons (e.g. double-blind).  For AIN457F2306 this is the 
first 24-weeks of treatment.  Comparative efficacy will be performed based on the FAS 
population using the randomized treatment.   After week 24, the active secukinumab regimens 
will be compared using confidence intervals on the FAS population using treatment sequence. 
Efficacy data following rescue/re-randomization 
Data will also be presented after Week 24, by a combination of the ‘original’ and ‘switch’ 
treatment groups and will be referred to as treatment sequence. These treatment sequences 
represent the treatment combinations the subjects experience over the course of the entire trial 
in case of rescue or re-randomization. 
All listings will be presented by treatment sequence. 
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4 Subjects and treatments 
4.1 Analysis Sets 
The following analysis sets will be used for the data analysis.  
Randomized set: The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis-randomized subjects (mis-randomized in IWRS/IVRS/IXRS) 
will be excluded from the randomized set.   
Mis-randomized subjects are defined as those subjects who were mistakenly randomized into 
the IVR prior to the site confirming all eligibility criteria had been met and to whom no study 
medication was given.  Mis-randomized patients are treated as screen failures.   
Full analysis set (FAS): The FAS will be comprised of all subjects from the randomized set 
to whom study treatment has been assigned. Following the intent-to-treat principle, subjects 
will be analyzed according to the treatment assigned to at randomization, but actual stratum, if 
stratified randomization is used.  
Safety set: The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period. Subjects will be evaluated according to treatment received. 
4.2 Treatment groups 
The summaries by treatment will be performed by the randomized treatment or treatment 
sequence.  For some safety summaries (e.g. exposure-adjusted) the ‘switch’ treatment may be 
summarized separately 
• Randomized treatment: 
• AIN457 10 mg/kg - 75 mg  
• AIN457 10 mg/kg - 150 mg  
• Placebo     
• Treatment sequence: 
• AIN457 10 mg/kg - 75 mg  
• AIN457 10 mg/kg - 150 mg  
• Placebo (non-responder) - AIN457 75 mg 
• Placebo (non-responder) - AIN457 150 mg 
• Placebo (responder) - AIN457 75 mg 
• Placebo (responder) - AIN457 150 mg 
• Switch treatments (for placebo patients who cross-over): 
• AIN457 75 mg no load  
• AIN457 150 mg no load 
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5 Subgroup definitions 
The primary endpoint(s) and secondary endpoints will be evaluated for TNF-alpha inhibitor 
status.  
6 Assessment windows, baseline and post baseline 
definitions, missing data handling 
Baseline and post-baseline definitions 
In general (except for X-ray and MRI structure data), a baseline value refers to the last 
measurement made prior to administration of the first dose of study treatment. A post-baseline 
value refers to a measurement taken after the first dose of study treatment. For X-ray, a 
baseline value is the last measurement prior to dosing if available, or the first value within 30 
days post dosing if no value available prior to dosing. For MRI, a baseline value is the last 
measurement prior to dosing if available, or a value within 7 days post dosing if no value 
available prior to dosing. 
Analysis visit windows 
Analysis visit windows will be used for the data that is summarized by visit; they are based on 
the study evaluation schedule and comprise a set of days around the nominal visit day. For 
any assessment, there are protocol defined scheduled visits around which analysis visit 
windows were created to cover the complete range of days within the study.  The analysis 
visit windows and rules for dealing with multiple measurements within the windows are 
described in the Appendix. 
 
7 Subject disposition, background and demographic 
characteristics 
7.1 Subject disposition 
The number of subjects screened will be presented. In addition, the reasons for screen failures 
will be provided. The number and percentage of subjects in the randomized set who 
completed the study periods and who discontinued the study prematurely (including the 
reason for discontinuation) will be presented at the end of each treatment period (Week 52 
and Week 104), if appropriate, for each treatment group and all subjects. 
The number and percentage of patients who meet the rescue criteria at week 16 will be 
presented. 
For each protocol deviation (PD), the number and percentage of subjects for whom the PD 
applies will be tabulated. 
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7.2 Background and demographic characteristics 
The following common background and demographic variables, if collected, will be analyzed 
in all studies: 
Continuous variables: 
• Age (which is derived from date of birth and the screening assessment date) 
• Height 
• Weight 
• Body mass index (BMI) = (body weight in kilograms) / (height in meters)2 
Categorical variables: 
• Age categories (<65 years, 65 years and older, 75 years and older) 
• Gender 
• Race 
• Ethnicity 
The following disease specific baseline characteristics and history of disease will be 
summarized as well: 
• CASPAR, TNFα history (naive or inadequate responder), ACR components, number of 
prior biologic PsA therapies, MTX use (yes or no) and dose at baseline, time since first 
diagnosis of PsA, and psoriasis involvement (proportion of patients with psoriasis of 
hands and feet, psoriasis of the nail, and target lesion diameter). 
Unless otherwise specified, summary statistics will be presented for continuous variables for 
each treatment group and for all subjects (total) in the randomized set. The number and 
percentage of subjects in each category will be presented for categorical variables for each 
treatment group and all subjects (total) in the randomized set.  
 
8 Medical history 
Any condition entered on the Relevant medical history / current medical conditions CRF will 
be coded using the MedDRA dictionary. They will be summarized by system organ class 
(SOC) and preferred term (PT) of the MedDRA dictionary. Summaries for cardiovascular 
medical history and psoriasis history will be provided as well. 
Smoking history will be summarized by treatment group. 
Chest x-ray (screening) results will be listed. 
Unless otherwise specified, analyses will be based on the randomized set. 
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9 Study medication 
The analysis of study treatment data will be based on the safety set. The number of active and 
placebo infusions and injections will be summarized by treatment group. The duration of 
exposure to study treatment will also be summarized by treatment group. In addition, the 
number and percentage of subjects with cumulative exposure levels (e.g. any exposure, ≥ 1 
week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
Duration of exposure will be defined as the time from first dose of study treatment to the time 
of treatment switch (for subjects who switch treatment) or end of treatment period (whichever 
is first). For subjects who discontinue, this will be the subject’s last visit in the corresponding 
treatment period.  
Duration of exposure (years) = duration of exposure (days) / 365.25 
Duration of exposure (100 subject years) = duration of exposure (years) / 100 
The analyses of duration of exposure described above will be done for the entire study 
treatment period. 
10 Concomitant medication 
Prior and concomitant medications will be summarized in separate tables by treatment group. 
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of randomized 
study treatment and the date of the last study visit will be a concomitant medication, including 
those which were started pre-baseline and continued into the period where study treatment is 
administered. 
Medications will be presented in alphabetical order, by Anatomical Therapeutic Classification 
(ATC) codes and grouped by anatomical main group. Tables will show the overall number 
and percentage of subjects receiving at least one treatment of a particular ATC code and at 
least one treatment in a particular anatomical main group. 
Significant prior and concomitant surgeries and procedures will be summarized by primary 
system organ class and MedDRA preferred term. 
The number and percentage of subjects receiving prior and concomitant psoriatic arthritis 
therapy will be presented by randomized treatment group as well as the reasons for stopping 
their therapies (primary lack of efficacy, secondary lack of efficacy, lack of tolerability, other) 
and the total duration of exposure to psoriatic arthritis therapies previously. 
Prior or concomitant medication will be identified by comparing recorded or imputed start 
and end dates of medication taken to the reference start date. Further rules will be given in 
RAP Module 8. 
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11 Efficacy evaluation 
11.1 Description of efficacy variables 
ACR 20/50/70 
ACR20 is a binary response variable defined for each subject. A subject will be considered a 
responder according to ACR20 criteria if he/she has at least (i.e., ≥): 
• 20% improvement from baseline in tender 78-joint count 
• 20% improvement from baseline in swollen 76-joint count 
• 20% improvement from baseline in at least 3 of the following 5 measures: 
• Patient’s assessment of PsA pain (VAS 100 mm) 
• Patient’s global assessment of PsA disease activity (VAS 100 mm) 
• Physician’s global assessment of PsA disease activity (VAS 100 mm) 
• Patient self-assessed disability (Health Assessment Questionnaire [HAQ©] 
score) 
• Acute phase reactant (C-reactive protein [hsCRP]) or Erythrocyte 
sedimentation rate (ESR). 
In the definition above, the baseline value refers to the last measurement made prior to 
administration of the first dose of study treatment.  
The primary endpoint is the proportion of subjects achieving ACR20 at Week 24. Primarily, 
CRP will be used to calculate ACR response: ESR will only be used in the event CRP is 
missing. 
ACR50 and ACR70 are defined in the same way as ACR20 by replacing the 20% with 50% 
and 70% improvement from baseline, respectively.  
ACRn represents the percent improvement on the continuous scale and from ACRn one can 
directly calculate ACR20, ACR50, and ACR70 using the appropriate cutoffs. This variable is 
defined as: 
 ACRn = min (x1, x2, x3), where  
x1 = % improvement from baseline in tender 68-joint count 
x2 = % improvement from baseline in swollen 66-joint count 
and x3 = 3rd largest value of x4, x5, x6, x7, x8 where,  
x4 = % improvement from baseline in Patient’s assessment of PsA pain (VAS 100 mm) 
x5 = % improvement from baseline in Patient’s global assessment of PsA disease 
activity (VAS 100 mm) 
x6 = % improvement from baseline in Physician’s global assessment of PsA disease 
activity (VAS 100 mm) 
x7 = % improvement from baseline in Patient self-assessed disability (Health 
Assessment Questionnaire [HAQ©] score) 
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x8 = % improvement from baseline in Acute phase reactant (C-reactive protein 
[hsCRP]) or Erythrocyte sedimentation rate (ESR) 
ACRn can be computed even if up to two values of x4, x5, x6, x7, x8 are missing. ACRn, 
theoretically, can not be computed, if one or both of x1, x2 is/are missing OR more than three 
values of x4, x5, x6, x7, x8 are missing.  
Health Assessment Questionnaire - Disability Index (HAQ-DI) 
The Health Assessment Questionnaire (HAQ©) was developed by Stanford University and is 
one of the most widely used measures to assess the long-term influence of chronic disease on 
a subject's level of functional ability and activity restriction. The disability assessment 
component of the HAQ (Health Assessment Questionnaire – Disability Index), the HAQ-DI, 
assesses a subject's level of functional ability and includes questions of fine movements of the 
upper extremity, locomotor activities of the lower extremity, and activities that involve both 
upper and lower extremities. There are 20 questions in eight categories of functioning 
including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem 
of each item asks over the past week "Are you able to …" perform a particular task. Each item 
is scored on a 4-point scale from 0 to 3, representing normal (normal, no difficulty [0]), some 
difficulty [1], much difficulty [2], and unable to do [3].  
Scoring for the eight functional categories and overall disability index scoring will be 
performed as follows:  
There are eight categories; first score within each category:  
• Dressing and Grooming, includes items 1 and 2  
• Arising, includes items 3 and 4  
• Eating, includes items 5, 6 and 7  
• Walking, includes items 8 and 9  
• Hygiene, includes items 10, 11, and 12  
• Reach, includes items 13 and 14  
• Grip, includes items 15, 16 and 17  
• Activities, includes items 18, 19, and 20 
The score for each category will be the single response within the category with the highest 
score (greatest difficulty). For example, in the "Eating" category, there are two answers (one 
for each item). If "Cut your food with a knife or fork" is marked as "3" and "Lift a full cup or 
glass to your mouth" is marked as "0", then the score for the "Eating" category would be "3" 
(the response indicating the greatest difficulty within the category). If a component question is 
left blank or the response is too ambiguous to assign a score, then the score that that category 
will be determined by the remaining completed question(s). However, if any "aids or devices" 
and/or "help from another person" items at the bottom of each page are checked, the category 
to which they apply will be adjusted upward to "2". If the basic score is already "2" or "3", 
the score remains unchanged. "Aids or devices" and "help from another person" can only 
change a category's score to "2"; they do not change the score to a "1" or a "3". 
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The score for the disability index will be the mean of the eight category scores. If more than 
two of the categories, or 25%, are missing, scale will not be scored. Otherwise, divide the sum 
of the categories by the number of answered categories. The higher score indicates greater 
disability. 
HAQ-DI response is defined by an improvement of at least 0.3 score points compared to 
baseline. 
Joint/bone structural damage 
The primary score for analyses will be total van der Heijde modified Sharpe (vdH-S) score 
(van der Heijde 1999), but the erosion score and joint space narrowing score will be analyzed 
in similar fashion. 
Erosions will be assessed each hand (20 locations per hand) and each foot (6 locations per 
foot). The maximum erosion score is 200 for all 40 hand locations, and 120 for all 12 feet 
locations. Thus, the total possible erosion score is 320.  
Joint space narrowing (JSN) will be assessed in each hand (20 locations per hand) and foot (6 
locations per foot). The maximum score is 160 for all 40 hand joints, and 48 for all 12 feet 
joints. Thus, the total possible JSN score is 208.  
Pencil-in-cup: Osteolysis of the proximal phalanx and the base of the distal phalanx resulting 
in a pencil like proximal phalanx covered by cup like base of the distal phalanx. Pencil-in-cup 
will be scored as “P” where applicable.  
Gross Osteolysis: Osteolysis of the phalanx resulting in a loss of the normal joint structure, 
usually accompanied by shortening of the length of the phalanx. Gross osteolysis will be 
scored as “G” where applicable.  
If a joint or bone is not visible (e.g. poor film quality, missing imaging, severe misalignment, 
flexion deformity, dislocation) at the timepoint, the individual joint or bone will be coded as 
Not Visible (N).  
If radiographs at the timepoint show a joint or bone with surgical fusion, replacement 
(prosthesis), or amputation, then the joint or bone will be scored Surgically Modified (S).  
To obtain the total vdH-S score, scores for erosions and JSN in both the hands and feet will be 
added together. Any “P” or “G” will be considered the maximal score for the feature (erosions 
and JSN) per location in the calculation of the total vdH-S score. Any “N” or “S” will be 
considered null in the calculation of the total vdH-S score. The range of scores is 0 ~ 528.  
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The joints are divided into 10 segments according to Table 11-1. In each segment an adequacy 
threshold is defined. For each segment, when the change from baseline values are available 
for at least the threshold number of joints, the change from baseline will be calculated for the 
segment, with missing joints imputed by the within-segment mean change over individual 
joints. Otherwise (i.e. if less than threshold number of joints have available change from 
baseline values), the segment change from baseline will be missing. When ≥ 5 segments have 
evaluable change from baseline values, the overall change from baseline value will be 
calculated, with missing segments imputed by the mean change over segments. Otherwise (i.e. 
if ≤ 4 segments have evaluable change from baseline values), the overall change from baseline 
value will be missing. 
Table 11-1 Segmental distribution 
 
Segment 
Total number 
of joints 
Adequacy 
threshold Joints at one side 
PIP erosions 8  5 PIP2, PIP3, PIP4, PIP5 
DIP  erosions 8 5 DIP2, DIP3, DIP4, DIP5 
MCP + 
thumb  erosions 12 7 
MCP1, MCP2, MCP3, MCP4, MCP5, 
INTERPHALANGEAL JOINT OF THE HAND 
Wrist erosions 12 7 
FIRST METACARPAL BONE, DISTAL RADIUS, 
DISTAL ULNA, TRAPEZOID-TRAPEZIUM, 
NAVICULAR BONE, LUNATE BONE 
Foot erosions 12 7 MTP1, MTP2, MTP3, MTP4, MTP5, INTERPHALANGEAL JOINT 1 
PIP JSN 8  5 PIP2, PIP3, PIP4, PIP5 
DIP JSN 8 5 DIP2, DIP3, DIP4, DIP5 
MCP + 
thumb  JSN 12 7 
MCP1, MCP2, MCP3, MCP4, MCP5, 
INTERPHALANGEAL JOINT OF THE HAND  
Wrist JSN 12 7 CMC3, CMC4, CMC5, RADIOCARPAL, SCAPHOID-TRAPEZIUM, CAPITATE-NAVICULAR-LUNATE 
Foot JSN 12 7 MTP1, MTP2, MTP3, MTP4, MTP5, INTERPHALANGEAL JOINT 1 
The readings of the x-rays and the scoring will be performed centrally. Two central 
independent radiograph readers, both blinded to treatment arm and radiograph sequence, will 
analyze the digitized images. In the case that adjudication is needed, a third consensus read 
will be performed. The statistical analysis will use the adjudicated score, if available, or the 
average score from the two readers otherwise. 
Major clinical response 
Major clinical response is defined as continuous six-months of ACR70 response for a subject. 
DAS28, low disease activity and remission  
The Disease Activity Score (DAS) is a combined index to measure the disease activity in 
patients with RA. It has been extensively validated for its use in clinical trials in combination 
with the EULAR response criteria. 
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The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, CRP 
or ESR, and the Patient Global Assessment. A DAS28 score > 5.1 implies active disease, ≤ 
3.2 low disease activity, and < 2.6 remission. 
The following 28 joints will be assessed for tenderness and swelling: metacarpophalangeal 
IV(10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow(2), 
shoulders (2), and knees (2). 
The following formulas can be used to calculate the DAS28 with CRP (mg/L) or ESR 
(mm/hour).  
DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 
DAS28-ESR = 0.56*sqrt(tender28) + 0.28*sqrt(swollen28) + 0.70*ln(ESR) + 0.014*PGA 
TJC28: 28 Tender joint count; SJC28: 28 Swollen joint count; CRP: C-reactive protein; PGA: 
Patient Global Assessment 
If any component measurement is missing, DAS28 will be missing. 
DAS28-CRP will be primary for analysis; DAS-ESR will be secondary. 
DAS28-CRP (or ESR) remission is defined as a DAS28-CRP (or ESR) index score less than 
2.6. Low disease activity is defined as DAS28-CRP (or ESR) index less than or equal to 3.2.  
EULAR response 
Using the DAS, several thresholds have been developed for high disease activity, low disease 
activity or remission. Also response criteria have been developed based on the DAS, so when 
the DAS of a patient is measured at two time-points (e.g. before the start of a treatment and 
after 3 months), the patients clinical response can be assessed. 
Comparing the DAS28-CRP (or ESR) from one patient on two different time-points, it is 
possible to define improvement or response. The EULAR response criteria are defined as 
follows: 
Table 11-2 EULAR response criteria 
Present DAS28 
DAS28 improvement 
 
>1.2 0.6 - 1.2 <0.6 
< 3.2 good response moderate response no response 
3.2 - 5.1 moderate response moderate response no response 
>5.1 moderate response no response no response 
Both the thresholds for high and low disease activity and remission and the above mentioned 
improvement criteria should give a feel how to interpret your DAS28 scores. 
Minimal disease activity  
A subject will be considered a responder of minimal disease activity (MDA, see Coates 2010) 
if he/she achieves at least 5 of the following 7 items: 
• ≤ 1 tender joint count 
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• ≤ 1 swollen joint count  
• PASI  ≤ 1 or IGA ≤ 1 
• patient pain VAS ≤ 15  
• patient global VAS ≤ 20  
• HAQ-DI ≤ 0.5 
• tender entheseal points ≤ 1 
ACR Components 
Tender 78 joint count and swollen 76 joint count  
The 78 joints assessed for tenderness include the 2 temporomandibular, 2 sternoclavicular, 2 
acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 2 first carpometacarpal, 10 
metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 
the 2 hip, 2 knee, 2 talo-tibial, 2 mid-tarsal, 10 metatarsophalangeal, 10 proximal 
interphalangeal, and 8 distal interphalangeal joints of the feet. All of these except for the hips 
are assessed for swelling. Joint tenderness and swelling are to be graded present (1) or absent 
(0). Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive 
result for swollen joint count. Dactylitis of a digit in the foot or hand counts as one tender and 
swollen joint. 
If the number of joints for which data were available (e.g., T) is less than 78/76 for the 
tender/swollen joint assessment, the number of tender/swollen joints (e.g., t) will be scaled up 
proportionately (i.e., 78*t/T or 76*t/T for tender or swollen joint count).   
Patient’s assessment of PsA Pain 
The patient’s assessment of pain will be performed using 100 mm visual analog scale (VAS) 
ranging from “no pain” to “unbearable pain” after the question “Please indicate with a 
vertical mark ( | ) through the horizontal line the most pain you had from your psoriatic 
arthritis today”. 
Patient’s global assessment of PsA disease activity 
The patient’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from ”very good” to ”very poor”, after the question "Considering all the ways 
psoriatic arthritis affects you, please indicate with a vertical mark ( | ) through the horizontal 
line how well you are doing today”.  
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Physician’s global assessment of PsA disease activity 
The physician’s global assessment of disease activity will be performed using 100 mm VAS 
ranging from no disease activity to maximal disease activity, after the question "Considering 
all the ways the disease affects your patient, draw a line on the scale for how well his or her 
condition is today”. To enhance objectivity, the physician must not be aware of the specific 
patient’s global assessment of disease activity, when performing his own assessment on that 
patient. 
Erythrocyte sedimentation rate (ESR) 
Blood for ESR, which is helpful in diagnosing inflammatory diseases and is used to monitor 
disease activity and response to therapy, will be obtained at scheduled visits. 
High-sensitivity C-reactive protein (hsCRP) 
Blood for this assessment will be obtained in order to identify the presence of inflammation, 
to determine its severity, and to monitor response to treatment. Since the results of this test 
may unblind study personnel, results from the central lab will be provided for screening and 
baseline only. The hsCRP results from samples collected during the treatment period will be 
revealed following database lock only. 
Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) will be performed in a subgroup of subjects with at least 
one swollen wrist at baseline at selected sites.  The independent reviewers shall perform MRI 
assessments according to the modified PsAMRIS scoring method (Ostergaard, Mikkel et al 
2009). Assessments will be performed on the hand with the more swollen wrist determined at 
baseline by the investigator. If both wrists are equally affected, the dominant hand/wrist will 
be chosen. The MRIs will be scored for the following assessments: 
• Synovitis 
• Tenosynovitis 
• Periarticular inflammation 
• Bone edema/osteitis 
• Bone erosion 
• Bone proliferation 
• Joint space narrowing 
Synovitis is defined as an area in the synovial compartment that shows greater than normal 
postgadolinium enhancement of a thickness greater than the estimated width of the normal 
synovium. A total of 17 locations in the hand and wrist will be evaluated for synovitis. 
Synovitis will be assessed on a scale of 0-3 for each location. The maximum possible score 
for synovitis is 51. 
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Tenosynovitis is defined as an area with signal characteristics that show greater than normal 
water content or greater than normal post-gadolinium enhancement adjacent to a tendon, in an 
area with tendon sheath. A total of 14 hand locations and 10 wrist regions will be evaluated 
for tenosynovitis. Synovitis will be assessed on a scale of 0-3 for each location. The 
maximum possible score for tenosynovitis in the hand and wrist is 72. 
Periarticular inflammation is defined as an area with signal characteristics that show greater 
than normal water content or greater than normal post-gadolinium enhancement at 
extraarticular sites including the periosteum and the entheses (not including tendon sheaths as 
this is defined as tenosynovitis). A total of 28 locations in the hand will be evaluated for 
periarticular inflammation. Periarticular inflammation will be assessed on a scale of 0-2 for 
each location. The maximum possible score for periarticular inflammation in the hand is 56. 
MRI edema/osteitis is defined as a lesion, that may occur alone or surrounding an erosion or 
other bone abnormalities, within the trabecular bone, often with ill-defined margins and signal 
characteristics consistent with increased water. A total of 43 locations will be evaluated for 
bone edema/osteitis.Bone edema/osteitis is scored on a scale of 0-3 based on the proportion of 
estimated originally noneroded bone involved. The maximum possible score for bone 
edema/osteitis is 129. 
MRI bone erosion is defined as a sharply marginated bone lesion, with correct juxta-articular 
localization and typical signal characteristics, with a cortical break seen in at least one plane. 
A total of 43 locations will be evaluated for bone erosions. Each bone is scored on a scale of 
0-10. The maximum possible score for bone erosions is 430. 
Bone proliferation is defined as an abnormal bone formation in the periarticular region such as 
at the entheses and across the joint. A total of 14 joints will be evaluated for bone proliferation. 
Bone proliferation will be assessed on a scale of 0-2 for each location. The maximum possible 
score for Bone proliferation is 28. 
Joint space narrowing (JSN) is defined as the reduction in joint space. JSN is scored on a scale 
of 0-4 based on the amount of narrowing present in a given joint. The maximum possible 
score for JSN in all 29 hand joints is 116. 
If a joint or bone is not visible (e.g. poor image quality, missing imaging, severe misalignment, 
flexion deformity, dislocation, ankylosis of >50% of articular surface [for erosion score only]) 
at the timepoint, the individual joint or bone will be coded as Not Visible (N). If MRIs at the 
timepoint show a joint or bone with surgical fusion, replacement (prosthesis), or amputation, 
then the joint or bone will be scored Surgically Modified (S).To obtain the total score per 
feature, any “N” or “S” will be considered null in the calculation. 
The score per feature will be calculated as the sum of scores from all available locations per 
feature. 
PsARC response 
A subject is defined as a PsARC responder if, and only if, they have an improvement in two 
of the following four factors (with at least one factor being a joint count) and no worsening in 
the remaining factors 
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• Patient global assessment (0-100 mm VAS scale, improvement defined as decrease of at 
least 20 mm) 
• Physician global assessment (0-100 mm VAS scale, improvement defined as decrease of 
at least 20 mm) 
• Tender 78-joint count (improvement defined as decrease of at least 30%) 
• Swollen 76-joint count (improvement defined as decrease of at least 30%) 
PsARC response won’t be calculated if any of the four components are missing. 
Leeds Enthesitis Index (LEI) 
LEI is a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral 
epicondyle humerus L + R, proximal achilles L + R and medial condyle femur L + R. 
Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 
sites, for an overall score range of 0–6. Higher count represents greater enthesitis burden.  
In this study, the lateral condyle femur L + R data were collected instead of required medial 
condyle femur L + R. Therefore, a 4-site LEI (LEI-4) will be calculated with the four correct 
sites: lateral epicondyle humerus L + R, proximal achilles L + R. If measures are missing for 
any of these four sites, the LEI-4 won’t be calculated. 
Presence of enthesitis 
If enthesitis is present with any of the 4 sites (lateral epicondyle humerus L + R, proximal 
achilles L + R), the patient is counted as a patient with enthesitis. 
Leeds Dactylitis Index (LDI) 
The LDI measures the ratio of the circumference of the affected digit to the circumference of 
the digit on the opposite hand or foot: a minimum difference of 10% is used to define a 
dactylitic digit. If both sides are considered involved, a table of normative values is used to 
provide the comparison. The ratio of circumference is multiplied by a tenderness score, 
originally based on the Ritchie index (graded 0–3), but a later modification amended this to a 
binary score (0 for nontender, 1 for tender) — this later modification is referred to as the LDI 
basic, and is adopted in this study. For each dactylitic digit, the final score is: 
[{(A/B) - 1} * 100 ] * C, 
where A is circumference of involved digit, B circumference of opposite (unaffected or from 
reference) and C is tenderness (0 or 1 in this case). The results from each digit with dactylitis 
are then summed to produce a final score. Only involved digits are assessed. 
Dactylitis count 
The dactylitis count is the number of fingers and toes with dactylitis, with a range of 0-20.  
Presence of dactylitis 
If dactylitis is present with any finger or toe, the patient is counted as a patient with dactylitis. 
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Psoriasis Area and Severity Index (PASI) 
The PASI assessment will be conducted for subjects in whom at least 3% of the body surface 
area (BSA) was affected by psoriatic skin involvement at baseline (Visit 2). The PASI 
assesses the extent of psoriasis on four body surface areas (head, trunk and upper and lower 
limbs) and the degree of plaque erythema, scaling and thickness. A PASI score will be 
derived as indicated in Table 11-3. The head, trunk, upper limbs and lower limbs are assessed 
separately for erythema, thickening (plaque elevation, induration), and scaling (desquamation). 
The average degree of severity of each sign in each of the four body regions is assigned a 
score of 0-4. The area covered by lesions on each body region is estimated as a percentage of 
the total area of that particular body region. Further practical details help the assessment: 
1. The neck is assessed as part of the head. 
2. The axillae and groin are assessed as part of the trunk. 
3. The buttocks are assessed as part of the lower limbs. 
4. When scoring the severity of erythema, scales should not be removed. 
Table 11-3 The PASI scoring system 
Body  
region 
Erythema (E) 
 
Thickening 
(plaque elevation,
induration, I) 
Scaling 
(desquamation) 
(D) 
Area score 
(based on true 
area %, A)* 
Head  (H)** 0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Trunk,   
(T)*** 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Upper  
limbs (U) 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0=none  
1=slight  
2=moderate  
3=severe 
4=very severe 
0 = 0% 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
 
Lower  0=none  0=none  0=none  0 = 0% 
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Body  
region 
Erythema (E) 
 
Thickening 
(plaque elevation,
induration, I) 
Scaling 
(desquamation) 
(D) 
Area score 
(based on true 
area %, A)* 
limbs  
(L)**** 
1=slight  
2=moderate  
3=severe 
4=very severe 
1=slight  
2=moderate  
3=severe 
4=very severe 
1=slight  
2=moderate  
3=severe 
4=very severe 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-100% 
Percentage (not score) of body region (not whole body) affected will be entered in the eCRF 
**Neck is assessed as part of the Head (H) body region. 
***Axillae and groin are assessed as part of the Trunk (T) body region. 
****Buttocks are assessed as part of the Lower limbs (L) body region. 
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the PASI score is calculated 
using the formula: 
PASI = 0.1(EH+IH+DH)AH + 0.2(EU+IU+DU)AU + 0.3(ET+IT+DT)AT + 0.4(EL+IL+DL)AL 
The keys for the letters are provided in Table 11-3. 
PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a 
theoretic maximum of 72.0. The total score comes from eCRF. 
IGA mod 2011 
IGA mod 2011 will be conducted for overall psoriatic disease for subjects in whom at least 
3% of the body surface area (BSA) was affected by psoriatic skin involvement at baseline. It 
is recommended that the same evaluator conducts the assessment throughout the study 
wherever possible. 
The IGA mod 2011 rating scale for overall psoriatic disease is displayed in Table 11-4. 
Table 11-4 The IGA mod 2011 rating scale 
Score Short Description Detailed Description 
0 Clear No signs of psoriasis. Post-inflammatory hyperpigmentation may be present. 
1 Almost clear Normal to pink coloration of lesions; no thickening; no to minimal focal scaling. 
2 Mild Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling. 
3 Moderate Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling. 
4 Severe 
Bright to deep dark red coloration; severe thickening with 
hard edges; severe / coarse scaling covering almost all or 
all lesions. 
Note:  Involvement of nails is not part of the assessment. 
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The IGA mod 2011 scale has been developed based on a previous version of the scale used in 
secukinumab phase II psoriasis studies in collaboration with health authorities in particular the 
FDA. The explanations/descriptions of the points on the scale have been improved to ensure 
appropriate differentiation between the points. 
The IGA mod 2011 used in this study is static, i.e. it refers exclusively to the subject’s disease 
state at the time of the assessments, and does not attempt a comparison with any of the 
subject’s previous disease states, whether at baseline or at a previous visit. 
Based on this scale, subjects will be considered as IGA mod 2011 0 or 1 responder if they 
achieve a score of 0 or 1 and improve by at least 2 points on the IGA scale compared to 
baseline. 
Target lesion score (TLS) 
The Target Lesion Score will be done for subjects enrolled in the study having a psoriatic 
target lesion that is at least 2 cm in diameter identified at baseline. At specified visits this 
target lesion will be scored for erythema, scaling, and thickness, each on a scale of 0 to 4 (0 = 
none, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). The parameter scores will be 
summed automatically in the eCRF, giving a score ranging from 0 to 12. 
Modified Nail Psoriasis Severity Index (mNAPSI) 
The mNAPSI is an instrument to assess psoriatic nail involvement in subjects with PsA and 
nail psoriasis. It will be collected only in subjects with psoriatic nail involvement. The 
modifications on the original NAPSI to create the mNAPSI were made by rheumatologists, 
with dermatologists’ input, as a tool for clinical trials. The creators’ goal was to develop a tool 
to assess disease severity and response to treatment in clinical trials, keeping in mind that the 
assessor in a clinical trial most likely would not be a trained dermatologist. The mNAPSI 
scores range from 0-130 for all finger nails. The total mNAPSI score will be calculated as the 
sum of all the scores from available nails.  
11.2 Description of Health-related Quality of Life Endpoints 
SF-36 
The Short Form Health Survey (SF-36) is a widely used and extensively studied instrument to 
measure health-related quality of life among healthy subjects and patients with acute and 
chronic conditions. It consists of eight subscales that can be scored individually: Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- 
Emotional, and Mental Health. Two overall summary scores, the Physical Component 
Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The SF-
36 has proven useful in monitoring general and specific populations, comparing the relative 
burden of different disease, differentiating the health benefits produced by different treatments, 
and in screening individual patients. The eight domains are based on a scale from 0-100 while 
PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. 
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FACIT - Fatigue  
The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue©) is a 13- 
item questionnaire that assesses self-reported fatigue and its impact upon daily activities and 
function. 
Subjects respond to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = 
somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 
2 weeks. The scale score is computed by summing the item scores, after reversing those items 
that are worded in the negative direction. Numbering the questions from 1 to 13, it is evident 
that questions 7 and 8 are worded in the positive direction (4 indicates a desirable response) 
and all other questions are worded in the negative directions (4 indicates an undesirable 
response). Thus, it is necessary to reverse the responses for questions 7 and 8 (i.e. original 
response of 0 gets mapped to 4, 1=3, 2=2, 3=1, and 4=0) for scoring purposes. 
When there are missing item scores, the subscale score was computed by summing the non-
missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by 
the number of non-missing items (i.e. normalizing the results). The latter rule applied only 
when at least half of the items (seven or more) are non-missing.  
FACT Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue 
(Cella D et al., 2004). 
EuroQol 5D (EQ-5D) 
The EQ-5D is a widely used, self-administered questionnaire designed to assess health status 
in adults. The measure is divided into two distinct sections. The first section includes one item 
addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and 
anxiety/depression). Subjects rate each of these items from "no problem," "some problem," or 
"extreme problem." A composite health index is then defined by combining the levels for each 
dimension. The second section of the questionnaire measures self-rated (global) health status 
utilizing a vertically oriented visual analogue scale where 100 represents the "best possible 
health state" and 0 represents the "worst possible health state." Respondents are asked to rate 
their current health by placing a mark along this continuum. The recall period is "today," and 
the questionnaire requires approximately 5 to 10 minutes to complete. 
The EQ-5D contains six items designed to assess health status in terms of a single index value 
or health utility score. One of the strengths of the EQ-5D approach is that it allows 
"weighting" by the patient of particular health states and the generation of patient utilities. 
Published weights are available that allow for the creation of a single summary health utility 
score. Overall scores range from 0 to 1, with lower scores representing a higher level of 
dysfunction.  
PsAQoL 
The PsA quality of life (PsAQoL) questionnaire contains 20 individual yes/no questions 
where the total score is determined by the number of questions that received a “yes” response. 
A higher score reflects a poorer quality of life.  
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The PsAQoL score will not be calculated if more than 4 questions are missing. Otherwise, 
divide the number of ‘yes’ by the number of answered questions, multiply by 20.  
Dermatology Life Quality Index (DLQI) 
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability 
index designed to assess health-related quality of life in adult subjects with skin diseases such 
as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes 
domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, 
and work/school. The measure is widely used: it has been tested across 32 different skin 
conditions and is available in multiple languages. The recall period is the past week, and the 
instrument requires 1 to 2 minutes for completion. 
Each item has four response categories ranging from 0 (not at all) to 3 (very much). “Not 
relevant” is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 
questions. Scores range from 0 to 30, and higher scores indicate greater health-related quality 
of life impairment. If two or more questions are left unanswered, the total score will not be 
calculated. 
Work Productivity and Activity Impairment - General Health (WPAI-GH) 
The Work Productivity and Activity Impairment (WPAI-GH) questionnaire is an instrument 
to measure impairments in both paid work and unpaid work. It measures absenteeism, 
presenteeism as well as the impairments in unpaid activity because of health problem during 
the past seven days. The WPAI-GH consists of six questions: 
1 = currently employed 
2 = hours missed due to health problems 
3 = hours missed other reasons 
4 = hours actually worked 
5 = degree health affected productivity while working (VAS) 
6 = degree health affected productivity in regular unpaid activities (VAS) 
The recall period for the questions 2 to 6 is seven days.  
Four main outcomes can be generated from the WPAI-GH and expressed in percentages by 
multiplying the following scores by 100:  
1) percent work time missed due to health = Q2/(Q2 + Q4) for those who were currently 
employed;  
2) percent impairment while working due to health = Q5/10 for those who were currently 
employed and actually worked in the past seven days;  
3) percent overall work impairment due to health Q2/(Q2 + Q4) + ((1 - Q2/(Q2 + Q4)) × 
(Q5/10)) for those who were currently employed; 
4) percent activity impairment due to health Q6/10 for all respondents.  
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For those who missed work and did not actually work in the past seven days, the percent 
overall work impairment due to health will be equal to the percent work time missed due to 
health. 
11.3 Handling of missing data 
Missing data 
Missing data for ACR20 response and other binary efficacy variables for data up to 1-year 
(Week 52) will be handled as follows: 
• Subjects who drop out of the trial for any reason will be considered non-responders from 
the time they drop out through Week 52. 
• Subjects who do not have the required data to compute ACR20 response at baseline and at 
the specific time point will be classified as non-responders. 
Patients who were unblinded prior to the scheduled timepoint will be considered non-
responders from the time of unblinding up to the end of the placebo-controlled period (Week 
24). The primary analysis will use the non-responder imputation.  
Continuous variables (e.g. ACR20 components) will be analyzed using a mixed-effects 
repeated measures model (MMRM) which is valid under the missing at random (MAR) 
assumption.  As such, single-point imputation of missing data will not be performed (e.g. 
LOCF).  For analyses of these parameters, if all post-baseline values are missing then these 
missing values will not be imputed and this subject will be removed from the analysis of the 
corresponding variable, i.e. it might be that the number of subjects providing data to an 
analysis is smaller than the number of subjects in the FAS. 
Data post-rescue 
In general, the handling of data for subjects who are rescued at Week 16 will be handled in 
the following fashion (up to Week 24):  
• For binary endpoints, subjects will be considered non-responders.   This will be done for 
all treatment regimens in order to minimize bias.  
• For continuous endpoints, the goal of the analyses would be to estimate what would have 
happened if the patients had stayed on the original treatment.  Thus, the data collected 
after the patient switches to secukinumab will be treated as missing for placebo patients 
and will be analyzed using a mixed-effects repeated measures model (MMRM) which is 
valid under the missing at random (MAR) assumption.  For secukinumab patients, the 
actual values will be used in the analysis. 
Data collected after Week 52 will generally be presented as ‘observed case’; i.e. all available 
data for each time point will be included in the analyses. 
11.4 Analysis of Primary variable 
The primary efficacy variable will be ACR20 response at Week 24. The analysis of the 
primary efficacy variable will be based on the FAS. Primarily, CRP will be used instead of 
ESR to calculate ACR response; ESR will only be used in the event CRP is missing.   
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Statistical analysis 
The statistical hypothesis for ACR20 being tested is that there is no difference in the 
proportion of subjects fulfilling the ACR20 criteria at Week 24 in any of the secukinumab 
regimens versus placebo regimen. 
Let pj denote the proportion of ACR20 responders at Week 24 for treatment regimens j, j=0, 1, 
2, where  
• 0 corresponds to placebo regimen, 
• 1 corresponds to secukinumab 75 mg s.c., 
• 2 corresponds to secukinumab 150 mg s.c., 
In statistical terms, Hj: pj = p0, HAj: pj ≠ p0, for the jth secukinumab regimen, i.e. 
H1: secukinumab 75 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24  
H2: secukinumab 150 mg s.c. is not different to placebo regimen with respect to signs and 
symptoms (ACR20 response) at Week 24  
The primary endpoint of ACR20 at Week 24 will be analyzed via logistic regression with 
treatment and TNF-alpha inhibitor status as factors and weight as a covariate.  Odds ratios 
will be computed for comparisons of secukinumab regimens versus placebo regimen utilizing 
the logistic regression model fitted.   
For subjects meeting the criteria for early escape at Week 16, their ACR20 will be set to non-
response at Week 24.  This applies for all three treatment regimens in order to minimize bias. 
Supportive analyses 
Sensitivity analyses and supportive analyses will be conducted in order to provide evidence 
that the results seen from the primary analysis are robust.  These analyses will center on the 
deviations in model assumptions, and the treatment of missing data. 
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ACR20 response at Week 24 will also be evaluated using a non-parametric 
regression (Koch et. al 1998) model with the same independent variables as the logistic 
regression model.  In addition, further logistic regression models may be conducted which 
explore the impact of other baseline or disease characteristics on response.  Treatment by 
factor interactions will be explored. 
The impact of missing data on the analysis results will be assessed as well by repeating the 
logistic regression model using ways to handle missing data.  These may include, but are not 
limited to: 
• Multiple imputation 
• Observed data analysis 
11.5 Analysis of secondary variables 
The secondary efficacy variables include:  
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• response to treatment at Week 24 according to the PASI75 criteria in the subgroup of 
subjects who have ≥3% skin involvement 
• response to treatment at Week 24 according to the PASI90 criteria in the subgroup of 
subjects who have ≥3% skin involvement 
• change from baseline in DAS28-CRP at Week 24 in the FAS 
• change in SF-36 PCS from baseline at Week 24 in the FAS 
• change in HAQ-DI from baseline at Week 24 in the FAS 
• response to treatment at Week 24 according to the ACR50 criteria in the FAS 
• change from baseline in mTSS at Week 24 pooled secukinumab regimen vs placebo in the 
FAS 
• presence of dactylitis at Week 24 pooled secukinumab regimen vs placebo in the subset of 
subjects who have dactylitis at baseline 
• presence of enthesitis at Week 24 pooled secukinumab regimen vs placebo in the subset of 
subjects who have enthesitis at baseline 
• change from baseline in mTSS at Week 24 individual secukinumab regimen vs placebo in 
the FAS 
Testing strategy to control type I error 
The following hypotheses will be included in the testing strategy, and type-I-errors will be set 
such that a family-wise type-I-error of 5% is kept: 
Primary objectives: 
H1: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to ACR20 
response at Week 24  
H2: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to ACR20 
response at Week 24  
Secondary objectives: 
H3: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to PASI75 
response at Week 24  
H4: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to PASI75 
response at Week 24  
H5: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to PASI90 
response at Week 24  
H6: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to PASI90 
response at Week 24  
H7: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for DAS28-CRP at Week 24  
H8: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for DAS28-CRP at Week 24   
H9: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for SF36-PCS at Week 24  
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H10: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for SF36-PCS at Week 24   
H11: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for HAQ-DI at Week 24  
H12: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to the 
improvement (change) from baseline for HAQ-DI at Week 24   
H13: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to ACR50 
response at Week 24  
H14: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to ACR50 
response at Week 24  
H15: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to structural damage (van der Heijde modified total Sharp score) at week 24  
H16: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to presence of dactylitis at Week 24  
H17: Secukinumab pooled regimen (75 mg and 150 mg s.c.) is not different to placebo regimen 
with respect to presence of enthesitis at Week 24  
H18: Secukinumab 75 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24 
H19: Secukinumab 150 mg s.c. is not different to placebo regimen with respect to structural 
damage (van der Heijde modified total Sharp score) at week 24  
 
The graphical approach of (Bretz 2009) for sequentially rejective testing procedures is used to 
illustrate the testing strategy: 
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Figure 11-1 Testing strategy 
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The family-wise error will be set to α=5% and it will be controlled with the proposed 
hierarchical testing strategy.  With this hierarchical testing approach, the hypotheses will be 
separated into two families, hypotheses of signs and symptoms (H1 ~ H14) will be the first 
family and hypotheses of structure damage (H15 ~ H19) will be the second family. The second 
family hypotheses will be tested only when all hypotheses in the first family have been 
rejected.  Each of the hypotheses (H1 and H2) for the primary objective (based on signs and 
symptoms at week 24) for each secukinumab regimen versus placebo will be tested 
simultaneously at α/2. If at least one of H1 and/or H2 are/is rejected, then H3 and/or H4, 
respectively.  If at least one of H3 and/or H4 is rejected, the hypothesis H5 and/or H6, is tested, 
respectively. Similar process applies until H13 and H14. Once all hypotheses within the first 
family for a secukinumab regimen are rejected, then the respective α/2 can be passed on to the 
other regimen’s hypotheses within the family, if they are not already rejected at α/2. Only 
when all H1 ~ H14 are rejected, the objective on joint structure endpoint at Week 24 for testing 
pooled secukinumab doses versus placebo (H15) will be tested at α. If H15 is rejected, then H16 
is tested at α. Similarly if H16 is rejected, then H17 is tested at α. If these pooled hypotheses are 
all rejected, then hypotheses concerning individual regimens of secukinumab versus placebo 
(H18 and H19) can be tested for a particular regimen at α/2. Once the hypothesis of structure 
damage for a secukinumab regimen is rejected, then the respective α/2 can be passed on to the 
other regimen’s hypothesis, if it is not already rejected at α/2.  Of note, in the description 
above, rejection of a hypothesis refers to rejection of the two-sided hypothesis; however the 
level of a rejected hypothesis is only passed on according to the graphical procedure for the 
test of another hypothesis if the treatment effect is in favor of secukinumab. 
PASI 75 and PASI 90 response 
PASI 75 response and PASI 90 at Week 24 will be evaluated for those subjects in whom the 
assessment occurred (which is planned to be a subset of the FAS).  These binary variables will 
be evaluated in the same fashion as ACR response, i.e. a logistic regression model with 
treatment and randomization strata as factors and weight as a covariate. 
Changes in DAS28-CRP  
Between-treatment differences in the change from baseline in DAS28-CRP will be compared 
by means of a mixed model repeated measures (MMRM) with treatment regimen, analysis 
visit, and TNF-alpha inhibitor status as factors, and weight and baseline as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits.  
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SF-36 PCS 
Between-treatment differences in the change in SF-36 PCS will be evaluated using a mixed 
effect repeated measures model (MMRM).  Treatment group, analysis visit and TNF-alpha 
inhibitor status as factors and baseline SF-36 score and weight as continuous covariates. 
Treatment by analysis visit and baseline SF-36 score by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
Physical function (HAQ-DI)  
Between-treatment differences in the change in HAQ-DI will be evaluated using a mixed 
effect repeated measures model (MMRM) with treatment regimen, analysis visit and TNF-
alpha inhibitor status as factors, and weight and baseline HAQ-DI score as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits.  
ACR50 at Week 24  
Response at Week 24 to ACR50 in the FAS will be evaluated using a logistic regression 
model with treatment and randomization stratum (TNFα status -naive or IR) as factors and 
weight as a covariate.     
Joint/bone structural damage at Week 24 
The change at Week 24 from baseline van der Heijde total modified Sharp score will be 
evaluated using a non-parametric ANCOVA model with treatment regimen and TNF-alpha 
inhibitor status as factors, and weight and baseline van der Heijde total modified Sharp score 
as covariates. The pooled secukinumab regimens (75 mg s.c. and 150 mg s.c.) will be 
compared to placebo, then each of the secukinumab regimens will be compared versus the 
placebo regimen via pairwise comparisons. 
For subjects who meet the criteria for early escape at Week 16 and subjects who discontinue 
the study prior to Week 24, linear extrapolation will be used to impute the value at Week 24.  
In order to minimize bias, the extrapolation will use baseline and all post-baseline data up to 
the point the subject meets criteria for early escape treatment, or discontinues the study.  If 
baseline or all post-baseline total modified Sharp score/s is/are missing for a subject, the 
subject will be excluded from the analyses.  
The primary analysis of joint/bone structural damage will define baseline as the last 
measurement prior to dosing if available, or the first value within 30 days post dosing if no 
value available prior to dosing. A sensitivity analysis will be performed excluding patients 
whose baseline measure is after Day 1. 
Dactylitis at Week 24  
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Presence of dactylitis at Week 24 in the subset of subjects who have dactylitis at baseline will 
be evaluated using a logistic regression model with treatment and randomization stratum 
(TNFα status -naive or IR) as factors and weight as a covariate.  
Enthesitis at Week 24  
Presence of enthesitis at Week 24 in the subset of subjects who have enthesitis at baseline will 
be evaluated using a logistic regression model with treatment and randomization stratum 
(TNFα status -naive or IR) as factors and weight as a covariate.  
11.6 Analysis of exploratory variables 
All the following exploratory efficacy variables will be analyzed on the FAS for all applicable 
analysis visits unless otherwise specified.  
• HAQ-DI response 
• Major clinical response by Week 52 and 104 
• Joint/bone structural damage at Week 52 and 104 
• Evidence of no disease progression at Week 24, 52 and 104 
• PsARC, ACR20/50/70 response over time 
• DAS28 remission, low disease activity, EULAR response at Week 24 and over time 
• Minimal disease activity 
• ACR components 
o Changes in tender joint counts over time 
o Change in swollen joint counts over time 
o Change in Patient’s global assessment in disease activity 
o Change in Physician’s global assessment in disease activity 
o Change in PsA Pain 
o Change in HAQ-DI over time 
o Change in erythrocyte sedimentation rate (ESR) 
o Change in high-sensitivity C-reactive protein (hsCRP) 
• PASI 75, PASI 90, and IGA response over time 
• Target lesion score 
• mNAPSI 
• LDI and dactylitis count 
• LEI-4 
Between-treatment comparisons for binary variables in the FAS population (e.g PsARC, 
ACR20, etc.) at individual analysis visits will be evaluated using a logistic regression model 
with treatment and TNF-alpha inhibitor status as factors and baseline score (if appropriate) 
and weight as covariates.   
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Continuous variables (e.g. change from baseline in PsA pain) will be evaluated using a mixed-
effect model repeated measures (MMRM) with treatment regimen, TNF-alpha inhibitor status, 
and analysis visit as factors and weight and baseline score as continuous covariates.  
Treatment by analysis visit and baseline by analysis visit will be included as interaction terms 
in the model.  An unstructured covariance structure will be assumed for this model.  The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo at the appropriate analysis visits. Variables such as hsCRP whose distribution is not 
anticipated to be normal will be transformed and analyzed on the loge scale. 
Joint/bone structural damage at Week 52 and 104 
The change in joint/bone structural damage from baseline to Week 52 will be evaluated using 
evaluable data similarly to the analysis for Week 24. The pooled secukinumab regimens (75 
mg s.c. and 150 mg s.c.) will be compared to placebo, then each of the secukinumab regimens 
will be compared versus the placebo regimen via pairwise comparisons. 
As sensitivity analysis,  for subjects with missing modified Sharp score values at Week 52, 
their Week 52 value will be imputed by linear extrapolation from baseline, Week 16 and 
Week 24, and at subject discontinuation visit (if subject discontinued prior to Week 52) to 
Week 52. 
Summary statistics of evaluable data at Week 52 will be provided for each treatment regimens: 
secukinumab 75 mg,  secukinumab 150 mg, placebo escape or switch to secukinumab 75 mg 
at Week 16 or 24, placebo escape or switch to secukinumab 150 mg at Week 16 or 24. 
Summary statistics include mean, standard deviation, minimum, lower quartile, median, upper 
quartile and maximum. 
Evaluable Joint/bone structure data at Week 104 will be summarized by treatment group.  In 
addition, the change from week 52 will also be summarized within treatment regimen. 
Evidence of no disease progression at Week 24, 52 and 104 
The proportion of subjects without disease progression will be defined as those subjects who 
have a change in van der Heijde total modified Sharp score at Week 24 relative to baseline ≤ 0.  
The proportion of subjects without disease progression at Week 24 will be evaluated using a 
logistic regression model with treatment group and randomization strata, as factors, weight 
and baseline van der Heijde total modified Sharp score as covariates. 
The proportion of subjects without disease progression at Week 52 and 104 will be evaluated 
in the same manner.  At week 104, the proportion of subjects with disease progression from 
week 52 will also be examined. 
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EULAR response at Week 24 and over time 
Based on the EULAR response criteria (good responder, moderate responder, and non-
responder) as determined based on the value of DAS28-CRP achieved and the magnitude of 
change from baseline, between-treatment differences in EULAR response at Week 24 and 
other analysis visits will be evaluated using a proportional odds regression model with 
treatment group and randomization strata as factors and weight and baseline DAS28-CRP 
score as covariates. Frequency tables will also be presented to show the response rate over 
time up to Week 24 and Week 52, as appropriate. 
Magnetic Resonance Imaging 
MRI Analysis will be based on the patients who have MRI performed at selected centers. 
The change in synovitis between Week 24 and baseline will be evaluated using a 
nonparametric ANCOVA model with treatment regimen as a factor, weight and baseline as 
covariates. Pair-wise comparison versus placebo will be made for each of the secukinumab 
regimens. Tenosynovitis, periarticular inflammation, bone edema/osteitis, bone erosion, bone 
proliferation, and joint space narrowing will be evaluated in the same manner. 
For subjects with missing data at Week 24, linear extrapolation will be used to impute missing 
data. In order to minimize bias, the extrapolation will use baseline and week 12. Change from 
baseline will be summarized by analysis visit with summary statistics including mean, 
standard deviation, minimum, lower quartile, median, upper quartile and maximum. 
LEI-4 
The 4-site LEI (i.e. score with the four correct sites: lateral epicondyle humerus L + R and 
proximal achilles L + R) will be summarized by treatment group and visit. Change from 
baseline in the 4-site LEI will be analyzed using a nonparametric ANCOVA model with 
treatment regimen and randomization strata as factors, weight and baseline score as covariates. 
Pair-wise comparison versus placebo will be made for each of the secukinumab regimens by 
visit.  
 
11.7 Analysis of Health-related Quality of life variables 
PsAQoL 
Between-treatment differences in the change from baseline for PsAQoL scores will be 
evaluated using a mixed effect repeated measures model (MMRM) with treatment group, 
analysis visit and TNF-alpha inhibitor status as factors and baseline and weight as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
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SF-36 
The following variables will be evaluated: 
• SF-36 domain scores (based on a scale of 0-100). 
• SF-36 PCS and MCS scores (norm-based scores). 
• SF-36 PCS responder (improvement of ≥ 2.5 points, Lubeck 2004) 
Between-treatment differences in the change from baseline for SF-36 summary scores 
(PCS/MCS) will be evaluated using a mixed effect repeated measures model (MMRM).  
Treatment group, analysis visit and TNF-alpha inhibitor status as factors and baseline SF-36 
score and weight as continuous covariates. Treatment by analysis visit and baseline SF-36 
score by analysis visit will be included as interaction terms in the model. An unstructured 
covariance structure will be assumed for the model. The significance of the treatment effects 
for secukinumab regimens at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate 
analysis visits. 
In the responder analyses, treatment groups will be compared with respect to response to 
treatment using a logistic regression model with treatment and TNF-alpha inhibitor status as 
factors, baseline SF-36 summary score and weight as covariates. Odds ratios with 
corresponding 95% confidence intervals will be estimated in addition.   
Individual SF-36 domain scores will be summarized. 
FACIT-Fatigue 
Between-treatment differences in the change from baseline for FACIT-Fatigue scores will be 
evaluated using a mixed effect repeated measures model (MMRM) with treatment group, 
analysis visit and TNF-alpha inhibitor status as factors and baseline and weight as continuous 
covariates. Treatment by analysis visit and baseline by analysis visit will be included as 
interaction terms in the model. An unstructured covariance structure will be assumed for the 
model. The significance of the treatment effects for secukinumab regimens at different 
analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
EuroQol 5D (EQ-5D) 
The number and percentage of subjects in each of the three categories for each question will 
be presented by visit and treatment group.  
Summary statistics will be shown for the health state assessment by visit and treatment group.  
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For the change in EQ-5D overall health state (VAS), between-treatment differences in the 
change in EQ-5D overall health state (VAS) will be evaluated using a mixed effect repeated 
measures model (MMRM) with treatment group, analysis visit and TNF-alpha inhibitor status 
as factors and baseline EQ-5D overall health state (VAS) and weight as continuous covariates. 
Treatment by analysis visit and baseline EQ-5D overall health state (VAS) by analysis visit 
will be included as interaction terms in the model. An unstructured covariance structure will 
be assumed for the model. The significance of the treatment effects for secukinumab regimens 
at different analysis visits will be determined from the pairwise comparisons performed 
between secukinumab regimens and placebo at the appropriate analysis visits. 
Dermatology Life Quality Index (DLQI) 
Between-treatment differences in the change from baseline for DLQI will be evaluated using a 
mixed effect repeated measures model (MMRM) with treatment group, analysis visit and 
TNF-alpha inhibitor status as factors and baseline and weight as continuous covariates. 
Treatment by analysis visit and baseline by analysis visit will be included as interaction terms 
in the model. An unstructured covariance structure will be assumed for the model. The 
significance of the treatment effects for secukinumab regimens at different analysis visits will 
be determined from the pairwise comparisons performed between secukinumab regimens and 
placebo at the appropriate analysis visits. 
WPAI-GH 
Summary statistics will be shown for the WPAI-GH assessment by visit and treatment group. 
 
12 Pharmacokinetic evaluations (change / add PD, PK/PD, 
Biomarkers, as needed) 
12.1 Pharmacokinetics 
All completed subjects with quantifiable pharmacokinetic (PK) measurements of 
secukinumab will be included in the pharmacokinetic data analysis. Serum concentrations will 
be expressed in mass per volume units. All concentrations below the limit of quantification as 
well as missing data will be labeled as such in the concentration data listings. PK 
concentrations will be summarized by visit and treatment group. In addition to mean, standard 
deviation (SD), coefficient of variation (CV), median and quartiles, the geometric mean and 
geometric coefficient of variation (CV) and n(log) will be presented. The formula for deriving 
the geometric mean and CV (%) is as following:  
• CV (%) = (SD/mean)*100, 
• geometric mean=exp( (sum of log transformed data) / number of non-missing data points 
after log transformation), 
• geometric CV = sqrt( exp( variance of log-transformed data)-1)*100. 
In addition, sample number, concentration, sample date, sample time at pre-dose and minutes 
pre-dose will be listed by treatment sequence. 
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Values below lower limit of quantification/below detection limit will be imputed by 0. 
Pharmacokinetic data of the study treatment will be analyzed with a population-
pharmacokinetic mixed effects model. The analysis will be based on a pooled data set, 
including pharmacokinetic samples from previous studies. The modeling approach will be 
further detailed in a modeling plan. Results will be reported separately. 
12.2 Pharmacogenetics 
The exploratory pharmacogenetic studies are designed to investigate the association between 
genetic factors (genotypes) and clinical assessments (phenotypes) which are collected during 
the clinical trial. Without prior evidence of a strong association, a number of possible 
associations will be evaluated with exploratory analyses.  A range of statistical tests (chi-
square tests, analysis of covariance (ANCOVA), linear and logistic regression) will be used 
for the analyses.  Additional data, from subsequent clinical trials, are often needed to confirm 
associations.  Alternatively, if the numbers of subjects enrolled in the study are too small to 
complete proper statistical analyses, these data may be combined, as appropriate, with those 
from other studies to enlarge the data set for analysis. 
Results will be reported separately. 
12.3 Biomarkers 
Soluble marker panel studies investigate differences in the level of expression of proteins or 
peptides between individuals in a given biofluid.  The goal of such studies is to allow the 
identification of potential protein or peptide biomarkers of drug action or disease, and to 
better understand the associated underlying molecular mechanisms.  By applying statistical 
analysis methods (e.g. principal component analysis) between subject groups, distinct study 
time points, or between study groups from other clinical trials, it may be possible to identify 
patterns which are associated with disease state or response to drug treatment.  However, the 
exact type of data analysis method will depend on the type of data obtained in the study and 
thus the analysis of this data will be data driven. 
Results will be reported separately. 
12.4 PK/PD 
Exploratory analysis to investigate the correlation between the PK data and efficacy outcomes 
will be performed. 
An indirect response model, driven by study treatment concentration, will be used to 
characterize the time course of efficacy response. Further details of the modeling approach 
will be specified in a modeling plan. Results will be reported separately. 
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13 Safety evaluation 
Summaries may be performed separately for initial (Week 1-16) and entire treatment periods.  
Week 16 is chosen due to the fact that placebo patients may be rescued as early as week 16. 
Use of data up to and including the last visit before rescue provides and unbiased comparison 
between AIN and placebo; data collected beyond week 16 are included in analyses which 
summarize the entire treatment period.  The analyses of the follow-up period will be limited to 
summaries for treatment-emergent adverse events, serious adverse events and risks based on 
adverse events.  
Safety analyses will be performed on treatment received or actual treatment as described 
below: 
The actual treatment or treatment received for summaries of safety data will differ to the 
treatment assigned at randomization only if a subject received the wrong treatment during the 
entire study. 
For those subjects who received not the treatment randomized, i.e. who received erroneously 
the wrong treatment at least once, an additional AE listing will be prepared displaying which 
events occurred after the treatment errors. 
13.1 Adverse events 
The crude incidence of treatment emergent adverse events (i.e. events started after the first 
dose of study treatment or events present prior to the first dose of study treatment but 
increased in severity based on preferred term) will be summarized by primary system organ 
class and preferred term. Confidence intervals for the crude rate will be derived as described 
in Section 18.2.4.1. In addition, exposure time-adjusted rates (incidence rate) including 95% 
confidence intervals will be provided for the entire treatment period (see Section 18.2.5.1) to 
adjust for differences in exposure.  Graphical displays of the crude incidence rates and 
exposure-adjusted rates will be presented for all AEs and serious AEs by system organ class. 
Adverse events reported will be presented in descending frequency according to its incidence 
in total secukinumab group (combining all secukinumab treatment groups) starting from the 
most common event. Summaries (crude incidences only) will also be presented for AEs by 
severity and for study treatment related AEs. If a particular AE ‘severity’ is missing, this 
variable will be listed as missing and treated as missing in summaries. If a subject reported 
more than one adverse event with the same preferred term, the adverse event with the greatest 
severity will be presented. If a subject reported more than one adverse event within the same 
primary system organ class, the subject will be counted only once with the greatest severity at 
the system organ class level, where applicable.   
Separate summaries will be provided for adverse events suspected to be related to study drug, 
deaths, serious adverse events, and adverse events leading to discontinuation and adverse 
events requiring concomitant medication. 
Adverse events will also be reported separately by SMQ according to MedDRA. The 
MedDRA version used for reporting the study will be described in a footnote. 
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Follow-up period summaries will be done for all subjects in follow-up who do not go on to 
the extension study (completers and early discontinuations).  
A listing of non-treatment emergent adverse events will be done.  These adverse events 
occurred before the first dose of the study treatment.  The crude incidence rate will be 
provided without treatment information. 
Algorithms for date imputations will be provided in RAP M8. 
For SAEs occurred during screening a listing will be prepared for all subjects screened 
including screening failures. 
An overview of the safety analyses and which will be performed for each analysis period is 
described in Table 13-1. 
Table 13-1 Overview of analyses on some safety endpoints 
Analysis 
period 
AEs & SAEs AEs by 
severity 
Study drug 
related AEs 
AEs-SMQ Risk Notables for 
(vitals/ 
ECG), lab 
criteria 
Day 1 – 
Week 16 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
• crude 
incidence 
Day 1 – 
Week 24 
• exposure 
time 
adjusted 
incidence* 
     
Entire 
Treatment 
(up to week 
104) 
 
• crude 
incidence 
• exposure 
time 
adjusted 
incidence* 
• crude 
incidence 
 
• crude 
incidence 
 
• exposure 
time 
adjusted 
incidence 
• crude 
incidence 
• exposure 
time 
adjusted 
incidence 
• crude 
incidence 
 
follow-up 
(week 104 to 
112) 
• crude 
incidence 
   • crude 
incidence  
 
*Exposure-adjusted incidence rates will be done at the PSOC for AE and SAE and Level 1 for Risks and SMQ 
analyses 
13.2 Laboratory data 
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, chemistry and urinalysis). In addition to the individual laboratory parameters the 
ratios “total cholesterol / HDL” and “apolipoprotein B / apolipoprotein A1” will be derived 
and summarized. 
For urinalysis, frequency tables will be presented. 
Descriptive summary statistics for the change from baseline to each study visit will be 
presented. These descriptive summaries will be presented by laboratory test and treatment 
group. Change from baseline will only be summarized for subjects with both baseline and 
post baseline values and will be calculated as: 
change from baseline = post baseline value – baseline value 
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For each parameter, the maximum change (maximum decrease and maximum increase) from 
baseline, if appropriate for each study phase, will be analyzed analogously.  
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal 
laboratory ranges will be used to evaluate whether a particular laboratory test value was 
normal, low, or high for each visit value relative to whether or not the baseline value was 
normal, low, or high. If appropriate, the shifts to the most extreme laboratory test value within 
a treatment phase (either initial or entire) will be presented as well (including category “high 
and low”). These summaries will be presented by laboratory test and treatment group. 
The following laboratory parameters will be analyzed with respect to numerical Common 
Terminology Criteria for Adverse Events (CTCAE) grades, given in Table 13-2: hemoglobin, 
platelets, white blood cell count, neutrophils, lymphocytes, creatinine, total bilirubin (TBL), 
gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), glucose, cholesterol, triglycerides (TG). 
These summaries will be split into hematology and chemistry for study level reports and the 
pooled summary of clinical safety. 
Table 13-2 CTCAE grades for laboratory parameters to be analyzed 
CTCAE v4.0 Term Grade 1    Grade 2    Grade 3    Grade 4    
HGB decreased 
(Anemia) <LLN – 100 g/L <100 – 80 g/L <80 g/L  
Platelet count 
decreased <LLN – 75.0 x10e9 /L <75.0 - 50.0 x10e9 /L <50.0 – 25.0 x10e9 /L <25.0 x 10e9 /L 
White blood cell 
decreased <LLN - 3.0 x 10e9 /L <3.0 - 2.0 x 10e9 /L <2.0 - 1.0 x 10e9 /L <1.0 x 10e9 /L 
Neutrophil count 
decreased <LLN - 1.5 x 10e9 /L <1.5 - 1.0 x 10e9 /L <1.0 - 0.5 x 10e9 /L <0.5 x 10e9 /L 
Lymphocyte count 
decreased <LLN - 0.8 x 10e9/L <0.8 - 0.5 x 10e9 /L 
 
<0.5 - 0.2 x 10e9 /L <0.2 x 10e9 /L 
Creatinine increased* 
 
>1 - 1.5 x baseline;  
>ULN - 1.5 x ULN 
>1.5 - 3.0 x 
baseline; >1.5 - 3.0 x 
ULN 
>3.0 baseline;  
>3.0 - 6.0 x ULN >6.0 x ULN 
TBL increased >ULN - 1.5 x ULN >1.5 - 3.0 x ULN >3.0 - 10.0 x ULN >10.0 x ULN 
GGT increased >ULN - 2.5 x ULN >2.5 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
ALT increased >ULN - 3.0 x ULN >3.0 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
AST increased >ULN - 3.0 x ULN >3.0 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
ALP increased >ULN - 2.5 x ULN >2.5 - 5.0 x ULN >5.0 - 20.0 x ULN >20.0 x ULN 
Glucose increased 
(Hyperglycemia )  
  
>ULN - 8.9 mmol/L >8.9 - 13.9 mmol/L >13.9 - 27.8 mmol/L >27.8 mmol/L 
Glucose decreased 
(Hypoglycemia) <LLN - 3.0 mmol/L <3.0 - 2.2 mmol/L <2.2 - 1.7 mmol/L <1.7 mmol/L 
Cholesterol high >ULN - 7.75 mmol/L >7.75 - 10.34 mmol/L >10.34 - 12.92 mmol/L >12.92 mmol/L 
Hypertriglyceridemia 1.71 - 3.42 mmol/L >3.42 - 5.7mmol/L >5.7 - 11.4 mmol/L >11.4 mmol/L 
*Note: for “creatinine increased” the baseline criteria do not apply 
Shift tables will be presented comparing baseline laboratory result (CTCAE grade) with the 
worst results (expressed in CTCAE grade) during the treatment phase (either initial or entire) 
analyzed. Of note, baseline will be defined as last assessment prior to first dosing in initial 
treatment phase. Subjects with abnormal laboratory values will be listed and values outside 
the normal ranges will be flagged. 
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Summaries for newly occurring or worsening clinically notable lipid abnormalities will also 
be provided cumulatively for each of the following parameters and categories: 
• HDL: 
• <=LLN 
• <0.8 x LLN 
• LDL, cholesterol, triglycerides: 
• >=ULN  
• >1.5 x ULN  
• >2.5 x ULN 
Newly occurring or worsening liver enzyme abnormalities will also be summarized based on 
the event criteria given in Table 13-3: 
Table 13-3 Liver-related events 
Parameter Criterion 
ALT >3xULN; >5xULN; >8xULN;>10xULN, >20xULN 
AST >3xULN; >5xULN; >8xULN >10xULN; >20xULN 
ALT or AST >3xULN; >5xULN; >8xULN >10xULN; >20xULN 
TBL >1.5xULN, >2xULN, >3xULN, 
ALP >2xULN, >3xULN. >5xULN 
ALT or AST & 
TBL 
ALT or AST>3xULN & TBL >2xULN; 
ALT or AST >5xULN & TBL >2xULN; 
ALT or AST >8xULN & TBL >2xULN; 
ALT or AST >10xULN & TBL >2xULN 
ALP & TBL ALP >3xULN & TBL >2xULN 
ALP >5xULN & TBL >2xULN 
ALT or AST & 
TBL & ALP 
ALT or AST>3xULN & TBL >2xULN & ALP <2xULN (Hy’s Law) 
Note: elevated ALP may suggest obstruction as a consequence of gall bladder or 
bile duct disease; ALP may also be increased in malignancy. FDA therefore terms 
Hy’s Law cases as indicators of pure hepatocellular injury. This does not mean 
that cases of ALT or AST >3xULN & TBL >2xULN & ALP ≥2xULN may not result 
in severe DILI. 
Notes: 
1) In studies which enroll subjects with pre-existing liver disease, baseline LFT may be increased 
above ULN; in such a case it is meaningful to add the condition “and worse than baseline” to the 
abnormality criteria 
For a combined criterion to be fulfilled, all conditions have to be fulfilled on the same visit. 
The criteria are not mutually exclusive, e.g. a subject with ALT = 6.42xULN is counted for 
ALT >3xULN and ALT>5x ULN. 
Individual subject data listings will be provided for subjects with abnormal laboratory data. 
Data of subjects with newly occurring or worsening liver enzyme abnormalities will be listed 
in an additional listing. 
Box plots over time will be presented for selected laboratory parameters (neutrophils, liver 
and lipid parameters).  
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13.3 Vital signs 
Analysis in vital sign measurement using descriptive summary statistics for the change from 
baseline for each post-baseline visit will be performed. These descriptive summaries will be 
presented by vital sign and treatment group. Change from baseline will only be summarized 
for subjects with both baseline and post-baseline values and will be calculated as: 
change from baseline = post-baseline value – baseline value 
The number and percentage of subjects with newly occurring notable vital signs will be 
presented. Criteria for notable vital sign abnormalities are provided in Table 13-4 below. 
Table 13-4 Criteria for notable vital sign abnormalities 
Vital sign (unit) Notable abnormalities 
Systolic blood pressure (mmHg) >= 140 mmHg or < 90 mmHg 
Diastolic blood pressure (mmHg) >=90 mmHg or <60 mmHg 
Pulse (bpm) > 100 bpm or <60 bpm 
13.4   Electrocardiogram (ECG) 
The following quantitative variables will be summarized: ventricular rate, RR interval, PR 
interval, QRS duration, QT interval, and corrected QT interval (QTc). Both Bazett (QTcB) 
and Fridericia (QTcF) corrections will be presented for QTc.  
QTc will be summarized by computing the number and percentage of subjects (including 95% 
confidence intervals for pooled analyses, e.g. DMC or SCS) with: 
• QTc > 500 msec  
• QTc > 480 msec 
• QTc > 450 msec 
• QTc changes from baseline > 30 msec 
• QTc changes from baseline > 60 msec 
• PR > 250 msec 
Summary statistics will be presented for ECG variables by visit and treatment group. 
In addition, shift tables comparing baseline ECG interpretation (normal, abnormal, not 
available, total) with the worst on-study interpretation (normal, abnormal, not available, total) 
will be provided. 
A listing of all newly occurring or worsening abnormalities will be provided, as well as a by-
subject listing of all quantitative ECG parameters.   
13.5   Immunogenicity 
A listing of immunogenicity (anti-AIN457 antibodies) will be provided. 
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13.6   Compound specific safety evaluation 
Safety topics of interest, such as risks defined in the Safety Profiling Plan, Risk Management 
Plan or topics of interest regarding signal detection or routine analysis are defined in the 
Program Case Retrieval Sheet that is stored in CREDI at the path Cabinets/CREDI 
Projects/A/AIN457A/Integrated Medical Safety. 
The crude incidence and exposure-adjusted incidence rates for potential compound and class-
related risks and routine risks will be summarized. In addition, listings will be provided 
presenting which subjects experienced which risk. 
Important note: For the evaluation of SPP risks primary and secondary system organ classes 
of the MedDRA dictionary will be considered. 
14 Sample size calculation 
The original power calculations used in the protocol have been updated to incorporate more 
recent published data in the PsA population.  In addition, the statistical hierarchy (primary 
plus ranked secondary variables) was expanded to include more endpoints important in the 
treatment of psoriatic arthritis patients.  No adjustment was made to the sample size as a result 
of the updated power calculations; the original sample size of N=200 per treatment regimen 
was retained.  The adjustments to the power calculations and the statistical hierarchy were 
done before the unblinding of the trial in order to prevent bias. 
A 5% two-sided type I error rate will be used to control for type I error.  Two secukinumab 
doses will be tested versus placebo with respect to the primary endpoint (ACR20 response at 
Week 24), thus the type-I-error will be split to 2.5% two-sided for each comparison. Sample 
sizes will be based on this type I error assumption. 
A placebo response rate of about 25% after 24 weeks was reported for the TNFα inhibitor 
naive population in the PSUMMIT I study (McInnes et al 2013), and 15% was reported for 
the TNFα inhibitor IR population in the PSUMMIT II study (Ritchlin et al 2013).  Based on 
the weighted average, the overall placebo rate is expected to be 22%. 
The response on secukinumab is expected to be 55% in the TNFα inhibitor naïve population 
and 35% in the TNFα inhibitor IR-population.  Based on the weighted average, the overall 
rate on a dose of secukinumab is expected to be 49%. 
For the primary endpoint, ACR20 in the overall population, 200 subjects per group would 
yield approximately 99% power to detect a treatment difference of 27% (Fisher’s exact test, 
nQuery 7.0). 
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15 Power for analysis of secondary variables 
Power for secondary variables was calculated using a two-sided 2.5% type I error. With an 
assumed placebo rate of 7.6% and secukinumab 58.1%, the study is over 99% powered to 
detect a treatment difference of PASI75 in the full FAS population, assuming 135 subjects per 
treatment arm (Fisher’s exact test, nQuery 7.0). Similarly, with an assumed placebo rate of 
5% and secukinumab 44%, the study is over 99% powered to detect a treatment difference of 
PASI90 in the full FAS population, assuming 135 subjects per treatment arm. It is assumed 
that about 67.5% of enrolled patients have ≥3% skin involvement. Assumptions of PASI75 
and PASI90 rates are based on PSUMMIT I and II studies (McInnes et al 2013 and Ritchlin et 
al 2013). 
A difference of 1.31 and standard deviation of 1.34 has been observed for the change from 
baseline in DAS28-CRP in Golimumab (Kavanaugh et al 2009) for the TNFα inhibitor naïve 
population. Assuming the difference is half in the TNFα inhibitor IR population, the overall 
population has a difference of 1.12. With these assumptions, the study has approximately over 
99% power to detect a difference between secukinumab and placebo (Two group t-test, 
nQuery Advisor 7.0), assuming 200 subjects per arm.  
A standard deviation of approximately 10.1 and a treatment difference of 6.32 has been 
observed for the change from baseline at week 24 in SF36-PCS in Ustekinumab trial 
(Mclnnes et al 2013). Using those assumptions, the study has approximately 99% power to 
detect a difference between secukinumab and placebo (Two group t-test, NQuery Advisor 7.0), 
assuming 200 subjects per arm. 
A standard deviation of approximately 0.5 and a treatment difference of 0.25 has been 
observed for the change from baseline at week 24 in HAQ-DI in Ustekimumab trial (McInnes 
et al 2013; Ritchlin et al 2012; Ritchlin et al 2013). Using those assumptions, the study has 
approximately 99% power to detect a difference between secukinumab and placebo (Two 
group t-test, NQuery Advisor 7.0), assuming 200 subjects per arm. 
With an assumed placebo rate of 7.4% (McInnes et al 2013 and Ritchlin et al 2013) and 
secukinumab 25.5%, the study is over 99% powered to detect a treatment difference of 
ACR50 in the full FAS population, assuming 200 subjects per treatment arm (Fisher’s exact 
test, nQuery 7.0). 
For structural endpoint, historical data (adalimumab) showed a standard deviation of 1.2 on 
active treatment and 2.4 on placebo at week 26, and a difference of 0.6 for the TNFα inhibitor 
naïve population. Assuming the difference is half in the TNFα inhibitor IR population, the 
overall population has a difference of 0.51. Using the above assumptions, there is 80% power 
to show statistically significant differences between secukinumab (pooled 400 subjects) and 
placebo (200 subjects).  Individual comparisons between secukinumab and placebo would 
have 66% power (Satterthwaite t-test, nQuery 7.0). 
For the presence of dactylitis at Week 24 in the subset of patients who have dactylitis at 
baseline, with an assumed placebo rate of 76% (McInnes et al 2013) and secukinumab 57%, 
there is about 89% power to show statistically significant difference between secukinumab 
(pooled 200 subjects) and placebo (100 subjects), assuming 50% patients have dactylitis at 
baseline (Fisher’s exact test, nQuery 7.0).   
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For the presence of enthesitis at Week 24 in the subset of patients who have enthesitis at 
baseline, with an assumed placebo rate of 81% (McInnes et al 2013) and secukinumab 65%, 
there is about 87% power to show statistically significant difference between secukinumab 
(pooled 240 subjects) and placebo (120 subjects), assuming 60% patients have enthesitis at 
baseline (Fisher’s exact test, nQuery 7.0).   
16 Interim Analysis 
The Week 52 analysis will be performed after all subjects have completed the Week 52 visit. 
For this analysis, all subjects will have completed the assessments related to the primary and 
secondary objectives. Thus, no adjustment will be made to the type I error rate for this 
analysis and an interim clinical study report will be produced. 
17 DMC 
A project-level DMC will monitor the trials’ progress for unexpectedly large differences in 
toxicity between treatment groups on a regular basis or per the request of the DMC. Details 
regarding the reasons for the DMC and the grounds for stopping/continuing studies, as well as 
the DMC procedures are provided in the project-level DMC charter. 
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18 Appendix 
18.1 Visit Windows 
When visit windows are used, all visits will be re-aligned, i.e., they will be mapped into one 
of the visit windows. E.g., if the Week 4 visit of a subject is delayed and occurs on Day 46 
instead of on Day 29, say, it will be re-aligned to visit window Week 8. In the case of major 
deviations from the visit schedule, or due to unscheduled visits, several assessments of a 
subject may fall in a particular visit window (either scheduled or unscheduled). Statistical 
approaches to handle multiple assessments in a given visit window are specified below.  
Of note, subjects are allowed to have gaps in visits.  All data collected will be displayed in 
listings.  
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Table 18-1 Analysis visit windows  
Analysis 
Visit 
Target 
Day 
Analysis 
Visit 
Window  
Group1 Group2 Group3 Group4 Group5 Group6 Group7 Group8 Group9 Group10 Group11 
Baseline 1 Up to 1* Up to 1* Up to 1* Up to 7 Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 1* Up to 30 
Week 1 8 2-11 2-11 2-11     2-11     
Week 2 15 12-22  12-22  12-22     2-22  12-22     
Week 4 29 23-43  23-43  23-43    2-71 23-43  23-43 2-43    
Week 8 57 44-71  44-71  44-71     44-71  44-71 44-71  2-85    
Week 12 85 72-99 72-99 72-99 8-127   72-99 72-99 72-99    
Week 16 113 100-127 100-127 100-127  2-141 72-141 100-141 100-141 100-141 86-141 2-239 31-141 
Week 20 141 128-155 128-155 128-155          
Week 24 169 156-183 156-183 156-183 128-449 142-267 142-267 142-197 142-197 142-267 142-267  142-267 
Week 28 197 184-211 184-211 184-211          
Week 32 225 212-239 212-239 212-253    198-253 198-253     
Week 36 253 240-267 240-267           
Week 40 281 268-295 268-295 254-323    254-323 254-323     
Week 44 309 296-323 296-323           
Week 48 337 324-351 324-351           
Week 52 365 352-379 352-393 324-393  268-547 268-547 324-393 324-393 268-547 268-449 240-547 268-547 
Week 56 393 380-407            
Week 60 421 408-435 394-449 394-449    394-449 394-449     
Week 64 449 436-463            
Week 68 477 464-491 450-505 450-505    450-505 450-505     
Week 72 505 492-519            
Week 76 533 520-547 506-561 506-561    506-561 506-561  450-631   
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Week 80 561 548-575            
Week 84 589 576-603 562-617 562-617    562-617 562-617     
Week 88 617 604-631            
Week 92 645 632-659 618-687 618-687    618-687 618-687     
Week 96 673 660-687            
Week 100 701 688-715            
Week 104 729 716-743 688-743 688-743 450-743 548-743 548-743 688-743 688-743 548-743 632-743 548-743 548-743 
Group1: ACR components, Vital signs 
Group2: Hematology, blood chemistry, urinalysis 
Group3: MRI  
Group4: WPAI-GH 
Group5: PK 
Group6: Presence of enthesitis, LEI, presence of dactylitis, LDI, dactylitis count 
Group7: PASI, IGA, TLS, mNAPSI 
Group8: SF-36, FACIT, PsAQoL, EQ-5D, DLQI 
Group9: Lipids 
Group10: ECG 
Group11: X-ray 
* The first administration of randomized study treatment (first dose) is defined as 1. 
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The following rules are used to determine the window for an applicable visit post baseline: 
“Lower limit” = “upper limit of prior applicable visit” + 1. “Upper limit” = “target day of 
current visit” + integer part of (“target day of next applicable visit” – “target day of current 
visit”)/2. Lower limit of the first applicable visit is always Day 2. 
The mapping described above applies to all visits (not just scheduled visits).  Repeat and/or 
unscheduled visits (which will be numbered in the database according to new NCDS 
standards) will be mapped for analysis purposes in the same way as scheduled visits.  This 
leaves the possibility, then, for multiple measurements within an analysis window.  The 
following conventions will be used to determine the appropriate measurement to be 
summarized in the event of multiple measurements within a visit window. 
Table 18-2 Rules for flagging variables 
Timing of measurement Type of data Rule 
Baseline All data The last measurement made prior to administration of the first dose of 
study treatment – note this may include measurements taken on the day 
of randomization (e.g. lab). If a patient did not receive any dose of study 
treatment then the randomization date will be used. 
Post-baseline efficacy All data • For visits without switch of treatment in the window, the measurement 
closest to the target will be used. In the event two measurements are 
taken equally apart (e.g. 1 before target date and 1 after) the first one 
will be used.  
• For visits during which the patient switches from placebo to AIN the 
following will be done based on whether or not the patient met the 
rescue criteria: 
o If the analysis visit window is <= week 16(for non-responders) or 
week 24 (for responders), then:  
 If available, the closest measurement to the target 
date which is ON or BEFORE the switch date will be 
used (i.e. the closest measurement to target which is 
on placebo). 
 If there are no data on or before the switch then the 
closest measurement to the target date after the 
switch will be used. 
o If the analysis visit window is > week 16(for non-responders) or 
week 24 (for responders), then  
 If available, the closest measurement to the target 
date which is AFTER the switch date will be used (i.e. 
the closest measurement to target which is on AIN). 
 If there are no data AFTER the switch then the closest 
measurement to the target date before the switch will 
be used. 
Post-baseline safety Summary visit 
information (e.g. lab, 
ECG, etc.) 
• For visits without switch of treatment in the window, the measurement 
closest to the target will be used. In the event two measurements are 
taken equally apart (e.g. 1 before target date and 1 after) the first one 
will be used.  
• For visits during which the patient switches from placebo to AIN the 
following will be done based on whether or not the patient met the 
rescue criteria: 
o If the analysis visit window is <= week 16(for non-responders) or 
week 24 (for responders), then:  
 If available, the closest measurement to the target 
date which is ON or BEFORE the switch date will be 
used (i.e. the closest measurement to target which is 
on placebo). 
 If there are no data on or before the switch then the 
closest measurement to the target date after the 
switch will be used. 
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Timing of measurement Type of data Rule 
o If the analysis visit window is > week 16(for non-responders) or 
week 24 (for responders), then  
 If available, the closest measurement to the target 
date which is AFTER the switch date will be used (i.e. 
the closest measurement to target which is on AIN). 
 If there are no data AFTER the switch then the closest 
measurement to the target date before the switch will 
be used. 
Post-baseline safety  Notable 
abnormalities (e.g. 
lab) 
The most extreme measurement in the window will be used.  Note this 
means a patient can have a notably high and notably low measurement 
within a window.  
18.2 Statistical methodology and assumptions 
18.2.1 Analysis of continuous data 
18.2.1.1 Summary statistics for continuous data 
Summary statistics (including N, mean, standard deviation, minimum, lower quartile, median, 
upper quartile, maximum) will be provided for continuous data by visit and treatment group.  
18.2.1.2 Mixed-effects repeated measures model 
Endpoints with continuous data type expected to be normally distributed (e.g, DAS28) will be 
analyzed using a mixed-effects repeated measures model (MMRM) with treatment, 
stratification factor and analysis visit as factors; and weight, baseline value, treatment by visit 
and baseline by visit interactions as covariates. An unstructured covariance structure will be 
assumed for this model. The significance of the treatment effects for secukinumab regimens at 
different analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropriate analysis visits. 
SAS code for mixed model: 
proc mixed data=aaa; 
class TRT USUBJID AVISITN STRATA; 
model CHG=TRT STRATA AVISITN WEIGHT BASE TRT*AVISITN BASE*AVISITN 
           / s ddfm=kr; 
lsmeans TRT*AVISITN / diff cl; 
repeated AVISITN / type=un subject=USUBJID; 
Run; 
In case the MMRM model does not converge the following sequential steps will be used: 
1. change ddfm=kr to ddfm=bw. If still no convergence, perform step 2. 
2. change type=un to type=cs. If still no convergence, perform step 3. 
3. remove covariates in the following order until convergence: WEIGHT, BASE*AVISITN,  
STRATA. 
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18.2.1.3 Non-parametric analysis of covariance 
A non-parametric ANCOVA model (Koch 1998) will be used for the endpoints that are not 
normally distributed, e.g. X-ray, MRI, et. ctrl. The macro NParCov3 will be used, see Zink 
and Koch 2012. 
• For continuous response variable, the macro call will be as follows: 
%NParCov3(OUTCOMES = response, COVARS = weight baseline, C=1, 
HYPOTH = ALT, STRATA = TNFα status, TRTGRPS = treatment, TRANSFORM = NONE, 
COMBINE = FIRST, DSNIN = RESP, DSNOUT = OUTDAT); 
Data set _OUTDAT_DEPTEST provides results for the treatment difference, and 
_OUTDAT_CI  provides a 95% confidence interval for the treatment estimate. 
• For binary response variable, the macro call will be as follows: 
%NParCov3(OUTCOMES = response, COVARS = weight, C = 1, HYPOTH = ALT, 
STRATA = TNFα status, TRTGRPS = treatment, TRANSFORM = LOGISTIC, 
COMBINE = FIRST, DSNIN = RESP, DSNOUT = OUTDAT); 
The odds ratio and condence interval are to be obtained from _OUTDAT_RATIOCI. 
18.2.2 Analysis of binary (and categorical) data 
18.2.2.1 Summary statistics for binary and categorical data 
Summary statistics for discrete variables will be presented in contingency tables and will 
include count and frequency in each category. If applicable, confidence intervals will be 
derived as well based on the score method including continuity correction [Newcombe 
(1998)]: 
With z as (1-alpha/2)-quantile of the standard normal distribution (SAS: z=PROBIT(1-
alpha/2), n  as total number of subjects (i.e. number of subjects in the denominator), and p as 
estimated crude incidence (number of subjects with event / n ) it is pq −=1  
Then the lower limit is 
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For binary response variables (e.g. for ACR20/50/70, HAQ-DI responder, PASI 75, IGA 
response) the placebo-adjusted response rates including 95% confidence interval will be 
derived.  
SAS code for risk difference: 
Proc freq data=acr order=formatted;  
Tables response*trt/ riskdiff; 
Run; 
(Note the response value should be sorted with ‘1’ ahead of ‘0’.) 
Fisher’s exact test will be applied to rare events (e.g., MCR), pairwise treatment group 
comparisons to placebo or active controls. 
SAS code for Fisher’s exact test: 
Proc freq data=mcr order=formmatted; 
Tables response*trt/Fisher; 
Run; 
Figures will be provided for primary and secondary variables, with means and 95% 
confidence intervals displayed across time for all the treatment groups. 
18.2.2.2 Logistic regression 
Certain binary outcome variables, e.g. response outcomes, will be evaluated using a logistic 
regression model with treatment regimen, weight, stratum if applicable. Odds ratios will be 
computed for comparisons of AIN457 regimens versus control(s) utilizing the logistic 
regression model fitted.  
 SAS code for logistic regression: 
 Proc logistic data=aaa; 
 Class TRT STRATA / param=glm; 
 Model AVAL = TRT WEIGHT STRATA; 
 Lsmeans TRT / diff cl exp; 
 Ods output diffs=lsm_diff; 
 Run; 
In cases where separation is a concern, e.g. 0% response in one treatment (sub)group, an exact 
logistic regression model will be applied. To ensure convergence, this model will not include 
any continuous covariates. 
 Proc logistic data=aaa exactonly; 
 Class TRT STRATA / param=glm; 
 Model AVAL = TRT STRATA; 
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 Exact TRT / estimate=both; 
 Ods output exactoddsratio=exactoddsratio; 
 Run; 
18.2.3 Multiple Imputation 
A multiple imputation will be performed based on MAR by treatment group for baseline 
weight, baseline and post-baseline of each parameter for visits up to the primary time point 
(Week 24) using Markov Chain Monte Carlo (MCMC) method with EM algorithm. 
Impute the missing values 100 times (NIMPUTE) with a seed=457<studycode> as shown 
below: 
proc mi data= min= max= out=imp minmaxiter=10000000 nimpute=100 seed=4572306; 
            by trt; 
            var weight_base strata var1_base var1_week1-var1_week24; 
            mcmc chain=multiple initial=em;   
run; 
If needed repeat for each component necessary to calculate the final score, e.g. as follows:  
proc mi data=imp min=<min of scale> max=<max of scale> out=imp2 minmaxiter=10000000 
nimpute=100 seed=4572306; 
            by trt _imputation_; 
            var weight_base strata var2_base var2_week1-var2_week24; 
            mcmc chain=multiple initial=em;   
run; 
 
The score and ACR response can now be calculated based on the complete data. The response 
rate will be calculated for each imputation and then combined using Rubin’s rules. 
In order to calculate the response rate for each imputation, PROC FREQ will be used as 
follows. 
Calculate binomial proportion and standard error for each imputation. 
proc freq data=<ACR20>; 
  by treat visit _imputation_ ; 
  tables <response> / binomial (level=2 cl=wilson correct) ; 
  ods output BinomialProp=imp_bpr; 
run; 
 
Transpose the dataset for subsequent use with PROC MIANALYZE. 
proc transpose data=imp_bpr out=imp_trs(drop=_name_) ; 
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  by treat visit _imputation_ ; 
  var nvalue1; id name1; idlabel label1; 
run; 
 
Apply LOGIT transformation: y=log(p/(1-p)) and std. err. transformation: <new se> = 
se/(p*(1-p))  
data logit; 
  set imp_trs(rename=(_bin_=p e_bin=se)); 
  by treat visit _imputation_ ; 
  lmean=log(p/(1-p)); 
  lse=se/(p*(1-p)); 
run; 
 
The transformed binomial proportion estimates and standard errors are combined by applying 
Rubin’s rules for multiple imputed data sets. 
proc mianalyze data=logit; 
  by treat visit ; 
  modeleffects lmean; 
  stderr lse; 
  ods output ParameterEstimates=logitres; 
run; 
 
The combined data should be transformed back using the following formula: p=1/(1+exp(-y)) 
data miexpres; 
  set logitres; 
  by treat visit ; 
  resti = 1/(1+exp(-estimate)); 
  rlow = 1/(1+exp(-lclmean)); 
  rupp = 1/(1+exp(-uclmean)); 
run; 
 
Of note, sometimes all responses may be imputed to 0 or 1 at a given combination of response 
variable, treatment group and visit. Such cases should be considered separately. The 
combined final response rate would be the same as the original response but the 95% CI will 
be undefined. 
 
The odds ratio will be derived using GENMOD for each imputation, then combined using 
Rubin’s rules again. 
proc genmod data = acr20_mi descending; 
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   by avisitn _imputation_; 
    class trt_ TNFRESN ; 
   model aval = trt_ TNFRESN  weight  / link=logit dist=bin; 
   lsmeans trt_ / diff; 
   estimate 'AIN457 75mg mg vs Placebo' trt_ 1 0 -1; 
   estimate 'AIN457 150mg mg vs Placebo' trt_ 0 1 -1; 
   ods output Estimates=imp_est; 
run; 
proc mianalyze data=imp_est; 
 by avisitn trt_ ; 
           modeleffects LBetaEstimate; 
   stderr StdErr; 
   ods output ParameterEstimates=_res; 
run; 
18.2.4 Crude incidence and related risk estimates  
18.2.4.1 Crude incidence and 100*(1-α)% confidence interval 
For n subjects, each at risk to experience a certain event with probability π, the crude 
incidence is estimated as p=x/n, where x is the number of subjects with the event. 
Absolute and relative frequencies will be displayed as well as 95% confidence interval for the 
relative frequency based on the score method including continuity correction (Newcombe 
1998).  
With z  as (1-α/2)-quantile of the standard normal distribution (SAS: z=PROBIT(1-alpha/2), 
n  as total number of subjects (i.e. number of subjects in the denominator), and p as estimated 
crude incidence (number of subjects with event / n ) it is pq −=1 . 
Then the lower limit is 
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Note: if p = 0 then L = 0  and if p = 1 then U = 1. 
If appropriate, an exact 100*(1-α)% confidence interval (Clopper-Pearson 1934) will be 
obtained by using the SAS procedure PROC FREQ with the EXACT BINOMIAL statement. 
However, the confidence interval derived via the score method including continuity correction 
will be the default in safety analyses. 
18.2.4.2 Odds ratio and 100*(1-α)% confidence interval 
For an investigational drug group with n1 subjects at risk, independent from the control group 
(e.g. placebo or comparator) with n0 subjects at risk,  of whom x1 and x0 experience a certain 
event with probability π1 and π0 respectively, the odds ratio is estimated as 
)1/(
)1/(
00
11
pp
pp
−
−
  with p1= x1/n1 and p0=x0/n0.  A conditional exact 100*(1-α)% confidence 
interval will be obtained by using the SAS procedure PROC FREQ with statement EXACT 
OR. 
18.2.4.3 Risk difference and 100*(1-α)% confidence interval 
For an investigational drug group with n1 subjects at risk, independent from the control group 
(e.g. placebo or comparator) with n0 subjects at risk, of whom x1 and x0 experience a certain 
event, the risk difference is estimated as p1-p0 with p1= x1/n1 and p0=x0/n0.  
Exact unconditional confidence limits for the risk difference will be obtained with SAS 
procedure PROC FREQ and option RISKDIFF in the TABLES statement, specifying the 
RISKDIFF option also in the EXACT statement.   
18.2.5 Exposure adjusted incidence rate and related risk estimates 
18.2.5.1 Exposure adjusted incidence rate and 100*(1-α)% confidence interval 
It will be assumed that for each of n subjects in a clinical trial the time tj (j=1,...,n) to the first 
occurrence of a certain event is observed, or if the event was not experienced, the (censored) 
time to the end of the observation period. The sequence of first occurrences of an event will 
be modeled to follow approximately a Poisson process with constant intensity θ. The rate 
parameter θ will be estimated as λ=D/T, where ∑
=
=
n
j
jtT
1
 and D is the number of subjects 
with at least one event. Conditionally on T, an exact 100*(1-α)% confidence interval for a 
Poisson variable with parameter θT and observed value D can be obtained based on (Garwood, 
1936), from which an exact 100*(1-α)% confidence interval for D/T will be derived as 
follows (Sahai, 1993; Ulm, 1990): 
Lower confidence limit   
T
c
L D2,2/
5.0 α
=  for D>0, 0 otherwise, 
Upper confidence limit 
T
c
U D 22,2/1
5.0 +−
=
α  
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where kc ,α  is the αth quantile of the Chi-square distribution with k degrees of freedom. 
The example below shows how this should be handled for cases where subjects switch 
treatment.  In particular for summarizing ‘Any AIN’ as a group, one should take into 
consideration the sequence of treatments while calculating exposure time for subjects.   
Table 18-3 Examples for calculating exposure time for incidence rates (IR) 
1st 
treatment 
1st  exposur
e 
2nd 
treatment 
2nd 
exposure 
Event days (in 
terms of study 
day) 
Exposure for IR 
Placebo 100 days 150 mg  200 days 50 (1st trt) 
110 (10 days 
into 2nd trt) 
Placebo:  50 days 
(event) 
150 mg:  10 days 
(event) 
Any AIN:  10 days 
(event) 
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